cholesterol, Primary Sclerosing Cholangitis Literature

Primary Sclerosing Cholangitis Literature

Home Page

FAQ

PSC Partners

www Resources

Scientific Literature

Scientific Literature, cholesterol

Aarsetoey H, Ponitz V, Grundt H, Staines H, Harris WS, Nilsen DW. (n-3) Fatty acid content of red blood cells does not predict risk of future cardiovascular events following an acute coronary syndrome. J. Nutr. 139: 507-513 (2009). *
Aasheim ET, Bjorkman S, Sovik TT, Engstrom M, Hanvold SE, Mala T, Olbers T, Bohmer T. Vitamin status after bariatric surgery: a randomized study of gastric bypass and duodenal switch. Am. J. Clin. Nutr. May 13 [Epub ahead of print] (2009). *
Abad-Lacruz A, Fernandez-Banares F, Cabre E, Gil A, Esteve M, Gonzalez-Huix F, Xiol X, Gassull MA. The effect of total enteral tube feeding on the vitamin status of malnourished patients with inflammatory bowel disease. Int. J. Vitam. Nutr. Res. 58: 428-435 (1988).
Abba K, Sudarsanam TD, Grobler L, Volmink J. Nutritional supplements for people being treated for active tuberculosis. Cochrane Database Syst. Rev. 4: CD006086 (2008).
Aberle J, Fedderwitz I, Klages N, George E, Beil FU. Genetic variation in two proteins of the endocannabinoid system and their influence on body mass index and metabolism under low fat diet. Horm. Metab. Res. 39: 395-397 (2007).
Aberle J, Flitsch J, Beck NA, Mann O, Busch P, Peitsmeier P, Beil FU. Genetic variation may influence obesity only under conditions of diet: analysis of three candidate genes. Mol. Genet. Metab. 95: 188-191 (2008). *
Abifadel M, Rabes JP, Jambart S, Halaby G, Gannage-Yared MH, Sarkis A, Beaino G, Varret M, Salem N, Corbani S, Aydenian H, Junien C, Munnich A, Boileau C. The molecular basis of familial hypercholesterolemia in Lebanon: spectrum of LDLR mutations and role of PCSK9 as a modifier gene. Hum. Mutat. Mar 24 [Epub ahead of print] (2009). *
Abildayeva K, Jansen PJ, Hirsch-Reinshagen V, Bloks VW, Bakker AH, Ramaekers FC, De Vente J, Groen AK, Wellington CL, Kuipers F, Mulder M. 24(S)-Hydroxycholesterol participates in a liver X receptor-controlled pathway in astrocytes that regulates apolipoprotein E-mediated cholesterol efflux. J. Biol. Chem. 281: 12799-12808 (2006). *
Abou-Raya S, Abou-Raya A, Naim A, Abuelkheir H. Chronic inflammatory autoimmune disorders and atherosclerosis. Ann. N. Y. Acad. Sci. 1107: 56-67 (2007). *
Abraham SC, Cruz-Correa M, Argani P, Furth EE, Hruban RH, Boitnott JK. Lymphoplasmacytic chronic cholecystitis and biliary tract disease in patients with lymphoplasmacytic sclerosing pancreatitis. Am. J. Surg. Pathol. 27: 441-451 (2003).
Abraham SC, Cruz-Correa M, Argani P, Furth EE, Hruban RH, Boitnott JK. Diffuse lymphoplasmacytic chronic cholecystitis is highly specific for extrahepatic biliary tract disease but does not distinguish between primary and secondary sclerosing cholangiopathy. Am. J. Surg. Pathol. 27: 1313-1320 (2003).
Abrahamsson A, Gafvels M, Reihner E, Bjorkhem I, Einarsson C, Eggertsen G. Polymorphism in the coding part of the sterol 12alpha-hydroxylase gene does not explain the marked differences in the ratio of cholic acid and chenodeoxycholic acid in human bile. Scand. J. Clin. Lab. Invest. 65: 595-600 (2005). *
Abrahamsson A, Krapivner S, Gustafsson U, Muhrbeck O, Eggertsen G, Johansson I, Persson I, Angelin B, Ingelman-Sundberg M, Bjorkhem I, Einarsson C, Hooft FM. Common polymorphisms in the CYP7A1 gene do not contribute to variation in rates of bile acid synthesis and plasma LDL cholesterol concentration. Atherosclerosis 182: 37-45 (2005).
Abumweis SS, Jones PJ. Cholesterol-lowering effect of plant sterols. Curr. Atheroscler. Rep. 10: 467-472 (2008).
Acosta-Perez G, Maximina Bertha Moreno-Altamirano M, Rodriguez-Luna G, Javier Sanchez-Garcia F. Differential dependence of the ingestion of necrotic cells and TNF-alpha/IL-1beta production by murine macrophages on lipid rafts. Scand. J. Immunol. 68: 423-429 (2008). *
Adibhatla RM, Hatcher JF. Altered lipid metabolism in brain injury and disorders. Subcell. Biochem. 49: 241-268 (2008).
Adibhatla RM, Hatcher JF. Altered lipid metabolism in brain injury and disorders. Subcell. Biochem. 48: nihpa41041 (2008). *
Adighibe O, Arepalli S, Duckworth J, Hardy J, Wavrant-De Vrieze F. Genetic variability at the LXR gene (NR1H2) may contribute to the risk of Alzheimer's disease. Neurobiol. Aging 27: 1431-1434 (2006).
Agarwal DK, Choudhuri G, Saraswat VA, Negi TS, Kapoor VK, Saxena R. Duodenal bile examination in identifying potential non-responders to bile salt treatment and its comparison with gall bladder bile examination. Gut 35: 112-116 (1994). *
Agte VV, Tarwadi KV. Combination of diabetes and cataract worsens the oxidative stress and micronutrient status in Indians. Nutrition 24: 617-624 (2008). *
Aguirre AL, Center SA, Randolph JF, Yeager AE, Keegan AM, Harvey HJ, Erb HN. Gallbladder disease in Shetland sheepdogs: 38 cases (1995-2005). J. Am. Vet. Med. Assoc. 231: 79-88 (2007).
Ahmed I, Furlong K, Flood J, Treat VP, Goldstein BJ. Dual PPAR alpha/gamma agonists: promises and pitfalls in type 2 diabetes. Am. J. Ther. 14: 49-62 (2007).
Ahmed RA, Murao K, Imachi H, Yu X, Li J, Wong NC, Ishida T. Human scavenger receptor class B type 1 is regulated by activators of peroxisome proliferators-activated receptor-gamma in hepatocytes. Endocrine 35: 233-242 (2009).
Ahn KS, Sethi G, Chaturvedi MM, Aggarwal BB. Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand through modulation of NF-kappaB pathway. Int. J. Cancer 123: 1733-1740 (2008). *
Ahuja HS, Szanto A, Nagy L, Davies PJ. The retinoid X receptor and its ligands: versatile regulators of metabolic function, cell differentiation and cell death. J. Biol. Regul. Homeost. Agents 17: 29-45 (2003).
Akaogi J, Barker T, Kuroda Y, Nacionales DC, Yamasaki Y, Stevens BR, Reeves WH, Satoh M. Role of non-protein amino acid L-canavanine in autoimmunity. Autoimmun. Rev. 5: 429-435 (2006).
Akerlund JE, Bjorkhem I, Angelin B, Liljeqvist L, Einarsson K. Apparent selective bile acid malabsorption as a consequence of ileal exclusion: effects on bile acid, cholesterol, and lipoprotein metabolism. Gut 35: 1116-1120 (1994). *
Akhyani M, Ehsani AH, Robati RM, Robati AM. The lipid profile in psoriasis: a controlled study. J. Eur. Acad. Dermatol. Venereol. 21: 1330-1332 (2007). *
Akimoto T, Kobayashi S, Tamura N, Ohsawa T, Kawano T, Tanaka M, Hashimoto H. Risk factors for recurrent thrombosis: prospective study of a cohort of Japanese systemic lupus erythematosus. Angiology 56: 601-609 (2005).
Akiyama TE, Sakai S, Lambert G, Nicol CJ, Matsusue K, Pimprale S, Lee YH, Ricote M, Glass CK, Brewer HB Jr, Gonzalez FJ. Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol. Cell. Biol. 22: 2607-2619 (2002). *
Akoume MY, Perwaiz S, Yousef IM, Plaa GL. Synergistic role of 3-hydroxy-3-methylglutaryl coenzyme A reductase and cholesterol 7alpha-hydroxylase in the pathogenesis of manganese-bilirubin-induced cholestasis in rats. Toxicol. Sci. 73: 378-385 (2003). *
Akoume MY, Tuchweber B, Plaa GL, Yousef IM. The role of mdr2 in manganese-bilirubin induced cholestasis in mice. Toxicol. Lett. 148: 41-51 (2004). *
Aksungar FB, Topkaya AE, Yildiz Z, Sahin S, Turk U. Coagulation status and biochemical and inflammatory markers in multiple sclerosis. J. Clin. Neurosci. 15: 393-397 (2008).
Al-Attas OS, Al-Daghri NM, Al-Rubeaan KA, da Silva NF, Sabico SL, Kumar S, McTernan PG, Harte AL. Changes in endotoxin levels in T2DM subjects on anti-diabetic therapies. Cardiovasc. Diabetol. 8: 20 (2009).
Al-Zahrani AM, Al-Raddadi RM. Nutritional knowledge of primary health care physicians in Jeddah, Saudi Arabia. Saudi Med. J. 30: 284-287 (2009).
Alazmi WM, Fogel EL, Watkins JL, McHenry L, Sherman S, Lehman GA. The effect of biliary sphincterotomy on serum cholesterol level in postcholecystectomy patients: a pilot study. Can. J. Gastroenterol. 21: 81-84 (2007).
Albahrani AI, Usher J, Marks E, Ranganath L, Shenkin A. Atypical presentation of a middle age male with severe hypertriglyceridaemia: a case report. J. Med. Case Reports 1: 51 (2007). *
Albano E, Mottaran E, Vidali M, Reale E, Saksena S, Occhino G, Burt AD, Day CP. Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut 54: 987-993 (2005). *
Albers M, Blume B, Schlueter T, Wright MB, Kober I, Kremoser C, Deuschle U, Koegl M. A novel principle for partial agonism of liver X receptor ligands. Competitive recruitment of activators and repressors. J. Biol. Chem. 281: 4920-4930 (2006). *
Alberti S, Schuster G, Parini P, Feltkamp D, Diczfalusy U, Rudling M, Angelin B, Bjorkhem I, Pettersson S, Gustafsson JA. Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRbeta-deficient mice. J. Clin. Invest. 107: 565-573 (2001). *
Albiin N, Smith IC, Arnelo U, Lindberg B, Bergquist A, Dolenko B, Bryksina N, Bezabeh T. Detection of cholangiocarcinoma with magnetic resonance spectroscopy of bile in patients with and without primary sclerosing cholangitis. Acta Radiol. 49: 855-862 (2008).
Albrecht C, Elliott JI, Sardini A, Litman T, Stieger B, Meier PJ, Higgins CF. Functional analysis of candidate ABC transporter proteins for sitosterol transport. Biochim. Biophys. Acta 1567: 133-142 (2002). *
Aldamiz-Echevarria L, Sanjurjo P, Elorz J, Prieto JA, Perez C, Andrade F, Rodriguez-Soriano J. Effect of docosahexaenoic acid administration on plasma lipid profile and metabolic parameters of children with methylmalonic acidaemia. J. Inherit. Metab. Dis. 29: 58-63 (2006). *
Alempijevic T, Krstic M, Jesic R, Jovanovic I, Sokic Milutinovic A, Kovacevic N, Krstic S, Popovic D. Biochemical markers for non-invasive assessment of disease stage in patients with primary biliary cirrhosis. World J. Gastroenterol. 15: 591-594 (2009). *
Alfter K, von Kugelgen I, Haenisch B, Frieling T, Hulsdonk A, Haars U, Rolfs A, Noe G, Kolck UW, Homann J, Molderings GJ. New aspects of liver abnormalities as part of the systemic mast cell activation syndrome. Liver Int. 29: 181-186 (2009). *
Ali MF, Salah M, Rafea M, Saleh N. Liposomal methotrexate hydrogel for treatment of localized psoriasis: preparation, characterization and laser targeting. Med. Sci. Monit. 14: PI66-PI74 (2008).
Alipour M, Suntres ZE, Halwani M, Azghani AO, Omri A. Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosis. PLoS ONE 4: e5724 (2009). *
Alkofer BJ, Chiche L, Khayat A, Deshayes JP, Lepage A, Saloux E, Reznik Y. Liver transplant combined with heart transplant in severe heterozygous hypercholesterolemia: report of the first case and review of the literature. Transplant. Proc. 37: 2250-2252 (2005). *
Aller R, de Luis DA, Fernandez L, Calle F, Velayos B, Olcoz JL, Izaola O, Sagrado MG, Conde R, Gonzalez JM. Influence of insulin resistance and adipokines in the grade of steatosis of nonalcoholic fatty liver disease. Dig. Dis. Sci. 53: 1088-1092 (2008). *
Alles N, Soysa NS, Hussain MA, Tomomatsu N, Saito H, Baron R, Morimoto N, Aoki K, Akiyoshi K, Ohya K. Polysaccharide nanogel delivery of a TNF-alpha and RANKL antagonist peptide allows systemic prevention of bone loss. Eur. J. Pharm. Sci. 37: 83-88 (2009).
Allocca M, Crosignani A, Battezzati PM, Gritti A, Podda M. Hypercholesterolaemia is not associated with increased carotid-artery intima and media thickness in primary biliary cirrhosis. J. Hepatol. 40 Suppl. 1: 159 (2004).
Allocca M, Crosignani A, Gritti A, Ghilardi G, Gobatti D, Caruso D, Zuin M, Podda M, Battezzati PM. Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis. Gut 55: 1795-1800 (2006). *
Almendingen K, Fausa O, Hostmark AT, Bratlie J, Morkerid L, Aabakken L, Vatn MH. Serum nutrients and habitual dietary intake in colectomized FAP patients in Norway. Eur. J. Nutr. 48: 129-136 (2009). *
Alnounou M, Munoz SJ. Nutrition Issues In Gastroenterology, Series #37. Nutrition concerns of the patient with primary biliary cirrhosis or primary sclerosing cholangitis. [http://www.healthsystem.virginia.edu/internet/digestive-health/nutritionarticles/April2006.pdf] Practical Gastroenterology April 2006: 92-100 (2006). *
Alonso L AG. Effect of pregnancy on pre-existing liver disease physiological changes during pregnancy. Ann. Hepatol. 5: 184-186 (2006). *
Alpy F, Legueux F, Bianchetti L, Tomasetto C. START domain-containing proteins: a review of their role in lipid transport and exchange. Med. Sci. (Paris) 25: 181-191 (2009).
Alpy F, Tomasetto C. Give lipids a START: the StAR-related lipid transfer (START) domain in mammals. J. Cell. Sci. 118: 2791-2801 (2005). *
Alrefai WA, Gill RK. Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm. Res. 24: 1803-1823 (2007). *
Alrefai WA, Sarwar Z, Tyagi S, Saksena S, Dudeja PK, Gill RK. Cholesterol modulates human intestinal sodium-dependent bile acid transporter. Am. J. Physiol. Gastrointest. Liver Physiol. 288: G978-G985 (2005). *
Alsaadi G, Quirynen M, Michiles K, Teughels W, Komarek A, van Steenberghe D. Impact of local and systemic factors on the incidence of failures up to abutment connection with modified surface oral implants. J. Clin. Periodontol. 35: 51-57 (2008).
Altman RS, Altman LJ, Altman JS. A proposed set of new guidelines for routine blood tests during isotretinoin therapy for acne vulgaris. Dermatology 204: 232-235 (2002).
Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, Wang L, Murgolo N, Graziano MP. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 303: 1201-1204 (2004). *
Alvarez F. Treatments in chronic cholestasis in children. Ann. Nestle [Engl.] 66: 127-135 (2008).
Alvaro A, Rosales R, Masana L, Vallve JC. Polyunsaturated fatty acids down-regulate in vitro expression of the key intestinal cholesterol absorption protein NPC1L1: no effect of monounsaturated nor saturated fatty acids. J. Nutr. Biochem. May 13 [Epub ahead of print] (2009). *
Alves Cde A, Lima DS. Cystic fibrosis-related dyslipidemia. J. Bras. Pneumol. 34: 829-837 (2008).
Aly A, Carlson K, Johansson C, Kirstein P, Rossner S, Wallentin L. Lipoprotein abnormalities in patients with early primary biliary cirrhosis. Eur. J. Clin. Invest. 14: 155-162 (1984).
Amaral JD, Viana RJ, Ramalho RM, Steer CJ, Rodrigues CM. Bile acids: regulation of apoptosis by ursodeoxycholic acid. J. Lipid Res. May 5 [Epub ahead of print] (2009). *
Amarapurka DN, Amarapurkar AD, Patel ND, Agal S, Baigal R, Gupte P, Pramanik S. Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis. Ann. Hepatol. 5: 30-33 (2006). *
Ambinder EP, Cohen LB, Wolke AM, Field SP, Adelsberg B, Schaffner F, Zaroulis CG. The clinical effectiveness and safety of chronic plasmapheresis in patients with primary biliary cirrhosis. J. Clin. Apheresis 2: 219-223 (1985).
Ambrosi P, Drici MD, Herpin D, Pathak A. The best of clinical pharmacology in 2006. Arch. Mal. Coeur. Vaiss. 100 Spec. No. 1: 99-102 (2007).
Ambye L, Rasmussen S, Fenger M, Jorgensen T, Borch-Johnsen K, Madsbad S, Urhammer SA. Studies of the Gly482Ser polymorphism of the peroxisome proliferator-activated receptor gamma coactivator 1alpha (PGC-1alpha) gene in Danish subjects with the metabolic syndrome. Diabetes Res. Clin. Pract. 67: 175-179 (2005).
Amigo L, Castro J, Miquel JF, Zanlungo S, Young SG, Nervi F. Inactivation of hepatic microsomal triglyceride transfer protein protects mice from diet-induced gallstones. Gastroenterology 131: 1870-1878 (2006). *
Amrouche Ch, Jamoussi Kamoun H, Trabelsi N, Blouza Chabchoub S. Latent autoimmune diabetes in Tunisian adults (LADA): identification of autoimmune markers. Tunis. Med. 86: 316-318 (2008).
An S, Jang YS, Park JS, Kwon BM, Paik YK, Jeong TS. Inhibition of acyl-coenzyme A:cholesterol acyltransferase stimulates cholesterol efflux from macrophages and stimulates farnesoid X receptor in hepatocytes. Exp. Mol. Med. 40: 407-417 (2008). *
Anand PK, Kaul D. Downregulation of TACO gene transcription restricts mycobacterial entry/survival within human macrophages. FEMS Microbiol. Lett. 250: 137-144 (2005). *
Anandan R, Mathew S, Sankar TV, Viswanathan Nair PG. Protective effect of n-3 polyunsaturated fatty acids concentrate on isoproterenol-induced myocardial infarction in rats. Prostaglandins Leukot. Essent. Fatty Acids 76: 153-158 (2007). *
Andersen O, Eugen-Olsen J, Kofoed K, Iversen J, Haugaard SB. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy. J. Med. Virol. 80: 209-216 (2007).
Anderson HA, Hiltbold EM, Roche PA. Concentration of MHC class II molecules in lipid rafts facilitates antigen presentation. Nat. Immunol. 1: 156-162 (2000). *
Anderson SP, Dunn C, Laughter A, Yoon L, Swanson C, Stulnig TM, Steffensen KR, Chandraratna RA, Gustafsson JA, Corton JC. Overlapping transcriptional programs regulated by the nuclear receptors peroxisome proliferator-activated receptor alpha, retinoid X receptor and liver X receptor in mouse liver. Mol. Pharmacol. 66: 1440-1452 (2004). *
Andersson S, Gustafsson N, Warner M, Gustafsson JA. Inactivation of liver X receptor beta leads to adult-onset motor neuron degeneration in male mice. Proc. Natl. Acad. Sci. U.S.A. 102: 3857-3862 (2005). *
Ando H, Tsuruoka S, Yamamoto H, Takamura T, Kaneko S, Fujimura A. Effects of pravastatin on the expression of ATP-binding cassette transporter A1. J. Pharmacol. Exp. Ther. 311: 420-425 (2004). *
Ange-van Heugten KD, Burns R, Verstegen MW, Jansen WL, Ferket PR, van Heugten E. Evaluation of diabetes determinants in woolly monkeys (Lagothrix lagotricha). J. Anim. Physiol. Anim. Nutr. (Berl.) 91: 481-491 (2007). *
Angelin B, Bjorkhem I, Einarsson K, Ewerth S. Hepatic uptake of bile acids in man. Fasting and postprandial concentrations of individual bile acids in portal venous and systemic blood serum. J. Clin. Invest. 70: 724-731 (1982). *
Angelin B, Eriksson M, Parini P, Rudling M. Bile acids and lipoproteins. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 31. June 18-19 (2004). *
Angelin B, Ewerth S, Einarsson K. Ursodeoxycholic acid treatment in cholesterol gallstone disease: effects on hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity, biliary lipid composition, and plasma lipid levels. J. Lipid Res. 24: 461-468 (1983). *
Angulo P. Use of ursodeoxycholic acid in patients with liver disease. Curr. Gastroenterol. Rep. 4: 37-44 (2002).
Angulo P. Non-alcoholic steatohepatitis. Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper�s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 87-88. October 17 - 19 (2003). *
Annaba F, Sarwar Z, Kumar P, Saksena S, Turner JR, Dudeja PK, Gill RK, Alrefai WA. Modulation of ileal bile acid transporter (ASBT) activity by depletion of plasma membrane cholesterol: association with lipid rafts. Am. J. Physiol. Gastrointest. Liver Physiol. 294: G489-G497 (2008). *
Annaloro C, Usardi P, Airaghi L, Giunta V, Forti S, Orsatti A, Baldini M, Delle Volpe A, Lambertenghi Deliliers G. Prevalence of metabolic syndrome in long-term survivors of hematopoietic stem cell transplantation. Bone Marrow Transplant. 41: 797-804 (2008).
Annilo T, Tammur J, Hutchinson A, Rzhetsky A, Dean M, Allikmets R. Human and mouse orthologs of a new ATP-binding cassette gene, ABCG4. Cytogenet. Cell. Genet. 94: 196-201 (2001).
Ansquer JC, Foucher C, Aubonnet P, Le Malicot K. Fibrates and microvascular complications in diabetes - insight from the FIELD study. Curr. Pharm. Des. 15: 537-552 (2009).
Antalis CJ, Arnold T, Lee B, Buhman KK, Siddiqui RA. Docosahexaenoic acid is a substrate for ACAT1 and inhibits cholesteryl ester formation from oleic acid in MCF-10A cells. Prostaglandins Leukot. Essent. Fatty Acids 80: 165-171 (2009). *
Antsaklis G, Lewin MR, Sutor DJ, Cowie AG, Clark CG. Gallbladder function, cholesterol stones, and bile composition. Gut 16: 937-942 (1975). *
Appel LJ. Dietary approaches to reduce blood pressure. J. Anim. Physiol. Anim. Nutr. (Berl.) 89: 433 (2005). *
Aprahamian T, Bonegio R, Rizzo J, Perlman H, Lefer DJ, Rifkin IR, Walsh K. Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model. J. Immunol. 177: 3028-3034 (2006). *
Arakawa T, Kita Y, Niikura T. A rescue factor for Alzheimer's diseases: discovery, activity, structure, and mechanism. Curr. Med. Chem. 15: 2086-2098 (2008).
Aranda A, Pascual A. Nuclear hormone receptors and gene expression. Physiol. Rev. 81: 1269-1304 (2001). *
Aravindhan K, Webb CL, Jaye M, Ghosh A, Willette RN, Dinardo NJ, Jucker BM. Assessing the effects of LXR agonists on cellular cholesterol handling: a stable isotope tracer study. J. Lipid Res. 47: 1250-1260 (2006). *
Archer A, Lauter G, Hauptmann G, Mode A, Gustafsson JA. Transcriptional activity and developmental expression of liver X receptor (lxr) in zebrafish. Dev. Dyn. 237: 1090-1098 (2008).
Arendt BM, Mohammed SS, Aghdassi E, Prayitno NR, Ma DW, Nguyen A, Guindi M, Sherman M, Heathcote EJ, Allard JP. Hepatic fatty acid composition differs between chronic hepatitis C patients with and without steatosis. J. Nutr. 139: 691-695 (2009).
Argo CK, Loria P, Caldwell SH, Lonardo A. Statins in liver disease: a molehill, an iceberg, or neither? Hepatology 48: 662-669 (2008).
Arias-Vasquez A, Isaacs A, Aulchenko YS, Hofman A, Oostra BA, Breteler M, van Duijn CM. The cholesteryl ester transfer protein (CETP) gene and the risk of Alzheimer's disease. Neurogenetics 8: 189-193 (2007).
Arikan H, Koc M, Sari H, Tuglular S, Ozener C, Akoglu E. Associations between apolipoprotein E gene polymorphism and plasminogen activator inhibitor-1 and atherogenic lipid profile in dialysis patients. Ren. Fail. 29: 713-719 (2007).
Arnedo M, Taffe P, Sahli R, Furrer H, Hirschel B, Elzi L, Weber R, Vernazza P, Bernasconi E, Darioli R, Bergmann S, Beckmann JS, Telenti A, Tarr PE; the Swiss HIV Cohort Study. Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. Pharmacogenet. Genomics 17: 755-764 (2007).
Arnon R, Yoshimura T, Reiss A, Budai K, Lefkowitch JH, Javitt NB. Cholesterol 7-hydroxylase knockout mouse: a model for monohydroxy bile acid-related neonatal cholestasis. Gastroenterology 115: 1223-1228 (1998). *
Arrese M, Miquel JF, Ananthanarayanan M. BetaKlotho: a new kid on the bile acid biosynthesis block. Hepatology 43: 191-193 (2006). *
Arslan G, Brunborg LA, Froyland L, Brun JG, Valen M, Berstad A. Effects of duodenal seal oil administration in patients with inflammatory bowel disease. Lipids 37: 935-940 (2002).
Artis DR, Lin JJ, Zhang C, Wang W, Mehra U, Perreault M, Erbe D, Krupka HI, England BP, Arnold J, Plotnikov AN, Marimuthu A, Nguyen H, Will S, Signaevsky M, Kral J, Cantwell J, Settachatgull C, Yan DS, Fong D, Oh A, Shi S, Womack P, Powell B, et al. Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. Proc. Natl. Acad. Sci. U.S.A. 106: 262-267 (2009). *
Arundel C, Lewis JH. Drug-induced liver disease in 2006. Curr. Opin. Gastroenterol. 23: 244-254 (2007).
Arzuaga X, Ren N, Stromberg A, Black EP, Arsenescu V, Cassis LA, Majkova Z, Toborek M, Hennig B. Induction of gene pattern changes associated with dysfunctional lipid metabolism induced by dietary fat and exposure to a persistent organic pollutant. Toxicol. Lett. May 22 [Epub ahead of print] (2009). *
Asaki T, Aoki T, Hamamoto T, Sugiyama Y, Ohmachi S, Kuwabara K, Murakami K, Todo M. Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists. Bioorg. Med. Chem. 16: 981-994 (2008). *
Asleh R, Blum S, Kalet-Litman S, Alsheik J, Miller-Lotan R, Asaf R, Rock W, Aviram M, Milman U, Shapira C, Abassi Z, Levy AP. Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype. Diabetes 57: 2794-2800 (2008).
Asleh R, Miller-Lotan R, Aviram M, Hayek T, Yulish M, Levy JE, Miller B, Blum S, Milman U, Shapira C, Levy AP. Haptoglobin genotype is a regulator of reverse cholesterol transport in diabetes in vitro and in vivo. Circ. Res. 99: 1419-1425 (2006). *
Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP. Antisense technology for the prevention or the treatment of cardiovascular disease: the next blockbuster? Expert Opin. Investig. Drugs 17: 969-972 (2008).
Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Didangelos TP, Carina MV, Kranitsas DF, Kontopoulos AG. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am. J. Cardiol. 80: 608-613 (1997). *
Attaran M, Schneider A, Grote C, Zwiens C, Flemming P, Gratz KF, Jochheim A, Bahr MJ, Manns MP, Ott M. Regional and transient ischemia/reperfusion injury in the liver improves therapeutic efficacy of allogeneic intraportal hepatocyte transplantation in low-density lipoprotein receptor deficient Watanabe rabbits. J. Hepatol. 41: 837-844 (2004). *
Attie AD, Flowers MT, Flowers JB, Groen AK, Kuipers F, Ntambi JM. Stearoyl-CoA desaturase deficiency, hypercholesterolaemia, cholestasis and diabetes. Novartis Found. Symp. 286: 47-53 (2007).
Austria JA, Richard MN, Chahine MN, Edel AL, Malcolmson LJ, Dupasquier CM, Pierce GN. Bioavailability of alpha-linolenic acid in subjects after ingestion of three different forms of flaxseed. J. Am. Coll. Nutr. 27: 214-221 (2008).
Avallone R, Demers A, Rodrigue-Way A, Bujold K, Harb D, Anghel S, Wahli W, Marleau S, Ong H, Tremblay A. A growth hormone-releasing peptide that binds scavenger receptor CD36 and ghrelin receptor upregulates ABC sterol transporters and cholesterol efflux in macrophages through a PPARgamma-dependent pathway. Mol. Endocrinol. 20: 3165-3178 (2006). *
Avezov SA, Mansurov FKh. Efficacy of combined administration of ursodeoxycholic acid and hepthral in the treatment of primary biliary cirrhosis. Klin. Med. (Mosk.) 82: 55-58 (2004).
Avezov SA, Mansurova FKh. Efficacy of combined use of ursodeoxycholic acid and heptral in the treatment of primary biliary cirrhosis. Klin. Med. (Mosk.) 82: 46-49 (2004).
Aviram M, Rosenblat M. Paraoxonases (PON1, PON2, PON3) analyses in vitro and in vivo in relation to cardiovascular diseases. Methods Mol. Biol. 477: 259-276 (2009).
Axelson M. Studies on biosynthetic pathways to bile acids in human liver cells. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 22. June 18-19 (2004). *
Axelson M, Mork B, Everson GT. Bile acid synthesis in cultured human hepatoblastoma cells. J. Biol. Chem. 266: 17770-17777 (1991). *
Ayaki Y, Kok E, Javitt NB. Cholic acid synthesis from 26-hydroxycholesterol and 3-hydroxy-5-cholestenoic acid in the rabbit. J. Biol. Chem. 264: 3818-3821 (1989). *
Ayaori M, Sawada S, Yonemura A, Iwamoto N, Ogura M, Tanaka N, Nakaya K, Kusuhara M, Nakamura H, Ohsuzu F. Glucocorticoid receptor regulates ATP-binding cassette transporter-A1 expression and apolipoprotein-mediated cholesterol efflux from macrophages. Arterioscler. Thromb. Vasc. Biol. 26: 163-168 (2006). *
Azambuja MI. Connections: can the 20th century coronary heart disease epidemic reveal something about the 1918 influenza lethality? Braz. J. Med. Biol. Res. 41: 1-4 (2008). *
Aziz A, Xiao CW, Cockell KA, Sarwar Gilani G, Cruz-Hernandez C, Nimal Ratnayake WM. Impact of dietary protein on lipid metabolism in hamsters is source-dependent and associated with changes in hepatic gene expression. Br. J. Nutr. 100: 503-511 (2008). *
Baba MI, Kaul D, Grover A. Importance of blood cellular genomic profile in coronary heart disease. J. Biomed. Sci. 13: 17-26 (2006). *
Bachmann K, Patel H, Batayneh Z, Slama J, White D, Posey J, Ekins S, Gold D, Sambucetti L. PXR and the regulation of apoA1 and HDL-cholesterol in rodents. Pharmacol. Res. 50: 237-246 (2004). *
Bachs L, Pares A, Elena M, Piera C, Rodes J. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 102: 2077-2080 (1992).
Backes JM, Gibson CA, Howard PA. Optimal lipid modification: the rationale for combination therapy. Vasc. Health Risk Manag. 1: 317-331 (2005).
Backes JM, Gibson CA, Ruisinger JF, Moriarty PM. Fibrates: what have we learned in the past 40 years? Pharmacotherapy 27: 412-424 (2007).
Bai D, Brar P, Holleran S, Ramakrishnan R, Green P. Effect of gender on the manifestations of celiac disease: evidence for greater malabsorption in men. Scand. J. Gastroenterol. 40: 183-187 (2005). *
Baiocchi L, Alpini G, Glaser S, Angelico M, Alvaro D, Francis H, Marzioni M, Phinizy JL, Barbaro B, LeSage G. Taurohyodeoxycholate- and tauroursodeoxycholate-induced hypercholeresis is augmented in bile duct ligated rats. J. Hepatol. 38: 136-147 (2003).
Balan V, Dickson ER, Jorgensen RA, Lindor KD. Effect of ursodeoxycholic acid on serum lipids of patients with primary biliary cirrhosis. Mayo Clin. Proc. 69: 923-929 (1994).
Balasubramaniyan N, Shahid M, Suchy FJ, Ananthanarayanan M. Multiple mechanisms of ontogenic regulation of nuclear receptors during rat liver development. Am. J. Physiol. Gastrointest. Liver Physiol. 288: G251-G260 (2005). *
Balcerzyk A, Zak I, Krauze J. Synergistic effect between polymorphisms of PPARA and ABCA1 genes on the premature coronary artery disease. Acta Cardiol. 62: 233-238 (2007).
Balcerzyk A, Zak I, Krauze J. Synergistic effects between Q192R polymorphism of paraoxonase 1 gene and some conventional risk factors in premature coronary artery disease. Arch. Med. Res. 38: 545-550 (2007).
Baldan A, Bojanic DD, Edwards PA. The ABCs of sterol transport. J. Lipid Res. 50: S80-S85 (2009). *
Baldan A, Tarr P, Lee R, Edwards PA. ATP-binding cassette transporter G1 and lipid homeostasis. Curr. Opin. Lipidol. 17: 227-232 (2006).
Baldo-Enzi G, Baiocchi MR, Grotto M, Floreani AR, Zagolin M, Chiaramonte M, Cera F, Fellin R. Lipoprotein pattern and plasma lipoprotein lipase activities in patients with primary biliary cirrhosis. Relationship with increase of HDL2 fraction in Lp-X-positive and Lp-X-negative subjects. Dig. Dis. Sci. 33: 1201-1207 (1988).
Balistreri WF. Genetic liver disease. 54th Annual Meeting of the American Association for the Study of Liver Diseases (2003).
Balistreri WF. Bile acid therapy in pediatric hepatobiliary disease: the role of ursodeoxycholic acid. J. Pediatr. Gastroenterol. Nutr. 24: 573-589 (1997). *
Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 189: 19-30 (2006).
Balkova K, Gbelska Y. ABC transporter proteins in multidrug resistance of microorganisms. Epidemiol. Mikrobiol. Imunol. 56: 129-139 (2007).
Ballatori N, Fang F, Christian WV, Li N, Hammond CL. Ostalpha-Ostbeta is required for bile acid and conjugated steroid disposition in the intestine, kidney, and liver. Am. J. Physiol. Gastrointest. Liver Physiol. 295: G179-G186 (2008). *
Balmer M, Dufour J. Treatment of hypercholesterolemia in patients with primary biliary cirrhosis might be more beneficial than indicated. Swiss Med. Wkly. 138: 415-419 (2008). *
Banerjee A, Hussainzada N, Khandelwal A, Swaan PW. Electrostatic and potential cation-pi forces may guide the interaction of extracellular loop III with Na+ and bile acids for human apical Na+-dependent bile acid transporter. Biochem. J. 410: 391-400 (2008). *
Banos G, Perez-Torres I, El Hafidi M. Medicinal agents in the metabolic syndrome. Cardiovasc. Hematol. Agents Med. Chem. 6: 237-252 (2008).
Baranowski M. Biological role of liver X receptors. J. Physiol. Pharmacol. 59 Suppl. 7: 31-55 (2008).
Barbier O, Duran-Sandoval D, Pineda-Torra I, Kosykh V, Fruchart JC, Staels B. Peroxisome proliferator-activated receptor alpha induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme. J. Biol. Chem. 278: 32852-32860 (2003). *
Barbier O, Torra IP, Duguay Y, Blanquart C, Fruchart JC, Glineur C, Staels B. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 22: 717-726 (2002). *
Barbier O, Trottier J, Kaeding J, Caron P, Verreault M. Lipid-activated transcription factors control bile acid glucuronidation. Mol. Cell. Biochem. 326: 3-8 (2009). *
Barbosa FA, de Labio RW, de Oliveira S Rigolin V, Minett T, Bertolucci PH, de Arruda Cardoso Smith M, Payao SL. Apolipoprotein A-V gene polymorphism -1131T>C and Alzheimer's disease. J. Alzheimers Dis. 10: 365-369 (2006).
Barcelo-Coblijn G, Collison LW, Jolly CA, Murphy EJ. Dietary alpha-linolenic acid increases brain but not heart and liver docosahexaenoic acid levels. Lipids 40: 787-798 (2005).
Barcelo-Coblijn G, Golovko MY, Weinhofer I, Berger J, Murphy EJ. Brain neutral lipids mass is increased in alpha-synuclein gene-ablated mice. J. Neurochem. 101: 132-141 (2007).
Barnard ND, Noble EP, Ritchie T, Cohen J, Jenkins DJ, Turner-McGrievy G, Gloede L, Green AA, Ferdowsian H. D2 dopamine receptor Taq1A polymorphism, body weight, and dietary intake in type 2 diabetes. Nutrition 25: 58-65 (2009).
Barnes DS. Intrahepatic cholestatic liver disease. http://www.clevelandclinicmeded.com/diseasemanagement/gastro/intrahepatic/intrahepatic1.htm (2002). *
Barre DE. The role of consumption of alpha-linolenic, eicosapentaenoic and docosahexaenoic acids in human metabolic syndrome and type 2 diabetes - a mini-review. J. Oleo. Sci. 56: 319-325 (2007). *
Barter P, Ginsberg HN. Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia. Am. J. Cardiol. 102: 1040-1045 (2008). *
Barth JH, Macdonald-Hull SP, Mark J, Jones RG, Cunliffe WJ. Isotretinoin therapy for acne vulgaris: a re-evaluation of the need for measurements of plasma lipids and liver function tests. Br. J. Dermatol. 129: 704-707 (1993).
Baruch Y, Brook JG, Eidelman S, Aviram M. Increased concentration of high density lipoprotein in plasma and decreased platelet aggregation in primary biliary cirrhosis. Atherosclerosis 53: 151-162 (1984).
Basciano H, Miller AE, Naples M, Baker C, Kohen R, Xu E, Su Q, Allister E, Wheeler M, Adeli K. Metabolic effects of dietary cholesterol in an animal model of insulin resistance and hepatic steatosis. Am. J. Physiol. Endocrinol. Metab. Jun 9 [Epub ahead of print] (2009). *
Basso F, Freeman LA, Ko C, Joyce C, Amar MJ, Shamburek RD, Tansey T, Thomas F, Wu J, Paigen B, Remaley AT, Santamarina-Fojo S, Brewer HB Jr. Hepatic ABCG5/G8 overexpression reduces apoB-lipoproteins and atherosclerosis when cholesterol absorption is inhibited. J. Lipid Res. 48: 114-126 (2007). *
Basu A, Devaraj S, Jialal I. Dietary factors that promote or retard inflammation. Arterioscler. Thromb. Vasc. Biol. 26: 995-1001 (2006). *
Bate C, Marshall V, Colombo L, Diomede L, Salmona M, Williams A. Docosahexaenoic and eicosapentaenoic acids increase neuronal death in response to HuPrP82-146 and Abeta(1-42). Neuropharmacology 54: 934-943 (2008).
Bate C, Tayebi M, Diomede L, Salmona M, Williams A. Docosahexaenoic and eicosapentaenoic acids increase prion formation in neuronal cells. BMC Biol. 6: 39 (2008). *
Bateson MC, Hill A, Bouchier IA. Analysis of response to ursodeoxycholic acid for gallstone dissolution. Digestion 20: 358-364 (1980).
Bateson MC, Ross PE, Murison J, Bouchier IA. Effect of prolonged feeding with chenodeoxycholic acid on bile in patients with and without gallstones. Gut 18: 599-605 (1997). *
Bateson MC, Ross PE, Murison J, Saunders JH, Bouchier IA. Ursodeoxycholic acid therapy and biliary lipids - a dose-response study. Gut 21: 305-310 (1980). *
Battochio AP, Sartori MS, Coelho CA. Water-soluble extract of Coleus barbatus modulates weight gain, energy utilization and lipid metabolism in secondary biliary cirrhosis: an experimental study in young rats. Acta Cir. Bras. 20: 229-236 (2005).
Bayliss M, Somers G. Isolation and culture of human hepatocytes. Methods Mol. Med. 107: 249-268 (2004).
Bays H. Clinical overview of omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. Am. J. Cardiol. 98: S71-S76 (2006). *
Beattie AD, Sherlock S. Ascorbic acid deficiency in liver disease. Gut 17: 571-575 (1976). *
Bedu E, Wahli W, Desvergne B. Peroxisome proliferator-activated receptor beta/delta as a therapeutic target for metabolic diseases. Expert Opin. Ther. Targets 9: 861-873 (2005).
Bell Iii TA, Kelley K, Wilson MD, Sawyer JK, Rudel LL. Dietary fat-induced alterations in atherosclerosis are abolished by ACAT2-deficiency in ApoB100 only, LDLr-/- mice. Arterioscler. Thromb. Vasc. Biol. 27: 1396-1402 (2007).
Bellentani S. Immunomodulating and anti-apoptotic action of ursodeoxycholic acid: where are we and where should we go? Eur. J. Gastroenterol. Hepatol. 17: 137-140 (2005). *
Belli DC, Fournier LA, Lepage G, Yousef I, Roy CC. S-Adenosylmethionine prevents total parenteral nutrition-induced cholestasis in the rat. J. Hepatol. 21: 18-23 (1994).
Bellosta S, Bernini F. Modulation of macrophage function and metabolism. Handb. Exp. Pharmacol. 170: 665-695 (2005).
Beltowski J. Liver X receptors (LXR) as therapeutic targets in dyslipidemia. Cardiovasc. Ther. 26: 297-316 (2008).
Beltowski J, Wojcicka G, Jamroz-Wisniewska A. Adverse effects of statins - mechanisms and consequences. Curr. Drug Saf. Sep 1 [Epub ahead of print] (2009).
Ben-Ari Z, Schafer Z, Sulkes J, Manhaim V, Tur-Kaspa R, Fainaru M. Alterations in serum leptin in chronic liver disease. Dig. Dis. Sci. 47: 183-189 (2002). *
Ben-Ari Z, Tur-Kaspa R, Schafer Z, Baruch Y, Sulkes J, Atzmon O, Greenberg A, Levi N, Fainaru M. Basal and post-methionine serum homocysteine and lipoprotein abnormalities in patients with chronic liver disease. J. Investig. Med. 49: 325-329 (2001).
Benabdeslam H, Garcia I, Bellon G, Gilly R, Revol A. Biochemical assessment of the nutritional status of cystic fibrosis patients treated with pancreatic enzyme extracts. Am. J. Clin. Nutr. 67: 912-918 (1998). *
Bendlova B, Vejralkova D, Vcelak J, Lukalova P, Burkonova D, Kunelova M, Vrbikova J, Dvorakova K, Vondra K, Vankova M. PPARgamma2 Pro12Ala polymorphism in relation to free fatty acids concentration and composition in lean healthy Czech individuals with and without family history of diabetes type 2. Physiol. Res. 57 Suppl. 1: S77-S90 (2008). *
Benito P, Caballero J, Moreno J, Gutierrez-Alcantara C, Munoz C, Rojo G, Garcia S, Soriguer FC. Effects of milk enriched with omega-3 fatty acid, oleic acid and folic acid in patients with metabolic syndrome. Clin. Nutr. 25: 581-587 (2006).
Bennett DJ, Cooke AJ, Edwards AS. Non-steroidal LXR agonists; an emerging therapeutic strategy for the treatment of atherosclerosis. Recent Patents Cardiovasc. Drug Discov. 1: 21-46 (2006).
Benno P, Leijonmarck CE, Monsen U, Uribe A, Midtvedt T. Functional alterations of the microflora in patients with ulcerative colitis. Scand. J. Gastroenterol. 28: 839-844 (1993).
Bensinger SJ, Bradley MN, Joseph SB, Zelcer N, Janssen EM, Hausner MA, Shih R, Parks JS, Edwards PA, Jamieson BD, Tontonoz P. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell 134: 97-111 (2008). *
Benson MK, Devi K. Influence of omega-6/omega-3 rich dietary oils on lipid profile and antioxidant enzymes in normal and stressed rats. Indian J. Exp. Biol. 47: 98-103 (2009).
Bentinger M, Turunen M, Zhang XX, Wan YJ, Dallner G. Involvement of retinoid X receptor alpha in coenzyme Q metabolism. J. Mol. Biol. 326: 795-803 (2003). *
Benton JL, Ding J, Tsai MY, Shea S, Rotter JI, Burke GL, Post W. Associations between two common polymorphisms in the ABCA1 gene and subclinical atherosclerosis: Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 193: 352-360 (2007).
Berard AM, Dumon MF, Darmon M. Dietary fish oil up-regulates cholesterol 7alpha-hydroxylase mRNA in mouse liver leading to an increase in bile acid and cholesterol excretion. FEBS Lett. 559: 125-128 (2004). *
Berg KK, Madsen HO, Garred P, Wiseth R, Gunnes S, Videm V. The additive contribution from inflammatory genetic markers on the severity of cardiovascular disease. Scand. J. Immunol. 69: 36-42 (2009). *
Bergasa NV. The pruritus of cholestasis. J. Hepatol. 43: 1078-1088 (2005). *
Bergasa NV. Treatment of the pruritus of cholestasis. Curr. Treat. Options Gastroenterol. 7: 501-508 (2004).
Bergasa NV, Mason A, Floreani A, Heathcote J, Swain MG, Jones DE, Lindor KM, Bassendine MF, Worman HJ. Primary biliary cirrhosis: report of a focus study group. Hepatology 40: 1013-1020 (2004). *
Berge KE, von Bergmann K, Lutjohann D, Guerra R, Grundy SM, Hobbs HH, Cohen JC. Heritability of plasma noncholesterol sterols and relationship to DNA sequence polymorphism in ABCG5 and ABCG8. J. Lipid Res. 43: 486-494 (2002). *
Berger K, Stogbauer F, Stoll M, Wellmann J, Huge A, Cheng S, Kessler C, John U, Assmann G, Ringelstein EB, Funke H. The glu298asp polymorphism in the nitric oxide synthase 3 gene is associated with the risk of ischemic stroke in two large independent case-control studies. Hum. Genet. 121: 169-178 (2007). *
Bergheim I, Harsch S, Mueller O, Schimmel S, Fritz P, Stange EF. Apical sodium bile acid transporter and ileal lipid binding protein in gallstone carriers. J. Lipid Res. 47: 42-50 (2006). *
Berkowitz CM, Shen CS, Bilir BM, Guibert E, Gumucio JJ. Different hepatocytes express the cholesterol 7 alpha-hydroxylase gene during its circadian modulation in vivo. Hepatology 21: 1658-1667 (1995).
Bernard D, Christophe A, Delanghe J, Langlois M, De Buyzere M, Comhaire F. The effect of supplementation with an antioxidant preparation on LDL-oxidation is determined by haptoglobin polymorphism. Redox Rep. 8: 41-46 (2003).
Berrougui H, Khalil A. Age-associated decrease of high-density lipoprotein-mediated reverse cholesterol transport activity. Rejuvenation Res. 12: 117-126 (2009).
Bersamin A, Luick BR, King IB, Stern JS, Zidenberg-Cherr S. Westernizing diets influence fat intake, red blood cell fatty acid composition, and health in remote Alaskan native communities in the Center for Alaska Native Health study. J. Am. Diet. Assoc. 108: 266-273 (2008).
Bersot T, Haffner S, Harris WS, Kellick KA, Morris CM. Hypertriglyceridemia: management of atherogenic dyslipidemia. J. Fam. Pract. 55: S1-S8 (2006).
Berthold HK, Laaksonen R, Lehtimaki T, Gylling H, Krone W, Gouni-Berthold I. SREBP-1c gene polymorphism is associated with increased inhibition of cholesterol-absorption in response to ezetimibe treatment. Exp. Clin. Endocrinol. Diabetes 116: 262-267 (2008).
Bertok L. Bile acids in physico-chemical host defence. Pathophysiology 11: 139-145 (2004).
Bertolotti M, Gabbi C, Anzivino C, Carulli L, Loria P, Carulli N. Nuclear receptors as potential molecular targets in cholesterol accumulation conditions: insights from evidence on hepatic cholesterol degradation and gallstone disease in humans. Curr. Med. Chem. 15: 2271-2284 (2008).
Bertolotti M, Gabbi C, Anzivino C, Crestani M, Mitro N, Del Puppo M, Godio C, De Fabiani E, Macchioni D, Carulli L, Rossi A, Ricchi M, Loria P, Carulli N. Age-related changes in bile acid synthesis and hepatic nuclear receptor expression. Eur. J. Clin. Invest. 37: 501-508 (2007). *
Bertolotti M, Gabbi C, Anzivino C, Mitro N, Godio C, De Fabiani E, Crestani M, Del Puppo M, Ricchi M, Carulli L, Rossi A, Loria P, Carulli N. Decreased hepatic expression of PPAR-gamma coactivator-1 in cholesterol cholelithiasis. Eur. J. Clin. Invest. 36: 170-175 (2006).
Bertolotti M, Zambianchi L, Carulli L, Simonini MS, Del Puppo M, Kienle MG, Loria P, Pinetti A, Carulli N. Influence of newly synthesized cholesterol on bile acid synthesis during chronic inhibition of bile acid absorption. Hepatology 38: 939-946 (2003). *
Besler C, Doerries C, Giannotti G, Luscher TF, Landmesse U. Pharmacological approaches to improve endothelial repair mechanisms. Expert Rev. Cardiovasc. Ther. 6: 1071-1082 (2008).
Besnard P, Landrier JF, Grober J, Niot I. Is the ileal bile acid-binding protein (I-BABP) gene involved in cholesterol homeostasis? Med. Sci. (Paris) 20: 73-77 (2004).
Betteridge DJ. Lipid-lowering trials in diabetes. Curr. Opin. Lipidol. 12: 619-623 (2001).
Betteridge DJ. Lipid lowering in diabetes mellitus. Curr. Opin. Lipidol. 19: 579-584 (2008).
Beukeveld GJ, In 't Veld G, Havinga R, Groen AK, Wolthers BG, Kuipers F. Relationship between biliary lipid and protoporphyrin secretion; potential role of mdr2 P-glycoprotein in hepatobiliary organic anion transport. J. Hepatol. 24: 343-352 (1996). *
Beyea MM, Heslop CL, Sawyez CG, Edwards JY, Markle JG, Hegele RA, Huff MW. Selective up-regulation of LXR-regulated genes ABCA1, ABCG1 and APOE in macrophages through increased endogenous synthesis of 24(S),25-epoxycholesterol. J. Biol. Chem. 282: 5207-5216 (2007). *
Beyer TP, Chen Y, Porter RK, Lu D, Schmidt RJ, Mantlo NB, Konrad RJ, Cao G. Peroxisome proliferator-activated receptor alpha agonists regulate cholesterol ester transfer protein. Lipids 43: 611-618 (2008).
Beyer TP, Schmidt RJ, Foxworthy P, Zhang Y, Dai J, Bensch WR, Kauffman RF, Gao H, Ryan TP, Jiang XC, Karathanasis SK, Eacho PI, Cao G. Coadministration of a liver X receptor agonist and a peroxisome proliferator activator receptor-alpha agonist in mice: effects of nuclear receptor interplay on high-density lipoprotein and triglyceride metabolism in vivo. J. Pharmacol. Exp. Ther. 309: 861-868 (2004). *
Bhalla S, Ozalp C, Fang S, Xiang L, Kemper JK. Ligand-activated PXR interferes with HNF-4 signaling by targeting a common coactivator PGC-1alpha: functional implications in hepatic cholesterol and glucose metabolism. J. Biol. Chem. 279: 45139-45147 (2004). *
Bhat B, Esau C, Davis S, Propp S, Kinberger G, Gaus H, Freier S, Swayze EE, Bennett CF. 2'-O-Methoxyethyl/2'-fluoro modified oligonucleotides result in more potent inhibition of micro RNA-122 in vivo: a target implicated in HCV replication. Nucleic Acids Symp. Ser. (Oxf.) 52: 69 (2008).
Biasi F, Mascia C, Poli G. TGFbeta1 expression in colonic mucosa: modulation by dietary lipids. Genes Nutr. 2: 233-243 (2007). *
Bickler SW, Demaio A. Western diseases: current concepts and implications for pediatric surgery research and practice. Pediatr. Surg. Int. 24: 251-255 (2008).
Bijl N, van Roomen CP, Triantis V, Sokolovic M, Ottenhoff R, Scheij S, van Eijk M, Boot RG, Aerts JM, Groen AK. Reduction of glycosphingolipid biosynthesis stimulates biliary lipid secretion in mice. Hepatology 49: 637-645 (2009). *
Bilhartz LE. Cholesterol gallstone disease: the current status of nonsurgical therapy. Am. J. Med. Sci. 296: 45-56 (1988).
Bilz S, Samuel V, Morino K, Savage D, Choi CS, Shulman GI. Activation of the farnesoid X receptor improves lipid metabolism in combined hyperlipidemic hamsters. Am. J. Physiol. Endocrinol. Metab. 290: E716-E722 (2006). *
Bird JE, Giancarli MR, Kurihara T, Kowala MC, Valentine MT, Gitlitz PH, Pandya DG, French MH, Durham SK. Increased severity of glomerulonephritis in C-C chemokine receptor 2 knockout mice. Kidney Int. 57: 129-136 (2000). *
Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology 71: 1390-1395 (2008).
Birrell MA, Catley MC, Hardaker E, Wong S, Willson TM, McCluskie K, Leonard T, Farrow SN, Collins JL, Haj-Yahia S, Belvisi MG. Novel role for the liver X nuclear receptor in the suppression of lung inflammatory responses. J. Biol. Chem. 282: 31882-31890 (2007). *
Bischoff ED, Daige CL, Petrowski M, Dedman H, Pattison J, Juliano J, Li AC, Schulman IG. Macrophage-independent functions contribute to the anti-atherogenic activity of LXRalpha. J. Lipid Res. Mar 28 [Epub ahead of print] (2009). *
Bishop-Bailey D. FXR as a novel therapeutic target for vascular disease. Drug News Perspect. 17: 499-504 (2004).
Bishop-Bailey D, Walsh DT, Warner TD. Expression and activation of the farnesoid X receptor in the vasculature. Proc. Natl. Acad. Sci. U.S.A. 101: 3668-3673 (2004). *
Bisschop PH, Bandsma RH, Stellaard F, Ter Harmsel A, Meijer AJ, Sauerwein HP, Kuipers F, Romijn JA. Low-fat, high-carbohydrate and high-fat, low-carbohydrate diets decrease primary bile acid synthesis in humans. Am. J. Clin. Nutr. 79: 570-576 (2004). *
Bjorkhem I. Are side-chain oxidized oxysterols regulators also in vivo? J. Lipid Res. 50: S213-S218 (2009). *
Bjorkhem I, Araya Z, Rudling M, Angelin B, Einarsson C, Wikvall K. Differences in the regulation of the classical and the alternative pathway for bile acid synthesis in human liver. No coordinate regulation of CYP7A1 and CYP27A1. J. Biol. Chem. 277: 26804-26807 (2002). *
Bjorkhem I, Meaney S, Heverin M, Andersson U, Axelsson M, Panzenboek U, Sattler W. Role of oxysterols and cholestenoic acids in a crosstalk between the brain and the liver. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 23 (2006). *
Blaha V, Mistr�k E. Hypolipidemic drugs and diabetes mellitus. Vnitr. Lek. 55: 357-362 (2009).
Blaner WS, O'Byrne SM, Wongsiriroj N, Kluwe J, D'Ambrosio D, Jiang H, Schwabe RF, Hillman EM, Piantedosi R, Libien J. Hepatic stellate cell lipid droplets: a specialized lipid droplet for retinoid storage. Biochim. Biophys. Acta Nov 24 [Epub ahead of print] (2008). *
Blasi C. The autoimmune origin of atherosclerosis. Atherosclerosis May 23 [Epub ahead of print] (2008).
Blazovics A, Hagymasi K, Pronai L. Cytokines, prostaglandins, nutritive and non-nuitritive factors in inflammatory bowel diseases. Orv. Hetil. 145: 2523-2529 (2004).
Bleie O, Semb AG, Grundt H, Nordrehaug JE, Vollset SE, Ueland PM, Nilsen DW, Bakken AM, Refsum H, Nygard OK. Homocysteine-lowering therapy does not affect inflammatory markers of atherosclerosis in patients with stable coronary artery disease. J. Intern. Med. 262: 244-253 (2007). *
Bloch AS. Low carbohydrate diets, pro: time to rethink our current strategies. Nutr. Clin. Pract. 20: 3-12 (2005).
Block G, Jensen CD, Norkus EP, Dalvi TB, Wong LG, McManus JF, Hudes ML. Usage patterns, health, and nutritional status of long-term multiple dietary supplement users: a cross-sectional study. Nutr. J. 6: 30 (2007). *
Bloks VW, Bakker-Van Waarde WM, Verkade HJ, Kema IP, Wolters H, Vink E, Groen AK, Kuipers F. Down-regulation of hepatic and intestinal Abcg5 and Abcg8 expression associated with altered sterol fluxes in rats with streptozotocin-induced diabetes. Diabetologia 47: 104-112 (2004). *
Bloomer JR, Boyer JL. Phenobarbital effects in cholestatic liver diseases. Ann. Intern. Med. 82: 310-317 (1975).
Blum HE. Gene therapy for liver diseases: experimental strategies. Falk Symposium 156. XIII Falk Liver Week (Part II). GENETICS IN LIVER DISEASES, Freiburg (Germany), October 8-9, 2006, p. 44-45 (2006). *
Boadu E, Choi HY, Lee DW, Waddington EI, Chan T, Asztalos B, Vance JE, Chan A, Castro G, Francis GA. Correction of apolipoprotein A-I-mediated lipid efflux and HDL particle formation in human Niemann-Pick type C disease fibroblasts. J. Biol. Chem. 281: 37081-37090 (2006). *
Bocher V, Pineda-Torra I, Fruchart JC, Staels B. PPARs: transcription factors controlling lipid and lipoprotein metabolism. Ann. N. Y. Acad. Sci. 967: 7-18 (2002). *
Bock HH, Lammert F. Nuclear xeno-sensors as receptors for cholestatic bile acids: the second line of defense. Hepatology 35: 232-234 (2002). *
Bock J, Liebisch G, Schweimer J, Schmitz G, Rogler G. Exogenous sphingomyelinase causes impaired intestinal epithelial barrier function. World J. Gastroenterol. 13: 5217-5225 (2007). *
Bodin K. Role of CYP3A4 as a cholesterol and bile acid metabolizing enzyme. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 25. June 18-19 (2004). *
Bodin K, Andersson U, Rystedt E, Ellis E, Norlin M, Pikuleva I, Eggertsen G, Bjorkhem I, Diczfalusy U. Metabolism of 4 beta -hydroxycholesterol in humans. J. Biol. Chem. 277: 31534-31540 (2002). *
Bodolay E, Seres I, Szodoray P, Csipo I, Jakab Z, Vegh J, Szilagyi A, Szegedi G, Paragh G. Evaluation of paraoxonase activity in patients with mixed connective tissue disease. J. Rheumatol. 35: 237-243 (2008).
Bodor ET, Offermanns S. Nicotinic acid: an old drug with a promising future. Br. J. Pharmacol. 153 Suppl. 1: S68-S75 (2008). *
Bogdanovic M, Bulat P. Biliary function in workers occupationally exposed to aluminium dust and fumes. Arh. Hig. Rada. Toksikol. 59: 135-139 (2008).
Bohan A, Chen WS, Denson LA, Held MA, Boyer JL. Tumor necrosis factor alpha-dependent up-regulation of Lrh-1 and Mrp3(Abcc3) reduces liver injury in obstructive cholestasis. J. Biol. Chem. 278: 36688-36698 (2003). *
Boillot O, Mayer DA, Boudjema K, Salizzoni M, Gridelli B, Filipponi F, Trunecka P, Krawczyk M, Clavien PA, Ducerf C, Margarit C, Margreiter R, Pallardo JM, Hoeckerstedt K, Pageaux GP. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study. Liver Transpl. 11: 61-67 (2005). *
Boland B, Beguin C, Zech F, Desager JP, Lambert M. Serum beta-carotene in anorexia nervosa patients: a case-control study. Int. J. Eat. Disord. 30: 299-305 (2001).
Bongardt F, Schopfer-Wendels A, Huth C, Heid I, Rathmann W, Martin S, Vollmert C, Holle R, Thorand B, Wichmann HE, Koenig W, Kolb H, Herder C. Genetics of type 2 diabetes: impact of interleukin-6 gene variants. Gesundheitswesen 67 Suppl. 1: 122-126 (2005).
Bonnet J, McPherson R, Tedgui A, Simoneau D, Nozza A, Martineau P, Davignon J; for the CAP Investigators. Comparative effects of 10-mg versus 80-mg atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Clin. Ther. 30: 2298-2313 (2008).
Bookman ID, Pham J, Guindi M, Heathcote EJ. Distinguishing nonalcoholic steatohepatitis from fatty liver: serum-free fatty acids, insulin resistance, and serum lipoproteins. Liver Int. 26: 566-571 (2006). *
Borba EF, Carvalho JF, Bonfa E. Mechanisms of dyslipoproteinemias in systemic lupus erythematosus. Clin. Dev. Immunol. 13: 203-208 (2006). *
Bordoni A, Di Nunzio M, Danesi F, Biagi PL. Polyunsaturated fatty acids: from diet to binding to PPARs and other nuclear receptors. Genes & Nutrition 1: 95-106 (2006). *
Bordoni A, Di Nunzio M, Danesi F, Biagi PL. Polyunsaturated fatty acids: from diet to binding to PPARs and other nuclear receptors. Genes Nutr. 1: 95-106 (2006).
Borggreve SE, de Vries R, Dallinga-Thie GM, Wolffenbuttel BH, Groen AK, van Tol A, Dullaart RP. The ability of plasma to stimulate fibroblast cholesterol efflux is associated with the -629C-->A cholesteryl ester transfer protein promoter polymorphism: role of lecithin:cholesterol acyltransferase activity. Biochim. Biophys. Acta 1781: 10-15 (2008). *
Borst P, Zelcer N, van Helvoort A. ABC transporters in lipid transport. Biochim. Biophys. Acta 1486: 128-144 (2000). *
Borthwick F, Taylor JM, Bartholomew C, Graham A. Differential regulation of the STARD1 subfamily of START lipid trafficking proteins in human macrophages. FEBS Lett. 583: 1147-1153 (2009). *
Borthwick L; on behalf of the UK Study Group. The effects of an omega-3 ethyl ester concentrate on blood lipid concentrations in patients with hyperlipidaemia. Clin. Drug Investig. 15: 397-404 (1998).
Bosch T. Therapeutic apheresis - state of the art in the year 2005. Ther. Apher. Dial. 9: 459-468 (2005). *
Botes L, van der Westhuizen FH, Loots du T. Phytochemical contents and antioxidant capacities of two Aloe greatheadii var. davyana extracts. Molecules 13: 2169-2180 (2008).
Boulias K, Katrakili N, Bamberg K, Underhill P, Greenfield A, Talianidis I. Regulation of hepatic metabolic pathways by the orphan nuclear receptor SHP. EMBO J. 24: 2624-2633 (2005). *
Bourke B, Goggin N, Walsh D, Kennedy S, Setchell KD, Drumm B. Byler-like familial cholestasis in an extended kindred. Arch. Dis. Child. 75: 223-227 (1996).
Bourre JM, Galea F. An important source of omega-3 fatty acids, vitamins D and E, carotenoids, iodine and selenium: a new natural multi-enriched egg. J. Nutr. Health Aging 10: 371-376 (2006).
Bourrie B, Bribes E, Derocq JM, Vidal H, Casellas P. Sigma receptor ligands: applications in inflammation and oncology. Curr. Opin. Investig. Drugs 5: 1158-1163 (2004).
Bouvier J, Zemski Berry KA, Hullin-Matsuda F, Makino A, Michaud S, Geloen A, Murphy RC, Kobayashi T, Lagarde M, Delton-Vandenbroucke I. Selective decrease of bis(monoacylglycero)phosphate content in macrophages by high supplementation with docosahexaenoic acid. J. Lipid Res. 50: 243-255 (2009). *
Bowden K, Ridgway ND. OSBP negatively regulates ABCA1 protein stability. J. Biol. Chem. 283: 18210-18217 (2008). *
Boyer JL. Nuclear receptor ligands: rational and effective therapy for chronic cholestatic liver disease? Gastroenterology 129: 735-740 (2005). *
Boyer JL. New perspectives for the treatment of cholestasis: lessons from basic science applied clinically. J. Hepatol. 46: 365-371 (2007). *
Boyle PJ. Diabetes mellitus and macrovascular disease: mechanisms and mediators. Am. J. Med. 120: S12-S17 (2007). *
Bradley MN, Hong C, Chen M, Joseph SB, Wilpitz DC, Wang X, Lusis AJ, Collins A, Hseuh WA, Collins JL, Tangirala RK, Tontonoz P. Ligand activation of LXRbeta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXRalpha and apoE. J. Clin. Invest. 117: 2337-2346 (2007). *
Braeckman L, De Bacquer D, Delanghe J, Claeys L, De Backer G. Associations between haptoglobin polymorphism, lipids, lipoproteins and inflammatory variables. Atherosclerosis 143: 383-388 (1999).
Braga MF, Grace MG, Lenis J, Kennedy FP, Teplinsky AL, Roederer G, Palumbo PJ, Colin P, Leiter LA. Efficacy and safety of ursodeoxycholic acid in primary, type IIa or IIb hypercholesterolemia: a multicenter, randomized, double-blind clinical trial. Atherosclerosis 203: 479-482 (2009).
Brailski Kh, Damianov B. Primary biliary cirrhosis. Vutr. Boles. 22: 27-37 (1983).
Bramlett KS, Yao S, Burris TP. Correlation of farnesoid X receptor coactivator recruitment and cholesterol 7alpha-hydroxylase gene repression by bile acids. Mol. Genet. Metab. 71: 609-615 (2000). *
Branten AJ, Swinkels DW, Klasen IS, Wetzels JF. Serum ferritin levels are increased in patients with glomerular diseases and proteinuria. Nephrol. Dial. Transplant. 19: 2754-2760 (2004). *
Brar P, Kwon GY, Holleran S, Bai D, Tall AR, Ramakrishnan R, Green PH. Change in lipid profile in celiac disease: beneficial effect of gluten-free diet. Am. J. Med. 119: 786-790 (2006). *
Braun N, Wade N, Wakeland E, Major A. Accelerated atherosclerosis is independent of feeding high fat diet in systemic lupus erythematosus-susceptible LDLr-/- mice. Lupus 17: 1070-1078 (2008).
Bravo E, Napolitano M, Lopez-Soldado I, Valeri M, Botham KM, Stefanutti C. Hypercholesterolaemia alters the responses of the plasma lipid profile and inflammatory markers to supplementation of the diet with n-3 polyunsaturated fatty acids from fish oil. Eur. J. Clin. Invest. 36: 788-795 (2006). *
Bravo I, Amigo L, Cohen DE, Nervi F, Rigotti A, Francone O, Zanlungo S. Role of plasma and liver cholesterol- and lipoprotein-metabolism determinants in LpX formation in the mouse. Biochim. Biophys. Acta 1770: 979-988 (2007). *
Brenol CV, Monticielo OA, Xavier RM, Brenol JC. Rheumatoid arthritis and atherosclerosis. Rev. Assoc. Med. Bras. 53: 465-470 (2007).
Brewer HB Jr, Santamarina-Fojo S. New insights into the role of the adenosine triphosphate-binding cassette transporters in high-density lipoprotein metabolism and reverse cholesterol transport. Am. J. Cardiol. 91: 3E-11E (2003). *
Brock JW, Jenkins AJ, Lyons TJ, Klein RL, Yim E, Lopes-Virella M, Carter RE, Thorpe SR, Baynes JW. Increased methionine sulfoxide content of ApoAI in type 1 diabetes. J. Lipid Res. 49: 847-855 (2008). *
Brousseau ME. Statins, super-statins and cholesterol absorption inhibitors. IDrugs 6: 458-463 (2003).
Brousseau ME. ATP-binding cassette transporter A1, fatty acids, and cholesterol absorption. Curr. Opin. Lipidol. 14: 35-40 (2003).
Brousseau ME, Hoeg JM. Transgenic rabbits as models for atherosclerosis research. J. Lipid Res. 40: 365-375 (1999). *
Brousseau ME, Schaefer EJ. New targets for medical treatment of lipid disorders. Curr. Atheroscler. Rep. 4: 343-349 (2002).
Brousseau ME, Schaefer EJ, Dupuis J, Eustace B, Van Eerdewegh P, Goldkamp AL, Thurston LM, FitzGerald MG, Yasek-McKenna D, O'Neill G, Eberhart GP, Weiffenbach B, Ordovas JM, Freeman MW, Brown RH Jr, Gu JZ. Novel mutations in the gene encoding ATP-binding cassette 1 in four tangier disease kindreds. J. Lipid Res. 41: 433-441 (2000). *
Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N. Engl. J. Med. 350: 1505-1515 (2004). *
Brouwers A, Langlois M, Delanghe J, Billiet J, De Buyzere M, Vercaemst R, Rietzschel E, Bernard D, Blaton V. Oxidized low-density lipoprotein, iron stores, and haptoglobin polymorphism. Atherosclerosis 176: 189-195 (2004).
Brown J, Theisler C, Silberman S, Magnuson D, Gottardi-Littell N, Lee JM, Yager D, Crowley J, Sambamurti K, Rahman MM, Reiss AB, Eckman CB, Wolozin B. Differential expression of cholesterol hydroxylases in Alzheimer's disease. J. Biol. Chem. 279: 34674-34681 (2004). *
Bruemmer D, Law RE. Liver X receptors: potential novel targets in cardiovascular diseases. Curr. Drug Targets Cardiovasc. Haematol. Disord. 5: 533-540 (2005).
Bruinsma KA, Taren DL. Dieting, essential fatty acid intake, and depression. Nutr. Rev. 58: 98-108 (2000).
Brumeanu TD, Goldstein R, Casares S. Down-regulation of autoreactive T-cells by HMG CoA reductase inhibitors. Clin. Immunol. 119: 1-12 (2006). *
Brunham LR, Kastelein JJ, Hayden MR. ABCA1 gene mutations, HDL cholesterol levels, and risk of ischemic heart disease. JAMA 300: 1997-1998 (2008). *
Brunham LR, Kruit JK, Iqbal J, Fievet C, Timmins JM, Pape TD, Coburn BA, Bissada N, Staels B, Groen AK, Hussain MM, Parks JS, Kuipers F, Hayden MR. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J. Clin. Invest. 116: 1052-1062 (2006). *
Brunham LR, Kruit JK, Pape TD, Parks JS, Kuipers F, Hayden MR. Tissue-specific induction of intestinal ABCA1 expression with a liver X receptor agonist raises plasma HDL cholesterol levels. Circ. Res. 99: 672-674 (2006). *
Brunham LR, Kruit JK, Pape TD, Timmins JM, Reuwer AQ, Vasanji Z, Marsh BJ, Rodrigues B, Johnson JD, Parks JS, Verchere CB, Hayden MR. beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat. Med. 13: 340-347 (2007). *
Brunham LR, Singaraja RR, Pape TD, Kejariwal A, Thomas PD, Hayden MR. Accurate prediction of the functional significance of single nucleotide polymorphisms and mutations in the ABCA1 gene. PLoS Genet. 1: e83 (2005). *
Brunner J, Parhofer KG, Schwandt P, Bronisch T. Cholesterol, essential fatty acids, and suicide. Pharmacopsychiatry 35: 1-5 (2002).
Brunser O, Gotteland M, Cruchet S. Functional fermented milk products. Nestle Nutr. Workshop Ser. Pediatr. Program 60: 235-250 (2007).
Brydges S, Kastner DL. The systemic autoinflammatory diseases: inborn errors of the innate immune system. Curr. Top. Microbiol. Immunol. 305: 127-160 (2006).
Bryhn M, Hansteen H, Schanche T, Aakre SE. The bioavailability and pharmacodynamics of different concentrations of omega-3 acid ethyl esters. Prostaglandins Leukot. Essent. Fatty Acids 75: 19-24 (2006). *
Buch S, Schafmayer C, Volzke H, Becker C, Franke A, von Eller-Eberstein H, Kluck C, Bassmann I, Brosch M, Lammert F, Miquel JF, Nervi F, Wittig M, Rosskopf D, Timm B, Holl C, Seeger M, Elsharawy A, Lu T, Egberts J, Fandrich F, Folsch UR, Krawczak M, et al. A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease. Nat. Genet. 39: 995-999 (2007). *
Buckles DC, Lindor KD, Larusso NF, Petrovic LM, Gores GJ. In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. Am. J. Gastroenterol. 97: 1138-1142 (2002). *
Buettner C, Phillips RS, Davis RB, Gardiner P, Mittleman MA. Use of dietary supplements among United States adults with coronary artery disease and atherosclerotic risks. Am. J. Cardiol. 99: 661-666 (2007). *
Buis CI, Geuken E, Visser DS, Kuipers F, Haagsma EB, Verkade HJ, Porte RJ. Altered bile composition after liver transplantation is associated with the development of nonanastomotic biliary strictures. J. Hepatol. 50: 69-79 (2009). *
Bujold K, Rhainds D, Jossart C, Febbraio M, Marleau S, Ong H. CD36-mediated cholesterol efflux is associated with PPARgamma activation via a MAPK-dependent COX-2 pathway in macrophages. Cardiovasc. Res. Apr 17 [Epub ahead of print] (2009). *
Bultel S, Helin L, Clavey V, Chinetti-Gbaguidi G, Rigamonti E, Colin M, Fruchart JC, Staels B, Lestavel S. Liver X receptor activation induces the uptake of cholesteryl esters from high density lipoproteins in primary human macrophages. Arterioscler. Thromb. Vasc. Biol. 28: 2288-2295 (2008).
Buono C, Li Y, Waldo SW, Kruth HS. Liver X receptors inhibit human monocyte-derived macrophage foam cell formation by inhibiting fluid-phase pinocytosis of LDL. J. Lipid Res. 48: 2411-2418 (2007). *
Buraczynska M, Jozwiak L, Ksiazek P, Borowicz E, Mierzicki P. Interleukin-6 gene polymorphism and faster progression to end-stage renal failure in chronic glomerulonephritis. Transl. Res. 150: 101-105 (2007). *
Buraczynska M, Swatowski A, Buraczynska K, Dragan M, Ksiazek A. Heat-shock protein gene polymorphisms and the risk of nephropathy in type 2 diabetes patients. Clin. Sci. (Lond.) 116: 81-86 (2009).
Burgess BL, Parkinson PF, Racke MM, Hirsch-Reinshagen V, Fan J, Wong C, Stukas S, Theroux L, Chan JY, Donkin J, Wilkinson A, Balik D, Christie B, Poirier J, Lutjohann D, Demattos RB, Wellington CL. ABCG1 influences brain cholesterol synthesis but does not affect amyloid precursor protein or apolipoprotein E metabolism in vivo. J. Lipid Res. 49: 1254-1267 (2008). *
Burgess JW, Neville TA, Rouillard P, Harder Z, Beanlands DS, Sparks DL. Phosphatidylinositol raises HDL-C levels in humans. J. Lipid Res. 46: 350-355 (2005). *
Burke KT, Horn PS, Tso P, Heubi JE, Woollett LA. Hepatic bile acid metabolism in the neonatal hamster: expansion of the bile acid pool parallels increased Cyp7a1 expression levels. Am. J. Physiol. Gastrointest. Liver Physiol. Apr 23 [Epub ahead of print] (2009).
Burnett JR, Huff MW. Cholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemia. Expert Opin. Investig. Drugs 15: 1337-1351 (2006).
Burns MP, Vardanian L, Pajoohesh-Ganji A, Wang L, Cooper M, Harris DC, Duff K, Rebeck GW. The effects of ABCA1 on cholesterol efflux and Abeta levels in vitro and in vivo. J. Neurochem. 98: 792-800 (2006). *
Burns T, Maciejewski SR, Hamilton WR, Zheng M, Mooss AN, Hilleman DE. Effect of omega-3 fatty acid supplementation on the arachidonic acid:eicosapentaenoic acid ratio. Pharmacotherapy 27: 633-638 (2007).
Burris TP, Eacho PI, Cao G. Genetic disorders associated with ATP binding cassette cholesterol transporters. Mol. Genet. Metab. 77: 13-20 (2002). *
Buse JB, Rubin CJ, Frederich R, Viraswami-Appanna K, Lin KC, Montoro R, Shockey G, Davidson JA. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. Clin. Ther. 27: 1181-1195 (2005). *
Buters JT, Zysset T, Reichen J. Metabolism of antipyrine in vivo in two rat models of liver cirrhosis. Its relationship to intrinsic clearance in vitro and microsomal membrane lipid composition. Biochem. Pharmacol. 46: 983-991 (1993).
Butt MS, Tahir-Nadeem M, Khan MK, Shabir R, Butt MS. Oat: unique among the cereals. Eur. J. Nutr. 47: 68-79 (2008). *
Buysschaert M, Tomasi JP, Hermans MP. Prospective screening for biopsy proven coeliac disease, autoimmunity and malabsorption markers in Belgian subjects with type 1 diabetes. Diabet. Med. 22: 889-892 (2005). *
Byrd-Bredbenner C, Abbot JM. Differences in food supplies of U.S. households with and without overweight individuals. Appetite 52: 479-484 (2009).
Caamano JM, Pacheco A, Lanas F, Salazar LA. Single nucleotide polymorphisms in ABCG5 and ABCG8 genes in Chilean subjects with polygenic hypercholesterolemia and controls. Clin. Chem. Lab. Med. 46: 1581-1585 (2008). *
Caballeria L, Pares A, Rodes J. Treatment of primary biliary cirrhosis. Contributions to Science 1: 79-85 (1999). *
Cabezas Gelabert R. Effect of ursodeoxycholic acid combined with statins in hypercholesterolemia treatment: a prospective clinical trial. Rev. Clin. Esp. 204: 632-635 (2004).
Cable EE, Finn PD, Stebbins JW, Hou J, Ito BR, van Poelje PD, Linemeyer DL, Erion MD. Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist. Hepatology 49: 407-417 (2009).
Cabrero A, Cubero M, Llaverias G, Alegret M, Sanchez R, Laguna JC, Vazquez-Carrera M. Leptin down-regulates peroxisome proliferator-activated receptor gamma (PPAR-gamma) mRNA levels in primary human monocyte-derived macrophages. Mol. Cell. Biochem. 275: 173-179 (2005). *
Cabrero A, Cubero M, Llaverias G, Jove M, Planavila A, Alegret M, Sanchez R, Laguna JC, Carrera MV. Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages. Metabolism 52: 652-657 (2003). *
Calayir E, M T, Kratzer BA, Ebner B, Panzenbock U, Stefujl J, Kostner GM. LXR-agonists regulate ApoM expression differentially in liver and intestine. Curr. Pharm. Biotechnol. 9: 516-521 (2008).
Calkin AC, Allen TJ, Lassila M, Tikellis C, Jandeleit-Dahm KA, Thomas MC. Increased atherosclerosis following treatment with a dual PPAR agonist in the ApoE knockout mouse. Atherosclerosis 195: 17-22 (2007).
Calpe-Berdiel L, Escola-Gil JC, Blanco-Vaca F. New insights into the molecular actions of plant sterols and stanols in cholesterol metabolism. Atherosclerosis 203: 18-31 (2009).
Calpe-Berdiel L, Rotllan N, Fievet C, Roig R, Blanco-Vaca F, Escola-Gil JC. Liver X receptor-mediated activation of reverse cholesterol transport from macrophages to feces in vivo requires ATP-binding cassette (ABC) G5/G8. J. Lipid Res. 49: 1904-1911 (2008). *
Campana G, Pasini P, Roda A, Spampinato S. Regulation of ileal bile acid-binding protein expression in Caco-2 cells by ursodeoxycholic acid: role of the farnesoid X receptor. Biochem. Pharmacol. 69: 1755-1763 (2005). *
Campbell IW. The clinical significance of PPAR gamma agonism. Curr. Mol. Med. 5: 349-363 (2005).
Canales A, Bastida S, Librelottto J, Nus M, Sanchez-Muniz FJ, Benedi J. Platelet aggregation, eicosanoid production and thrombogenic ratio in individuals at high cardiovascular risk consuming meat enriched in walnut paste. A crossover, placebo-controlled study. Br. J. Nutr. Dec 10 [Epub ahead of print] (2008). *
Canani LH, Capp C, Ng DP, Choo SG, Maia AL, Nabinger GB, Santos K, Crispim D, Roisemberg I, Krolewski AS, Gross JL. The fatty acid-binding protein-2 A54T polymorphism is associated with renal disease in patients with type 2 diabetes. Diabetes 54: 3326-3330 (2005). *
Caniato RN, Alvarenga ME, Garcia-Alcaraz MA. Effect of omega-3 fatty acids on the lipid profile of patients taking clozapine. Aust. N. Z. J. Psychiatry 40: 691-697 (2006). *
Canton RF, Peijnenburg AA, Hoogenboom RL, Piersma AH, van der Ven LT, van den Berg M, Heneweer M. Subacute effects of hexabromocyclododecane (HBCD) on hepatic gene expression profiles in rats. Toxicol. Appl. Pharmacol. 231: 267-272 (2008). *
Cantwell MM, Flynn MA, Gibney MJ. Acute postprandial effect of hydrogenated fish oil, palm oil and lard on plasma cholesterol, triacylglycerol and non-esterified fatty acid metabolism in normocholesterolaemic males. Br. J. Nutr. 95: 787-794 (2006). *
Cao F, Castrillo A, Tontonoz P, Re F, Byrne GI. Chlamydia pneumoniae-induced macrophage foam cell formation is mediated by Toll-like receptor 2. Infect. Immun. 75: 753-759 (2007). *
Cao G, Bales KR, Demattos RB, Paul SM. Liver X receptor-mediated gene regulation and cholesterol homeostasis in brain: relevance to Alzheimer's disease therapeutics. Curr. Alzheimer Res. 4: 179-184 (2007).
Cao G, Beyer TP, Yang XP, Schmidt RJ, Zhang Y, Bensch WR, Kauffman RF, Gao H, Ryan TP, Liang Y, Eacho PI, Jiang XC. Phospholipid transfer protein is regulated by liver X receptors in vivo. J. Biol. Chem. 277: 39561-39565 (2002). *
Cao G, Liang Y, Jiang XC, Eacho PI. Liver X receptors as potential therapeutic targets for multiple diseases. Drug News Perspect. 17: 35-41 (2004).
Cao WM, Murao K, Imachi H, Yu X, Dobashi H, Yoshida K, Muraoka T, Kotsuna N, Nagao S, Wong NC, Ishida T. Insulin like growth factor-I regulation of hepatic scavenger receptor class BI. Endocrinology 145: 5540-5547 (2004). *
Capell WH, Eckel RH. Severe hypertriglyceridemia with a history of treatment failure. Nat. Clin. Pract. Endocrinol. Metab. 1: 53-58 (2005). *
Capobianco E, Mart�nez N, Higa R, White V, Jawerbaum A. The effects of maternal dietary treatments with natural PPAR ligands on lipid metabolism in fetuses from control and diabetic rats. Prostaglandins Leukot. Essent. Fatty Acids 79: 191-199 (2008). *
Capristo E, Addolorato G, Mingrone G, Scarfone A, Greco AV, Gasbarrini G. Low-serum high-density lipoprotein-cholesterol concentration as a sign of celiac disease. Am. J. Gastroenterol. 95: 3331-3332 (2000). *
Cardona J, Houssin D, Gauthier F, Devictor D, Losay J, Hadchouel M, Bernard O. Liver transplantation in children with Alagille syndrome - a study of twelve cases. Transplantation 60: 339-342 (1995).
Carlson SE. Early determinants of development: a lipid perspective. Am. J. Clin. Nutr. 89: 1523S-1529S (2009).
Carmel JF, Tarnus E, Cohn JS, Bourdon E, Davignon J, Bernier L. High expression of apolipoprotein E impairs lipid storage and promotes cell proliferation in human adipocytes. J. Cell. Biochem. 106: 608-617 (2009). *
Carmena R, Betteridge DJ. Statins and diabetes. Semin. Vasc. Med. 4: 321-332 (2004).
Carpentier YA, Portois L, Malaisse WJ. n-3 Fatty acids and the metabolic syndrome. Am. J. Clin. Nutr. 83: 1499S-1504S (2006). *
Carrella M, Roda E. Evolving concepts in the pathophysiology of biliary lipid secretion. Ital. J. Gastroenterol. Hepatol. 31: 643-648 (1999).
Carrero JJ, Fonolla J, Marti JL, Jimenez J, Boza JJ, Lopez-Huertas E. Intake of fish oil, oleic acid, folic acid, and vitamins B-6 and E for 1 year decreases plasma C-reactive protein and reduces coronary heart disease risk factors in male patients in a cardiac rehabilitation program. J. Nutr. 137: 384-390 (2007). *
Carter CJ. Convergence of genes implicated in Alzheimer's disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis. Neurochem. Int. 50: 12-38 (2007).
Carter CJ. Interactions between the products of the Herpes simplex genome and Alzheimer's disease susceptibility genes: relevance to pathological-signalling cascades. Neurochem. Int. 52: 920-934 (2008).
Carulli N, Loria P, Bertolotti M, Ponz de Leon M, Menozzi D, Medici G, Piccagli I. Effects of acute changes of bile acid pool composition on biliary lipid secretion. J. Clin. Invest. 74: 614-624 (1984). *
Carulli N, Ponz de Leon M, Podda M, Zuin M, Strata A, Frigerio G, Digrisolo A. Chenodeoxycholic acid and ursodeoxycholic acid effects in endogenous hypertriglyceridemias. A controlled double-blind trial. J. Clin. Pharmacol. 21: 436-442 (1981).
Carulli N, Ponz De Leon M, Zironi F, Pinetti A, Smerieri A, Iori R, Loria P. Hepatic cholesterol and bile acid metabolism in subjects with gallstones: comparative effects of short term feeding of chenodeoxycholic and ursodeoxycholic acid. J. Lipid Res. 21: 35-43 (1980). *
Cases Amenos A, Goicoechea Diezhandino M, de Alvaro Moreno F. Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment. Nefrologia 28 Suppl. 3: 39-48 (2008).
Caslake MJ, Miles EA, Kofler BM, Lietz G, Curtis P, Armah CK, Kimber AC, Grew JP, Farrell L, Stannard J, Napper FL, Sala-Vila A, West AL, Mathers JC, Packard C, Williams CM, Calder PC, Minihane AM. Effect of sex and genotype on cardiovascular biomarker response to fish oils: the FINGEN study. Am. J. Clin. Nutr. 88: 618-629 (2008). *
Casos K, Saiz MP, Ruiz-Sanz JI, Mitjavila MT. Atherosclerosis prevention by a fish oil-rich diet in apoE(-/-) mice is associated with a reduction of endothelial adhesion molecules. Atherosclerosis 201: 306-317 (2008).
Castano G, Fernandez L, Mas R, Illnait J, Mesa M, Fernandez JC. Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation in patients with dyslipidaemia and type 2 diabetes mellitus. Clin. Drug Investig. 23: 639-650 (2003).
Castellote J, Ariza J, Rota R, Girbau A, Xiol X. Serious drug-induced liver disease secondary to ezetimibe. World J. Gastroenterol. 14: 5098-5099 (2008). *
Castrillo A, Joseph SB, Vaidya SA, Haberland M, Fogelman AM, Cheng G, Tontonoz P. Crosstalk between LXR and Toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol. Cell. 12: 805-816 (2003). *
Castro IA, Monteiro VC, Barroso LP, Bertolami MC. Effect of eicosapentaenoic/docosahexaenoic fatty acids and soluble fibers on blood lipids of individuals classified into different levels of lipidemia. Nutrition 23: 127-137 (2007). *
Castro J, Amigo L, Miquel JF, Galman C, Crovari F, Raddatz A, Zanlungo S, Jalil R, Rudling M, Nervi F. Increased activity of hepatic microsomal triglyceride transfer protein and bile acid synthesis in gallstone disease. Hepatology 45: 1261-1266 (2007). *
Catakoglu AB, Duman BS, Kurtoglu H, Ersoz M, Sener M, Celebi H, Cagatay P, Aytekin V, Aytekin S. Common variants in the ATP-binding cassette transporter 1 gene with decreased HDL-cholesterol levels and coronary artery disease. Arch. Med. Res. 39: 735-742 (2008).
Cavelier C, Lorenzi I, Rohrer L, von Eckardstein A. Lipid efflux by the ATP-binding cassette transporters ABCA1 and ABCG1. Biochim. Biophys. Acta 1761: 655-666 (2006). *
Cavelier LB, Qiu Y, Bielicki JK, Afzal V, Cheng JF, Rubin EM. Regulation and activity of the human ABCA1 gene in transgenic mice. J. Biol. Chem. 276: 18046-18051 (2001). *
Cazzola R, Russo-Volpe S, Miles EA, Rees D, Banerjee T, Roynette CE, Wells SJ, Goua M, Wahle KW, Calder PC, Cestaro B. Age- and dose-dependent effects of an eicosapentaenoic acid-rich oil on cardiovascular risk factors in healthy male subjects. Atherosclerosis 193: 159-167 (2007).
Celik S, Doesch A, Erbel C, Blessing E, Ammon K, Koch A, Katus HA, Dengler TJ. Beneficial effect of omega-3 fatty acids on sirolimus- or everolimus-induced hypertriglyceridemia in heart transplant recipients. Transplantation 86: 245-250 (2008).
Celinska-Lowenhoff M, Undas A. Nonlipid effects of fibrates. Przegl. Lek. 61: 99-101 (2004).
Cerf E, Gasper R, Rychnovsky S, Chang XB, Buyse F, Ruysschaert JM. Multidrug resistance protein 1 is not associated to detergent-resistant membranes. Biochem. Biophys. Res. Commun. 355: 1025-1030 (2007). *
Cerkauskiene R, Kaminskas A, Kaltenis P, Vitkus D. Influence of omega-3 fatty acids on lipid metabolism in children with steroid sensitive nephrotic syndrome. Medicina (Kaunas) 39 Suppl. 1: 82-87 (2003).
Ceryak S, Bouscarel B, Malavolti M, Robins SJ, Caslow KL, Fromm H. Effect of ursodeoxycholic acid on hepatic LDL binding and uptake in dietary hypercholesterolemic hamsters. Atherosclerosis 153: 59-67 (2000).
Cha JY, Repa JJ. The liver X receptor and hepatic lipogenesis: the carbohydrate-response element binding protein is a target gene of LXR. J. Biol. Chem. 282: 743-751 (2007). *
Chakravarthy MV, Pan Z, Zhu Y, Tordjman K, Schneider JG, Coleman T, Turk J, Semenkovich CF. "New" hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis. Cell. Metab. 1: 309-322 (2005). *
Chan DC, Watts GF, Barrett PH, Whitfield AJ, Van Bockxmeer FM. ATP-binding cassette transporter G8 gene as a determinant of apolipoprotein B-100 kinetics in overweight men. Arterioscler. Thromb. Vasc. Biol. 24: 2188-2191 (2004). *
Chan DC, Watts GF, Nguyen MN, Barrett PH. Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity. Am. J. Clin. Nutr. 84: 37-43 (2006). *
Chan E, Tan CS, Deurenberg-Yap M, Chia KS, Chew SK, Tai ES. The V227A polymorphism at the PPARA locus is associated with serum lipid concentrations and modulates the association between dietary polyunsaturated fatty acid intake and serum high density lipoprotein concentrations in Chinese women. Atherosclerosis 187: 309-315 (2006).
Chang CL, Seo T, Matsuzaki M, Worgall TS, Deckelbaum RJ. n-3 Fatty acids reduce arterial LDL-cholesterol delivery and arterial lipoprotein lipase levels and lipase distribution. Arterioscler. Thromb. Vasc. Biol. 29: 555-561 (2009).
Chang F, Jaber LA, Berlie HD, O'Connell MB. Evolution of peroxisome proliferator-activated receptor agonists. Ann. Pharmacother. 41: 973-983 (2007).
Chang HH, Chen CS, Lin JY. Dietary perilla oil lowers serum lipids and ovalbumin-specific IgG1, but increases total IgE levels in ovalbumin-challenged mice. Food Chem. Toxicol. 47: 848-854 (2009).
Chang PY, Lu SC, Su TC, Chou SF, Huang WH, Morrisett JD, Chen CH, Liau CS, Lee YT. Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation. J. Lipid Res. 45: 2116-2122 (2004). *
Chang SJ, Tsai PC, Chen CJ, Lai HM, Ko YC. The polymorphism -863C/A in tumour necrosis factor-alpha gene contributes an independent association to gout. Rheumatology (Oxford) 46: 1662-1666 (2007). *
Chapidze G E, Kapanadze SD, Dolidze NK, Latsabidze NE, Bakhutashvili ZV. Combination treatment with coenzyme Q10 and simvastatin in patients with coronary atherosclerosis. Kardiologiia 46: 11-13 (2006).
Chapkin RS, McMurray DN, Davidson LA, Patil BS, Fan YY, Lupton JR. Bioactive dietary long-chain fatty acids: emerging mechanisms of action. Br. J. Nutr. 100: 1152-1157 (2008). *
Chapkin RS, Wang N, Fan YY, Lupton JR, Prior IA. Docosahexaenoic acid alters the size and distribution of cell surface microdomains. Biochim. Biophys. Acta 1778: 466-471 (2008). *
Chapman C, Morgan LM, Murphy MC. Maternal and early dietary fatty acid intake: changes in lipid metabolism and liver enzymes in adult rats. J. Nutr. 130: 146-151 (2000). *
Charoensit P, Kawakami S, Higuchi Y, Hashida M. Incorporation of all-trans retinoic acid into lipoplexes inhibits nuclear factor kappaB activation mediated liver injury induced by lipoplexes in mice. J. Gene Med. 10: 61-69 (2008). *
Chatterjee B, Echchgadda I, Song CS. Vitamin D receptor regulation of the steroid/bile acid sulfotransferase SULT2A1. Methods Enzymol. 400: 165-191 (2005).
Chavarro JE, Rich-Edwards JW, Rosner BA, Willett WC. Dietary fatty acid intakes and the risk of ovulatory infertility. Am. J. Clin. Nutr. 85: 231-237 (2007). *
Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. Nuclear receptors and lipid physiology: opening the X-files. Science 294: 1866-1870 (2001). *
Chechi K, Cheema SK. Maternal diet rich in saturated fats has deleterious effects on plasma lipids of mice. Exp. Clin. Cardol. 11: 129-135 (2006). *
Cheema SK, Agarwal-Mawal A, Murray CM, Tucker S. Lack of stimulation of cholesterol ester transfer protein by cholesterol in the presence of a diet high in monounsaturated fatty acids. J. Lipid Res. 46: 2356-2366 (2005). *
Chen BC, Kuo KK, Chen YH, Liu CH, Tsai LY, Hsu HK, Hsu C. Retinoid X receptor alpha participation in dexamethasone induced rat bile acid coenzyme A-amino acid N-acyltransferase expression in septic liver. Shock Nov 11 [Epub ahead of print] (2008).
Chen J, Raymond K. Treatment effect of rifampicin on cholestasis. The Internet Journal of Pharmacology Vol. 4 (http://www.ispub.com/ostia/index.php?xmlFilePath=journals/ijpharm/vol4n2/colestasis.xml) (2006). *
Chen M, Li W, Wang N, Zhu Y, Wang X. ROS and NF-kappaB but not LXR mediate IL-1beta signaling for the downregulation of ATP-binding cassette transporter A1. Am. J. Physiol. Cell Physiol. 292: C1493-C1501 (2007). *
Chen S, Li Y, Li S, Yu C. A Val227Ala substitution in the peroxisome proliferator activated receptor alpha (PPAR alpha) gene associated with non-alcoholic fatty liver disease and decreased waist circumference and waist-to-hip ratio. J. Gastroenterol. Hepatol. 23: 1415-1418 (2008). *
Chen S, Sorrentino R, Shimada K, Bulut Y, Doherty TM, Crother TR, Arditi M. Chlamydia pneumoniae-induced foam cell formation requires MyD88-dependent and -independent signaling and is reciprocally modulated by liver X receptor activation. J. Immunol. 181: 7186-7193 (2008).
Chen SJ, Rader DJ, Tazelaar J, Kawashiri M, Gao G, Wilson JM. Prolonged correction of hyperlipidemia in mice with familial hypercholesterolemia using an adeno-associated viral vector expressing very-low-density lipoprotein receptor. Mol. Ther. 2: 256-261 (2000).
Chen W, Chiang JY. Regulation of human sterol 27-hydroxylase gene (CYP27A1) by bile acids and hepatocyte nuclear factor 4alpha (HNF4alpha). Gene 313: 71-82 (2003). *
Chen W, Gluud C. Bile acids for liver transplanted patients. Cochrane Database Syst. Rev. 2: CD004384 (2004). *
Chen W, Jump DB, Esselman WJ, Busik JV. Inhibition of cytokine signaling in human retinal endothelial cells through modification of caveolae/lipid rafts by docosahexaenoic acid. Invest. Ophthalmol. Vis. Sci. 48: 18-26 (2007). *
Chen W, Owsley E, Yang Y, Stroup D, Chiang JY. Nuclear receptor-mediated repression of human cholesterol 7alpha-hydroxylase gene transcription by bile acids. J. Lipid Res. 42: 1402-1412 (2001). *
Chen X, Matthews J, Zhou L, Pelton P, Liang Y, Xu J, Yang M, Cryan E, Rybczynski P, Demarest K. Improvement of dyslipidemia, insulin sensitivity, and energy balance by a peroxisome proliferator-activated receptor alpha agonist. Metabolism 57: 1516-1525 (2008). *
Chen Y, Thelin WR, Yang B, Milgram SL, Jacobson K. Transient anchorage of cross-linked glycosyl-phosphatidylinositol-anchored proteins depends on cholesterol, Src family kinases, caveolin, and phosphoinositides. J. Cell Biol. 175: 169-178 (2006). *
Chen YJ, Wu CY, Shen JL, Chu SY, Chen CK, Chang YT, Chen CM. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch. Dermatol. 144: 1571-1575 (2008). *
Chen ZC, Shin SJ, Kuo KK, Lin KD, Yu ML, Hsiao PJ. Significant association of ABCG8:D19H gene polymorphism with hypercholesterolemia and insulin resistance. J. Hum. Genet. 53: 757-763 (2008). *
Chen ZQ, Annilo T, Shulenin S, Dean M. Three ATP-binding cassette transporter genes, Abca14, Abca15, and Abca16, form a cluster on mouse chromosome 7F3. Mamm. Genome 15: 335-343 (2004). *
Cheng AY, Leiter LA. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Curr. Opin. Cardiol. 21: 400-404 (2006).
Cheng D, Kim WS, Garner B. Regulation of alpha-synuclein expression by liver X receptor ligands in vitro. Neuroreport 19: 1685-1689 (2008).
Cheng HH, Hu XJ, Ruan QR. Dehydroepiandrosterone anti-atherogenesis effect is not via its conversion to estrogen. Acta Pharmacol. Sin. 30: 42-53 (2009).
Cheng JB, Motola DL, Levine MA, Bell NH, Mangelsdorf DJ, Russell DW. Identification and characterization of CYP2R1, a microsomal vitamin D 25-hydroxylase. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 21. June 18-19 (2004). *
Cheng JB, Jacquemin E, Gerhardt M, Nazer H, Cresteil D, Heubi JE, Setchell KD, Russell DW. Molecular genetics of 3beta-hydroxy-Delta5-C27-steroid oxidoreductase deficiency in 16 patients with loss of bile acid synthesis and liver disease. J. Clin. Endocrinol. Metab. 88: 1833-1841 (2003). *
Cheng JF, Zapf J, Takedomi K, Fukushima C, Ogiku T, Zhang SH, Yang G, Sakurai N, Barbosa M, Jack R, Xu K. Combination of virtual screening and high throughput gene profiling for identification of novel liver X receptor modulators. J. Med. Chem. 51: 2057-2061 (2008). *
Chernev K, Bakalov V. Clinical-dispensary finding of patients with primary biliary cirrhosis. Vutr. Boles. 24: 42-46 (1985).
Chevailler A, Saint-Andre JP, Preel JL, Boyer J, Joubaud F, Hurez D. Clinico-immunological profile of hepatic and extrahepatic diseases accompanied by anti-mitochondrial antibodies. Ann. Med. Interne. (Paris) 139: 19-23 (1988).
Chianale J, Vollrath V, Wielandt AM, Amigo L, Rigotti A, Nervi F, Gonzalez S, Andrade L, Pizarro M, Accatino L. Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse. Biochem. J. 314: 781-786 (1996). *
Chiang JY. Bile acid regulation of gene expression: roles of nuclear hormone receptors. Endocr. Rev. 23: 443-463 (2002). *
Chiang JY. Regulation of bile acid synthesis. Front. Biosci. 3: d176-d193 (1998).
Chiang JY. Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms. J. Hepatol. 40: 539-551 (2004). *
Chiang JY. Bile acid regulation of hepatic physiology: III. Bile acids and nuclear receptors. Am. J. Physiol. Gastrointest. Liver Physiol. 284: G349-G356 (2003). *
Chiang JY. Bile acids: regulation of synthesis. J. Lipid Res. Apr 3 [Epub ahead of print] (2009). *
Chiang JY. Hepatocyte nuclear factor 4alpha regulation of bile acid and drug metabolism. Expert Opin. Drug Metab. Toxicol. 5: 137-147 (2009).
Chiang JY, Kimmel R, Stroup D. Regulation of cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription by the liver orphan receptor (LXRalpha). Gene 262: 257-265 (2001). *
Chiang JY, Kimmel R, Weinberger C, Stroup D. Farnesoid X receptor responds to bile acids and represses cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription. J. Biol. Chem. 275: 10918-10924 (2000). *
Chiang JYL, Li T, Jahan A. Mechanisms of bile acid inhibition of genes in bile acid synthesis. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 23. June 18-19 (2004). *
Chiarla C, Giovannini I, Giuliante F, Vellone M, Ardito F, Masi A, Nuzzo G. Plasma bilirubin correlations in non-obstructive cholestasis after partial hepatectomy. Clin. Chem. Lab. Med. 46: 1598-1601 (2008). *
Chiba H, Osaka T, Iwasaki N, Suzuki H, Akizawa K, Fujisawa S, Intoh S, Watanabe M, Yoshida J, Matsuno K, et al. Spurious elevation of serum high-density lipoprotein cholesterol in patients with cholestatic liver diseases. Biochem. Med. Metab. Biol. 46: 329-343 (1991).
Chinetti G, Fruchart JC, Staels B. Transcriptional regulation of macrophage cholesterol trafficking by PPARalpha and LXR. Biochem. Soc. Trans. 34: 1128-1131 (2006). *
Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and inflammation: from basic science to clinical applications. Int. J. Obes. Relat. Metab. Disord. 27 Suppl. 3: S41-S45 (2003).
Chinetti G, Zawadski C, Fruchart JC, Staels B. Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR. Biochem. Biophys. Res. Commun. 314: 151-158 (2004). *
Chinetti-Gbaguidi G, Rigamonti E, Helin L, Mutka AL, Lepore M, Fruchart JC, Clavey V, Ikonen E, Lestavel S, Staels B. Peroxisome proliferator-activated receptor-alpha controls cellular cholesterol trafficking in macrophages. J. Lipid Res. 46: 2717-2725 (2005). *
Chira EC, McMillen TS, Wang S, Haw A 3rd, O'Brien KD, Wight TN, Chait A. Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice. Atherosclerosis 195: 100-109 (2007).
Chitturi S, Farrell GC. Drug-induced cholestasis. Semin. Gastrointest. Dis. 12: 113-124 (2001).
Chiu HM, Lin JT, Shun CT, Liang JT, Lee YC, Huang SP, Wu MS. Association of metabolic syndrome with proximal and synchronous colorectal neoplasm. Clin. Gastroenterol. Hepatol. 5: 221-229 (2007).
Chiu IM, Chen A, Zheng Y, Kosaras B, Tsiftsoglou SA, Vartanian TK, Brown RH Jr, Carroll MC. T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc. Natl. Acad. Sci. U.S.A. 105: 17913-17918 (2008). *
Chiu WC, Wang YC, Chien YW, Hou YC, Hu YM, Yeh SL. Effects of dietary fish oil supplementation on cellular adhesion molecule expression and tissue myeloperoxidase activity in hypercholesterolemic mice with sepsis. J. Nutr. Biochem. 20: 254-260 (2009). *
Choe SS, Choi AH, Lee JW, Kim KH, Chung JJ, Park J, Lee KM, Park KG, Lee IK, Kim JB. Chronic activation of liver X receptor induces beta-cell apoptosis through hyperactivation of lipogenesis. Diabetes 56: 1534-1543 (2007). *
Choi BG, Vilahur G, Viles-Gonzalez JF, Badimon JJ. The role of high-density lipoprotein cholesterol in atherothrombosis. Mt. Sinai J. Med. 73: 690-701 (2006). *
Choi EM. Oxidative status of DBA/1J mice with type II collagen-induced arthritis. J. Appl. Toxicol. 27: 472-481 (2007). *
Choi J, Park JK, Lee KT, Park KK, Kim WB, Lee JH, Jung HJ, Park HJ. In vivo antihepatotoxic effects of Ligularia fischeri var. spiciformis and the identification of the active component, 3,4-dicaffeoylquinic acid. J. Med. Food 8: 348-352 (2005).
Chopra R, Sambaiah K. Effects of rice bran oil enriched with n-3 PUFA on liver and serum lipids in rats. Lipids 44: 37-46 (2009).
Chrencik JE, Orans J, Moore LB, Xue Y, Peng L, Collins JL, Wisely GB, Lambert MH, Kliewer SA, Redinbo MR. Structural disorder in the complex of human PXR and the macrolide antibiotic rifampicin. Mol. Endocrinol. 19: 1125-1134 (2005). *
Christenson LK, McAllister JM, Martin KO, Javitt NB, Osborne TF, Strauss JF 3rd. Oxysterol regulation of steroidogenic acute regulatory protein gene expression. Structural specificity and transcriptional and posttranscriptional actions. J. Biol. Chem. 273: 30729-30735 (1998). *
Chu K, Miyazaki M, Man WC, Ntambi JM. Stearoyl-coenzyme A desaturase 1 deficiency protects against hypertriglyceridemia and increases plasma high-density lipoprotein cholesterol induced by liver X receptor activation. Mol. Cell. Biol. 26: 6786-6798 (2006). *
Chung CP, Avalos I, Oeser A, Gebretsadik T, Shintani A, Raggi P, Stein CM. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann. Rheum. Dis. 66: 208-214 (2007). *
Chung CP, Oeser A, Solus J, Avalos I, Gebretsadik T, Shintani A, Linton MF, Fazio S, Stein CM. Inflammatory mechanisms affecting the lipid profile in patients with systemic lupus erythematosus. J. Rheumatol. 34: 1849-1854 (2007).
Chuu CP, Kokontis JM, Hiipakka RA, Liao S. Modulation of liver X receptor signaling as novel therapy for prostate cancer. J. Biomed. Sci. 14: 543-553 (2007). *
Ciacci C, Cirillo M, Cavallaro R, Mazzacca G. Long-term follow-up of celiac adults on gluten-free diet: prevalence and correlates of intestinal damage. Digestion 66: 178-185 (2002).
Cigliano L, Maresca B, Salvatore A, Nino M, Monfrecola G, Ayala F, Carlucci A, Pugliese RC, Pedone C, Abrescia P. Haptoglobin from psoriatic patients exhibits decreased activity in binding haemoglobin and inhibiting lecithin-cholesterol acyltransferase activity. J. Eur. Acad. Dermatol. Venereol. 22: 417-425 (2008). *
Cignarella A, Bellosta S, Corsini A, Bolego C. Hypolipidemic therapy for the metabolic syndrome. Pharmacol. Res. 53: 492-500 (2006). *
Cignarella A, Engel T, Eckardstein A, Kratz M, Lorkowski S, Lueken A, Assmann G, Cullen P. Pharmacological regulation of cholesterol efflux in human monocyte-derived macrophages in the absence of exogenous cholesterol acceptors. Atherosclerosis 179: 229-236 (2005).
Cindoruk M, Kerem M, Karakan T, Salman B, Akin O, Alper M, Erdem O, Unal S. Peroxisome proliferators-activated alpha agonist treatment ameliorates hepatic damage in rats with obstructive jaundice: an experimental study. BMC Gastroenterol. 7: 44 (2007). *
Clark E, Hoare C, Tanianis-Hughes J, Carlson GL, Warhurst G. Interferon gamma induces translocation of commensal Escherichia coli across gut epithelial cells via a lipid raft-mediated process. Gastroenterology 128: 1258-1267 (2005). *
Clark WF, Parbtani A, Huff MW, Reid B, Holub BJ, Falardeau P. Omega-3 fatty acid dietary supplementation in systemic lupus erythematosus. Kidney Int. 36: 653-660 (1989).
Clarke GA, Bouchard G, Paigen B, Carey MC. Cholesterol synthesis inhibition distal to squalene upregulates biliary phospholipid secretion and counteracts cholelithiasis in the genetically prone C57L/J mouse. Gut 53: 136-142 (2004). *
Clarke R, Shipley M, Armitage J, Collins R, Harris W. Plasma phospholipid fatty acids and CHD in older men: Whitehall study of London civil servants. Br. J. Nutr. Dec 24 [Epub ahead of print] (2008). *
Claudel T, Leibowitz MD, Fievet C, Tailleux A, Wagner B, Repa JJ, Torpier G, Lobaccaro JM, Paterniti JR, Mangelsdorf DJ, Heyman RA, Auwerx J. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc. Natl. Acad. Sci. U.S.A. 98: 2610-2615 (2001). *
Claudel T, Staels B, Kuipers F. The farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler. Thromb. Vasc. Biol. 25: 2020-2030 (2005). *
Claudel T, Sturm E, Kuipers F, Staels B. The farnesoid X receptor: a novel drug target? Expert Opin. Investig. Drugs 13: 1135-1148 (2004).
Clayton PT. Inborn errors of bile acid metabolism. J. Inherit. Metab. Dis. 14: 478-496 (1991).
Clayton PT. Hereditary liver diseases: screening strategies. Falk Symposium 156. XIII Falk Liver Week (Part II). GENETICS IN LIVER DISEASES, Freiburg (Germany), October 8-9, 2006, p. 42-43 (2006). *
Clayton PT, Mills KA, Johnson AW, Barabino A, Marazzi MG. Delta 4-3-oxosteroid 5 beta-reductase deficiency: failure of ursodeoxycholic acid treatment and response to chenodeoxycholic acid plus cholic acid. Gut 38: 623-628 (1996). *
Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, Hobbs HH. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 305: 869-872 (2004). *
Cohen LB, Ambinder EP, Wolke AM, Field SP, Schaffner F. Role of plasmapheresis in primary biliary cirrhosis. Gut 26: 291-294 (1985). *
Cohran VC, Heubi JE. Treatment of pediatric cholestatic liver disease. Curr. Treat. Options Gastroenterol. 6: 403-415 (2003).
Colecchia A, Larocca A, Scaioli E, Bacchi-Reggiani ML, Di Biase AR, Azzaroli F, Gualandi R, Simoni P, Vestito A, Festi D. Natural history of small gallbladder polyps is benign: evidence from a clinical and pathogenetic study. Am. J. Gastroenterol. 104: 624-629 (2009).
Colecchia A, Mazzella G, Sandri L, Azzaroli F, Magliuolo M, Simoni P, Bacchi-Reggiani ML, Roda E, Festi D. Ursodeoxycholic acid improves gastrointestinal motility defects in gallstone patients. World J. Gastroenterol. 12: 5336-5343 (2006). *
Colin A, Reggers J, Castronovo V, Ansseau M. Lipids, depression and suicide. Encephale 29: 49-58 (2003).
Colin S, Bourguignon E, Boullay AB, Tousaint JJ, Huet S, Caira F, Staels B, Lestavel S, Lobaccaro JM, Delerive P. Intestine-specific regulation of PPARalpha gene transcription by liver X receptors. Endocrinology 149: 5128-5135 (2008). *
Collet-Gaudillat C, Billon-Bancel A, Beressi JP. Long-term improvement of metabolic control with pioglitazone in a woman with diabetes mellitus related to Dunnigan syndrome: a case report. Diabetes Metab. 35: 151-154 (2009).
Collins JL. Therapeutic opportunities for liver X receptor modulators. Curr. Opin. Drug Discov. Devel. 7: 692-702 (2004).
Collins JL, Fivush AM, Watson MA, Galardi CM, Lewis MC, Moore LB, Parks DJ, Wilson JG, Tippin TK, Binz JG, Plunket KD, Morgan DG, Beaudet EJ, Whitney KD, Kliewer SA, Willson TM. Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. J. Med. Chem. 45: 1963-1966 (2002). *
Conchillo A, Valencia I, Puente A, Ansorena D, Astiasaran I. Functional components in fish and algae oils. Nutr. Hosp. 21: 369-373 (2006).
Conklin SM, Harris JI, Manuck SB, Yao JK, Hibbeln JR, Muldoon MF. Serum omega-3 fatty acids are associated with variation in mood, personality and behavior in hypercholesterolemic community volunteers. Psychiatry Res. 152: 1-10 (2007).
Conklin SM, Manuck SB, Yao JK, Flory JD, Hibbeln JR, Muldoon MF. High omega-6 and low omega-3 fatty acids are associated with depressive symptoms and neuroticism. Psychosom. Med. 69: 932-934 (2007).
Cooper AD, Craig WY, Taniguchi T, Everson GT. Characteristics and regulation of bile salt synthesis and secretion by human hepatoma HepG2 cells. Hepatology 20: 1522-1531 (1994).
Corey DA, Kelley TJ. Elevated small GTPase activation influences the cell proliferation signaling control in Niemann-Pick type C fibroblasts. Biochim. Biophys. Acta 1772: 748-754 (2007). *
Cornick CL, Strongitharm BH, Sassano G, Rawlins C, Mayes AE, Joseph AN, O'Dowd J, Stocker C, Wargent E, Cawthorne MA, Brown AL, Arch JR. Identification of a novel agonist of peroxisome proliferator-activated receptors alpha and gamma that may contribute to the anti-diabetic activity of guggulipid in Lep(ob)/Lep(ob) mice. J. Nutr. Biochem. Oct 14 [Epub ahead of print] (2008). *
Cornwell PD, De Souza AT, Ulrich RG. Profiling of hepatic gene expression in rats treated with fibric acid analogs. Mutat. Res. 549: 131-145 (2004).
Corradini SG, Elisei W, Giovannelli L, Ripani C, Della Guardia P, Corsi A, Cantafora A, Capocaccia L, Ziparo V, Stipa V, Chirletti P, Caronna R, Lomanto D, Attili AF. Impaired human gallbladder lipid absorption in cholesterol gallstone disease and its effect on cholesterol solubility in bile. Gastroenterology 118: 912-920 (2000). *
Costenbader KH, Liang MH, Chibnik LB, Aizer J, Kwon H, Gall V, Karlson EW. A pravastatin dose-escalation study in systemic lupus erythematosus. Rheumatol. Int. 27: 1071-1077 (2007). *
Costet P, Cariou B, Lambert G, Lalanne F, Lardeux B, Jarnoux AL, Grefhorst A, Staels B, Krempf M. Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory-element binding protein 1c. J. Biol. Chem. 281: 6211-6218 (2006). *
Costet P, Lalanne F, Gerbod-Giannone MC, Molina JR, Fu X, Lund EG, Gudas LJ, Tall AR. Retinoic acid receptor-mediated induction of ABCA1 in macrophages. Mol. Cell. Biol. 23: 7756-7766 (2003). *
Costet P, Luo Y, Wang N, Tall AR. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J. Biol. Chem. 275: 28240-28245 (2000). *
Coutinho JM, Singaraja RR, Kang M, Arenillas DJ, Bertram LN, Bissada N, Staels B, Fruchart JC, Fievet C, Joseph-George AM, Wasserman WW, Hayden MR. Complete functional rescue of the ABCA1-/-mouse by human BAC transgenesis. J. Lipid Res. 46: 1113-1123 (2005). *
Couvert P, Giral P, Dejager S, Gu J, Huby T, Chapman MJ, Bruckert E, Carrie A. Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics 9: 1217-1227 (2008).
Crabb DW, Liangpunsakul S. Alcohol and lipid metabolism. J. Gastroenterol. Hepatol. 21 Suppl. 3: S56-S60 (2006). *
Craig WJ. Health effects of vegan diets. Am. J. Clin. Nutr. 89: 1627S-1633S (2009). *
Crawford AR, Smith AJ, Hatch VC, Oude Elferink RP, Borst P, Crawford JM. Hepatic secretion of phospholipid vesicles in the mouse critically depends on mdr2 or MDR3 P-glycoprotein expression. Visualization by electron microscopy. J. Clin. Invest. 100: 2562-2567 (1997). *
Cree MG, Newcomer BR, Read LK, Sheffield-Moore M, Paddon-Jones D, Chinkes D, Aarsland A, Wolfe RR. Plasma triglycerides are not related to tissue lipids and insulin sensitivity in elderly following PPAR-alpha agonist treatment. Mech. Ageing Dev. 128: 558-565 (2007).
Crestani M, De Fabiani E, Caruso D, Mitro N, Gilardi F, Vigil Chacon AB, Patelli R, Godio C, Galli G. LXR (liver X receptor) and HNF-4 (hepatocyte nuclear factor-4): key regulators in reverse cholesterol transport. Biochem. Soc. Trans. 32: 92-96 (2004). *
Crestani M, Sadeghpour A, Stroup D, Galli G, Chiang JY. Transcriptional activation of the cholesterol 7alpha-hydroxylase gene (CYP7A) by nuclear hormone receptors. J. Lipid Res. 39: 2192-2200 (1998). *
Crippin JS, Lindor KD, Jorgensen R, Kottke BA, Harrison JM, Murtaugh PA, Dickson ER. Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk? Hepatology 15: 858-862 (1992).
Crosignani A, Battezzati PM, Setchell KD, Invernizzi P, Covini G, Zuin M, Podda M. Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A dose-response study. Dig. Dis. Sci. 41: 809-815 (1996).
Crosignani A, Del Puppo M, Longo M, De Fabiani E, Caruso D, Zuin M, Podda M, Javitt NB, Kienle MG. Changes in classic and alternative pathways of bile acid synthesis in chronic liver disease. Clin. Chim. Acta 382: 82-88 (2007). *
Cruz-Garcia L, Minghetti M, Navarro I, Tocher DR. Molecular cloning, tissue expression and regulation of liver X receptor (LXR) transcription factors of Atlantic salmon (Salmo salar) and rainbow trout (Oncorhynchus mykiss). Comp. Biochem. Physiol. B. Biochem. Mol. Biol. Feb 4 [Epub ahead of print] (2009). *
Cui J, Heard TS, Yu J, Lo JL, Huang L, Li Y, Schaeffer JM, Wright SD. The amino acid residues asparagine 354 and isoleucine 372 of human farnesoid X receptor confer the receptor with high sensitivity to chenodeoxycholate. J. Biol. Chem. 277: 25963-25969 (2002). *
Cui J, Huang L, Zhao A, Lew JL, Yu J, Sahoo S, Meinke PT, Royo I, Pelaez F, Wright SD. Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump. J. Biol. Chem. 278: 10214-10220 (2003). *
Cui J, Lew J-L, Zhao A, Huang L, Wright SD. The farnesoid X receptor controls gene expression in a ligand and promoter-selective fashion. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 32. June 18-19 (2004). *
Cui NQ, Zhang SK, Cui YF, Li DH, Chen C, Wu XZ. Overexpression of sterol carrier protein-2 mRNA in patients with cholesterol gallstones. Hepatobiliary Pancreat Dis. Int. 4: 117-120 (2005). *
Cummins CL, Volle DH, Zhang Y, McDonald JG, Sion B, Lefrancois-Martinez AM, Caira F, Veyssiere G, Mangelsdorf DJ, Lobaccaro JM. Liver X receptors regulate adrenal cholesterol balance. J. Clin. Invest. 116: 1902-1912 (2006). *
Cundiff DK, Lanou AJ, Nigg CR. Relation of omega-3 fatty acid intake to other dietary factors known to reduce coronary heart disease risk. Am. J. Cardiol. 99: 1230-1233 (2007). *
Cunnane SC, Manku MS, Horrobin DF. The pineal and regulation of fibrosis: pinealectomy as a model of primary biliary cirrhosis: roles of melatonin and prostaglandins in fibrosis and regulation of T lymphocytes. Med. Hypotheses 5: 403-414 (1979).
Cuomo R, Rodino S, Rizzoli R, Simoni P, Roda E, Cantoni L, Rizzardini M, De Rosa G, Le Grazie C, Di Padova C, et al. Bile and biliary lipid secretion in rats with hexachlorobenzene-induced porphyria. Effect of S-adenosyl-L-methionine administration. J. Hepatol. 12: 87-93 (1991).
Curtiss LK, Tobias PS. Emerging role of Toll-like receptors in atherosclerosis. J. Lipid Res. 50: S340-S345 (2009). *
Czaja AJ. Variant forms of autoimmune hepatitis. Curr. Gastroenterol. Rep. 1: 63-70 (1999).
Czech C, Burns MP, Vardanian L, Augustin A, Jacobsen H, Baumann K, Rebeck GW. Cholesterol independent effect of LXR agonist TO-901317 on gamma-secretase. J. Neurochem. 101: 929-936 (2007).
Dai J, Su YX, Bartell S, Le NA, Ling WH, Liang YQ, Gao L, Wu HY, Veledar E, Vaccarino V. Beneficial effects of designed dietary fatty acid compositions on lipids in triacylglycerol-rich lipoproteins among Chinese patients with type 2 diabetes mellitus. Metabolism 58: 510-518 (2009). *
Dai XY, Ou X, Hao XR, Cao DL, Tang YL, Hu YW, Li XX, Tang CK. The effect of T0901317 on ATP-binding cassette transporter A1 and Niemann-Pick type C1 in ApoE-/- mice. J. Cardiovasc. Pharmacol. 51: 467-475 (2008).
Dai Y, Liang YH, Xie PY, Chen BW, Liu XG. Clinical analysis of primary biliary cirrhosis: a report of 42 cases. Beijing Da Xue Xue Bao 37: 410-414 (2005).
Dall TL, Bays H. Addressing lipid treatment targets beyond cholesterol: a role for prescription omega-3 fatty acid therapy. South. Med. J. 102: 390-396 (2009).
Dalmeijer GW, Olthof MR, Verhoef P, Bots ML, van der Schouw YT. Prospective study on dietary intakes of folate, betaine, and choline and cardiovascular disease risk in women. Eur. J. Clin. Nutr. 62: 386-394 (2008). *
Daly C, Fitzgerald AP, O'Callaghan P, Collins P, Cooney MT, Graham IM; on behalf of the COMAC Group. Homocysteine increases the risk associated with hyperlipidaemia. Eur. J. Cardiovasc. Prev. Rehabil. 16: 150-155 (2009).
Damiano F, Gnoni GV, Siculella L. Functional analysis of rat liver citrate carrier promoter: differential responsiveness to polyunsaturated fatty acids. Biochem. J. 417: 561-571 (2009). *
Damsgaard CT, Frokiaer H, Andersen AD, Lauritzen L. Fish oil in combination with high or low intakes of linoleic acid lowers plasma triacylglycerols but does not affect other cardiovascular risk markers in healthy men. J. Nutr. 138: 1061-1066 (2008). *
Damsgaard CT, Schack-Nielsen L, Michaelsen KF, Fruekilde MB, Hels O, Lauritzen L. Fish oil affects blood pressure and the plasma lipid profile in healthy Danish infants. J. Nutr. 136: 94-99 (2006). *
Danaei G, Ding EL, Mozaffarian D, Taylor B, Rehm J, Murray CJ, Ezzati M. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med. 6: e1000058 (2009). *
Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 350: 1387-1397 (2004). *
Dang H, Liu Y, Pang W, Wang N, Shyy JY, Zhu Y. Suppression of 2,3-oxidosqualene cyclase by high-fat diet contributes to liver X receptor-alpha-mediated improvement of hepatic lipid profile. J. Biol. Chem. 284: 6218-6226 (2009). *
Dann AT, Kenyon AP, Wierzbicki AS, Seed PT, Shennan AH, Tribe RM. Plasma lipid profiles of women with intrahepatic cholestasis of pregnancy. Obstet. Gynecol. 107: 106-114 (2006).
Darimont C, Avanti O, Zbinden I, Leone-Vautravers P, Mansourian R, Giusti V, Mace K. Liver X receptor preferentially activates de novo lipogenesis in human preadipocytes. Biochimie 88: 309-318 (2006).
Das A, Fernandez-Zapico ME, Cao S, Yao J, Fiorucci S, Hebbel RP, Urrutia R, Shah VH. Disruption of an SP2/KLF6 repression complex by SHP is required for farnesoid X receptor-induced endothelial cell migration. J. Biol. Chem. 281: 39105-39113 (2006). *
Das JB, Poulos ND, Ansari GG. Biliary lipid composition and bile acid profiles during and after enteral fast of total parenteral nutrition in the rabbit. J. Pediatr. Gastroenterol. Nutr. 22: 85-91 (1996). *
Das SK, Chakrabarti R. Role of PPAR in cardiovascular diseases. Recent Patents Cardiovasc. Drug Discov. 1: 193-209 (2006).
Das UN. Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules. Lipids Health Dis. 7: 37 (2008). *
Das UN. Do polyunsaturated fatty acids behave like an endogenous "polypill"? Med. Hypotheses 70: 430-434 (2008).
Das UN. A defect in the activity of Delta(6) and Delta(5) desaturases may be a factor in the initiation and progression of atherosclerosis. Prostaglandins Leukot. Essent. Fatty Acids 76: 251-268 (2007). *
Dastani Z, Engert JC, Genest J, Marcil M. Genetics of high-density lipoproteins. Curr. Opin. Cardiol. 21: 329-335 (2006).
Davi G, Falco A. Oxidant stress, inflammation and atherogenesis. Lupus 14: 760-764 (2005).
David A, Fridlich R, Aviram I. The presence of membrane proteinase 3 in neutrophil lipid rafts and its colocalization with FcgammaRIIIb and cytochrome b558. Exp. Cell Res. 308: 156-165 (2005). *
Davidson MH. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin. Drug Saf. 5: 145-156 (2006).
Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am. J. Cardiol. 99: S3-S18 (2007). *
Davies R, Schuurman A, Barker CR, Clothier B, Chernova T, Higginson FM, Judah DJ, Dinsdale D, Edwards RE, Greaves P, Gant TW, Smith AG. Hepatic gene expression in protoporphyic fech mice is associated with cholestatic injury but not a marked depletion of the heme regulatory pool. Am. J. Pathol. 166: 1041-1053 (2005). *
Davis HR Jr, Basso F, Hoos LM, Tetzloff G, Lally SM, Altmann SW. Cholesterol homeostasis by the intestine: lessons from Niemann-Pick C1 like 1 (NPC1L1). Atheroscler. Suppl. 9: 77-81 (2008).
Davis KG, Wertin TM, Schriver JP. The use of simvastatin for the prevention of gallstones in the lithogenic prairie dog model. Obes. Surg. 13: 865-868 (2003).
Davis RA, Attie AD. Deletion of the ileal basolateral bile acid transporter identifies the cellular sentinels that regulate the bile acid pool. Proc. Natl. Acad. Sci. U.S.A. 105: 4965-4966 (2008). *
Davis RA, Miyake JH, Hui TY, Spann NJ. Regulation of cholesterol-7alpha-hydroxylase: BAREly missing a SHP. J. Lipid Res. 43: 533-543 (2002). *
Davis W Jr, Boyd JT, Ile KE, Tew KD. Human ATP-binding cassette transporter-2 (ABCA2) positively regulates low-density lipoprotein receptor expression and negatively regulates cholesterol esterification in Chinese hamster ovary cells. Biochim. Biophys. Acta 1683: 89-100 (2004). *
Davis W, Rockway S, Kwasny M. Effect of a combined therapeutic approach of intensive lipid management, omega-3 fatty acid supplementation, and increased serum 25 (OH) vitamin D on coronary calcium scores in asymptomatic adults. Am. J. Ther. Dec 15 [Epub ahead of print] (2008).
Dawson PA, Haywood J, Craddock AL, Wilson M, Tietjen M, Kluckman K, Maeda N, Parks JS. Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice. J. Biol. Chem. 278: 33920-33927 (2003). *
de Campo A, Toplak H, Wascher TC, Schallmoser K, Friehs A, Schmidt H, Kostner GM. Evaluation of a newly discovered LDL receptor mutation (exon 10, GAC>AAC, D271N, "FH Graz-1") in familial hypercholesterolemia - a family study. Acta Med. Austriaca 26: 20-25 (1999).
De Cosmo S, Minenna A, Zhang YY, Thompson R, Miscio G, Vedovato M, Rauseo A, Saller A, Mastroianno S, Pellegrini F, Trevisan R, Fioretto P, Doria A, Trischitta V. Association of the Q121 variant of ENPP1 gene with decreased kidney function among patients with type 2 diabetes. Am. J. Kidney Dis. 53: 273-280 (2009).
De Fabiani E, Mitro N, Anzulovich AC, Pinelli A, Galli G, Crestani M. The negative effects of bile acids and tumor necrosis factor-alpha on the transcription of cholesterol 7alpha-hydroxylase gene (CYP7A1) converge to hepatic nuclear factor-4: a novel mechanism of feedback regulation of bile acid synthesis� J. Biol. Chem. 276: 30708-30716 (2001). *
De Fabiani E, Mitro N, Gilardi F, Caruso D, Galli G, Crestani M. Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle. J. Biol. Chem. 278: 39124-39132 (2003). *
De Fabiani E, Mitro N, Godio C, Gilardi F, Caruso D, Crestani M. Bile acid signaling to the nucleus: finding new connections in the transcriptional regulation of metabolic pathways. Biochimie 86: 771-778 (2004).
De Gottardi A, Vinciguerra M, Sgroi A, Moukil M, Ravier-Dall'Antonia F, Pazienza V, Pugnale P, Foti M, Hadengue A. Microarray analyses and molecular profiling of steatosis induction in immortalized human hepatocytes. Lab. Invest. 87: 792-806 (2007). *
de Haan W, de Vries-van der Weij J, Mol IM, Hoekstra M, A Romijn J, Jukema JW, Havekes LM, Princen HM, Rensen PC. PXR agonism decreases plasma HDL levels in apoE3-Leiden.CETP mice. Biochim. Biophys. Acta 1791: 191-197 (2009). *
de Jong A, Plat J, Lutjohann D, Mensink RP. Effects of long-term plant sterol or stanol ester consumption on lipid and lipoprotein metabolism in subjects on statin treatment. Br. J. Nutr. 100: 937-941 (2008).
De Luis D, Aller R, Zarzuelo S. Dietary salt in the era of anthypertensive drugs. Med. Clin. (Barc.) 127: 673-675 (2006).
de Luis DA, Aller R, Izaola O, Sagrado MG, Conde R. Influence of G308A promoter variant of tumor necrosis factor-alpha gene on insulin resistance and weight loss secondary to two hypocaloric diets: a randomized clinical trial. Arch. Med. Res. 40: 36-41 (2009).
De Luis DA, Conde R, Aller R, Izaola O, Gonzalez Sagrado M, Perez Castrillon JL, Duenas A, Romero E. Effect of omega-3 fatty acids on cardiovascular risk factors in patients with type 2 diabetes mellitus and hypertriglyceridemia: an open study. Eur. Rev. Med. Pharmacol. Sci. 13: 51-55 (2009).
de Luis DA, Pacheco D, Aller R, Gonzalez Sagrado M, Izaola O, Terroba MC, Cuellar L, Conde R, Martin T. Influence of G308A polymorphism of tumor necrosis factor alpha gene on surgical results of biliopancreatic diversion. Obes. Surg. Jun 20 [Epub ahead of print] (2008).
de Luis DA, Pacheco D, Aller R, Gonzalez Sagrado M, Izaola O, Terroba MC, Cuellar L, Conde R, Martin T, Perez Castrillon JL. Influence of -55CT polymorphism of UCP3 gene on surgical results of biliopancreatic diversion. Obes. Surg. May 17 [Epub ahead of print] (2008).
de Luis DA, Pacheco D, Izaola O, Terroba MC, Cuellar L, Martin T. Clinical results and nutritional consequences of biliopancreatic diversion: three years of follow-up. Ann. Nutr. Metab. 53: 234-239 (2008).
de Luis DA, Sagrado MG, Izaola O, Terroba MC, Cuellar L, Conde R, Martin T. Influence of Ala54Thr polymorphism of fatty acid-binding protein-2 on clinical results of biliopancreatic diversion. Nutrition 24: 300-304 (2008).
de Nigris F, Williams-Ignarro S, Lerman LO, Crimi E, Botti C, Mansueto G, D'Armiento FP, De Rosa G, Sica V, Ignarro LJ, Napoli C. Beneficial effects of pomegranate juice on oxidation-sensitive genes and endothelial nitric oxide synthase activity at sites of perturbed shear stress. Proc. Natl. Acad. Sci. U.S.A. 102: 4896-4901 (2005). *
de Oliveira CP, Stefano JT, de Siqueira ER, Silva LS, de Campos Mazo DF, Lima VM, Furuya CK, Mello ES, Souza FG, Rabello F, Santos TE, Nogueira MA, Caldwell SH, Alves VA, Carrilho FJ. Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis. Hepatol. Res. 38: 159-165 (2008). *
de Roos B, Geelen A, Ross K, Rucklidge G, Reid M, Duncan G, Caslake M, Horgan G, Brouwer IA. Identification of potential serum biomarkers of inflammation and lipid modulation that are altered by fish oil supplementation in healthy volunteers. Proteomics 8: 1965-1974 (2008). *
De Truchis P, Kirstetter M, Perier A, Meunier C, Zucman D, Force G, Doll J, Katlama C, Rozenbaum W, Masson H, Gardette J, Melchior JC; and the Maxepa-HIV Group. Reduction in triglyceride level with n-3 polyunsaturated fatty acids in HIV-infected patients taking potent antiretroviral therapy: a randomized prospective study. J. Acquir. Immune Defic. Syndr. 44: 278-285 (2007).
de Vogel-van den Bosch HM, Bunger M, de Groot PJ, Bosch-Vermeulen H, Hooiveld GJ, Muller M. PPARalpha-mediated effects of dietary lipids on intestinal barrier gene expression. BMC Genomics 9: 231 (2008). *
de Vrese M, Schrezenmeir J. Probiotics, prebiotics, and synbiotics. Adv. Biochem. Eng. Biotechnol. 111: 1-66 (2008). *
de Vries-van der Weij J, de Haan W, Hu L, Kuif M, Oei HL, van der Hoorn JW, Havekes LM, Princen HM, Romijn JA, Smit JW, Rensen PC. Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein. Endocrinology 150: 2368-2375 (2009). *
Deak G, Ruzicska E, Somogyi A. Association of IgA nephropathy, hypothyroidism and hypercholesterolemia. J. Nephrol. 18: 773-776 (2005).
Deakin S, Guernier S, James RW. Pharmacogenetic interaction between paraoxonase-1 gene promoter polymorphism C-107T and statin. Pharmacogenet. Genomics 17: 451-457 (2007).
Dean M. The genetics of ATP-binding cassette transporters. Methods Enzymol. 400: 409-429 (2005).
Dean M, Allikmets R. Complete characterization of the human ABC gene family. J. Bioenerg. Biomembr. 33: 475-479 (2001). *
Dean M, Annilo T. Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. Annu. Rev. Genomics Hum. Genet. 6: 123-142 (2005). *
Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J. Lipid Res. 42: 1007-1017 (2001). *
Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 11: 1156-1166 (2001). *
Decarlis S, Agostoni C, Ferrante F, Scarlino S, Riva E, Giovannini M. Combined hyperlipidaemia as a presenting sign of cholesteryl ester storage disease. J. Inherit. Metab. Dis. Feb 15 [Epub ahead of print]] (2009). *
Decochez K, Rippley RK, Miller JL, De Smet M, Yan KX, Matthijs Z, Riffel KA, Song H, Zhu H, Maynor HO, Tanaka W, Johnson-Levonas AO, Davies MJ, Gottesdiener KM, Keymeulen B, Wagner JA. A dual PPAR alpha/gamma agonist increases adiponectin and improves plasma lipid profiles in healthy subjects. Drugs R. D. 7: 99-110 (2006).
Dedoussis GV, Maumus S, Choumerianou DM, Skoumas J, Pitsavos C, Stefanadis C, Visvikis-Siest S. Different genes and polymorphisms affecting high-density lipoprotein cholesterol levels in Greek familial hypercholesterolemia patients. Genet. Test. 10: 192-199 (2006).
Dedoussis GV, Maumus S, Skoumas J, Choumerianou DM, Pitsavos C, Stefanadis C, Visvikis-Siest S. Natriuretic peptide Val7Met substitution and risk of coronary artery disease in Greek patients with familial hypercholesterolemia. J. Clin. Lab. Anal. 20: 98-104 (2006).
Deedwania PC, Gupta R. Management issues in the metabolic syndrome. J. Assoc. Physicians India 54: 797-810 (2006).
del Castillo-Olivares A, Campos JA, Pandak WM, Gil G. The role of alpha1-fetoprotein transcription factor/LRH-1 in bile acid biosynthesis: a known nuclear receptor activator that can act as a suppressor of bile acid biosynthesis. J. Biol. Chem. 279: 16813-16821 (2004). *
del Castillo-Olivares A, Gil G. Role of FXR and FTF in bile acid-mediated suppression of cholesterol 7alpha-hydroxylase transcription. Nucleic Acids Res. 28: 3587-3593 (2000). *
Del Puppo M, Galli Kienle M, Crosignani A, Petroni ML, Amati B, Zuin M, Podda M. Cholesterol metabolism in primary biliary cirrhosis during simvastatin and UDCA administration. J. Lipid Res. 42: 437-441 (2001). *
Del Puppo M, Kienle MG, Petroni ML, Crosignani A, Podda M. Serum 27-hydroxycholesterol in patients with primary biliary cirrhosis suggests alteration of cholesterol catabolism to bile acids via the acidic pathway. J. Lipid Res. 39: 2477-2482 (1998). *
Delang L, Paeshuyse J, Vliegen I, Leyssen P, Obeid S, Durantel D, Zoulim F, Op de Beeck A, Neyts J. Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. Hepatology Feb 18 [Epub ahead of print] (2009).
Delerive P, Galardi CM, Bisi JE, Nicodeme E, Goodwin B. Identification of liver receptor homolog-1 as a novel regulator of apolipoprotein AI gene transcription. Mol. Endocrinol. 18: 2378-2387 (2004). *
Dellavalle R, Drake A, Graber M, Heilig L, Hester E, Johnson K, McNealy K, Schilling L, Dellavalle R. Statins and fibrates for preventing melanoma. Cochrane Database Syst. Rev. 4: CD003697 (2005). *
Delva E, Jennings JM, Calkins CC, Kottke MD, Faundez V, Kowalczyk AP. Pemphigus vulgaris IgG-induced desmoglein-3 endocytosis and desmosomal disassembly are mediated by a clathrin and dynamin-independent mechanism. J. Biol. Chem. 283: 18303-18313 (2008). *
Delvecchio CJ, Bilan P, Nair P, Capone JP. LXR-induced reverse cholesterol transport in human airway smooth muscle is mediated exclusively by ABCA1. Am. J. Physiol. Lung Cell. Mol. Physiol. 295: L949-L957 (2008). *
Delvecchio CJ, Bilan P, Radford K, Stephen J, Trigatti BL, Cox G, Parameswaran K, Capone JP. Liver X receptor stimulates cholesterol efflux and inhibits expression of pro-inflammatory mediators in human airway smooth muscle cells. Mol. Endocrinol. 21: 1324-1334 (2007). *
Delvecchio CJ, Capone JP. Protein kinase C alpha modulates liver X receptor alpha transactivation. J. Endocrinol. 197: 121-130 (2008). *
Demerjian M, Choi EH, Man MQ, Chang S, Elias PM, Feingold KR. Activators of PPARs and LXR decrease the adverse effects of exogenous glucocorticoids on the epidermis. Exp. Dermatol. Feb 19 [Epub ahead of print].
Demirag MD, Onen HI, Karaoguz MY, Dogan I, Karakan T, Ekmekci A, Guz G. Apolipoprotein E gene polymorphism in nonalcoholic fatty liver disease. Dig. Dis. Sci. 52: 3399-3403 (2007). *
Demonty I, Chan YM, Pelled D, Jones PJ. Fish-oil esters of plant sterols improve the lipid profile of dyslipidemic subjects more than do fish-oil or sunflower oil esters of plant sterols. Am. J. Clin. Nutr. 84: 1534-1542 (2006). *
Deng R. Therapeutic effects of guggul and its constituent guggulsterone: cardiovascular benefits. Cardiovasc. Drug Rev. 25: 375-390 (2007).
Deng R, Yang D, Radke A, Yang J, Yan B. Hypolipidemic agent guggulsterone regulates the expression of human bile salt export pump: dominance of transactivation over FXR-mediated antagonism. J. Pharmacol. Exp. Ther. 320: 1153-1162 (2007). *
Deng R, Yang D, Yang J, Yan B. Oxysterol 22(R)-hydroxycholesterol induces the expression of the bile salt export pump through nuclear receptor FXR but not LXR. J. Pharmacol. Exp. Ther. 317: 317-325 (2006). *
Denis M, Bissonnette R, Haidar B, Krimbou L, Bouvier M, Genest J. Expression, regulation, and activity of ABCA1 in human cell lines. Mol. Genet. Metab. 78: 265-274 (2003). *
Denke MA. Dietary fats, fatty acids, and their effects on lipoproteins. Curr. Atheroscler. Rep. 8: 466-471 (2006).
Denke MA. Diet, lifestyle, and nonstatin trials: review of time to benefit. Am. J. Cardiol. 96: 3-10 (2005). *
Denson LA, Sturm E, Echevarria W, Zimmerman TL, Makishima M, Mangelsdorf DJ, Karpen SJ. The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp. Gastroenterology 121: 140-147 (2001). *
Deo AK, Bandiera SM. Identification of human hepatic cytochrome P450 enzymes involved in the biotransformation of cholic and chenodeoxycholic acid . Drug Metab. Dispos. 36: 1983-1991 (2008). *
Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Clin. Ther. 26: 1599-1607 (2004). *
Desai F, Ramanathan M, Fink CS, Wilding GE, Weinstock-Guttman B, Awad AB. Comparison of the immunomodulatory effects of the plant sterol beta-sitosterol to simvastatin in peripheral blood cells from multiple sclerosis patients. Int. Immunopharmacol. 9: 153-157 (2009).
Desideri G, Croce G, Tucci M, Passacquale G, Broccoletti S, Valeri L, Santucci A, Ferri C. Effects of bezafibrate and simvastatin on endothelial activation and lipid peroxidation in hypercholesterolemia: evidence of different vascular protection by different lipid-lowering treatments. J. Clin. Endocrinol. Metab. 88: 5341-5437 (2003). *
Desiderio S, Yoo JY. A genome-wide analysis of the acute-phase response and its regulation by Stat3beta. Ann. N. Y. Acad. Sci. 987: 280-284 (2003). *
Dessein PH, Tobias M, Veller MG. Metabolic syndrome and subclinical atherosclerosis in rheumatoid arthritis. J. Rheumatol. 33: 2425-2432 (2006).
Deters M, Kirchner G, Koal T, Resch K, Kaever V. Everolimus/cyclosporine interactions on bile flow and biliary excretion of bile salts and cholesterol in rats. Dig. Dis. Sci. 49: 30-37 (2004). *
Devroey D, Velkeniers B, Duquet W, Betz W. The benefit of fibrates in the treatment of 'bad HDL-C responders to statins'. Int. J. Cardiol. 101: 231-235 (2005).
Dhawan A, Mitry RR, Hughes RD. Hepatocyte transplantation for liver-based metabolic disorders. J. Inherit. Metab. Dis. 29: 431-435 (2006). *
Di Nisio M, Di Febbo C, Moretta V, Guglielmi MD, Stuppia L, Cuccurullo F, Porreca E. Effects of Toll-like receptor-4 gene polymorphisms on soluble P-selectin and von Willebrand factor levels in hypercholesterolemic patients. Thromb. Haemost. 98: 642-646 (2007).
Diaz Encarnacion MM, Warner GM, Gray CE, Cheng J, Keryakos HK, Nath KA, Grande JP. Signaling pathways modulated by fish oil in salt-sensitive hypertension. Am. J. Physiol. Renal Physiol. 294: F1323-F1335 (2008). *
Diblasio-Smith EA, Arai M, Quinet EM, Evans MJ, Kornaga T, Basso MD, Chen L, Feingold I, Halpern AR, Liu QY, Nambi P, Savio D, Wang S, Mounts WM, Isler JA, Slager AM, Burczynski ME, Dorner AJ, Lavallie ER. Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells. J. Transl. Med. 6: 59 (2008). *
Diczfalusy U. Analysis of cholesterol oxidation products in biological samples. J. AOAC Int. 87: 467-473 (2004).
Diczfalusy U, Olofsson KE, Carlsson AM, Gong M, Golenbock DT, Rooyackers O, Flaring U, Bjorkbacka H. Marked up-regulation of cholesterol 25-hydroxylase expression by lipopolysaccharide. J. Lipid Res. Jun 5 [Epub ahead of print] (2009). *
Dierkes J, Westphal S, Luley C. Fenofibrate-induced hyperhomocysteinaemia: clinical implications and management. Drug Saf. 26: 81-91 (2003).
Dierkes J, Westphal S, Luley C. The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels. Expert Opin. Drug Saf. 3: 101-111 (2004).
Dieter MZ, Maher JM, Cheng X, Klaassen CD. Expression and regulation of the sterol half-transporter genes ABCG5 and ABCG8 in rats. Comp. Biochem. Physiol. C. Toxicol. Pharmacol. 139: 209-218 (2004). *
Dikopoulos N, Schmid RM, Bachem M, Buttenschoen K, Adler G, Chiang JY, Weidenbach H. Bile synthesis in rat models of inflammatory bowel diseases. Eur. J. Clin. Invest. 37: 222-230 (2007). *
Dikopoulos N, Weidenbach H, Adler G, Schmid RM. Lipopolysaccharide represses cholesterol 7-alpha hydroxylase and induces binding activity to the bile acid response element II. Eur. J. Clin. Invest. 33: 58-64 (2003). *
Dimitrova-Sumkovska J, Djosic-Markovska B, Zafirova-Roganovic D, Anastasovska V. Effects of different dietary fatty acid supplements uppon lipoprotein metabolism and lipid peroxides production in hyperlipidemic rats. Prilozi. 27: 67-86 (2006).
Ding C, Jones G. Anti-interleukin-6 receptor antibody treatment in inflammatory autoimmune diseases. Rev. Recent Clin. Trials 1: 193-200 (2006).
Ding SY, Tigno XT, Braileanu GT, Ito K, Hansen BC. A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist ameliorates dyslipidemia and insulin resistance in prediabetic rhesus monkeys. Metabolism 56: 1334-1339 (2007). *
Dinler G, Kocak N, Ozen H, Yuce A, Gurakan F. Ursodeoxycholic acid treatment in children with Byler disease. Pediatr. Int. 41: 662-665 (1999).
Dinler G, Kocak N, Yuce A, Gurakan F, Ozen H. Ursodeoxycholic acid therapy in children with cholestatic liver disease. Turk. J. Pediatr. 41: 91-98 (1999).
Diwakar BT, Dutta PK, Lokesh BR, Naidu KA. Bio-availability and metabolism of n-3 fatty acid rich garden cress (Lepidium sativum) seed oil in albino rats. Prostaglandins Leukot. Essent. Fatty Acids 78: 123-130 (2008). *
Dixit M, Choudhuri G, Keshri LJ, Mittal B. Association of low density lipoprotein receptor related protein-associated protein (LRPAP1) gene insertion/deletion polymorphism with gallstone disease. J. Gastroenterol. Hepatol. 21: 847-849 (2006). *
do Prado R, D' Almeida VM, Guerra-Shinohara E, Galdieri LC, Terreri MT, Hilario MO. Increased concentration of plasma homocysteine in children with systemic lupus erythematosus. Clin. Exp. Rheumatol. 24: 594-598 (2006).
Doggrell SA. Farnesoid X receptor agonism - a new approach to the treatment of cholesterol gallstone disease. Expert Opin. Investig. Drugs 14: 535-538 (2005).
Doggrell SA. New targets in and potential treatments for cholesterol gallstone disease. Curr. Opin. Investig. Drugs 7: 344-348 (2006).
Doggrell SA. Muraglitazar: beneficial or detrimental in the treatment of type 2 diabetes? Expert Opin. Pharmacother. 7: 1229-1233 (2006).
Doisne JM, Castaigne JG, Deruyffelaere C, Dieu-Nosjean MC, Chamot C, Alcaide-Loridan C, Charron D, Al-Daccak R. The context of HLA-DR/CD18 complex in the plasma membrane governs HLA-DR-derived signals in activated monocytes. Mol. Immunol. 45: 709-718 (2008). *
Dolganiuc A, Bakis G, Kodys K, Mandrekar P, Szabo G. Acute ethanol treatment modulates Toll-like receptor-4 association with lipid rafts. Alcohol Clin. Exp. Res. 30: 76-85 (2006). *
Dolley G, Lamarche B, Despres JP, Bouchard C, Perusse L, Vohl MC. Myeloperoxidase gene sequence variations are associated with low-density-lipoprotein characteristics. J. Hum. Genet. 53: 439-446 (2008). *
Dombrecht EJ, Van Offel JF, Bridts CH, Ebo DG, Seynhaeve V, Schuerwegh AJ, Stevens WJ, De Clerck LS. Influence of simvastatin on the production of pro-inflammatory cytokines and nitric oxide by activated human chondrocytes. Clin. Exp. Rheumatol. 25: 534-539 (2007).
Dongxia L, Qi H, Lisong L, Jincheng G. Association of peroxisome proliferator-activated receptor-gamma gene Pro12Ala and C161T polymorphisms with metabolic syndrome. Circ. J. 72: 551-557 (2008). *
Dos Santos SM, Weber CC, Franke C, Muller WE, Eckert GP. Cholesterol: coupling between membrane microenvironment and ABC transporter activity. Biochem. Biophys. Res. Commun. 354: 216-221 (2007). *
Dourakis SP, Papanikolaou IS, Tzemanakis EN, Hadziyannis SJ. Acute hepatitis associated with herb (Teucrium capitatum L.) administration. Eur. J. Gastroenterol. Hepatol. 14: 693-695 (2002).
Downes M, Verdecia MA, Roecker AJ, Hughes R, Hogenesch JB, Kast-Woelbern HR, Bowman ME, Ferrer JL, Anisfeld AM, Edwards PA, Rosenfeld JM, Alvarez JG, Noel JP, Nicolaou KC, Evans RM. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol. Cell 11: 1079-1092 (2003). *
Dragsted LO, Krath B, Ravn-Haren G, Vogel UB, Vinggaard AM, Bo Jensen P, Loft S, Rasmussen SE, Sandstrom TB, Pedersen A. Biological effects of fruit and vegetables. Proc. Nutr. Soc. 65: 61-67 (2006). *
Dreiher J, Weitzman D, Davidovici B, Shapiro J, Cohen AD. Psoriasis and dyslipidaemia: a population-based study. Acta Derm. Venereol. 88: 561-565 (2008).
Du HQ, Yin M, Ye HY, Shang YJ, Dai XD, Jing W, Zhang L, Xiao N, Li JF, Pan J. Expression profiles of lipid metabolism-related genes in liver of apoE(-/-)/LDLR(-/-) mice. Zhonghua Bing Li Xue Za Zhi 36: 751-755 (2007).
Duan RD. Alkaline sphingomyelinase: an old enzyme with novel implications. Biochim. Biophys. Acta 1761: 281-291 (2006). *
Duane WC, Hartich LA, Bartman AE, Ho SB. Diminished gene expression of ileal apical sodium bile acid transporter explains impaired absorption of bile acid in patients with hypertriglyceridemia. J. Lipid Res. 41: 1384-1389 (2000). *
Duane WC, Javitt NB. Conversion of 7 alpha-hydroxycholesterol to bile acid in human subjects: is there an alternate pathway favoring cholic acid synthesis? J. Lab. Clin. Med. 139: 109-115 (2002). *
Duane WC, Javitt NB. 27-Hydroxycholesterol: production rates in normal human subjects. J. Lipid Res. 40: 1194-1199 (1999). *
Dubinsky MC, Fleshner PP. Treatment of Crohn's disease of inflammatory, stenotic, and fistulizing phenotypes. Curr. Treat. Options Gastroenterol. 6: 183-200 (2003).
Dubrac S, Lear SR, Ananthanarayanan M, Balasubramaniyan N, Bollineni J, Shefer S, Hyogo H, Cohen DE, Blanche PJ, Krauss RM, Batta AK, Salen G, Suchy FJ, Maeda N, Erickson SK. Role of CYP27A in cholesterol and bile acid metabolism. J. Lipid Res. 46: 76-85 (2005). *
Duckworth PF, Vlahcevic ZR, Studer EJ, Gurley EC, Heuman DM, Beg ZH, Hylemon PB. Effect of hydrophobic bile acids on 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and mRNA levels in the rat. J. Biol. Chem. 266: 9413-9418 (1991). *
Dueland S, Reichen J, Everson GT, Davis RA. Regulation of cholesterol and bile acid homoeostasis in bile-obstructed rats. Biochem. J. 280: 373-377 (1991).
Duez H, Chao YS, Hernandez M, Torpier G, Poulain P, Mundt S, Mallat Z, Teissier E, Burton CA, Tedgui A, Fruchart JC, Fievet C, Wright SD, Staels B. Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. J. Biol. Chem. 277: 48051-48057 (2002). *
Duez H, Fruchart JC, Staels B. PPARS in inflammation, atherosclerosis and thrombosis. J. Cardiovasc. Risk 8: 187-194 (2001).
Duez H, Lefebvre B, Poulain P, Pineda Torra I, Percevault F, Luc G, Peters JM, Gonzalez FJ, Gineste R, Helleboid S, Fruchart JC, Fievet C, Lefebvre P, Staels B. Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation. Arterioscler. Thromb. Vasc. Biol. 25: 585-591 (2005). *
Duez H, Veen JV, Duhem C, Pourcet B, Touvier T, Fontaine C, Derudas B, Bauge E, Havinga R, Bloks VW, Wolters H, van der Sluijs FH, Vennstrom B, Kuipers F, Staels B. Regulation of bile acid synthesis by the nuclear receptor Rev-erbalpha. Gastroenterology 135: 689-698.e5 (2008). *
Duffy D, Rader DJ. Drugs in development: targeting high-density lipoprotein metabolism and reverse cholesterol transport. Curr. Opin. Cardiol. 20: 301-306 (2005).
Dullens SP, Mensink RP, Mariman EC, Plat J. Differentiated CaCo-2 cells as an in-vitro model to evaluate de-novo apolipoprotein A-I production in the small intestine. Eur. J. Gastroenterol. Hepatol. 21: 642-649 (2009).
Duniec-Dmuchowski Z, Fang HL, Strom SC, Ellis E, Runge-Morris M, Kocarek T. Human pregnane X receptor activation and CYP3A4/CYP2B6 induction by 2,3-oxidosqualene:lanosterol cyclase inhibition. Drug Metab. Dispos. 37: 900-908 (2009). *
Dunn SE, Youssef S, Goldstein MJ, Prod'homme T, Weber MS, Zamvil SS, Steinman L. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J. Exp. Med. 203: 401-412 (2006). *
Duntas LH. Thyroid disease and lipids. Thyroid 12: 287-293 (2002).
Dupasquier CM, Dibrov E, Kostenuk AL, Cheung PK, Lee KG, Alexander HK, Yeganeh BK, Moghadasian MH, Pierce GN. Dietary flaxseed inhibits atherosclerosis in the LDL receptor-deficient mouse in part through antiproliferative and anti-inflammatory actions. Am. J. Physiol. Heart Circ. Physiol. 293: H2394-H2402 (2007). *
Duraisamy Y, Lambert D, O'Neill CA, Padfield PJ. Differential incorporation of docosahexaenoic acid into distinct cholesterol-rich membrane raft domains. Biochem. Biophys. Res. Commun. 360: 885-890 (2007). *
During A, Dawson HD, Harrison EH. Carotenoid transport is decreased and expression of the lipid transporters SR-BI, NPC1L1, and ABCA1 is downregulated in Caco-2 cells treated with ezetimibe. J. Nutr. 135: 2305-2312 (2005). *
Duseja A, Das A, Das R, Dhiman RK, Chawla Y, Bhansali A, Kalra N. The clinicopathological profile of Indian patients with nonalcoholic fatty liver disease (NAFLD) is different from that in the West. Dig. Dis. Sci. 52: 2368-2374 (2007). *
Dussault I, Beard R, Lin M, Hollister K, Chen J, Xiao JH, Chandraratna R, Forman BM. Identification of gene-selective modulators of the bile acid receptor FXR. J. Biol. Chem. 278: 7027-7033 (2003). *
Dussault I, Yoo HD, Lin M, Wang E, Fan M, Batta AK, Salen G, Erickson SK, Forman BM. Identification of an endogenous ligand that activates pregnane X receptor-mediated sterol clearance. Proc. Natl. Acad. Sci. U.S.A. 100: 833-838 (2003). *
Dutheil F, Dauchy S, Diry M, Sazdovitch V, Cloarec O, Mellottee L, Bieche I, Ingelman-Sundberg M, Flinois JP, de Waziers I, Beaune P, Decleves X, Duyckaerts C, Loriot MA. Xenobiotic metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function. Drug Metab. Dispos. Apr 9 [Epub ahead of print] (2009). *
Ebbesson SO, Ebbesson LO, Swenson M, Kennish JM, Robbins DC. A successful diabetes prevention study in Eskimos: the Alaska Siberia project. Int. J. Circumpolar Health 64: 409-424 (2005).
Ebbesson SO, Risica PM, Ebbesson LO, Kennish JM, Tejero ME. Omega-3 fatty acids improve glucose tolerance and components of the metabolic syndrome in Alaskan Eskimos: the Alaska Siberia project. Int. J. Circumpolar Health 64: 396-408 (2005).
Ebbesson SO, Tejero ME, Nobmann ED, Lopez-Alvarenga JC, Ebbesson L, Romenesko T, Carter EA, Resnick HE, Devereux RB, Maccluer JW, Dyke B, Laston SL, Wenger CR, Fabsitz RR, Comuzzie AG, Howard BV. Fatty acid consumption and metabolic syndrome components: the GOCADAN study. J. Cardiometab. Syndr. 2: 244-249 (2007).
Eckert GP, Vardanian L, Rebeck GW, Burns MP. Regulation of central nervous system cholesterol homeostasis by the liver X receptor agonist TO-901317. Neurosci. Lett. 423: 47-52 (2007). *
Edgar AD, Tomkiewicz C, Costet P, Legendre C, Aggerbeck M, Bouguet J, Staels B, Guyomard C, Pineau T, Barouki R. Fenofibrate modifies transaminase gene expression via a peroxisome proliferator activated receptor alpha-dependent pathway. Toxicol. Lett. 98: 13-23 (1998).
Edwards CM, Otal MP, Stacpoole PW. Lipoprotein-X fails to inhibit hydroxymethylglutaryl coenzyme A reductase in HepG2 cells. Metabolism 42: 807-813 (1993).
Edwards PA, Kast HR, Anisfeld AM. BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. J. Lipid Res. 43: 2-12 (2002). *
Edwards PA, Kennedy MA, Mak PA. LXRs; oxysterol-activated nuclear receptors that regulate genes controlling lipid homeostasis. Vascul. Pharmacol. 38: 249-256 (2002). *
Efferth T. Adenosine triphosphate-binding cassette transporter genes in ageing and age-related diseases. Ageing Res. Rev. 2: 11-24 (2003).
Egert S, Kannenberg F, Somoza V, Erbersdobler HF, Wahrburg U. Dietary alpha-linolenic acid, EPA, and DHA have differential effects on LDL fatty acid composition but similar effects on serum lipid profiles in normolipidemic humans. J. Nutr. 139: 861-868 (2009).
Eghdamian B, Ghose K. Mode of action and adverse effects of lipid lowering drugs. Drugs Today (Barc.) 34: 943-956 (1998).
Ehehalt R, Krautter M, Zorn M, Sparla R, Fullekrug J, Kulaksiz H, Stremmel W. Increased basolateral sorting of carcinoembryonic antigen in a polarized colon carcinoma cell line after cholesterol depletion: implications for treatment of inflammatory bowel disease. World J. Gastroenterol. 14: 1528-1533 (2008). *
Ek J, Hansen SP, Lajer M, Nicot C, Boesgaard TW, Pruhova S, Johansen A, Albrechtsen A, Yderstraede K, Lauenborg J, Parrizas M, Boj SF, Jorgensen T, Borch-Johnsen K, Damm P, Ferrer J, Lebl J, Pedersen O, Hansen T. A novel -192c/g mutation in the proximal P2 promoter of the hepatocyte nuclear factor-4alpha gene (HNF4A) associates with late-onset diabetes. Diabetes 55: 1869-1873 (2006). *
El Muhtaseb MS, Talwar D, Duncan A, O'Reilly DS, McKee RF, Anderson JH, Foulis A, Finlay IG. Free radical activity and lipid soluble anti-oxidant vitamin status in patients with long-term ileal pouch-anal anastomosis. Colorectal Dis. 11: 67-72 (2009). *
El-Beshbishy HA. Aqueous garlic extract attenuates hepatitis and oxidative stress induced by galactosamine/lipoploysaccharide in rats. Phytother. Res. 22: 1372-1379 (2008).
El-Mir MY, Monte MJ, Morales AI, Arevalo M, Serrano MA, Marin JJ. Effect of maternal cholestasis on biliary lipid and bile acid secretion in the infant rat. Hepatology 26: 527-536 (1997). *
El-Seraq HB, Johnson ML, Hachem C, Morgan RO. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 136: 1601-1608 (2009). *
Elamiri A, Perwaiz S, Tuchweber B, Yousef IM. Effect of mdr2 mutation with combined tandem disruption of canalicular glycoprotein transporters by cyclosporine A on bile formation in mice. Pharmacol. Res. 48: 467-472 (2003). *
Elias E. Hepatology highlights. Hepatology 42: 1241-1242 (2005). *
Elias PM, Williams ML, Holleran WM, Jiang YJ, Schmuth M. Pathogenesis of permeability barrier abnormalities in the ichthyoses: inherited disorders of lipid metabolism. J. Lipid Res. 49: 697-714 (2008). *
Elinav E, Ali M, Bruck R, Brazowski E, Phillips A, Shapira Y, Katz M, Solomon G, Halpern Z, Gertler A. Competitive inhibition of leptin signaling results in amelioration of liver fibrosis through modulation of stellate cell function. Hepatology 49: 278-286 (2009).
Elisaf M. Effects of fibrates on serum metabolic parameters. Curr. Med. Res. Opin. 18: 269-276 (2002).
Eliseo T, Ragona L, Catalano M, Assfalg M, Paci M, Zetta L, Molinari H, Cicero DO. Structural and dynamic determinants of ligand binding in the ternary complex of chicken liver bile acid binding protein with two bile salts revealed by NMR. Biochemistry 46: 12557-12567 (2007). *
Ellis E, Axelson M, Abrahamsson A, Eggertsen G, Thorne A, Nowak G, Ericzon BG, Bjorkhem I, Einarsson C. Feedback regulation of bile acid synthesis in primary human hepatocytes: evidence that CDCA is the strongest inhibitor. Hepatology 38: 930-938 (2003). *
Ellis EC. Suppression of bile acid synthesis by thyroid hormone in primary human hepatocytes. World J. Gastroenterol. 12: 4640-4645 (2006). *
Elta GH, Sepersky RA, Goldberg MJ, Connors CM, Miller KB, Kaplan MM. Increased incidence of hypothyroidism in primary biliary cirrhosis. Dig. Dis. Sci. 28: 971-975 (1983).
Elvevoll EO, Eilertsen KE, Brox J, Dragnes BT, Falkenberg P, Olsen JO, Kirkhus B, Lamglait A, Osterud B. Seafood diets: hypolipidemic and antiatherogenic effects of taurine and n-3 fatty acids. Atherosclerosis 200: 396-402 (2008).
Elwing JE, Gao F, Davidson NO, Early DS. Type 2 diabetes mellitus: the impact on colorectal adenoma risk in women. Am. J. Gastroenterol. 101: 1866-1871 (2006). *
Emerick KM, Elias ME, Melin-Aldana H, Strautnieks S, Thompson RJ, Bull LN, Knisely AS, Whitington PF, Green RM. Bile composition in Alagille syndrome and PFIC patients having partial external biliary diversion. BMC Gastroenterol. 8: 47 (2008). *
Emsley R, Niehaus DJ, Oosthuizen PP, Koen L, Ascott-Evans B, Chiliza B, van Rensburg SJ, Smit RM. Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized, placebo-controlled trial. Psychiatry Res. 161: 284-291 (2008).
Endres M. Statins: potential new indications in inflammatory conditions. Atheroscler. Suppl. 7: 31-35 (2006).
Engel T, Kannenberg F, Fobker M, Nofer JR, Bode G, Lueken A, Assmann G, Seedorf U. Expression of ATP binding cassette-transporter ABCG1 prevents cell death by transporting cytotoxic 7beta-hydroxycholesterol. FEBS Lett. 581: 1673-1680 (2007). *
Englyst NA, Grimble RF, Byrne CD. Long-chain n-3 fatty acid supplementation in men increases resistance to activated protein C. Metabolism 56: 547-551 (2007). *
Ercan E, Tengiz I, Altuglu I, Sekuri C, Aliyev E, Ercan HE, Akin M. Atorvastatin treatment decreases inflammatory and proteolytic activity in patients with hypercholesterolemia. Kardiol. Pol. 60: 454-458 (2004).
Ergen A, Isbir S, Tekeli A, Isbir T. Investigation of ABCA1 C69T and G-191C polymorphisms in coronary artery disease. In Vivo 22: 187-190 (2008).
Erickson RP, Bhattacharyya A, Hunter RJ, Heidenreich RA, Cherrington NJ. Liver disease with altered bile acid transport in Niemann-Pick C mice on a high fat, 1% cholesterol diet. Am. J. Physiol. Gastrointest. Liver Physiol. 289: G300-G307 (2005). *
Erickson SK, Lear SR, Deane S, Dubrac S, Huling SL, Nguyen L, Bollineni JS, Shefer S, Hyogo H, Cohen DE, Shneider B, Sehayek E, Ananthanarayanan M, Balasubramaniyan N, Suchy FJ, Batta AK, Salen G. Hypercholesterolemia and changes in lipid and bile acid metabolism in male and female cyp7A1-deficient mice. J. Lipid Res. 44: 1001-1009 (2003). *
Erion MD, Cable EE, Ito BR, Jiang H, Fujitaki JM, Finn PD, Zhang BH, Hou J, Boyer SH, van Poelje PD, Linemeyer DL. Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proc. Natl. Acad. Sci. U.S.A. 104: 15490-15495 (2007). *
Erlinger S. Drug-induced cholestasis. J. Hepatol. 26 Suppl. 1: 1-4 (1997).
Erlinger S. Cystic fibrosis: bile secretion. Br. Med. Bull. 48: 860-876 (1992).
Erlinger S. Formation of the bile. Rev. Prat. 41: 2341-2346 (1991).
Erridge C, Webb DJ, Spickett CM. 25-Hydroxycholesterol, 7beta-hydroxycholesterol and 7-ketocholesterol upregulate interleukin-8 expression independently of Toll-like receptor 1, 2, 4 or 6 signalling in human macrophages. Free Radic. Res. 41: 260-266 (2007).
Ertam I, Alper S, Unal I. Is it necessary to have routine blood tests in patients treated with isotretinoin? J. Dermatolog. Treat. 17: 214-216 (2006).
Ertas FS, Hasan T, Ozdol C, Gulec S, Atmaca Y, Tulunay C, Karabulut H, Kocum HT, Dincer I, Kose KS, Erol C. Relationship between angiotensin-converting enzyme gene polymorphism and severity of aortic valve calcification. Mayo Clin. Proc. 82: 944-950 (2007). *
Ertekin V, Selimoglu MA, Turkan Y, Akcay F. Serum nitric oxide levels in children with celiac disease. J. Clin. Gastroenterol. 39: 782-785 (2005).
Escobar Castro H, Garcia Novo Mf MD, Olivares P. Biliary lithiasis in childhood. Therapeutic approaches. An. Pediatr. (Barc.) 60: 170-174 (2004).
Eslick GD, Howe PR, Smith C, Priest R, Bensoussan A. Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis. Int. J. Cardiol. Sep 5 [Epub ahead of print] (2008).
Esterman AL, Baum H, Javitt NB, Darlington GJ. 26-Hydroxycholesterol: regulation of hydroxymethylglutaryl-CoA reductase activity in Chinese hamster ovary cell culture. J. Lipid Res. 24: 1304-1309 (1983). *
Esterman AL, Cohen BI, Javitt NB. Cholesterol metabolism: use of D2O for determination of synthesis rate in cell culture. J. Lipid Res. 26: 950-954 (1985). *
Esteve E, Villuendas G, Mallolas J, Vendrell J, Lopez-Bermejo A, Rodriguez M, Recasens M, Ricart W, San Millan JL, Escobar-Morreale H, Richart C, Fernandez-Real JM. Polymorphisms in the interleukin-6 receptor gene are associated with body mass index and with characteristics of the metabolic syndrome. Clin. Endocrinol. (Oxf.) 65: 88-91 (2006). *
Etienne J, Beucler I, Ayrault M, Cloarec M, Polonovski J, Debray J. Abnormal lipoproteins in a case of primary biliary cirrhosis. Biomedicine 29: 33-37 (1978).
Eusufzai S, Ericsson S, Cederlund T, Einarsson K, Angelin B. Effect of ursodeoxycholic acid treatment on ileal absorption of bile acids in man as determined by the SeHCAT test. Gut 32: 1044-1048 (1991). *
Evans D, Beil FU. The E670G SNP in the PCSK9 gene is associated with polygenic hypercholesterolemia in men but not in women. BMC Med. Genet. 7: 66 (2006). *
Evans J, Collins M, Jennings C, van der Merwe L, S�derstr�m I, Olsson T, Levitt NS, Lambert EV, Goedecke JH. The association of interleukin-18 genotype and serum levels with metabolic risk factors for cardiovascular disease. Eur. J. Endocrinol. 157: 633-640 (2007). *
Evans JL, Lin JJ, Goldfine ID. Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta. Curr. Diabetes Rev. 1: 299-307 (2005).
Evans MJ, Mahaney PE, Borges-Marcucci L, Lai K, Wang S, Krueger JA, Gardell SJ, Huard C, Martinez RV, Vlasuk GP, Harnish DC. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. Am. J. Physiol. Gastrointest. Liver Physiol. 296: G543-G552 (2009). *
Everson GT, Daggy BP, McKinley C, Story JA. Effects of Psyllium hydrophilic mucilloid on LDL-cholesterol and bile acid synthesis in hypercholesterolemic men. J. Lipid Res. 33: 1183-1192 (1992). *
Everson GT, Fennessey P, Kern F Jr. Contraceptive steroids alter the steady-state kinetics of bile acids. J. Lipid Res. 29: 68-76 (1988). *
Everson GT, McKinley C, Kern F Jr. Mechanisms of gallstone formation in women. Effects of exogenous estrogen (Premarin) and dietary cholesterol on hepatic lipid metabolism. J. Clin. Invest. 87: 237-246 (1991). *
Everson GT, McKinley C, Lawson M, Johnson M, Kern F Jr. Gallbladder function in the human female: effect of the ovulatory cycle, pregnancy, and contraceptive steroids. Gastroenterology 82: 711-719 (1982).
Everson GT, Polokoff MA. HepG2. A human hepatoblastoma cell line exhibiting defects in bile acid synthesis and conjugation. J. Biol. Chem. 261: 2197-2201 (1986). *
Everson GT, Trouillot T, Wachs M, Bak T, Steinberg T, Kam I, Shrestha R, Stegall M. Early steroid withdrawal in liver transplantation is safe and beneficial. Liver Transpl. Surg. 5: S48-S57 (1999).
Ewerth S. On the enterohepatic circulation of bile acids in man. Acta Chir. Scand. Suppl. 513: 1-38 (1982).
Ezzidi I, Mtiraoui N, Kacem M, Mallat SG, Mohamed MB, Chaieb M, Mahjoub T, Almawi WY. Interleukin-10 -592C/A, -819C/T, and -1082A/G promoter variants affect the susceptibility to nephropathy in Tunisian type 2 diabetes patients. Clin. Endocrinol. (Oxf.) 70: 401-407 (2009).
Ezzidi I, Mtiraoui N, Mohamed MB, Mahjoub T, Kacem M, Almawi WY. Endothelial nitric oxide synthase Glu298Asp, 4b/a, and T-786C polymorphisms in type 2 diabetic retinopathy. Clin. Endocrinol. (Oxf.) 68: 542-546 (2008). *
Fabian E, Elmadfa I. Nutritional situation of the elderly in the European Union: data of the European Nutrition and Health Report (2004). Ann. Nutr. Metab. 52 Suppl. 1: 57-61 (2008).
Fabris C, Smirne C, Fangazio S, Toniutto P, Burlone M, Minisini R, Bitetto D, Falleti E, Cerutti A, Pirisi M. Influence of angiotensin-converting enzyme I/D gene polymorphism on clinical and histological correlates of chronic hepatitis C. Hepatol. Res. Apr 23 [Epub ahead of print] (2009). *
Fabris C, Toniutto P, Bitetto D, Minisini R, Fornasiere E, Smirne C, Pirisi M. Sex-related influence of angiotensin-converting enzyme polymorphisms on fibrosis progression due to recurrent hepatitis C after liver transplantation. J. Gastroenterol. 42: 543-549 (2007). *
Falasca K, Ucciferri C, Mancino P, Vitacolonna E, De Tullio D, Pizzigallo E, Conti P, Vecchiet J. Treatment with silybin-vitamin E-phospholipid complex in patients with hepatitis C infection. J. Med. Virol. 80: 1900-1906 (2008).
Fan JG, Zhong L, Tia LY, Xu ZJ, Li MS, Wang GL. Effects of ursodeoxycholic acid and/or low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia. World J. Gastroenterol. 11: 2346-2350 (2005). *
Fan P, Zhang B, Kuroki S, Saku K. Pitavastatin, a potent hydroxymethylglutaryl coenzyme A reductase inhibitor, increases cholesterol 7 alpha-hydroxylase gene expression in HepG2 cells. Circ. J. 68: 1061-1066 (2004). *
Fan X, Kim HJ, Bouton D, Warner M, Gustafsson JA. Expression of liver X receptor beta is essential for formation of superficial cortical layers and migration of later-born neurons. Proc. Natl. Acad. Sci. U.S.A. 105: 13445-13450 (2008). *
Fan YY, Ly LH, Barhoumi R, McMurray DN, Chapkin RS. Dietary docosahexaenoic acid suppresses T cell protein kinase C theta lipid raft recruitment and IL-2 production. J. Immunol. 173: 6151-6160 (2004). *
Fang HL, Strom SC, Cai H, Falany CN, Kocarek TA, Runge-Morris M. Regulation of human hepatic hydroxysteroid sulfotransferase gene expression by the peroxisome proliferator-activated receptor alpha transcription factor. Mol. Pharmacol. 67: 1257-1267 (2005). *
Farias AQ, Goncalves LL, Bittencourt PL, De Melo ES, Abrantes-Lemos CP, Porta G, Nakhle MC, Carrilho FJ, Cancado EL. Applicability of the IAIHG scoring system to the diagnosis of antimitochondrial/anti-M2 seropositive variant form of autoimmune hepatitis. J. Gastroenterol. Hepatol. 21: 887-893 (2006). *
Farkkila M, Rautiainen H, Karkkainen P, Karvonen AL, Nurmi H, Niemela O. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy. Liver Int. 28: 787-797 (2008). *
Farmer JA, Gotto AM Jr. Currently available hypolipidaemic drugs and future therapeutic developments. Baillieres Clin. Endocrinol. Metab. 9: 825-847 (1995).
Farnier M, Salko T, Isaacsohn JL, Troendle AJ, Dejager S, Gonasun L. Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil). Am. J. Cardiol. 92: 794-797 (2003). *
Farooqui AA, Ong WY, Horrocks LA, Chen P, Farooqui T. Comparison of biochemical effects of statins and fish oil in brain: the battle of the Titans. Brain Res. Rev. 56: 443-471 (2007).
Farshchian M, Zamanian A, Farshchian M, Monsef AR, Mahjub H. Serum lipid level in Iranian patients with psoriasis. J. Eur. Acad. Dermatol. Venereol. 21: 802-805 (2007).
Farzaneh-Far R, Harris WS, Garg S, Na B, Whooley MA. Inverse association of erythrocyte n-3 fatty acid levels with inflammatory biomarkers in patients with stable coronary artery disease: The Heart and Soul Study. Atherosclerosis Dec 14 [Epub ahead of print] (2008).
Faulkner LE, Panagotopulos SE, Johnson JD, Woollett LA, Hui DY, Witting SR, Maiorano JN, Davidson WS. An analysis of the role of a retroendocytosis pathway in ABCA1-mediated cholesterol efflux from macrophages. J. Lipid Res. 49: 1322-1332 (2008). *
Fayard E, Auwerx J, Schoonjans K. LRH-1: an orphan nuclear receptor involved in development, metabolism and steroidogenesis. Trends Cell Biol. 14: 250-260 (2004). *
Fayard E, Schoonjans K, Auwerx J. Xol INXS: role of the liver X and the farnesol X receptors. Curr. Opin. Lipidol. 12: 113-120 (2001).
Fazle Akbar SM, Furukawa S, Nakanishi S, Abe M, Horiike N, Onji M. Therapeutic efficacy of decreased nitrite production by bezafibrate in patients with primary biliary cirrhosis. J. Gastroenterol. 40: 157-163 (2005). *
Feart C, Peuchant E, Letenneur L, Samieri C, Montagnier D, Fourrier-Reglat A, Barberger-Gateau P. Plasma eicosapentaenoic acid is inversely associated with severity of depressive symptomatology in the elderly: data from the Bordeaux sample of the Three-City Study. Am. J. Clin. Nutr. 87: 1156-1162 (2008). *
Feher J, Lengyel G. Nutrition and cardiovascular mortality. Orv. Hetil. 147: 1491-1496 (2006).
Feige JN, Auwerx J. DisSIRTing on LXR and cholesterol metabolism. Cell. Metab. 6: 343-345 (2007). *
Feingold KR. The role of epidermal lipids in cutaneous permeability barrier homeostasis. J. Lipid Res. 48: 2531-2546 (2007). *
Feingold KR, Wang Y, Moser A, Shigenaga JK, Grunfeld C. LPS decreases fatty acid oxidation and nuclear hormone receptors in the kidney. J. Lipid Res. 49: 2179-2187 (2008). *
Feng X, Li H, Rumbin AA, Wang X, La Cava A, Brechtelsbauer K, Castellani LW, Witztum JL, Lusis AJ, Tsao BP. ApoE-/-Fas-/-C57BL/6 mice: a novel murine model simultaneously exhibits lupus nephritis, atherosclerosis and osteopenia. J. Lipid Res. 48: 794-805 (2007). *
Fenske SA, Yesilaltay A, Pal R, Daniels K, Barker C, Quinones V, Rigotti A, Krieger M, Kocher O. Normal hepatic cell-surface localization of the high-density lipoprotein receptor, SR-BI, depends on all four PDZ domains of PDZK1. J. Biol. Chem. 284: 5797-5806 (2009). *
Fenske SA, Yesilaltay A, Pal R, Daniels K, Rigotti A, Krieger M, Kocher O. Overexpression of the PDZ1 domain of PDZK1 blocks the activity of hepatic scavenger receptor, class B, type I by altering its abundance and cellular localization. J. Biol. Chem. 283: 22097-22104 (2008). *
Fernandez A, Colell A, Caballero F, Matias N, Garcia-Ruiz C, Fernandez-Checa JC. Mitochondrial S-adenosyl-L-methionine transport is insensitive to alcohol-mediated changes in membrane dynamics. Alcohol Clin. Exp. Res. Apr 9 [Epub ahead of print] (2009).
Fernandez A, Colell A, Garcia-Ruiz C, Fernandez-Checa JC. Cholesterol and sphingolipids in alcohol-induced liver injury. J. Gastroenterol. Hepatol. 23 Suppl. 1: S9-S15 (2008). *
Fernandez AZ. PPARs as targets for the modulation of cardiovascular risk factors associated with the metabolic syndrome. Curr. Opin. Investig. Drugs 5: 936-940 (2004).
Fernandez E, Galan AI, Moran D, Gonzalez-Buitrago JM, Munoz ME, Jimenez R. Reversal of cyclosporine A-induced alterations in biliary secretion by S-adenosyl-L-methionine in rats. J. Pharmacol. Exp. Ther. 275: 442-449 (1995).
Fernandez-Checa JC. Alcohol-induced liver disease: when fat and oxidative stress meet. Ann. Hepatol. 2: 69-75 (2003). *
Fernandez-Veledo S, Nieto-Vazquez I, Rondinone CM, Lorenzo M. Liver X receptor agonists ameliorate TNFalpha-induced insulin resistance in murine brown adipocytes by downregulating protein tyrosine phosphatase-1B gene expression. Diabetologia 49: 3038-3048 (2006). *
Ferno J, Vik-Mo AO, Jassim G, Havik B, Berge K, Skrede S, Gudbrandsen OA, Waage J, Lunder N, Mork S, Berge RK, Jorgensen HA, Steen VM. Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver. Psychopharmacology (Berl.) 203: 73-84 (2009).
Ferroni P, Basili S, Santilli F, Davi G. Low-density lipoprotein-lowering medication and platelet function. Pathophysiol. Haemost. Thromb. 35: 346-354 (2006).
Festi D, Montagnani M, Azzaroli F, Lodato F, Mazzella G, Roda A, Di Biase AR, Roda E, Simoni P, Colecchia A. Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases. Curr. Clin. Pharmacol. 2: 155-177 (2007).
Fickert P, Moustafa T, Fuchsbichler A, Claudel T, Halilbasic E, Kratky D, Zatloukal K, Denk H, Trauner M. Differential effects of ursodeoxycholic acid (UDCA) and sidechain-shortened norUDCA in the treatment of fatty liver and atherosclerosis. Falk Symposium 165: XX International Bile Acid Meeting. Bile Acid Biology and Therapeutic Actions. June 13-14, 2008, Amsterdam, Netherlands, p. 54 (2008). *
Fickert P, Wagner M, Marschall HU, Fuchsbichler A, Zollner G, Tsybrovskyy O, Zatloukal K, Liu J, Waalkes MP, Cover C, Denk H, Hofmann AF, Jaeschke H, Trauner M. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 130: 465-481 (2006). *
Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Pojer C, Zenz R, Lammert F, Stieger B, Meier PJ, Zatloukal K, Denk H, Trauner M. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology 121: 170-183 (2001). *
Fiegenbaum M, da Silveira FR, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC, Hutz MH. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin. Pharmacol. Ther. 78: 551-558 (2005). *
Field FJ, Born E, Mathur SN. LXR/RXR ligand activation enhances basolateral efflux of beta-sitosterol in CaCo-2 cells. J. Lipid Res. 45: 905-913 (2004). *
Fievet C, Staels B. Liver X receptor modulators: effects on lipid metabolism and potential use in the treatment of atherosclerosis. Biochem. Pharmacol. 77: 1316-1327 (2009). *
Figge A, Lammert F, Paigen B, Henkel A, Matern S, Korstanje R, Shneider BL, Chen F, Stoltenberg E, Spatz K, Hoda F, Cohen DE, Green RM. Hepatic overexpression of murine Abcb11 increases hepatobiliary lipid secretion and reduces hepatic steatosis. J. Biol. Chem. 279: 2790-2799 (2004). *
Figge A, Matern S, Lammert F. Molecular genetics of cholesterol cholelithiasis: identification of human and murine gallstone genes. Z. Gastroenterol. 40: 425-432 (2002).
Filipovic B, Opric M, Milicic A, Paranos S. Primary biliary cirrhosis. Srp. Arh. Celok. Lek. 130: 213-216 (2002).
Filus A, Trzmiel A, Kuliczkowska-Plaksej J, Tworowska U, Jedrzejuk D, Milewicz A, Medras M. Relationship between vitamin D receptor BsmI and FokI polymorphisms and anthropometric and biochemical parameters describing metabolic syndrome. Aging Male 11: 134-139 (2008).
Fiorucci S, Clerici C, Antonelli E, Orlandi S, Goodwin B, Sadeghpour B, Sabatino G, Russo G, Castellani D, Willson TM, Pellicciari R, Morelli A. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor (FXR) ligand, in estrogen induced cholestasis. J. Pharmacol. Exp. Ther. 313: 604-612 (2005). *
Fiorucci S, Rizzo G, Donini A, Distrutti E, Santucci L. Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol. Med. 13: 298-309 (2007). *
Fischer Aggarwal BA, Liao M, Mosca L. Physical activity as a potential mechanism through which social support may reduce cardiovascular disease risk. J. Cardiovasc. Nurs. 23: 90-96 (2008).
Fischer S, Muller I, Zundt BZ, Jungst C, Meyer G, Jungst D. Ursodeoxycholic acid decreases viscosity and sedimentable fractions of gallbladder bile in patients with cholesterol gallstones. Eur. J. Gastroenterol. Hepatol. 16: 305-311 (2004).
Fischler B, Papadogiannakis N, Nemeth A. Clinical aspects on neonatal cholestasis based on observations at a Swedish tertiary referral centre. Acta Paediatr. 90: 171-178 (2001).
Fitzgerald ML, Moore KJ, Freeman MW. Nuclear hormone receptors and cholesterol trafficking: the orphans find a new home. J. Mol. Med. 80: 271-281 (2002). *
Fitzgerald ML, Okuhira KI, Short GF 3rd, Manning JJ, Bell SA, Freeman MW. ATP-binding cassette transporter A1 contains a novel C-terminal VFVNFA motif that is required for its cholesterol efflux and apoA-I binding activities. J. Biol. Chem. 279: 48477-48485 (2004). *
Flanagan K, Modrusan Z, Cornelius J, Chavali A, Kasman I, Komuves L, Mo L, Diehl L. Intestinal epithelial cell up-regulation of LY6 molecules during colitis results in enhanced chemokine secretion. J. Immunol. 180: 3874-3881 (2008). *
Flatt B, Martin R, Wang TL, Mahaney P, Murphy B, Gu XH, Foster P, Li J, Pircher P, Petrowski M, Schulman I, Westin S, Wrobel J, Yan G, Bischoff E, Daige C, Mohan R. Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). J. Med. Chem. Jan 21 [Epub ahead of print] (2009). *
Flavell DM, Pineda Torra I, Jamshidi Y, Evans D, Diamond JR, Elkeles RS, Bujac SR, Miller G, Talmud PJ, Staels B, Humphries SE. Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in type II diabetic subjects. Diabetologia 43: 673-680 (2000). *
Flemming JA, Perkins KH, Luus L, Ferguson AR, Corley RB. Disruption of membrane cholesterol stimulates MyD88-dependent NF-kappaB activation in immature B cells. Cell. Immunol. 229: 68-77 (2004). *
Fletcher N, Wahlstrom D, Lundberg R, Nilsson CB, Nilsson KC, Stockling K, Hellmold H, Hakansson H. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) alters the mRNA expression of critical genes associated with cholesterol metabolism, bile acid biosynthesis, and bile transport in rat liver: a microarray study. Toxicol. Appl. Pharmacol. 207: 1-24 (2005). *
Floreani A. A novel approach for prevention and dissolution of cholesterol gallstones. Liver Int. 28: 906-907 (2008). *
Floreani A, Carderi I, Paternoster D, Soardo G, Azzaroli F, Esposito W, Montagnani M, Marchesoni D, Variola A, Rosa Rizzotto E, Braghin C, Mazzella G. Hepatobiliary phospholipid transporter ABCB4, MDR3 gene variants in a large cohort of Italian women with intrahepatic cholestasis of pregnancy. Dig. Liver Dis. 40: 366-370 (2008).
Floreani A, Carderi I, Paternoster D, Soardo G, Azzaroli F, Esposito W, Variola A, Tommasi AM, Marchesoni D, Braghin C, Mazzella G. Intrahepatic cholestasis of pregnancy: three novel MDR3 gene mutations. Aliment. Pharmacol. Ther. 23: 1649-1653 (2006). *
Floreani A, Variola A, Niro G, Premoli A, Baldo V, Gambino R, Musso G, Cassader M, Bo S, Ferrara F, Caroli D, Rizzotto ER, Durazzo M. Plasma adiponectin levels in primary biliary cirrhosis: a novel perspective for link between hypercholesterolemia and protection against atherosclerosis. Am. J. Gastroenterol. 103: 1959-1965 (2008). *
Flowers MT, Groen AK, Oler AT, Keller MP, Choi Y, Schueler KL, Richhards OC, Lan H, Miyazaki M, Kuipers F, Kendziorski CM, Ntambi JM, Attie AD. Cholestasis and hypercholesterolemia in SCD1-deficient mice fed a low-fat, high-carbohydrate diet. J. Lipid Res. 47: 2668-2680 (2006). *
Flowers MT, Keller MP, Choi Y, Lan H, Kendziorski CM, Ntambi JM, Attie AD. Liver gene expression analysis reveals endoplasmic reticulum stress and metabolic dysfunction in SCD1-deficient mice fed a very low-fat diet. Physiol. Genomics 33: 361-372 (2008). *
Foley KF, Silveira MG, Hornseth JM, Lindor KD, McConnell JP. A patient with primary biliary cirrhosis and elevated LDL cholesterol. Clin. Chem. 55: 187-192 (2009). *
Folzenlogen D. A case of atorvastatin combined toxic myopathy and inflammatory myositis. J. Clin. Rheumatol. 7: 340-345 (2001).
Fon Tacer K, Kuzman D, Seliskar M, Pompon D, Rozman D. TNF-alpha interferes with lipid homeostasis and activates acute and pro-atherogenic processes. Physiol. Genomics 31: 216-227 (2007). *
Fonolla J, Lopez-Huertas E, Machado FJ, Molina D, Alvarez I, Marmol E, Navas M, Palac�n E, Garcia-Valls MJ, Remon B, Boza JJ, Marti JL. Milk enriched with "healthy fatty acids" improves cardiovascular risk markers and nutritional status in human volunteers. Nutrition 25: 408-414 (2009).
Font J, Ramos-Casals M, Brito-Zeron P, Nardi N, Ibanez A, Suarez B, Jimenez S, Tassies D, Garcia-Criado A, Ros E, Sentis J, Reverter JC, Lozano F. Association of mannose-binding lectin gene polymorphisms with antiphospholipid syndrome, cardiovascular disease and chronic damage in patients with systemic lupus erythematosus. Rheumatology (Oxford) 46: 76-80 (2007). *
Fontaine C, Rigamonti E, Nohara A, Gervois P, Teissier E, Fruchart JC, Staels B, Chinetti-Gbaguidi G. Liver X receptor activation potentiates the lipopolysaccharide response in human macrophages. Circ. Res. 101: 40-49 (2007). *
Fontaine C, Rigamonti E, Pourcet B, Duez H, Duhem C, Fruchart JC, Chinetti-Gbaguidi G, Staels B. The nuclear receptor Rev-erbalpha is a liver X receptor (LXR) target gene driving a negative feedback loop on select LXR-induced pathways in human macrophages. Mol. Endocrinol. 22: 1797-1811 (2008). *
Fontaine-Bisson B, Wolever TM, Chiasson JL, Rabasa-Lhoret R, Maheux P, Josse RG, Leiter LA, Rodger NW, Ryan EA, Connelly PW, Corey PN, El-Sohemy A. Genetic polymorphisms of tumor necrosis factor-alpha modify the association between dietary polyunsaturated fatty acids and fasting HDL-cholesterol and apo A-I concentrations. Am. J. Clin. Nutr. 86: 768-774 (2007). *
Fontaine-Bisson B, Wolever TM, Connelly PW, Corey PN, El-Sohemy A. NF-kappaB -49Ins/Del ATTG polymorphism modifies the association between dietary polyunsaturated fatty acids and HDL-cholesterol in two distinct populations. Atherosclerosis 204: 465-470 (2009).
Ford DA, Monda JK, Brush RS, Anderson RE, Richards MJ, Fliesler SJ. Lipidomic analysis of the retina in a rat model of Smith-Lemli-Opitz syndrome: alterations in docosahexaenoic acid content of phospholipid molecular species. J. Neurochem. 105: 1032-1047 (2008).
Forman D, Bulwer BE. Cardiovascular disease: optimal approaches to risk factor modification of diet and lifestyle. Curr. Treat. Options Cardiovasc. Med. 8: 47-57 (2006).
Forrester JS, Shah PK. Emerging strategies for increasing high-density lipoprotein. Am. J. Cardiol. 98: 1542-1549 (2006). *
Foschini MP, Macchia S, Losi L, Dei Tos AP, Pasquinelli G, Di Tommaso L, Del Duca S, Roncaroli F, Dal Monte PR. Identification of mitochondria in liver biopsies. A study by immunohistochemistry, immunogold and Western blot analysis. Virchows. Arch. 433: 267-273 (1998). *
Fouassier L, Kinnman N, Lefevre G, Lasnier E, Rey C, Poupon R, Oude Elferink RP, Housset C. Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan. J. Hepatol. 37: 184-191 (2002). *
Fracchia M, Jazrawi RP, Galatola G. Determination of gallbladder bile lithogenicity in patients with primary biliary cirrhosis. Ital. J. Gastroenterol. 28: 255-260 (1996).
Fracchia M, Pellegrino S, Secreto P, Pera A, Galatola G. Biliary lipid composition in idiopathic bile acid malabsorption. Gut 43: 812-816 (1998). *
Franceschini G, Calabresi L, Colombo C, Favari E, Bernini F, Sirtori CR. Effects of fenofibrate and simvastatin on HDL-related biomarkers in low-HDL patients. Atherosclerosis 195: 385-391 (2007).
Franchimont D, Roland S, Gustot T, Quertinmont E, Toubouti Y, Gervy MC, Deviere J, Van Gossum A. Impact of infliximab on serum leptin levels in patients with Crohn's disease. J. Clin. Endocrinol. Metab. 90: 3510-3516 (2005). *
Francis GA, Fayard E, Picard F, Auwerx J. Nuclear receptors and the control of metabolism. Annu. Rev. Physiol. 65: 261-311 (2003). *
Francis GA, Li G, Casey R, Wang J, Cao H, Leff T, Hegele RA. Peroxisomal proliferator activated receptor-gamma deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3). BMC Med. Genet. 7: 3 (2006). *
Francke S, Manraj M, Lacquemant C, Lecoeur C, Lepr�tre F, Passa P, Hebe A, Corset L, Yan SL, Lahmidi S, Jankee S, Gunness TK, Ramjuttun US, Balgobin V, Dina C, Froguel P. A genome-wide scan for coronary heart disease suggests in Indo-Mauritians a susceptibility locus on chromosome 16p13 and replicates linkage with the metabolic syndrome on 3q27. Hum. Mol. Genet. 10: 2751-2765 (2001). *
Franco J, Saeian K. Biliary tract inflammatory disorders: primary sclerosing cholangitis and primary biliary cirrhosis. Curr. Gastroenterol. Rep. 1: 95-101 (1999).
Fraunberger P, Grone E, Grone HJ, Walli AK. Simvastatin reduces endotoxin-induced NF-kappaB activation and mortality in guinea pigs despite lowering circulating LDL cholesterol. Shock Nov 11 [Epub ahead of print] (2008).
Freudenberg F, Broderick AL, Yu BB, Leonard MR, Glickman JN, Carey MC. Pathophysiologic basis of liver disease in cystic fibrosis employing a DeltaF508 mouse model. Am. J. Physiol. Gastrointest. Liver Physiol. 294: G1411-G1420 (2008). *
Freudenberg F, Carey MC. Hepatobiliary manifestations in inflammatory bowel disease. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, pp. 56-57 (2005). *
Frey T, De Maio A. Increased expression of CD14 in macrophages after inhibition of the cholesterol biosynthetic pathway by lovastatin. Mol. Med. 13: 592-604 (2007). *
Frezza EE, Gerunda GE, Plebani M, Galligioni A, Giacomini A, Neri D, Faccioli AM, Tiribelli C. Effect of ursodeoxycholic acid administration on bile duct proliferation and cholestasis in bile duct ligated rat. Dig. Dis. Sci. 38: 1291-1296 (1993).
Frikke-Schmidt R, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A. Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. J. Clin. Invest. 114: 1343-1353 (2004). *
Fromm H, Roat JW, Gonzalez V, Sarva RP, Farivar S. Comparative efficacy and side effects of ursodeoxycholic and chenodeoxycholic acids in dissolving gallstones. A double-blind controlled study. Gastroenterology 85: 1257-1264 (1983).
Froy O. The relationship between nutrition and circadian rhythms in mammals. Front. Neuroendocrinol. 28: 61-71 (2007).
Fruchart JC, Duriez P. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc.) 42: 39-64 (2006).
Fruchart JC, Duriez P, Staels B. Molecular mechanism of action of the fibrates. J. Soc. Biol. 193: 67-75 (1999).
Fruchart JC, Duriez P, Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr. Opin. Lipidol. 10: 245-257 (1999).
Fruchart JC, Staels B, Duriez P. PPARS, metabolic disease and atherosclerosis. Pharmacol. Res. 44: 345-352 (2001). *
Fu J, Oveisi F, Gaetani S, Lin E, Piomelli D. Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats. Neuropharmacology 48: 1147-1153 (2005). *
Fu JF, Fang YL, Liang L, Wang CL, Hong F, Dong GP. A rabbit model of pediatric nonalcoholic steatohepatitis: the role of adiponectin. World J. Gastroenterol. 15: 912-918 (2009). *
Fu T, Kashireddy P, Borensztajn J. The peroxisome-proliferator-activated receptor alpha agonist ciprofibrate severely aggravates hypercholesterolaemia and accelerates the development of atherosclerosis in mice lacking apolipoprotein E. Biochem. J. 373: 941-947 (2003). *
Fu X, Menke JG, Chen Y, Zhou G, MacNaul KL, Wright SD, Sparrow CP, Lund EG. 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J. Biol. Chem. 276: 38378-38387 (2001). *
Fuchs M. Bile acid regulation of hepatic physiology: III. Regulation of bile acid synthesis: past progress and future challenges. Am. J. Physiol. Gastrointest. Liver Physiol. 284: G551-G557 (2003). *
Fuchs M, Stange EF. Cholesterol and cholestasis: a lesson from the Mdr2 (-/-) mouse. J. Hepatol. 34: 339-341 (2001). *
Fuda H, Javitt NB, Mitamura K, Ikegawa S, Strott CA. Oxysterols are substrates for cholesterol sulfotransferase. J. Lipid Res. 48: 1343-1352 (2007). *
Fuda H, Lee YC, Shimizu C, Javitt NB, Strott CA. Mutational analysis of human hydroxysteroid sulfotransferase SULT2B1 isoforms reveals that exon 1B of the SULT2B1 gene produces cholesterol sulfotransferase, whereas exon 1A yields pregnenolone sulfotransferase. J. Biol. Chem. 277: 36161-36166 (2002). *
Fujii T, Takada-Takatori Y, Kawashima K. Basic and clinical aspects of non-neuronal acetylcholine: expression of an independent, non-neuronal cholinergic system in lymphocytes and its clinical significance in immunotherapy. J. Pharmacol. Sci. 106: 186-192 (2008). *
Fujino T, Une M, Imanaka T, Inoue K, Nishimaki-Mogami T. Structure-activity relationship of bile acids and bile acid analogs in regard to FXR activation. J. Lipid Res. 45: 132-138 (2004). *
Fujisawa S, Chiba H, Akizawa K, Intoh S, Watanabe M, Matsuno K, Kobayashi K. Rapid alteration in serum lipoprotein profile after bile drainage in a patient with acute bile duct obstruction: contribution of cholestasis to cholesteryl ester-dominant ApoE-rich HDL accumulation. Rinsho Byori 41: 679-684 (1993).
Fujiwara Y, Yokoyama M, Sawada R, Seyama Y, Ishii M, Tsutsumi S, Aburatani H, Hanaka S, Itakura H, Matsumoto A. Analysis of the comprehensive effects of polyunsaturated fatty acid on mRNA expression using a gene chip. J. Nutr. Sci. Vitaminol. (Tokyo) 49: 125-132 (2003).
Fujiyoshi M, Ohtsuki S, Hori S, Tachikawa M, Terasaki T. 24S-Hydroxycholesterol induces cholesterol release from choroid plexus epithelial cells in an apical- and apoE isoform-dependent manner concomitantly with the induction of ABCA1 and ABCG1 expression. J. Neurochem. 100: 968-978 (2007). *
Fukuchi J, Song C, Dai Q, Hiipakka RA, Liao S. 5beta-Cholane activators of the farnesol X receptor. J. Steroid Biochem. Mol. Biol. 94: 311-318 (2005).
Fukuda W, Yamazaki T, Akaogi T, Hayashi H, Kusakabe T, Tsubouchi Y, Kawahito Y, Inoue M, Yoshikawa T. Malnutrition and disease progression in patients with rheumatoid arthritis. Mod. Rheumatol. 15: 104-107 (2005).
Fukuo Y, Kitami T, Nomoto T, Terashi A. A lipid lowering drug (bezafibrate) has a favorable effect on liver enzymes (Al-P and gamma-GTP). Nippon Ika Daigaku Zasshi 63: 424-430 (1996).
Furnsinn C, Willson TM, Brunmair B. Peroxisome proliferator-activated receptor-delta, a regulator of oxidative capacity, fuel switching and cholesterol transport. Diabetologia 50: 8-17 (2007). *
Furuya T, Urano T, Ikari K, Kotake S, Inoue S, Hara M, Momohara S, Kamatani N, Yamanaka H. A1330V polymorphism of low-density lipoprotein receptor-related protein 5 gene and self-reported incident fractures in Japanese female patients with rheumatoid arthritis. Mod. Rheumatol. 19: 140-146 (2009).
Gabbi C, Kim HJ, Hultenby K, Bouton D, Toresson G, Warner M, Gustafsson JA. Pancreatic exocrine insufficiency in LXRbeta(-/-) mice is associated with a reduction in aquaporin-1 expression. Proc. Natl. Acad. Sci. U.S.A. 105: 15052-15057 (2008). *
Gaede PH. Intensified multifactorial intervention in patients with type 2 diabetes and microalbuminuria: rationale and effect on late-diabetic complications. Dan. Med. Bull. 53: 258-284 (2006).
Gaiva MH, Couto RC, Oyama LM, Couto GE, Silveira VL, Ribeiro EB, Nascimento CM. Diets rich in polyunsaturated fatty acids: effect on hepatic metabolism in rats. Nutrition 19: 144-149 (2003). *
Galan AI, Munoz ME, Jimenez R. S-Adenosylmethionine protects against cyclosporin A-induced alterations in rat liver plasma membrane fluidity and functions. J. Pharmacol. Exp. Ther. 290: 774-781 (1999). *
Gallicchio L, Kalesan B, Huang HY, Strickland P, Hoffman SC, Helzlsouer KJ. Genetic polymorphisms of peroxisome proliferator-activated receptors and the risk of cardiovascular morbidity and mortality in a community-based cohort in Washington county, Maryland. PPAR Res. 2008: 276581 (2008). *
Galman C, Angelin B, Rudling M. Bile acid synthesis in humans has a rapid diurnal variation that is asynchronous with cholesterol synthesis. Gastroenterology 129: 1445-1453 (2005). *
Galman C, Ostlund-Lindqvist AM, Bjorquist A, Schreyer S, Svensson L, Angelin B, Rudling M. Pharmacological interference with intestinal bile acid transport reduces plasma cholesterol in LDL receptor/apoE deficiency. FASEB J. 17: 265-267 (2003). *
Gamerdinger M, Clement AB, Behl C. Cholesterol-like effects of selective COX inhibitors and fibrates on cellular membranes and amyloid-beta production. Mol. Pharmacol. 72: 141-151 (2007). *
Gandelman G, Aronow WS, Weiss MB. Resolving hyperlipidemia after liver transplantation in a patient with primary sclerosing cholangitis. Am. J. Ther. 13: 171-174 (2006).
Gao H, Zhang Z, Zhang J, Zhao N, Li Q, Bai M. Association of LT-alpha Ala252Gly gene polymorphism and the genetic predisposition of coronary heart disease in Chinese. Mol. Biol. Rep. Apr 14 [Epub ahead of print] (2009). *
Gao J, Xu Y, Yang Y, Yang Y, Zheng Z, Jiang W, Hong B, Yan X, Si S. Identification of upregulators of human ATP-binding cassette transporter A1 via high-throughput screening of a synthetic and natural compound library. J. Biomol. Screen. 13: 648-656 (2008).
Garcia MA, Margarita R, Mirta C, Hugo C, Pablo L, Estela A, de Davila MT. Alagille syndrome: cutaneous manifestations in 38 children. Pediatr. Dermatol. 22: 11-14 (2005).
Garcia Villarreal L, Zozaya JM, Macias E, Garcia Gonzalez N, Quiroga J, Conchillo F, Prieto J. The treatment of primary biliary cirrhosis with ursodeoxycholic acid. The short- and median-term results and their relation to the study of the disease. Rev. Esp. Enferm. Dig. 80: 311-315 (1991).
Garcia-Garcia AB, Gonzalez C, Real JT, Martin de Llano JJ, Gonzalez-Albert V, Civera M, Chaves FJ, Ascaso JF, Carmena R. Influence of microsomal triglyceride transfer protein promoter polymorphism -493 GT on fasting plasma triglyceride values and interaction with treatment response to atorvastatin in subjects with heterozygous familial hypercholesterolaemia. Pharmacogenet. Genomics 15: 211-218 (2005).
Garcia-Hejl C, Vest P, Renard C, Merens-Gonthier A, Boukhira A, Thefenne-Astier H. Falsely low LDL cholesterol results and cholestasis. Clin. Chem. 52: 2125-2127 (2006). *
Garcia-Ruiz C, Fernandez-Checa JC. Mitochondrial glutathione: hepatocellular survival-death switch. J. Gastroenterol. Hepatol. 21 Suppl. 3: S3-S6 (2006). *
Garduno-Siciliano L, Labarrios F, Tamariz J, Moreno MG, Chamorro G, Muriel P. Effect of alpha-asarone and a derivative on lipids, bile flow and Na(+)/K(+)-ATPase in ethinyl estradiol-induced cholestasis in the rat. Fundam. Clin. Pharmacol. 21: 81-88 (2007).
Garg A, Simha V. Update on dyslipidemia. J. Clin. Endocrinol. Metab. 92: 1581-1589 (2007). *
Garrido-Sanchez L, Garcia-Fuentes E, Rojo-Martinez G, Cardona F, Soriguer F, Tinahones FJ. Inverse relation between levels of anti-oxidized-LDL antibodies and eicosapentanoic acid (EPA). Br. J. Nutr. 100: 585-589 (2008). *
Gastaldelli A, Kozakova M, Hojlund K, Flyvbjerg A, Favuzzi A, Mitrakou A, Balkau B; The RISC Investigators. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 49: 1537-1544 (2009).
Gatfield D, Le Martelot G, Vejnar CE, Gerlach D, Schaad O, Fleury-Olela F, Ruskeepaa AL, Oresic M, Esau CC, Zdobnov EM, Schibler U. Integration of microRNA miR-122 in hepatic circadian gene expression. Genes Dev. 23: 1313-1326 (2009). *
Gautier EL, Huby T, Ouzilleau B, Doucet C, Saint-Charles F, Gremy G, Chapman MJ, Lesnik P. Enhanced immune system activation and arterial inflammation accelerates atherosclerosis in lupus-prone mice. Arterioscler. Thromb. Vasc. Biol. 27: 1625-1631 (2007). *
Gautier T, Tietge UJ, Boverhof R, Perton FG, Le Guern N, Masson D, Rensen PC, Havekes LM, Lagrost L, Kuipers F. Hepatic lipid accumulation in apolipoprotein CI-deficient mice is potentiated by cholesteryl ester transfer protein. J. Lipid Res. 48: 30-40 (2007). *
Gbaguidi GF, Agellon LB. The inhibition of the human cholesterol 7alpha-hydroxylase gene (CYP7A1) promoter by fibrates in cultured cells is mediated via the liver X receptor alpha and peroxisome proliferator-activated receptor alpha heterodimer. Nucleic Acids Res. 32: 1113-1121 (2004). *
Gbaguidi GF, Agellon LB. The atypical interaction of peroxisome proliferator-activated receptor alpha with liver X receptor alpha antagonizes the stimulatory effect of their respective ligands on the murine cholesterol 7alpha-hydroxylase gene promoter. Biochim. Biophys. Acta 1583: 229-236 (2002). *
Gehrig-Burger K, Kohout L, Gimpl G. CHAPSTEROL. A novel cholesterol-based detergent. FEBS J. 272: 800-812 (2005). *
Gennari L. Lasofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis. Drugs Today (Barc.) 42: 355-367 (2006).
Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Woodworth T, Gomez-Reino JJ. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug � Arthritis Rheum. 58: 2968-2980 (2008). *
Gentili C, Tutolo G, Pianezzi A, Cancedda R, Descalzi Cancedda F. Cholesterol secretion and homeostasis in chondrocytes: a liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein A1 expression. Matrix Biol. 24: 35-44 (2005).
Gentzsch M, Choudhury A, Chang XB, Pagano RE, Riordan JR. Misassembled mutant DeltaF508 CFTR in the distal secretory pathway alters cellular lipid trafficking. J. Cell. Sci. 120: 447-455 (2007). *
Genvigir FD, Hirata MH, Hirata RD. ABCA1 expression and statins: inhibitory effect in peripheral blood mononuclear cells. Pharmacogenomics 10: 997-1005 (2009).
George J, Liddle C. Nonalcoholic fatty liver disease: pathogenesis and potential for nuclear receptors as therapeutic targets. Mol. Pharm. 5: 49-59 (2008). *
Georgescu EF, Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J. Gastrointestin. Liver Dis. 16: 39-46 (2007). *
Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J. Gastroenterol. 15: 942-954 (2009). *
Geppert J, Kraft V, Demmelmair H, Koletzko B. Microalgal docosahexaenoic acid decreases plasma triacylglycerol in normolipidaemic vegetarians: a randomised trial. Br. J. Nutr. 95: 779-786 (2006). *
Geraghty JM, Goldin RD. Liver changes associated with cholecystitis. J. Clin. Pathol. 47: 457-460 (1994). *
Gerber JG, Kitch DW, Fichtenbaum CJ, Zackin RA, Charles S, Hogg E, Acosta EP, Connick E, Wohl D, Kojic EM, Benson CA, Aberg JA; for the AIDS Clinical Trial Group A5186 Team. Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J. Acquir. Immune Defic. Syndr. 47: 459-466 (2008).
Gerbod-Giannone MC, Del Castillo-Olivares A, Janciauskiene S, Gil G, Hylemon PB. Suppression of cholesterol 7alpha-hydroxylase transcription and bile acid synthesis by an alpha1-antitrypsin peptide via interaction with alpha1-fetoprotein transcription factor. J. Biol. Chem. 277: 42973-42980 (2002). *
Gerbod-Giannone MC, Li Y, Holleboom A, Han S, Hsu LC, Tabas I, Tall AR. TNFalpha induces ABCA1 through NF-kappaB in macrophages and in phagocytes ingesting apoptotic cells. Proc. Natl. Acad. Sci. U.S.A. 103: 3112-3117 (2006). *
Germann UA, Chambers TC. Molecular analysis of the multidrug transporter, P-glycoprotein. Cytotechnology 27: 31-60 (1998). *
Gervois P, Torra IP, Fruchart JC, Staels B. Regulation of lipid and lipoprotein metabolism by PPAR activators. Clin. Chem. Lab. Med. 38: 3-11 (2000).
Geuken E, Visser DS, Leuvenink HG, de Jong KP, Peeters PM, Slooff MJ, Kuipers F, Porte RJ. Hepatic expression of ABC transporters G5 and G8 does not correlate with biliary cholesterol secretion in liver transplant patients. Hepatology 42: 1166-1174 (2005). *
Geyer J, Wilke T, Petzinger E. The solute carrier family SLC10: more than a family of bile acid transporters regarding function and phylogenetic relationships. Naunyn. Schmiedebergs. Arch. Pharmacol. 372: 413-431 (2006). *
Geyeregger R, Zeyda M, Bauer W, Kriehuber E, Saemann MD, Zlabinger GJ, Maurer D, Stulnig TM. Liver X receptors regulate dendritic cell phenotype and function through blocked induction of the actin bundling protein fascin. Blood 109: 4288-4295 (2007). *
Geyeregger R, Zeyda M, Stulnig TM. Liver X receptors in cardiovascular and metabolic disease. Cell. Mol. Life Sci. 63: 524-539 (2006). *
Ghose R, Zimmerman TL, Thevananther S, Karpen SJ. Endotoxin leads to rapid subcellular re-localization of hepatic RXRalpha: a novel mechanism for reduced hepatic gene expression in inflammation. Nucl. Recept. 2: 4 (2004). *
Ghosh A. Obesity measures, metabolic profiles and dietary fatty acids in lean and obese postmenopausal diabetic Asian Indian women. Anthropol. Anz. 67: 83-93 (2009).
Gigliozzi A, Romeo R, Fraioli F, Cantafora A, Delle Monache M, Cardilli A, Attili AF, Scafato E, Carli L, Alvaro D. Effect of S-adenosyl-L-methionine and dilinoleoylphosphatidylcholine on liver lipid composition and ethanol hepatotoxicity in isolated perfused rat liver. Dig. Dis. Sci. 43: 2211-2222 (1998). *
Gill HS, Guarner F. Probiotics and human health: a clinical perspective. Postgrad. Med. J. 80: 516-526 (2004). *
Gill S, Chow R, Brown AJ. Sterol regulators of cholesterol homeostasis and beyond: the oxysterol hypothesis revisited and revised. Prog. Lipid Res. 47: 391-404 (2008). *
Gille A, Bodor ET, Ahmed K, Offermanns S. Nicotinic acid: pharmacological effects and mechanisms of action. Annu. Rev. Pharmacol. Toxicol. 48: 79-106 (2008). *
Ginanni Corradini S, Arancia G, Calcabrini A, Della Guardia P, Baiocchi L, Nistri A, Giacomelli L, Angelico M. Lamellar bodies coexist with vesicles and micelles in human gallbladder bile. Ursodeoxycholic acid prevents cholesterol crystal nucleation by increasing biliary lamellae. J. Hepatol. 22 :642-657 (1995). *
Gindro T, Arrigoni A, Martinasso G, Rosina F, Perardi S, Cappello N, Benedetti P, Actis GC, Verme G, Rizzetto M. Monoethyl glycine xylidide (MEGX) test evaluation in primary biliary cirrhosis: comparison with Mayo score. Eur. J. Gastroenterol. Hepatol. 9: 1155-1159 (1997).
Giorelli M, Livrea P, Minervini MG, Trojano M. Immunomodulatory properties of increased levels of liver X receptor beta in peripheral blood mononuclear cells from multiple sclerosis patients. Exp. Neurol. 204: 759-766 (2007).
Giorgi PL. Probiotics. A review. Recenti Prog. Med. 100: 40-47 (2009).
Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-Hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch. Intern. Med. 168: 1174-1180 (2008). *
Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, Giannetti A, Girolomoni G. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br. J. Dermatol. 157: 68-73 (2007). *
Glickerman DJ, Kim MH, Malik R, Lee SP. The gallbladder also secretes. Dig. Dis. Sci. 42: 489-491 (1997). *
Glueck CJ, Freiberg RA, Boppana S, Wang P. Thrombophilia, hypofibrinolysis, the eNOS T-786C polymorphism, and multifocal osteonecrosis. J. Bone Joint Surg. Am. 90: 2220-2229 (2008).
Glueck CJ, Pranikoff J, Aregawi D, Haque M, Zhu B, Tracy T, Wang P. The factor V Leiden mutation, high factor VIII, and high plasminogen activator inhibitor activity: etiologies for sporadic miscarriage. Metabolism 54: 1345-1349 (2005).
Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Ridker PM. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N. Engl. J. Med. 360: 1851-1861 (2009). *
Gnerre C, Schuster GU, Roth A, Handschin C, Johansson L, Looser R, Parini P, Podvinec M, Robertsson K, Gustafsson JA, Meyer UA. LXR deficiency and cholesterol feeding affect expression and phenobarbital mediated induction of cytochromes P450 in mouse liver. J. Lipid Res. 46: 1633-1642 (2005). *
Goa KL, Barradell LB, Plosker GL. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia. Drugs 52: 725-753 (1996).
Godard B, Ten Kate L, Evers-Kiebooms G, Ayme S. Population genetic screening programmes: principles, techniques, practices, and policies. Eur. J. Hum. Genet. 11 Suppl. 2: S49-S87 (2003). *
Godsland IF, Agbaje OF, Hovorka R. Evaluation of nonlinear regression approaches to estimation of insulin sensitivity by the minimal model with reference to Bayesian hierarchical analysis. Am. J. Physiol. Endocrinol. Metab. 291: E167-E174 (2006). *
Godsland IF, Johnston DG. Co-associations between insulin sensitivity and measures of liver function, subclinical inflammation, and hematology. Metabolism 57: 1190-1197 (2008). *
Goke B, Gause-Nilsson I, Persson A; On Behalf Of The Gallant 8 Study Group. The effects of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetes. Diab. Vasc. Dis. Res. 4: 204-213 (2007).
Goldberg RB, Sabharwal AK. Fish oil in the treatment of dyslipidemia. Curr. Opin. Endocrinol. Diabetes Obes. 15: 167-174 (2008).
Goldenberg I, Benderly M, Goldbourt U. Update on the use of fibrates: focus on bezafibrate. Vasc. Health Risk Manag. 4: 131-141 (2008).
Goldiner I, van der Velde AE, Vandenberghe KE, van Wijland MA, Halpern Z, Gilat T, Konikoff FM, Veldman RJ, Groen AK. ABCA1-dependent but ApoA-I-independent cholesterol efflux mediated by fatty acid-bile acid conjugates (FABACs). Biochem. J. 396: 529-536 (2006). *
Goldstein BJ, Rosenstock J, Anzalone D, Tou C, Ohman KP. Effect of tesaglitazar, a dual PPARalpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial. Curr. Med. Res. Opin. 22: 2575-2590 (2006).
Gomez M, Sanz-Gonzalez SM, Nabah YN, Lamana A, Sanchez-Madrid F, Andres V. Atherosclerosis development in apolipoprotein E-null mice deficient for CD69. Cardiovasc. Res. 81: 197-205 (2009).
Goncalves M, D'Almeida V, Guerra-Shinohara EM, Galdieri LC, Len CA, Hilario MO. Homocysteine and lipid profile in children with juvenile idiopathic arthritis. Pediatr. Rheumatol. Online J. 5: 2 (2007). *
Gonzales E, Davit-Spraul A, Baussan C, Buffet C, Maurice M, Jacquemin E. Liver diseases related to MDR3 (ABCB4) gene deficiency. Front. Biosci. 14: 4242-4256 (2009).
Gonzalez FJ. Recent update on the PPAR alpha-null mouse. Biochimie 79: 139-144 (1997).
Gonzalez FJ, Shah YM. PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. Toxicology 246: 2-8 (2008). *
Gonzalez MA, Roma MG, Bernal CA, Alvarez Mde L, Carrillo MC. Biliary secretory function in rats chronically intoxicated with aluminum. Toxicol. Sci. 79: 189-195 (2004). *
Gonzalez-Gay MA, Llorca J, Garcia-Unzueta MT, Gonzalez-Juanatey C, De Matias JM, Martin J, Redelinghuys M, Woodiwiss AJ, Norton GR, Dessein PH. High-grade inflammation, circulating adiponectin concentrations and cardiovascular risk factors in severe rheumatoid arthritis. Clin. Exp. Rheumatol. 26: 596-603 (2008).
Goodwin B, Kliewer SA. Nuclear receptors. I. Nuclear receptors and bile acid homeostasis. Am. J. Physiol. Gastrointest. Liver Physiol. 282: G926-G931 (2002). *
Goodwin B, Watson MA, Kim H, Miao J, Kemper JK, Kliewer SA. Differential regulation of rat and human CYP7A1 by the nuclear oxysterol receptor liver X receptor-alpha. Mol. Endocrinol. 17: 386-394 (2003). *
Goodwin BJ, Zuercher WJ, Collins JL. Recent advances in liver X receptor biology and chemistry. Curr. Top. Med. Chem. 8: 781-791 (2008).
Gopal DV, Pfau PR, Lucey MR. Endoscopic management of biliary complications after orthotopic liver transplantation. Curr. Treat. Options Gastroenterol. 6: 509-515 (2003).
Gordon RD, Shaw BW Jr, Iwatsuki S, Esquivel CO, Starzl TE. Indications for liver transplantation in the cyclosporine era. Surg. Clin. North Am. 66: 541-556 (1986).
Gotto AM Jr. Risks and benefits of continued aggressive statin therapy. Clin. Cardiol. 26: III3-III12 (2003).
Goumas GS. Is there evidence-based hypolipidemic treatment with clinical benefit beyond statins? Angiology 60: 93-98 (2009).
Gouni-Berthold I, Giannakidou E, Faust M, Berthold HK, Krone W. The peroxisome proliferator-activated receptor delta +294T/C polymorphism in relation to lipoprotein metabolism in patients with diabetes mellitus type 2 and in non-diabetic controls. Atherosclerosis 183: 336-341 (2005).
Gouni-Berthold I, Giannakidou E, Muller-Wieland D, Faust M, Kotzka J, Berthold HK, Krone W. The Pro387Leu variant of protein tyrosine phosphatase-1B is not associated with diabetes mellitus type 2 in a German population. J. Intern. Med. 257: 272-280 (2005). *
Gouni-Berthold I, Krone W. Favorable effects of decreasing lipids in patients with diabetes mellitus. Dtsch. Med. Wochenschr. 131 Suppl. 8: S252-S254 (2006).
Graf GA, Yu L, Li WP, Gerard R, Tuma PL, Cohen JC, Hobbs HH. ABCG5 and ABCG8 are obligate heterodimers for protein trafficking and biliary cholesterol excretion. J. Biol. Chem. 278: 48275-48282 (2003). *
Graham KL, Lee LY, Higgins JP, Steinman L, Utz PJ, Ho PP. Failure of oral atorvastatin to modulate a murine model of systemic lupus erythematosus. Arthritis Rheum. 58: 2098-2104 (2008). *
Graham TE, Yang Q, Bluher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson PA, Smith U, Kahn BB. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N. Engl. J. Med. 354: 2552-2563 (2006). *
Grattagliano I, Giudetti AM, Grattagliano V, Palmieri VO, Gnoni GV, Lapadula G, Palasciano G, Vendemiale G. Structural and oxidative modifications of erythrocyte ghosts in patients with primary biliary cirrhosis: relation with the disease stage and effect of bile acid treatment. Eur. J. Clin. Invest. 33: 868-874 (2003). *
Graziadei IW, Obermoser GE, Sepp NT, Erhart KH, Vogel W. Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis. Lupus 12: 409-412 (2003).
Green P, Anyakoha N, Yadid G, Gispan-Herman I, Nicolaou A. Arachidonic acid-containing phosphatidylcholine species are increased in selected brain regions of a depressive animal model: implications for pathophysiology. Prostaglandins Leukot. Essent. Fatty Acids 80: 213-220 (2009). *
Greenbaum L. Hippatitis rex. Lancet 362: 2032 (2003). *
Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat. Rev. Immunol. 6: 358-370 (2006). *
Grefhorst A, Parks EJ. Reduced insulin-mediated inhibition of VLDL secretion upon pharmacological activation on the liver X receptor in mice. J. Lipid Res. Mar 14 [Epub ahead of print] (2009). *
Gregory WL, Game FL, Farrer M, Idle JR, Laker MF, James OF. Reduced serum lipoprotein(a) levels in patients with primary biliary cirrhosis. Atherosclerosis 105: 43-50 (1994).
Gressier L, Pruvost-Balland C, Dubertret L, Viguier M. Atorvastatin-induced drug reaction with eosinophilia and systemic symptoms (DRESS). Ann. Dermatol. Venereol. 136: 50-53 (2009).
Grieco A, Miele L, Pompili M, Biolato M, Vecchio FM, Grattagliano I, Gasbarrini G. Acute hepatitis caused by a natural lipid-lowering product: when �alternative� medicine is no �alternative� at all? J. Hepatol. 50: 1273-1277 (2009).
Griel AE, Cao Y, Bagshaw DD, Cifelli AM, Holub B, Kris-Etherton PM. A macadamia nut-rich diet reduces total and LDL-cholesterol in mildly hypercholesterolemic men and women. J. Nutr. 138: 761-767 (2008). *
Grimes DS. Are statins analogues of vitamin D? Lancet 368: 83-86 (2006). *
Grimwood J, Gordon LA, Olsen A, Terry A, Schmutz J, Lamerdin J, Hellsten U et al. The DNA sequence and biology of human chromosome 19. Nature 428: 529-535 (2004). *
Groen A, Kunne C, Jongsma G, van den Oever K, Mok KS, Petruzzelli M, Vrins CL, Bull L, Paulusma CC, Oude Elferink RP. Abcg5/8 independent biliary cholesterol excretion in Atp8b1-deficient mice. Gastroenterology 134: 2091-2100 (2008). *
Groen AK. The emerging role of bile acids as integrators of intermediary metabolism. J. Hepatol. 45: 337-338 (2006). *
Groen AK, Kosters A, Kunne C, Oude Elferink RPJ. The molecular mechanism of biliary lipid secretion - influence of bile salt hydrophilicity and role of Abcg5 and Abcg8. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 50. June 18-19 (2004). *
Groen AK, Oude Elferink RP. Lipid transport into bile and role in bile formation. Curr. Drug Targets Immune Endocr. Metabol. Disord. 5: 131-135 (2005).
Groen AK, Oude Elferink RP, Verkade HJ, Kuipers F. The ins and outs of reverse cholesterol transport. Ann. Med. 36: 135-145 (2004).
Grossfield A, Feller SE, Pitman MC. A role for direct interactions in the modulation of rhodopsin by omega-3 polyunsaturated lipids. Proc. Natl. Acad. Sci. U.S.A. 103: 4888-4893 (2006). *
Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program; National Heart, Lung, and Blood Institute. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler. Thromb. Vasc. Biol. 24: e149-e161 (2004). *
Grunewald RW, Fiedler GM, Stockmann F, Schauer A, Muller GA. Unusual diagnosis in recurrent arthritis, erythema nodosum and arrhythmia. Dtsch. Med. Wochenschr. 122: 1516-1520 (1997).
Grunhage F, Acalovschi M, Tirziu S, Walier M, Wienker TF, Ciocan A, Mosteanu O, Sauerbruch T, Lammert F. Increased gallstone risk in humans conferred by common variant of hepatic ATP-binding cassette transporter for cholesterol. Hepatology 46: 793-801 (2007). *
Grunhage F, Lammert F. Pathogenesis of gallstones: a genetic perspective. Best Pract. Res. Clin. Gastroenterol. 20: 997-1015 (2006).
Guan JZ, Tamasawa N, Brunham LR, Matsui J, Murakami H, Suda T, Ochiai S, Tsutsui M, Kudou K, Satoh K, Hayden MR. A case of Tangier disease with a novel mutation in the C-terminal region of ATP-binding cassette transporter A1. Am. J. Med. Genet. 130A: 398-401 (2004). *
Guan JZ, Tamasawa N, Murakami H, Matsui J, Tanabe J, Matsuki K, Yamashita M, Suda T. HMG-CoA reductase inhibitor, simvastatin improves reverse cholesterol transport in type 2 diabetic patients with hyperlipidemia. J. Atheroscler. Thromb. 15: 20-25 (2008). *
Guan M, Zhang J, Chen Y, Liu W, Kong N, Zou H. High-resolution melting analysis for the rapid detection of an intronic single nucleotide polymorphism in SLC22A12 in male patients with primary gout in China. Scand. J. Rheumatol. Mar 20 [Epub ahead of print] (2009). *
Guaraldi G, Ventura P, Garlassi E, Orlando G, Squillace N, Nardini G, Stentarelli C, Zona S, Marchini S, Moriondo V, Tebas P. Hyperhomocysteinaemia in HIV-infected patients: determinants of variability and correlations with predictors of cardiovascular disease. HIV Med. 10: 28-34 (2009).
Guarino MP, Carotti S, Morini S, Perrone G, Behar J, Altomare A, Alloni R, Caviglia R, Emerenziani S, Rabitti C, Cicala M. Decreased number of activated macrophages in gallbladder muscle layer of cholesterol gallstone patients following ursodeoxycholic acid. Gut 57: 1740-1741 (2008).
Guarino MP, Cong P, Cicala M, Alloni R, Carotti S, Behar J. Ursodeoxycholic acid improves muscle contractility and inflammation in symptomatic gallbladders with cholesterol gallstones. Gut 56: 815-820 (2007). *
Guebre-Egziabher F, Rabasa-Lhoret R, Bonnet F, Bastard JP, Desage M, Skilton MR, Vidal H, Laville M. Nutritional intervention to reduce the n-6/n-3 fatty acid ratio increases adiponectin concentration and fatty acid oxidation in healthy subjects. Eur. J. Clin. Nutr. 62: 1287-1293 (2008). *
Gueguen Y, Souidi M, Baudelin C, Dudoignon N, Grison S, Dublineau I, Marquette C, Voisin P, Gourmelon P, Aigueperse J. Short-term hepatic effects of depleted uranium on xenobiotic and bile acid metabolizing cytochrome P450 enzymes in the rat. Arch. Toxicol. 80: 187-195 (2006). *
Guerreiro CS, Cravo ML, Brito M, Vidal PM, Fidalgo PO, Leitao CN. The D1822V APC polymorphism interacts with fat, calcium, and fiber intakes in modulating the risk of colorectal cancer in Portuguese persons. Am. J. Clin. Nutr. 85: 1592-1597 (2007). *
Guirado S, Conejo-Mir J, Munoz M, Wite J, Fernandez-Freire L, Ortiz J. Sitosterol xanthomatosis. J. Eur. Acad. Dermatol. Venereol. 21: 100-103 (2007). *
Guisasola MC, Dul�n E, Almendral J, Garcia-Barreno P. Reduction of heat shock protein antibody levels by statin therapy. Lipids 44: 317-324 (2009).
Guldutuna S, Deisinger B, Weiss A, Freisleben HJ, Zimmer G, Sipos P, Leuschner U. Ursodeoxycholate stabilizes phospholipid-rich membranes and mimics the effect of cholesterol: investigations on large unilamellar vesicles. Biochim. Biophys. Acta 1326: 265-274 (1997). *
Guldutuna S, Zimmer G, Leuschner M, Bhatti S, Elze A, Deisinger B, Hofmann M, Leuschner U. The effect of bile salts and calcium on isolated rat liver mitochondria. Biochim. Biophys. Acta 1453: 396-406 (1999). *
Gunji T, Matsuhashi N, Sato H, Fujibayashi K, Okumura M, Sasabe N, Urabe A. Helicobacter pylori infection is significantly associated with metabolic syndrome in the Japanese population. Am. J. Gastroenterol. 103: 3005-3010 (2008).
Gunn IR, Maxwell FK, Gaffney D, McMahon AD, Packard CJ. Haemochromatosis gene mutations and risk of coronary heart disease: a west of Scotland coronary prevention study (WOSCOPS) substudy. Heart 90: 304-306 (2004). *
Gunnarsdottir I, Tomasson H, Kiely M, Martinez JA, Bandarra NM, Morais MG, Thorsdottir I. Inclusion of fish or fish oil in weight-loss diets for young adults: effects on blood lipids. Int. J. Obes. (Lond.) 32: 1105-1112 (2008). *
Gunsar C, Melek M, Karaca I, Sencan A, Mir E, Ortac R, Canan O. The biochemical and histopathological effects of ursodeoxycholic acid and metronidazole on total parenteral nutrition-associated hepatic dysfunction: an experimental study. Hepatogastroenterology 49: 497-500 (2002).
Guo GL, Lambert G, Negishi M, Ward JM, Brewer HB Jr, Kliewer SA, Gonzalez FJ, Sinal CJ. Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. J. Biol. Chem. 278: 45062-45071 (2003). *
Guo GL, Santamarina-Fojo S, Akiyama TE, Amar MJ, Paigen BJ, Brewer B Jr, Gonzalez FJ. Effects of FXR in foam-cell formation and atherosclerosis development. Biochim. Biophys. Acta 1761: 1401-1409 (2006). *
Guo L, Fang H, Collins J, Fan XH, Dial S, Wong A, Mehta K, Blann E, Shi L, Tong W, Dragan YP. Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor alpha agonists. BMC Bioinformatics 7: S18 (2006). *
Guo L, Hu WR, Lian JH, Ji W, Deng T, Qian M, Gong BQ. Anti-hyperlipidemic properties of CM108 (a flavone derivative) in vitro and in vivo. Eur. J. Pharmacol. 551: 80-86 (2006). *
Gupta R, Dixon KM, Deo SS, Holliday CJ, Slater M, Halliday GM, Reeve VE, Mason RS. Photoprotection by 1,25 dihydroxyvitamin D3 is associated with an increase in p53 and a decrease in nitric oxide products. J. Invest. Dermatol. 127: 707-715 (2007). *
Gupta S, Pandak WM, Hylemon PB. LXR alpha is the dominant regulator of CYP7A1 transcription. Biochem. Biophys. Res. Commun. 293: 338-343 (2002). *
Gupta S, Stravitz RT, Dent P, Hylemon PB. Down-regulation of cholesterol 7alpha-hydroxylase (CYP7A1) gene expression by bile acids in primary rat hepatocytes is mediated by the c-Jun N-terminal kinase pathway. J. Biol. Chem. 276: 15816-15822 (2001). *
Gupta S, Todd Stravitz R, Pandak WM, Muller M, Reno Vlahcevic Z, Hylemon PB. Regulation of multidrug resistance 2 P-glycoprotein expression by bile salts in rats and in primary cultures of rat hepatocytes. Hepatology 32: 341-347 (2000). *
Gupte P, Amarapurkar D, Agal S, Baijal R, Kulshrestha P, Pramanik S, Patel N, Madan A, Amarapurkar A, Hafeezunnisa. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J. Gastroenterol. Hepatol. 19: 854-858 (2004). *
Gurantz D, Hofmann AF. Influence of bile acid structure on bile flow and biliary lipid secretion in the hamster. Am. J. Physiol. 247: G736-G748 (1984).
Gustafsson JA. Steroids and the scientist. Mol. Endocrinol. 19: 1412-1417 (2005). *
Gustafsson U, Benthin L, Granstrom L, Groen AK, Sahlin S, Einarsson C. Changes in gallbladder bile composition and crystal detection time in morbidly obese subjects after bariatric surgery. Hepatology 41: 1322-1328 (2005). *
Gutierrez A, Ratliff EP, Andres AM, Huang X, McKeehan WL, Davis RA. Bile acids decrease hepatic paraoxonase 1 expression and plasma high-density lipoprotein levels via FXR-mediated signaling of FGFR4. Arterioscler. Thromb. Vasc. Biol. 26: 301-306 (2006).
Gutierrez Macia MM, Mateo Garc�a MG, Vidal Marsal F, Domingo Pedrol P. Toxicogenetics of antiretroviral treatment (1): lipodystrophy, metabolic perturbations and atherosclerosis. Enferm. Infecc. Microbiol. Clin. 26 Suppl. 6: 18-23 (2008).
Gylling H, Farkkila M, Vuoristo M, Miettinen TA. Metabolism of cholesterol and low- and high-density lipoproteins in primary biliary cirrhosis: cholesterol absorption and synthesis related to lipoprotein levels and their kinetics. Hepatology 21: 89-95 (1995).
Gylling H, Hallikainen M, Pihlajamaki J, Agren J, Laakso M, Rajaratnam RA, Rauramaa R, Miettinen TA. Polymorphisms in the ABCG5 and ABCG8 genes associate with cholesterol absorption and insulin sensitivity. J. Lipid Res. 45: 1660-1665 (2004). *
Gylling H, Vuoristo M, Farkkila M, Miettinen TA. The metabolism of cholestanol in primary biliary cirrhosis. J. Hepatol. 24: 444-451 (1996). *
Haberbosch W. Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective? Herz. 32: 51-57 (2007).
Hachem C, Morgan R, Johnson M, Kuebeler M, El-Serag H. Statins and the risk of colorectal carcinoma: a nested case-control study in veterans with diabetes. Am. J. Gastroenterol. 104: 1241-1248 (2009).
Hachem SB, Mooradian AD. Familial dyslipidaemias: an overview of genetics, pathophysiology and management. Drugs 66: 1949-1969 (2006).
Haddy N, Sass C, Maumus S, Marie B, Droesch S, Siest G, Lambert D, Visvikis S. Biological variations, genetic polymorphisms and familial resemblance of TNF-alpha and IL-6 concentrations: STANISLAS cohort. Eur. J. Hum. Genet. 13: 109-117 (2005). *
Hager EJ, Tse HM, Piganelli JD, Gupta M, Baetscher M, Tse TE, Pappu AS, Steiner RD, Hoffmann GF, Gibson KM. Deletion of a single mevalonate kinase (Mvk) allele yields a murine model of hyper-IgD syndrome. J. Inherit. Metab. Dis. 30: 888-895 (2007). *
Haikal Z, Play B, Landrier JF, Giraud A, Ghiringhelli O, Lairon D, Jourdheuil-Rahmani D. NPC1L1 and SR-BI are involved in intestinal cholesterol absorption from small-size lipid donors. Lipids 43: 401-408 (2008).
Halder I, Muldoon MF, Ferrell RE, Manuck SB. Serotonin receptor 2A (HTR2A) gene polymorphisms are associated with blood pressure, central adiposity, and the metabolic syndrome. Metab. Syndr. Relat. Disord. 5: 323-330 (2007).
Hall EA, Ren S, Hylemon PB, Redford K, del Castillo A, Gil G, Pandak WM. Mitochondrial cholesterol transport: a possible target in the management of hyperlipidemia. Lipids 40: 1237-1244 (2005).
Hall EA, Ren S, Hylemon PB, Rodriguez-Agudo D, Redford K, Marques D, Kang D, Gil G, Pandak WM. Detection of the steroidogenic acute regulatory protein, StAR, in human liver cells. Biochim. Biophys. Acta 1733: 111-119 (2005). *
Hall MG, Quignodon L, Desvergne B. Peroxisome proliferator-activated receptor beta/delta in the brain: facts and hypothesis. PPAR Res. 2008: 780452 (2008). *
Halpern Z, Moshkowitz M, Laufer H, Peled Y, Gilat T. Effect of phospholipids and their molecular species on cholesterol solubility and nucleation in human and model biles. Gut 34: 110-115 (1993). *
Hamada T, Egashira N, Nishizono S, Tomoyori H, Nakagiri H, Imaizumi K, Ikeda I. Lymphatic absorption and deposition of various plant sterols in stroke-prone spontaneously hypertensive rats, a strain having a mutation in ATP binding cassette transporter G5. Lipids 42: 241-248 (2007).
Hamada T, Kotani K, Tsuzaki K, Sano Y, Murata T, Tabata M, Sato S, Sakane N. Association of Pro12Ala polymorphism in the peroxisome proliferator-activated receptor gamma2 gene with small dense low-density lipoprotein in the general population. Metabolism 56: 1345-1349 (2007). *
Hamai H, Keyserman F, Quittell LM, Worgall TS. Defective CFTR increases synthesis and mass of sphingolipids that modulate membrane composition and lipid signaling. J. Lipid Res. 50: 1101-1108 (2009). *
Hamelet J, Demuth K, Paul JL, Delabar JM, Janel N. Hyperhomocysteinemia due to cystathionine beta synthase deficiency induces dysregulation of genes involved in hepatic lipid homeostasis in mice. J. Hepatol. 46: 151-159 (2007). *
Hamelet J, Seltzer V, Petit E, Noll C, Andreau K, Delabar JM, Janel N. Cystathionine beta synthase deficiency induces catalase-mediated hydrogen peroxide detoxification in mice liver. Biochim. Biophys. Acta 1782: 482-488 (2008). *
Hammana I, Malet A, Costa M, Brochiero E, Berthiaume Y, Potvin S, Chiasson JL, Coderre L, Rabasa-Lhoret R. Normal adiponectin levels despite abnormal glucose tolerance (or diabetes) and inflammation in adult patients with cystic fibrosis. Diabetes Metab. 33: 213-219 (2007). *
Han J, Zhou X, He W, Huang Z, Gotto AM Jr, Hajjar DP. Genetic deletion of low density lipoprotein receptor impairs sterol-induced mouse macrophage ABCA1 expression: a new SREBP1 dependent mechanism. J. Biol. Chem. 283: 2129-2138 (2008). *
Han S, Chiang JY. Mechanism of vitamin D receptor inhibition of cholesterol 7alpha-hydroxylase gene transcription in human hepatocytes. Drug Metab. Dispos. 37: 469-478 (2009). *
Han SH, Lee OY, Eun CS, Roh BJ, Sohn W, Baeg SS, Yoon BC, Choi HS. A case of protein-losing enteropathy associated with small bowel villous atrophy. Korean J. Gastroenterol. 49: 31-36 (2007).
Hanada K. Sphingolipids in infectious diseases. Jpn. J. Infect. Dis. 58: 131-148 (2005).
Hand NJ, Master ZR, Le Lay J, Friedman JR. Hepatic function is preserved in the absence of mature microRNAs. Hepatology 49: 618-626 (2009).
Handelsman B, Bonorris G, Marks JW, Schoenfield LJ. Enrichment of bile with tauroursodeoxycholic acid and biliary cholesterol saturation in hamsters. Am. J. Physiol. 243: G424-G427 (1982).
Handschin C, Gnerre C, Fraser DJ, Martinez-Jimenez C, Jover R, Meyer UA. Species-specific mechanisms for cholesterol 7alpha-hydroxylase (CYP7A1) regulation by drugs and bile acids. Arch. Biochem. Biophys. 434: 75-85 (2005). *
Handschin C, Meyer UA. Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR. Arch. Biochem. Biophys. 433: 387-396 (2005). *
Handschin C, Meyer UA. Induction of drug metabolism: the role of nuclear receptors. Pharmacol. Rev. 55: 649-673 (2003). *
Handschin C, Podvinec M, Amherd R, Looser R, Ourlin JC, Meyer UA. Cholesterol and bile acids regulate xenosensor signaling in drug-mediated induction of cytochromes P450. J. Biol. Chem. 277: 29561-29567 (2002). *
Handschin C, Podvinec M, Looser R, Amherd R, Meyer UA. Multiple enhancer units mediate drug induction of CYP2H1 by xenobiotic-sensing orphan nuclear receptor chicken xenobiotic receptor. Mol. Pharmacol. 60: 681-689 (2001). *
Hanley K, Jiang Y, Crumrine D, Bass NM, Appel R, Elias PM, Williams ML, Feingold KR. Activators of the nuclear hormone receptors PPARalpha and FXR accelerate the development of the fetal epidermal permeability barrier. J. Clin. Invest. 100: 705-712 (1997). *
Hanniman EA, Lambert G, McCarthy TC, Sinal CJ. Loss of functional farnesoid X-receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice. J. Lipid Res. 46: 2595-2604 (2005). *
Hansen MK, Connolly TM. Nuclear receptors as drug targets in obesity, dyslipidemia and atherosclerosis. Curr. Opin. Investig. Drugs 9: 247-255 (2008).
Hanson RF, Szczepanik-VanLeeuwen P, Williams GC, Grabowski G, Sharp HL. Defects of bile acid synthesis in Zellweger's syndrome. Science 203: 1107-1108 (1979). *
Haque S, Bruce IN. Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease. Nat. Clin. Pract. Cardiovasc. Med. 2: 423-430 (2005).
Harada LM, Amigo L, Cazita PM, Salerno AG, Rigotti AA, Quintao EC, Oliveira HC. CETP expression enhances liver HDL-cholesteryl ester uptake but does not alter VLDL and biliary lipid secretion. Atherosclerosis 191: 313-318 (2007).
Harada LM, Carrilho AJ, Oliveira HC, Nakandakare ER, Quintao EC. Regulation of hepatic cholesterol metabolism in CETP/LDLr mice by cholesterol feeding and by drugs (cholestyramine and lovastatin) that lower plasma cholesterol. Clin. Exp. Pharmacol. Physiol. 33: 1209-1215 (2006). *
Hardison WG, Grundy SM. Effect of ursodeoxycholate and its taurine conjugate on bile acid synthesis and cholesterol absorption. Gastroenterology 87: 130-135 (1984).
Hardison WG, Grundy SM. Effect of bile acid conjugation pattern on bile acid metabolism in normal humans. Gastroenterology 84: 617-620 (1983).
Harris WS. Does treatment with eicosapentaenoic acid prevent major coronary events in patients with hypercholesterolemia? Nat. Clin. Pract. Cardiovasc. Med. 4: 532-533 (2007).
Harroun TA, Katsaras J, Wassall SR. Cholesterol is found to reside in the center of a polyunsaturated lipid membrane. Biochemistry 47: 7090-7096 (2008). *
Hartge MM, Unger T, Kintscher U. The endothelium and vascular inflammation in diabetes. Diab. Vasc. Dis. Res. 4: 84-88 (2007).
Hartleb M, Biernat L, Kochel A. Drug-induced liver damage - a three-year study of patients from one gastroenterological department. Med. Sci. Monit. 8: CR292-CR296 (2002). *
Hartman HB, Gardell SJ, Petucci CJ, Wang S, Krueger JA, Evans MJ. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice. J. Lipid Res. 50: 1090-1100 (2009). *
Hartman HB, Lai K, Evans MJ. Loss of small heterodimer partner expression in the liver protects against dyslipidemia. J. Lipid Res. 50: 193-203 (2009). *
Hartweg J, Farmer AJ, Holman RR, Neil A. Potential impact of omega-3 treatment on cardiovascular disease in type 2 diabetes. Curr. Opin. Lipidol. 20: 30-38 (2009).
Hartweg J, Farmer AJ, Perera R, Holman RR, Neil HA. Meta-analysis of the effects of n-3 polyunsaturated fatty acids on lipoproteins and other emerging lipid cardiovascular risk markers in patients with type 2 diabetes. Diabetologia 50: 1593-1602 (2007). *
Hartweg J, Perera R, Montori V, Dinneen S, Neil H, Farmer A. Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus. Cochrane Database Syst. Rev. 1: CD003205 (2008). *
Hascalovici JR, Song W, Vaya J, Khatib S, Fuhrman B, Aviram M, Schipper HM. Impact of heme oxygenase-1 on cholesterol synthesis, cholesterol efflux and oxysterol formation in cultured astroglia. J. Neurochem. 108: 72-81 (2009).
Hasebe A, Pennock ND, Mu HH, Chan FV, Taylor ML, Cole BC. A microbial TLR2 agonist imparts macrophage-activating ability to apolipoprotein A-1. J. Immunol. 177: 4826-4832 (2006). *
Hashimoto K, Cohen RN, Yamada M, Markan KR, Monden T, Satoh T, Mori M, Wondisford FE. Cross-talk between thyroid hormone receptor and liver X receptor regulatory pathways is revealed in a thyroid hormone resistance mouse model. J. Biol. Chem. 281: 295-302 (2006). *
Hashimoto K, Matsumoto S, Yamada M, Satoh T, Mori M. Liver X receptor alpha gene expression is positively regulated by thyroid hormone. Endocrinology 148: 4667-4675 (2007). *
Hashimoto M, Hossain S, Shido O. Docosahexaenoic acid but not eicosapentaenoic acid withstands dietary cholesterol-induced decreases in platelet membrane fluidity. Mol. Cell. Biochem. 293: 1-8 (2006). *
Hashimoto M, Hossain S, Shimada T, Shido O. Docosahexaenoic acid-induced protective effect against impaired learning in amyloid beta-infused rats is associated with increased synaptosomal membrane fluidity. Clin. Exp. Pharmacol. Physiol. 33: 934-939 (2006). *
Hashizume M, Yoshida H, Koike N, Suzuki M, Mihara M. Over-produced IL-6 decreases blood lipid levels via up-regulation of VLDLR. Ann. Rheum. Dis. May 10 [Epub ahead of print] (2009).
Hassan AS, Bunick D, Lund LA, Bottje WG. Glutathione and bile acid synthesis. Effect of GSH content of HepG2 cells on the activity and mRNA levels of cholesterol 7 alpha-hydroxylase. Biochem. Pharmacol. 44: 1475-1477 (1992).
Hattori H, Sato H, Ito D, Tanahashi N, Murata M, Saito I, Watanabe K, Suzuki N. A561C polymorphism of E-selectin is associated with ischemic cerebrovascular disease in the Japanese population without diabetes mellitus and hypercholesterolemia. Brain Res. 1108: 221-223 (2006).
Hayhurst GP, Lee YH, Lambert G, Ward JM, Gonzalez FJ. Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis. Mol. Cell. Biol. 21: 1393-1403 (2001). *
He F, Li J, Mu Y, Kuruba R, Ma Z, Wilson A, Alber S, Jiang Y, Stevens T, Watkins S, Pitt B, Xie W, Li S. Downregulation of endothelin-1 by farnesoid X receptor in vascular endothelial cells. Circ. Res. 98: 192-199 (2006). *
He X, Lu Y, Saha N, Yang H, Heng CK. Acyl-CoA: cholesterol acyltransferase-2 gene polymorphisms and their association with plasma lipids and coronary artery disease risks. Hum. Genet. 118: 393-403 (2005). *
Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, Michieletti P, Minuk GY, Pappas SC, Scully LJ, et al. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 19: 1149-1156 (1994).
Heathcote J, Ross A, Sherlock S. A prospective controlled trial of azathioprine in primary biliary cirrhosis. Gastroenterology 70: 656-660 (1976).
Hedenborg G, Jonsson G, Norman A, Wisen O. Bile constituents in ascitic fluid. Scand. J. Clin. Lab. Invest. 48: 543-552 (1988).
Hegele RA, Cao H. Single nucleotide polymorphisms of RXRA encoding retinoid X receptor alpha. J. Hum. Genet. 46: 423-425 (2001).
Hegele RA, Robinson JF. ABC transporters and sterol absorption. Curr. Drug Targets Cardiovasc. Haematol. Disord. 5: 31-37 (2005).
Heid IM, Vollmert C, Kronenberg F, Huth C, Ankerst DP, Luchner A, Hinney A, Bronner G, Wichmann HE, Illig T, Doring A, Hebebrand J. Association of the MC4R V103I polymorphism with the metabolic syndrome: the KORA study. Obesity (Silver Spring) 16: 369-376 (2008). *
Heimer S, Langmann T, Moehle C, Mauerer R, Dean M, Beil FU, von Bergmann K, Schmitz G. Mutations in the human ATP-binding cassette transporters ABCG5 and ABCG8 in sitosterolemia. Hum. Mutat. 20: 151 (2002). *
Heliovaara MK, Remitz A, Reitamo S, Teppo AM, Karonen SL, Ebeling P. 13-cis-Retinoic acid therapy induces insulin resistance, regulates inflammatory parameters, and paradoxically increases serum adiponectin concentration. Metabolism 56: 786-791 (2007).
Helland IB, Saugstad OD, Saarem K, Van Houwelingen AC, Nylander G, Drevon CA. Supplementation of n-3 fatty acids during pregnancy and lactation reduces maternal plasma lipid levels and provides DHA to the infants. J. Matern. Fetal Neonatal Med. 19: 397-406 (2006).
Henderson CJ, Wolf CR. Transgenic analysis of human drug-metabolizing enzymes: preclinical drug development and toxicology. Mol. Intervent. 3: 331-343 (2003). *
Heneghan HM, Sultan S. Homocysteine, the cholesterol of the 21st century. Impact of hyperhomocysteinemia on patency and amputation-free survival after intervention for critical limb ischemia. J. Endovasc. Ther. 15: 399-407 (2008).
Henningsson S, Hakansson A, Westberg L, Baghaei F, Rosmond R, Holm G, Ekman A, Nissbrandt H, Eriksson E. Interleukin-6 gene polymorphism -174G/C influences plasma lipid levels in women. Obesity (Silver Spring) 14: 1868-1873 (2006). *
Herath KB, Jayasuriya H, Guan Z, Schulman M, Ruby C, Sharma N, Macnaul K, Menke JG, Kodali S, Galgoci A, Wang J, Singh SB. Anthrabenzoxocinones from Streptomyces sp. as liver X receptor ligands and antibacterial agents. J. Nat. Prod. 68: 1437-1440 (2005). *
Hernandez-Morante JJ, Larque E, Lujan JA, Zamora S, Garaulet M. n-6 From different sources protect from metabolic alterations to obese patients: a factor analysis. Obesity (Silver Spring) 17: 452-459 (2009). *
Hernandez-Nazara A, Curiel-Lopez F, Martinez-Lopez E, Hernandez-Nazara Z, Panduro A. Genetic predisposition of cholesterol gallstone disease. Ann. Hepatol. 5: 140-149 (2006). *
Hernandez-Trujillo Y, Rodriguez-Esparragon F, Macias-Reyes A, Caballero-Hidalgo A, Rodriguez-Perez JC. Rosiglitazone but not losartan prevents Nrf-2 dependent CD36 gene expression up-regulation in an in vivo atherosclerosis model. Cardiovasc. Diabetol. 7: 3 (2008).
Herron KL, Lofgren IE, Adiconis X, Ordovas JM, Fernandez ML. Associations between plasma lipid parameters and APOC3 and APOA4 genotypes in a healthy population are independent of dietary cholesterol intake. Atherosclerosis 184: 113-120 (2006).
Herron KL, McGrane MM, Waters D, Lofgren IE, Clark RM, Ordovas JM, Fernandez ML. The ABCG5 polymorphism contributes to individual responses to dietary cholesterol and carotenoids in eggs. J. Nutr. 136: 1161-1165 (2006). *
Herszenyi L, Szalay L, Schaff Z, Gergely P, Feher J. Ursodeoxycholic acid therapy in biliary cirrhosis. Orv. Hetil. 134: 2085-2089 (1993).
Hertel JK, Johansson S, Raeder H, Midthjell K, Lyssenko V, Groop L, Molven A, Njolstad PR. Genetic analysis of recently identified type 2 diabetes loci in 1,638 unselected patients with type 2 diabetes and 1,858 control participants from a Norwegian population-based cohort (the HUNT study). Diabetologia 51: 971-977 (2008). *
Herzum I, Giehl C, Soufi M, Junclas H, Wahl HG. Interference in a homogeneous assay for low-density lipoprotein cholesterol by lipoprotein X. Clin. Chem. Lab. Med. 45: 667-671 (2007). *
Hettema ME, Zhang D, de Leeuw K, Stienstra Y, Smit AJ, Kallenberg CG, Bootsma H. Early atherosclerosis in systemic sclerosis and its relation to disease or traditional risk factors. Arthritis Res. Ther. 10: R49 (2008). *
Heubi JE, Setchell KD, Bove KE. Inborn errors of bile acid metabolism. Semin. Liver Dis. 27: 282-294 (2007).
Heuman DM, Hylemon PB, Vlahcevic ZR. Regulation of bile acid synthesis. III. Correlation between biliary bile salt hydrophobicity index and the activities of enzymes regulating cholesterol and bile acid synthesis in the rat. J. Lipid Res. 30: 1161-1171 (1989). *
Heuman DM, Vlahcevic ZR, Bailey ML, Hylemon PB. Regulation of bile acid synthesis. II. Effect of bile acid feeding on enzymes regulating hepatic cholesterol and bile acid synthesis in the rat. Hepatology 8: 892-897 (1988).
Heuman DM, Vlahcevic ZR, Pandak WM, Hylemon PB, Kim YS, Lillienau J, Hofmann AF. Effect of cholylsarcosine on hepatic cholesterol and bile acid synthesis and bile secretion in rats. Gastroenterology 103: 1641-1648 (1992).
Heverin M, Meaney S, Brafman A, Shafir M, Olin M, Shafaati M, von Bahr S, Larsson L, Lovgren-Sandblom A, Diczfalusy U, Parini P, Feinstein E, Bjorkhem I. Studies on the cholesterol-free mouse: strong activation of LXR-regulated hepatic genes when replacing cholesterol with desmosterol. Arterioscler. Thromb. Vasc. Biol. 27: 2191-2197 (2007).
Heynekamp JJ, Hunsaker LA, Vander Jagt TA, Royer RE, Deck LM, Vander Jagt DL. Isocoumarin-based inhibitors of pancreatic cholesterol esterase. Bioorg. Med. Chem. 16: 5285-5294 (2008). *
Higuchi N, Kato M, Shundo Y, Tajiri H, Tanaka M, Yamashita N, Kohjima M, Kotoh K, Nakamuta M, Takayanagi R, Enjoji M. Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. Hepatol. Res. 38: 1122-1129 (2008). *
Higuchi T, Shirai N, Suzuki H. Reduction in plasma glucose after lipid changes in mice fed fish oil, docosahexaenoic acid, and eicosapentaenoic acid diets. Ann. Nutr. Metab. 50: 147-154 (2006).
Higuchi T, Shirai N, Suzuki H, Kawashima M, Tamura Y. Effects of yogurt supplemented with fish oil on plasma lipid and glucose concentrations, and liver lipid contents in mice. Int. J. Vitam. Nutr. Res. 78: 129-138 (2008).
Hill AM, Buckley JD, Murphy KJ, Saint DA, Morris AM, Howe PR. Combined effects of omega-3 supplementation and regular exercise on body composition and cardiovascular risk factors. Asia Pac. J. Clin. Nutr. 14: S57 (2005).
Hingorani M, Nischal KK, Davies A, Bentley C, Vivian A, Baker AJ, Mieli-Vergani G, Bird AC, Aclimandos WA. Ocular abnormalities in Alagille syndrome. Ophthalmology 106: 330-227 (1999).
Hinrichs JW, Klappe K, van Riezen M, Kok JW. Drug resistance-associated changes in sphingolipids and ABC transporters occur in different regions of membrane domains. J. Lipid Res. 46: 2367-2376 (2005). *
Hirako S, Kim HJ, Arai T, Chiba H, Matsumoto A. Effect of concomitantly used fish oil and cholesterol on lipid metabolism. J. Nutr. Biochem. May 14 [Epub ahead of print] (2009). *
Hiraoka H, Yamashita S, Matsuzawa Y, Kubo M, Nozaki S, Sakai N, Hirano K, Kawata S, Tarui S. Decrease of hepatic triglyceride lipase levels and increase of cholesteryl ester transfer protein levels in patients with primary biliary cirrhosis: relationship to abnormalities in high-density lipoprotein. Hepatology 18: 103-110 (1993).
Hirashiki A, Yamada Y, Murase Y, Suzuki Y, Kataoka H, Morimoto Y, Tajika T, Murohara T, Yokota M. Association of gene polymorphisms with coronary artery disease in low- or high-risk subjects defined by conventional risk factors. J. Am. Coll. Cardiol. 42: 1429-1437 (2003). *
Hirayama T, Honda A, Matsuzaki Y, Miyazaki T, Ikegami T, Doy M, Xu G, Lea M, Salen G. Hypercholesterolemia in rats with hepatomas: increased oxysterols accelerate efflux but do not inhibit biosynthesis of cholesterol. Hepatology 44: 602-611 (2006). *
Hirayama T, Mizokami Y, Honda A, Homma Y, Ikegami T, Saito Y, Miyazaki T, Matsuzaki Y. Serum concentration of 27-hydroxycholesterol predicts the effects of high-cholesterol diet on plasma LDL cholesterol level. Hepatol. Res. 39: 149-156 (2009). *
Hirokane H, Nakahara M, Tachibana S, Shimizu M, Sato R. Bile acid reduces the secretion of very low density lipoprotein by repressing microsomal triglyceride transfer protein gene expression mediated by hepatocyte nuclear factor-4. J. Biol. Chem. 279: 45685-45692 (2004). *
Hirsch-Reinshagen V, Zhou S, Burgess BL, Bernier L, McIsaac SA, Chan JY, Tansley GH, Cohn JS, Hayden MR, Wellington CL. Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J. Biol. Chem. 279: 41197-41207 (2004). *
Hirschhorn JN. Genetic approaches to studying common diseases and complex traits. Pediatr. Res. 57: 74R-77R (2005). *
Hisadome T, Nakama T, Itoh H, Furusawa T. Physical-chemical properties of chenodeoxycholic acid and ursodeoxycholic acid. Gastroenterol. Jpn. 15: 257-263 (1980).
Hisaka S, Kato Y, Kitamoto N, Yoshida A, Kubushiro Y, Naito M, Osawa T. Chemical and immunochemical identification of propanoyl-lysine derived from oxidized n-3 polyunsaturated fatty acid. Free Radic. Biol. Med. 46: 1463-1471 (2009).
Hitoshi S. Lipid synthetic transcription factor, SREBP. Nippon Rinsho 63: 897-907 (2005).
Hiukka A, Leinonen E, Jauhiainen M, Sundvall J, Ehnholm C, Keech AC, Taskinen MR. Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus. Diabetologia 50: 2067-2075 (2007). *
Ho CH, Kuo BI, Kong CW, Chau WK, Hsu HC, Gau JP, Yu YB. Influence of methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism, B vitamins and other factors on plasma homocysteine and risk of thromboembolic disease in Chinese. J. Chin. Med. Assoc. 68: 560-565 (2005).
Hoashi S, Hinenoya T, Tanaka A, Ohsaki H, Sasazaki S, Taniguchi M, Oyama K, Mukai F, Mannen H. Association between fatty acid compositions and genotypes of FABP4 and LXR-alpha in Japanese Black cattle. BMC Genet. 9: 84 (2008). *
Hobbs HH, Cohen JC. ABCG5 and ABCG8 play major role in defense against sterol accumulation. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 55. June 18-19 (2004). *
Hoda F, Green RM. Hepatic canalicular membrane transport of bile salt in C57L/J and AKR/J mice: implications for cholesterol gallstone formation. J. Membr. Biol. 196: 9-14 (2003). *
Hodoglugil U, Tanyolac S, Williamson DW, Huang Y, Mahley RW. Apolipoprotein A5: potential modulator of plasma triglyceride levels in Turks. J. Lipid Res. 47: 144-153 (2006). *
Hoe HS, Cooper MJ, Burns MP, Lewis PA, van der Brug M, Chakraborty G, Cartagena CM, Pak DT, Cookson MR, Rebeck GW. The metalloprotease inhibitor TIMP-3 regulates amyloid precursor protein and apolipoprotein E receptor proteolysis. J. Neurosci. 27: 10895-10905 (2007).
Hoekstra M, Lammers B, Out R, Li Z, Van Eck M, Van Berkel TJ. Activation of the nuclear receptor PXR decreases plasma LDL-cholesterol levels and induces hepatic steatosis in LDL receptor knockout mice. Mol. Pharm. 6: 182-189 (2009). *
Hoekstra M, Out R, Kar Kruijt J, Van Eck M, Van Berkel TJ. Diet induced regulation of genes involved in cholesterol metabolism in rat liver parenchymal and Kupffer cells. J. Hepatol. 42: 400-407 (2005). *
Hoekstra M, Ye D, Hildebrand RB, Zhao Y, Lammers B, Stitzinger M, Kuiper J, Van Berkel TJ, Van Eck M. Scavenger receptor BI-mediated uptake of serum cholesterol is essential for optimal adrenal glucocorticoid production. J. Lipid Res. 50: 1039-1046 (2009). *
Hofman M, Princen H, Zwinderman A, Jukema J. Genetic variation in the rate-limiting enzyme in cholesterol catabolism (cholesterol 7alpha-hydroxylase) influences the progression of atherosclerosis and risk of new clinical events. Clin. Sci. (Lond.) 108: 539-545 (2005).
Hofman MK, Weggemans RM, Zock PL, Schouten EG, Katan MB, Princen HM. CYP7A1 A-278C polymorphism affects the response of plasma lipids after dietary cholesterol or cafestol interventions in humans. J. Nutr. 134: 2200-2204 (2004). *
Hofmann AF. Primary and secondary prevention of gallstone disease: implications for patient management and research priorities. Am. J. Surg. 165: 541-548 (1993).
Hofmann AF. Bile acids as drugs: principles, mechanisms of action and formulations. Ital. J. Gastroenterol. 27: 106-113 (1995).
Hofmann AF. Progress in idiopathic bile acid malabsorption. Gut 43: 738-739 (1998). *
Hofmann AF. Medical dissolution of gallstones by oral bile acid therapy. Am. J. Surg. 158: 198-204 (1989).
Hofmann AF. Current concepts of biliary secretion. Dig. Dis. Sci. 34: 16S-20S (1989).
Hofmann AF. Pharmacology of ursodeoxycholic acid, an enterohepatic drug. Scand. J. Gastroenterol. Suppl. 204: 1-15 (1994).
Hofmann AF. Bile acid secretion, bile flow and biliary lipid secretion in humans. Hepatology 12: 17S-22S (1990).
Hofmann AF. Bile acids: the good, the bad, and the ugly. News Physiol. Sci. 14: 24-29 (1999). *
Hofmann AF. Bile acids, cholesterol, gallstone calcification, and the enterohepatic circulation of bilirubin. Gastroenterology 116: 1276-1277 (1999). *
Hofmann AF. The continuing importance of bile acids in liver and intestinal disease. Arch. Intern. Med. 159: 2647-2658 (1999). *
Hofmann AF. Nonsurgical treatment of gallstone disease. Annu. Rev. Med. 41: 401-415 (1990). *
Hofmann AF. Admirand WH, Small DM. The physicochemical basis of cholesterol gallstone formation in man [J Clin Invest 1968;47:1043-1052]. J. Hepatol. 41: 195-200 (2004). *
Hofmann AF. Helicobacter and cholesterol gallstones: do findings in the mouse apply to man? Gastroenterology 128: 1126-1129 (2005). *
Hofmann AF. Bile acids: trying to understand their chemistry and biology with the hope of helping patients. Hepatology 49: 1403-1418 (2009). *
Hofmann AF, Zakko SF, Lira M, Clerici C, Hagey LR, Lambert KK, Steinbach JH, Schteingart CD, Olinga P, Groothuis GM. Novel biotransformation and physiological properties of norursodeoxycholic acid in humans. Hepatology 42: 1391-1398 (2005). *
Hofmann AF, Hagey LR. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell. Mol. Life Sci. 65: 2461-2483 (2008). *
Hofmann AF, Schteingart CD, Lillienau J. Biological and medical aspects of active ileal transport of bile acids. Ann. Med. 23: 169-175 (1991).
Hogenboom S, Romeijn GJ, Houten SM, Baes M, Wanders RJ, Waterham HR. Peroxisome deficiency does not result in deficiency of enzymes involved in cholesterol biosynthesis. Adv. Exp. Med. Biol. 544: 329-330 (2003).
Holden PR, Tugwood JD. Peroxisome proliferator-activated receptor alpha: role in rodent liver cancer and species differences. J. Mol. Endocrinol. 22: 1-8 (1999). *
Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am. J. Clin. Nutr. 80: 1678S-1688S (2004). *
Holick MF. Sunlight, UV-radiation, vitamin D and skin cancer: how much sunlight do we need? Adv. Exp. Med. Biol. 624: 1-15 (2008).
Holick MF, Chen TC, Lu Z, Sauter E. Vitamin D and skin physiology: a D-lightful story. J. Bone Miner. Res. 22 Suppl. 2: V28-V33 (2007). *
Holman RR, Paul S, Farmer A, Tucker L, Stratton IM, Neil HA; on behalf of the AFORRD study group. Atorvastatin in factorial with omega-3 EE90 risk reduction in diabetes (AFORRD): a randomised controlled trial. Diabetologia 52: 50-59 (2009). *
Holt JA, Luo G, Billin AN, Bisi J, McNeill YY, Kozarsky KF, Donahee M, Wang da Y, Mansfield TA, Kliewer SA, Goodwin B, Jones SA. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 17: 1581-1591 (2003). *
Holvoet P. Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease. Verh. K. Acad. Geneeskd. Belg. 70: 193-219 (2008).
Holzapfel J, Heun R, Lutjohann D, Jessen F, Maier W, Kolsch H. PPARD haplotype influences cholesterol metabolism but is no risk factor of Alzheimer's disease. Neurosci. Lett. 408: 57-61 (2006). *
Homsma SJ, Huijgen R, Middeldorp S, Sijbrands EJ, Kastelein JJ. Molecular screening for familial hypercholesterolaemia: consequences for life and disability insurance. Eur. J. Hum. Genet. 16: 14-17 (2008). *
Hong C, Tontonoz P. Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors. Curr. Opin. Genet. Dev. 18: 461-467 (2008).
Hong F, Radaeva S, Pan HN, Tian Z, Veech R, Gao B. Interleukin 6 alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver disease. Hepatology 40: 933-941 (2004). *
Hong I, Lee MH, Na TY, Zouboulis CC, Lee MO. LXRalpha enhances lipid synthesis in SZ95 sebocytes. J. Invest. Dermatol. 128: 1266-1272 (2008). *
Hong SH, Rhyne J, Zeller K, Miller M. ABCA1(Alabama): a novel variant associated with HDL deficiency and premature coronary artery disease. Atherosclerosis 164: 245-250 (2002).
Honjo Y, Sasaki S, Kobayashi Y, Misawa H, Nakamura H. 1,25-Dihydroxyvitamin D3 and its receptor inhibit the chenodeoxycholic acid-dependent transactivation by farnesoid X receptor. J. Endocrinol. 188: 635-643 (2006). *
Hontecillas R, Diguardo M, Duran E, Orpi M, Bassaganya-Riera J. Catalpic acid decreases abdominal fat deposition, improves glucose homeostasis and upregulates PPAR alpha expression in adipose tissue. Clin. Nutr. 27: 764-772 (2008).
Hoogerwerf WA, Soloway RD. Gallstones. Curr. Opin. Gastroenterol. 15: 442 (1999).
Hooijmans CR, Kiliaan AJ. Fatty acids, lipid metabolism and Alzheimer pathology. Eur. J. Pharmacol. 585: 176-196 (2008). *
Hooiveld GJ, Vos TA, Scheffer GL, Van Goor H, Koning H, Bloks V, Loot AE, Meijer DK, Jansen PL, Kuipers F, Muller M. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) induce hepatic expression of the phospholipid translocase mdr2 in rats. Gastroenterology 117: 678-687 (1999). *
Horton JD, Shimomura I, Ikemoto S, Bashmakov Y, Hammer RE. Overexpression of sterol regulatory element-binding protein-1a in mouse adipose tissue produces adipocyte hypertrophy, increased fatty acid secretion, and fatty liver. J. Biol. Chem. 278: 36652-36660 (2003). *
Horvath B, Szapary L, Debreceni L, Feher G, Kenyeres P, Fulop A, Battyani I, Toth K. Effect of Sclerovit on endothelial dysfunction, hemorheological parameters, platelet aggregation, plasma concentration of homocysteine and progression of atherosclerosis in patients with vascular diseases. Clin. Hemorheol. Microcirc. 42: 19-28 (2009).
Hosl M, Berneburg M. Vitamin D and the skin. Hautarzt. 59: 737-744 (2008).
Hosoyamada T. Clinical studies of pediatric malabsorption syndromes. Fukuoka Igaku Zasshi 97: 322-350 (2006).
Hossain MA, Tsujita M, Gonzalez FJ, Yokoyama S. Effects of fibrate drugs on expression of ABCA1 and HDL biogenesis in hepatocytes. J. Cardiovasc. Pharmacol. 51: 258-266 (2008).
Hotoleanu C, Porojan-Iuga M, Rusu ML, Andercou A. Hyperhomocysteinemia: clinical and therapeutical involvement in venous thrombosis. Rom. J. Intern. Med. 45: 159-164 (2007).
Hou CT. New bioactive fatty acids. Asia Pac. J. Clin. Nutr. 17 Suppl. 1: 192-195 (2008).
Houten S, Auwerx J. The enterohepatic nuclear receptors are major regulators of the enterohepatic circulation of bile salts. Ann. Med. 36: 482-491 (2004).
Houten SM, Watanabe M, Auwerx J. Endocrine functions of bile acids. EMBO J. 25: 1419-1425 (2006). *
Hovingh GK, de Groot E, van der Steeg W, Boekholdt SM, Hutten BA, Kuivenhoven JA, Kastelein JJ. Inherited disorders of HDL metabolism and atherosclerosis. Curr. Opin. Lipidol. 16: 139-145 (2005).
Howarth AG, Jiang Y, Pannirselvam M, Wiehler WB, Berger JP, Severson DL, Anderson TJ, Triggle CR. A non-thiazolidinedione PPARgamma agonist reverses endothelial dysfunction in diabetic (db/db -/-) mice. J. Pharmacol. Exp. Ther. 316: 364-370 (2006). *
Hoy SM, Keating GM. Omega-3 ethylester concentrate: a review of its use in secondary prevention post-myocardial infarction and the treatment of hypertriglyceridaemia. Drugs 69: 1077-1105 (2009).
Hozoji M, Munehira Y, Ikeda Y, Makishima M, Matsuo M, Kioka N, Ueda K. Direct interaction of nuclear liver X receptor-beta with ABCA1 modulates cholesterol efflux. J. Biol. Chem. 283: 30057-30063 (2008). *
Hrabovsky V, Zadak Z, Blaha V, Hyspler R, Karlik T. Changes in lipid metabolism in patients in the active phase of Crohn's disease. Vnitr. Lek. 53: 1035-1039 (2007).
Hrabovsky V, Zadak Z, Blaha V, Hyspler R, Ticha A, Karlik T. Lipid metabolism in active Crohn's disease: pre-results. Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc. Czech. Repub. 150: 363-366 (2006).
Hsieh J, Longuet C, Maida A, Bahrami J, Xu E, Baker CL, Brubaker PL, Drucker DJ, Adeli K. Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36. Gastroenterology May 28 [Epub ahead of print] (2009). *
Hsu JC, Su TC, Chen MF, Liau CS, Lee YT. Xanthoma striatum palmare in a patient with primary biliary cirrhosis and hypercholesterolemia. J. Gastroenterol. Hepatol. 20: 1799-1800 (2005). *
Hsun-Wei Huang T, Peng G, Qian Li G, Yamahara J, Roufogalis BD, Li Y. Salacia oblonga root improves postprandial hyperlipidemia and hepatic steatosis in Zucker diabetic fatty rats: activation of PPAR-alpha. Toxicol. Appl. Pharmacol. 210: 225-235 (2006). *
Hu B, Collini M, Unwalla R, Miller C, Singhaus R, Quinet E, Savio D, Halpern A, Basso M, Keith J, Clerin V, Chen L, Resmini C, Liu QY, Feingold I, Huselton C, Azam F, Farnegardh M, Enroth C, Bonn T, Goos-Nilsson A, Wilhelmsson A, Nambi P, Wrobel J. Discovery of phenyl acetic acid substituted quinolines as novel liver x receptor agonists for the treatment of atherosclerosis. J. Med. Chem. 49: 6151-6154 (2006). *
Hu C, Jia W, Fang Q, Zhang R, Wang C, Lu J, Xiang K. Peroxisome proliferator-activated receptor (PPAR) delta genetic polymorphism and its association with insulin resistance index and fasting plasma glucose concentrations in Chinese subjects. Diabet. Med. 23: 1307-1312 (2006). *
Hu T, Chouinard M, Cox AL, Sipes P, Marcelo M, Ficorilli J, Li S, Gao H, Ryan TP, Michael MD, Michael LF. Farnesoid X receptor agonist reduces serum asymmetric dimethylarginine levels through hepatic dimethylarginine dimethylaminohydrolase-1 gene regulation. J. Biol. Chem. 281: 39831-39838 (2006). *
Hu X, Li S, Wu J, Xia C, Lala DS. Liver X receptors interact with corepressors to regulate gene expression. Mol. Endocrinol. 17: 1019-1026 (2003). *
Hu YW, Ma X, Li XX, Liu XH, Xiao J, Mo ZC, Xiang J, Liao DF, Tang CK. Eicosapentaenoic acid reduces ABCA1 serine phosphorylation and impairs ABCA1-dependent cholesterol efflux through cyclic AMP/protein kinase A signaling pathway in THP-1 macrophage-derived foam cells. Atherosclerosis 204: e35-e43 (2009).
Huang JC, Hoogwerf RJ. Cholesterol guidelines update: more aggressive therapy for higher-risk patients. Cleve. Clin. J. Med. 72: 253-262 (2005). *
Huang Q, Wang TH, Lu WS, Mu PW, Yang YF, Liang WW, Li CX, Lin GP. Estrogen receptor alpha gene polymorphism associated with type 2 diabetes mellitus and the serum lipid concentration in Chinese women in Guangzhou. Chin. Med. J. (Engl.) 119: 1794-1801 (2006). *
Huang TH, Peng G, Kota BP, Li GQ, Yamahara J, Roufogalis BD, Li Y. Pomegranate flower improves cardiac lipid metabolism in a diabetic rat model: role of lowering circulating lipids. Br. J. Pharmacol. 145: 767-774 (2005). *
Huang TH, Razmovski-Naumovski V, Salam NK, Duke RK, Tran VH, Duke CC, Roufogalis BD. A novel LXR-alpha activator identified from the natural product Gynostemma pentaphyllum. Biochem. Pharmacol. 70: 1298-1308 (2005). *
Huang X, Yang C, Jin C, Luo Y, Wang F, McKeehan WL. Resident hepatocyte fibroblast growth factor receptor 4 limits hepatocarcinogenesis. Mol. Carcinog. 48: 553-562 (2009). *
Huang XS, Zhao SP, Hu M, Luo YP. Apolipoprotein M likely extends its anti-atherogenesis via anti-inflammation. Med. Hypotheses 69: 136-140 (2007).
Hubacek JA, Berge KE, Stefkova J, Pitha J, Skodova Z, Lanska V, Poledne R. Polymorphisms in ABCG5 and ABCG8 transporters and plasma cholesterol levels. Physiol. Res. 53: 395-401 (2004). *
Hubacek JA, Lanska V, Skodova Z, Adamkova V, Poledne R. Sex-specific interaction between APOE and APOA5 variants and determination of plasma lipid levels. Eur. J. Hum. Genet. 16: 135-138 (2008). *
Hubbert ML, Zhang Y, Lee FY, Edwards PA. Regulation of hepatic Insig-2 by the farnesoid X-receptor. Mol. Endocrinol. 21: 1359-1369 (2007). *
Huber RM, Murphy K, Miao B, Link JR, Cunningham MR, Rupar MJ, Gunyuzlu PL, Haws TF, Kassam A, Powell F, Hollis GF, Young PR, Mukherjee R, Burn TC. Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters. Gene 290: 35-43 (2002). *
Hui DY, Howles PN. Molecular mechanisms of cholesterol absorption and transport in the intestine. Semin. Cell. Dev. Biol. 16: 183-192 (2005). *
Hulzebos CV, Bijleveld CM, Stellaard F, Kuipers F, Fidler V, Slooff MJ, Peeters PM, Sauer PJ, Verkade HJ. Cyclosporine A-induced reduction of bile salt synthesis associated with increased plasma lipids in children after liver transplantation. Liver Transpl. 10: 872-880 (2004). *
Humaloja K, Roine RP, Vuoristo M, Farkkila M, Hockerstedt K, Salaspuro M. Serum dolichols in chronic cholestatic liver diseases. J. Hepatol. 31: 1014-1019 (1999). *
Humphries SE, Martin S, Cooper J, Miller G. Interaction between smoking and the stromelysin-1 (MMP3) gene 5A/6A promoter polymorphism and risk of coronary heart disease in healthy men. Ann. Hum. Genet. 66: 343-352 (2002). *
Humphries SE, Whittall RA, Hubbart CS, Maplebeck S, Cooper JA, Soutar AK, Naoumova R, Thompson GR, Seed M, Durrington PN, Miller JP, Betteridge DJ, Neil HA; Simon Broome Familial Hyperlipidaemia Register Group and Scientific Steering Committee. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J. Med. Genet. 43: 943-949 (2006). *
Hunt M, O'Byrne J, Solaas K, Frode Kase B, Alexson SEH. New insights into bile acid amidation. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 24. June 18-19 (2004). *
Hunt MC, Yang YZ, Eggertsen G, Carneheim CM, Gafvels M, Einarsson C, Alexson SE. The peroxisome proliferator-activated receptor alpha (PPARalpha) regulates bile acid biosynthesis. J. Biol. Chem. 275: 28947-28953 (2000). *
Hunter DJ, Kraft P. Drinking from the fire hose - statistical issues in genomewide association studies. N. Engl. J. Med. 357: 436-439 (2007). *
Huq MD, Tsai NP, Gupta P, Wei LN. Regulation of retinal dehydrogenases and retinoic acid synthesis by cholesterol metabolites. EMBO J. 25: 3203-3213 (2006). *
Hussaini SH, Pereira SP, Murphy GM, Kennedy C, Wass JA, Besser GM, Dowling RH. Composition of gall bladder stones associated with octreotide: response to oral ursodeoxycholic acid. Gut 36: 126-132 (1995). *
Hussein O, Grosovski M, Lasri E, Svalb S, Ravid U, Assy N. Monounsaturated fat decreases hepatic lipid content in non-alcoholic fatty liver disease in rats. World J. Gastroenterol. 13: 361-368 (2007). *
Hutchins GF, Gollan JL. Recent developments in the pathophysiology of cholestasis. Clin. Liver Dis. 8: 1-26 (2004).
Hutchins H. Omega-3 fatty acids: recommendations for therapeutics and prevention. MedGenMed. 7: 18 (2005). *
Huuskonen J, Vishnu M, Chau P, Fielding PE, Fielding CJ. Liver X receptor inhibits the synthesis and secretion of apolipoprotein A1 by human liver-derived cells. Biochemistry 45: 15068-15074 (2006). *
Huuskonen J, Vishnu M, Pullinger CR, Fielding PE, Fielding CJ. Regulation of ATP-binding cassette transporter A1 transcription by thyroid hormone receptor. Biochemistry 43: 1626-1632 (2004). *
Hwang SJ, Chan CY, Lee SD, Wu JC, Tsay SH, Lo KJ. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a short-term, randomized, double-blind controlled, cross-over study with long-term follow up. J. Gastroenterol. Hepatol. 8: 217-223 (1993).
Hylemon PB, Fang Y, Gupta S, Studer E, Mitchell C, Spiegel S, Pandak WM, Dent P. Conjugated bile acids promote activation of the ERK 1/2 and AKT pathways via a pertussis toxin-sensitive GI-dependent mechanism in primary rodent and human hepatocytes. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 24 (2006). *
Hylemon PB, Gupta S, Dent P. Regulation of bile acid biosynthesis by cell signaling pathways. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 29. June 18-19 (2004). *
Hylemon PB, Zhou H, Pandak WM, Ren S, Gil G, Dent P. Bile acids as regulatory molecules. J. Lipid Res. Apr 3 [Epub ahead of print] (2009). *
Hyogo H, Tazuma S, Cohen DE. Cholesterol gallstones. Curr. Opin. Gastroenterol. 18: 366-371 (2002).
Ide T, Shimano H, Yoshikawa T, Yahagi N, Amemiya-Kudo M, Matsuzaka T, Nakakuki M, Yatoh S, Iizuka Y, Tomita S, Ohashi K, Takahashi A, Sone H, Gotoda T, Osuga J, Ishibashi S, Yamada N. Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. II. LXRs suppress lipid degradation gene promoters through inhibition of PPAR signaling. Mol. Endocrinol. 17: 1255-1267 (2003). *
Igarashi M, Gao F, Kim HW, Ma K, Bell JM, Rapoport SI. Dietary n-6 PUFA deprivation for 15 weeks reduces arachidonic acid concentrations while increasing n-3 PUFA concentrations in organs of post-weaning male rats. Biochim. Biophys. Acta 1791: 132-139 (2009). *
Igarashi M, Hirata A, Yamaguchi H, Jimbu Y, Tominaga M. Pioglitazone reduces atherogenic outcomes in type 2 diabetic patients. J. Atheroscler. Thromb. 15: 34-40 (2008).
Igimi H, Asakawa S, Watanabe D, Shimura H. Liquid crystal formation in ursodeoxycholate-rich human gallbladder bile. Gastroenterol. Jpn. 18: 93-97 (1983).
Igimi H, Carey MC. Cholesterol gallstone dissolution in bile: dissolution kinetics of crystalline (anhydrate and monohydrate) cholesterol with chenodeoxycholate, ursodeoxycholate, and their glycine and taurine conjugates. J. Lipid Res. 22: 254-270 (1981). *
Ikeda F, Doi Y, Yonemoto K, Ninomiya T, Kubo M, Shikata K, Hata J, Tanizaki Y, Matsumoto T, Iida M, Kiyohara Y. Hyperglycemia increases risk of gastric cancer posed by Helicobacter pylori infection: a population-based cohort study. Gastroenterology 136: 1234-1241 (2009).
Ikeda I, Konno R, Shimizu T, Ide T, Takahashi N, Kawada T, Nagao K, Inoue N, Yanagita T, Hamada T, Morinaga Y, Tomoyori H, Imaizumi K, Suzuki K. Campest-5-en-3-one, an oxidized derivative of campesterol, activates PPARalpha, promotes energy consumption and reduces visceral fat deposition in rats. Biochim. Biophys. Acta 1760: 800-807 (2006). *
Ikegami T, Matsuzaki Y, Fukushima S, Shoda J, Olivier JL, Bouscarel B, Tanaka N. Suppressive effect of ursodeoxycholic acid on type IIA phospholipase A(2) expression in HepG2 cells. Hepatology 41: 896-905 (2005). *
Ilan Y, Shouval D. Primary biliary cirrhosis in Israel. Isr. J. Med. Sci. 28: 683-687 (1992).
Ile KE, Davis W, Boyd JT, Soulika AM, Tew KD. Identification of a novel first exon of the human ABCA2 transporter gene encoding a unique N-terminus. Biochim. Biophys. Acta 1678: 22-32 (2004). *
Ilhan N, Kahraman N, Seckin D, Ilhan N, Colak R. Apo E gene polymorphism on development of diabetic nephropathy. Cell. Biochem. Funct. 25: 527-532 (2007). *
Illingworth DR. An overview of lipid-lowering drugs. Drugs 36 Suppl. 3: 63-71 (1988).
Imamura A, Takahashi R, Murakami R, Kataoka H, Cheng XW, Numaguchi Y, Murohara T, Okumura K. The effects of endothelial nitric oxide synthase gene polymorphisms on endothelial function and metabolic risk factors in healthy subjects: the significance of plasma adiponectin levels. Eur. J. Endocrinol. 158: 189-195 (2008). *
Imayama I, Ichiki T, Patton D, Inanaga K, Miyazaki R, Ohtsubo H, Tian Q, Yano K, Sunagawa K. Liver X receptor activator downregulates angiotensin II type 1 receptor expression through dephosphorylation of Sp1. Hypertension 51: 1631-1636 (2008).
Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, Luo G, Jones SA, Goodwin B, Richardson JA, Gerard RD, Repa JJ, Mangelsdorf DJ, Kliewer SA. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell. Metab. 2: 217-225 (2005). *
Inamoto Y, Teramoto T, Shirai K, Tsukamoto H, Sanda T, Miyamura K, Yamamori I, Hirabayashi N, Kodera Y. Severe hypercholesterolemia associated with decreased hepatic triglyceride lipase activity and pseudohyponatremia in patients after allogeneic stem cell transplantation. Int. J. Hematol. 82: 362-366 (2005).
Infante J, Rodr�guez-Rodriguez E, Mateo I, Llorca J, Vazquez-Higuera JL, Berciano J, Combarros O. Gene-gene interaction between heme oxygenase-1 and liver X receptor-beta and Alzheimer's disease risk. Neurobiol. Aging Jun 30 [Epub ahead of print] (2008).
Innocenti F, Hepp J, Humeres R, Sanhueza E, Zapata R, Rios H, Suarez L, Sandoval R, Rius M, Zamboni M. Rapid steroid taper and neoral monotherapy in liver transplantation in Chile: a step in the right direction? Transplant Proc. 36: 1675-1676 (2004). *
Inokuchi A, Hinoshita E, Iwamoto Y, Kohno K, Kuwano M, Uchiumi T. Enhanced expression of the human multidrug resistance protein 3 by bile salt in human enterocytes. A transcriptional control of a plausible bile acid transporter. J. Biol. Chem. 276: 46822-46829 (2001). *
Inoue I. Lipid metabolism and magnesium. Clin. Calcium 15: 1827-1838 (2005).
Inoue I. Hyperlipidemia and peroxisome proliferator-activated receptor (PPAR) - regulation of the PPARalpha gene by CLOCK: BMAL1. Nippon Rinsho 63: 643-656 (2005).
Inoue I, Itoh F, Aoyagi S, Tazawa S, Kusama H, Akahane M, Mastunaga T, Hayashi K, Awata T, Komoda T, Katayama S. Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB. Biochem. Biophys. Res. Commun. 290: 131-139 (2002). *
Inoue K, Hirohara J, Nakano T, Seki T, Sasaki H, Higuchi K, Ohta Y, Onji M, Muto Y, Moriwaki H. Prediction of prognosis of primary biliary cirrhosis in Japan. Liver 15: 70-77 (1995).
Inoue Y, Inoue J, Lambert G, Yim SH, Gonzalez FJ. Disruption of hepatic C/EBPalpha results in impaired glucose tolerance and age-dependent hepatosteatosis. J. Biol. Chem. 279: 44740-44748 (2004). *
Inoue Y, Yu AM, Inoue J, Gonzalez FJ. Hepatocyte nuclear factor 4alpha is a central regulator of bile acid conjugation. J. Biol. Chem. 279: 2480-2489 (2004). *
Inoue Y, Yu AM, Yim SH, Ma X, Krausz KW, Inoue J, Xiang CC, Brownstein MJ, Eggertsen G, Bj�rkhem I, Gonzalez FJ. Regulation of bile acid biosynthesis by hepatocyte nuclear factor 4alpha. J. Lipid Res. 47: 215-227 (2006). *
Ioannou GN, Morrow OB, Connole ML, Lee SP. Association between dietary nutrient composition and the incidence of cirrhosis or liver cancer in the United States population. Hepatology Mar 3 [Epub ahead of print] (2009).
Iser JH, Sali A. Chenodeoxycholic acid: a review of its pharmacological properties and therapeutic use. Drugs 21: 90-119 (1981).
Ishida H, Kuruta Y, Gotoh O, Yamashita C, Yoshida Y, Noshiro M. Structure, evolution, and liver-specific expression of sterol 12alpha-hydroxylase P450 (CYP8B). J. Biochem. 126: 19-25 (1999).
Ishida H, Yamashita C, Kuruta Y, Yoshida Y, Noshiro M. Insulin is a dominant suppressor of sterol 12 alpha-hydroxylase P450 (CYP8B) expression in rat liver: possible role of insulin in circadian rhythm of CYP8B. J. Biochem. 127: 57-64 (2000).
Ishimoto K, Tachibana K, Sumitomo M, Omote S, Hanano I, Yamasaki D, Watanabe Y, Tanaka T, Hamakubo T, Sakai J, Kodama T, Doi T. Identification of human low-density lipoprotein receptor as a novel target gene regulated by liver X receptor alpha. FEBS Lett. 580: 4929-4933 (2006). *
Islam KK, Knight BL, Frayn KN, Patel DD, Gibbons GF. Deficiency of PPARalpha disturbs the response of lipogenic flux and of lipogenic and cholesterogenic gene expression to dietary cholesterol in mouse white adipose tissue. Biochim. Biophys. Acta 1734: 259-268 (2005). *
Ismail H, Kalicinski P, Markiewicz M, Jankowska I, Pawlowska J, Kluge P, Eliadou E, Kaminski A, Szymczak M, Drewniak T, Revillon Y. Treatment of progressive familial intrahepatic cholestasis: liver transplantation or partial external biliary diversion. Pediatr. Transplant. 3: 219-224 (1999).
Ismair MG, Hausler S, Stuermer CA, Guyot C, Meier PJ, Roth J, Stieger B. ABC-transporters are localized in caveolin-1-positive and reggie-1-negative and reggie-2-negative microdomains of the canalicular membrane in rat hepatocytes. Hepatology 49: 1673-1682 (2009).
Isoda K, Sawada S, Ayaori M, Matsuki T, Horai R, Kagata Y, Miyazaki K, Kusuhara M, Okazaki M, Matsubara O, Iwakura Y, Ohsuzu F. Deficiency of interleukin-1 receptor antagonist deteriorates fatty-liver and cholesterol metabolism in hypercholesterolemic mice. J. Biol. Chem. 280: 7002-7009 (2005). *
Ito K, Hoekstra D, van Ijzendoorn SC. Cholesterol but not association with detergent resistant membranes is necessary for the transport function of MRP2/ABCC2. FEBS Lett. 582: 4153-4157 (2008). *
Ito S, Yukawa T, Uetake S, Yamauchi M. Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis. Alcohol Clin. Exp. Res. 31: S83-S87 (2007). *
Ito T. Physiological function of ABCG1. Drug News Perspect. 16: 490-492 (2003).
Itoh S, Kono M, Akimoto T. Psoriasis treated with ursodeoxycholic acid: three case reports. Clin. Exp. Dermatol. 32: 398-400 (2007). *
Ivanisevic M, Vujovic S, Drezgic M. Effects of estro-progestagens on lipid and hormonal profiles in women with premature primary ovarian failure. Med. Pregl. 58: 296-300 (2005).
Iwaki T, Hirabayashi N, Miyazawa N, Takeuchi Y, Ishizaki K, Sakakura H, Kasai H, Maeda M, Araki T. The choleretic effects of N-acetylglucosaminides, major urinary metabolites of ursodeoxycholic acid, in bile fistula rats. Eur. J. Pharmacol. 363: 41-48 (1998).
Iwamura K. Changes of bile acid and lipid composition in blood and bile in the clinical course after the initiation of cheno- and ursodeoxycholic acid therapy in patients with cholesterol gallstones. Tokai. J. Exp. Clin. Med. 7: 671-683 (1982).
Iwano S, Nukaya M, Saito T, Asanuma F, Kamataki T. A possible mechanism for atherosclerosis induced by polycyclic aromatic hydrocarbons. Biochem. Biophys. Res. Commun. 335: 220-226 (2005). *
Jackson M, Ahmad Y, Bruce IN, Coupes B, Brenchley PE. Activation of transforming growth factor-beta1 and early atherosclerosis in systemic lupus erythematosus. Arthritis Res. Ther. 8: R81 (2006). *
Jacobson TA. Role of n-3 fatty acids in the treatment of hypertriglyceridemia and cardiovascular disease. Am. J. Clin. Nutr. 87: 1981S-1990S (2008).
Jacobson TA, Miller M, Schaefer EJ. Hypertriglyceridemia and cardiovascular risk reduction. Clin. Ther. 29: 763-777 (2007).
Jacobson TA, Zimmerman FH. Fibrates in combination with statins in the management of dyslipidemia. J. Clin. Hypertens. (Greenwich) 8: 35-41 (2006).
Jacquemin E. Progressive familial intrahepatic cholestasis and hereditary anomalies of hepatocellular metabolism of bile acids. Arch. Pediatr. 5: 45-53 (1998).
Jacquemin E. Role of multidrug resistance 3 deficiency in pediatric and adult liver disease: one gene for three diseases. Semin. Liver Dis. 21: 551-562 (2001). *
Jacquemin E, Setchell KD, O'Connell NC, Estrada A, Maggiore G, Schmitz J, Hadchouel M, Bernard O. A new cause of progressive intrahepatic cholestasis: 3 beta-hydroxy-C27-steroid dehydrogenase/isomerase deficiency. J. Pediatr. 125: 379-384 (1994).
Jaffe JR, Nag SS, Landsman PB, Alexander CM. Reassessment of cardiovascular risk in diabetes. Curr. Opin. Lipidol. 17: 644-652 (2006).
Jahan A, Chiang JY. Cytokine regulation of human sterol 12alpha-hydroxylase (CYP8B1) gene. Am. J. Physiol. Gastrointest. Liver Physiol. 288: G685-G695 (2005). *
Jahn CE, Schaefer EJ, Taam LA, Hoofnagle JH, Lindgren FT, Albers JJ, Jones EA, Brewer HB Jr. Lipoprotein abnormalities in primary biliary cirrhosis. Association with hepatic lipase inhibition as well as altered cholesterol esterification. Gastroenterology 89: 1266-1278 (1985).
Jahovic N, Gedik N, Ercan F, Sirvanci S, Yuksel M, Sener G, Alican I. Effects of statins on experimental colitis in normocholesterolemic rats. Scand. J. Gastroenterol. 41: 954-962 (2006). *
Jain R. Biliary sludge: when should it not be ignored? Curr. Treat. Options Gastroenterol. 7: 105-109 (2004).
Jakel H, Fruchart-Najib J, Fruchart JC. Retinoic acid receptor-related orphan receptor alpha as a therapeutic target in the treatment of dyslipidemia and atherosclerosis. Drug News Perspect. 19: 91-97 (2006).
Jakel H, Nowak M, Helleboid-Chapman A, Fruchart-Najib J, Fruchart JC. Is apolipoprotein A5 a novel regulator of triglyceride-rich lipoproteins? Ann. Med. 38: 2-10 (2006).
Jakobsen CH, St�rvold GL, Bremseth H, Follestad T, Sand K, Mack M, Olsen KS, Lundemo AG, Iversen JG, Krokan HE, Sch�nberg SM. DHA induces ER stress and growth arrest in human colon cancer cells - associations with cholesterol and calcium homeostasis. J. Lipid Res. 49: 2089-2100 (2008). *
Jakobsson T, Venteclef N, Toresson G, Damdimopoulos AE, Ehrlund A, Lou X, Sanyal S, Steffensen KR, Gustafsson JA, Treuter E. GPS2 is required for cholesterol efflux by triggering histone demethylation, LXR recruitment, and coregulator assembly at the ABCG1 locus. Mol. Cell 34: 510-518 (2009). *
Jalving M, Koornstra JJ, Jong S, Vries EG, Kleibeuker JH. Review article: the potential of combinational regimen with non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer. Aliment. Pharmacol. Ther. 21: 321-339 (2005). *
Jamroz-Wisniewska A, Wojcicka G, Horoszewicz K, Beltowski J. Liver X receptors (LXRs). Part II: non-lipid effects, role in pathology, and therapeutic implications. Postepy. Hig. Med. Dosw. (Online) 61: 760-785 (2007). *
Janowski BA, Grogan MJ, Jones SA, Wisely GB, Kliewer SA, Corey EJ, Mangelsdorf DJ. Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta. Proc. Natl. Acad. Sci. U.S.A. 96: 266-271 (1999). *
Jansen AC, van Aalst-Cohen ES, Tanck MW, Cheng S, Fontecha MR, Li J, Defesche JC, Kastelein JJ. Genetic determinants of cardiovascular disease risk in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 25: 1475-1481 (2005). *
Jansen GR. Effect of delta(22)-5beta-taurocholenic acid on hepatic cholesterol and fatty acid in gold thioglucose obese mice fed low- or high-fat diets. J. Nutr. Biochem. 10: 638-643 (1999).
Jansen H. Hepatic lipase: friend or foe and under what circumstances? Curr. Atheroscler. Rep. 6: 343-347 (2004).
Jansen PL. Genetics of cholestasis. Falk Symposium 156. XIII Falk Liver Week (Part II). GENETICS IN LIVER DISEASES, Freiburg (Germany), October 8-9, 2006, p. 37-40 (2006). *
Jansen PL, Sturm E. Genetic cholestasis, causes and consequences for hepatobiliary transport. Liver Int. 23: 315-322 (2003). *
Jansen PL, van der Lelie H. Intrahepatic cholestasis and biliary cirrhosis associated with extrahepatic Hodgkin's disease. Neth. J. Med. 44: 99-102 (1994).
Jasinska M, Owczarek J, Orszulak-Michalak D. Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol. Rep. 59: 483-99 (2007). *
Jatwa R, Parmar HS, Panda S, Kar A. Amelioration of corticosteroid-induced type 2 diabetes mellitus by rosiglitazone is possibly mediated through stimulation of thyroid function and inhibition of tissue lipid peroxidation in mice. Basic Clin. Pharmacol. Toxicol. 101: 177-180 (2007).
Javitt NB. Oxysterols: novel biologic roles for the 21st century. Steroids 73: 149-157 (2008).
Javitt NB. Metabolite regulation of cholesterol synthesis. Hosp. Pract. (Off. Ed). 20: 109-112, 116-117, 120-121 (1985).
Javitt NB. Hep G2 cells as a resource for metabolic studies: lipoprotein, cholesterol, and bile acids. FASEB J. 4: 161-168 (1990). *
Javitt NB. 26-Hydroxycholesterol: synthesis, metabolism, and biologic activities. J. Lipid Res. 31: 1527-1533 (1990). *
Javitt NB. Cholic acid synthesis from 27-hydroxycholesterol in humans. Gastroenterology 115: 509 (1998).
Javitt NB. Cholesterol homeostasis: role of the LDL receptor. FASEB J. 9: 1378-1381 (1995). *
Javitt NB. Biologic role(s) of the 25(R),26-hydroxycholesterol metabolic pathway. Biochim. Biophys. Acta 1529: 136-141 (2000). *
Javitt NB. Oxysteroids: a new class of steroids with autocrine and paracrine functions. Trends Endocrinol. Metab. 15: 393-397 (2004). *
Javitt NB. Oxysterols: functional significance in fetal development and the maintenance of normal retinal function. Curr. Opin. Lipidol. 18: 283-288 (2007).
Javitt NB. 25R,26-Hydroxycholesterol revisited: synthesis, metabolism, and biologic roles. J. Lipid Res. 43: 665-670 (2002). *
Javitt NB. Cholesterol, hydroxycholesterols, and bile acids. Biochem. Biophys. Res. Commun. 292: 1147-1153 (2002). *
Javitt NB. Bile acid synthesis from cholesterol: regulatory and auxiliary pathways. FASEB J. 8: 1308-1311 (1994). *
Javitt NB, Budai K. Cholesterol and bile acid synthesis in Hep G2 cells. Metabolic effects of 26- and 7 alpha-hydroxycholesterol. Biochem. J. 262: 989-992 (1989). *
Javitt NB, Javitt JI. Cholesterol and bile acid synthesis: utilization of D2O for metabolic studies. Biomed. Environ. Mass Spectrom. 18: 624-628 (1989).
Javitt NB, Lee YC, Shimizu C, Fuda H, Strott CA. Cholesterol and hydroxycholesterol sulfotransferases: identification, distinction from dehydroepiandrosterone sulfotransferase, and differential tissue expression. Endocrinology 142: 2978-2984 (2001). *
Javitt NB, Pfeffer R, Kok E, Burstein S, Cohen BI, Budai K. Bile acid synthesis in cell culture. J. Biol. Chem. 264: 10384-10387 (1989). *
Jean-Louis S, Akare S, Ali MA, Mash EA Jr, Meuillet E, Martinez JD. Deoxycholic acid induces intracellular signaling through membrane perturbations. J. Biol. Chem. 281: 14948-14960 (2006). *
Jeannesson E, Siest G, Bastien B, Albertini L, Aslanidis C, Schmitz G, Visvikis-Siest S. Association of ABCB1 gene polymorphisms with plasma lipid and apolipoprotein concentrations in the Stanislas Cohort. Clin. Chim. Acta 403: 198-202 (2009). *
Jefcoate CR. Liver X receptor opens a new gateway to StAR and to steroid hormones. J. Clin. Invest. 116: 1832-1835 (2006). *
Jeffrey GP, Muller DP, Burroughs AK, Matthews S, Kemp C, Epstein O, Metcalfe TA, Southam E, Tazir-Melboucy M, Thomas PK, et al. Vitamin E deficiency and its clinical significance in adults with primary biliary cirrhosis and other forms of chronic liver disease. J. Hepatol. 4: 307-317 (1987).
Jehn M, Clark JM, Guallar E. Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 27: 2422-2428 (2004). *
Jelinek DF, Andersson S, Slaughter CA, Russell DW. Cloning and regulation of cholesterol 7 alpha-hydroxylase, the rate-limiting enzyme in bile acid biosynthesis. J. Biol. Chem. 265: 8190-8197 (1990). *
Jenkins DJ, Kendall CW. Resistant starches. Curr. Opin. Gastroenterol. 16: 178-183 (2000).
Jessup W, Gelissen IC, Gaus K, Kritharides L. Roles of ATP binding cassette transporters A1 and G1, scavenger receptor BI and membrane lipid domains in cholesterol export from macrophages. Curr. Opin. Lipidol. 17: 247-257 (2006).
Jetten AM. Recent advances in the mechanisms of action and physiological functions of the retinoid-related orphan receptors (RORs). Curr. Drug Targets Inflamm. Allergy 3: 395-412 (2004).
Ji C, Shinohara M, Kuhlenkamp J, Chan C, Kaplowitz N. Mechanisms of protection by the betaine-homocysteine methyltransferase/betaine system in HepG2 cells and primary mouse hepatocytes. Hepatology 46: 1586-1596 (2007). *
Jia D, Otsuki M. Bezafibrate, a peroxisome proliferator-activated receptor (PPAR)-alpha activator, prevents pancreatic degeneration in obese and diabetic rats. Pancreas 26: 286-291 (2003).
Jia M, Xue N, Cao Z, Liu H. Effects of dietary different ratios of n-3 to n-6 polyunsaturated fatty acids influence lipid metabolism and appetite of rats. Wei Sheng Yan Jiu 38: 175-178 (2009).
Jia XW, Tian YP, Wang Y, Deng XX, Dong ZN. Correlation of polymorphism in IL-6 gene promoter with BMI, inflammatory factors, and pathogenesis and progression of CHD. Zhongguo Shi Yan Xue Ye Xue Za Zhi 15: 1270-1275 (2007).
Jiang D, Fang D, Kelley TJ, Burgess JD. Electrochemical analysis of cell plasma membrane cholesterol at the airway surface of mouse trachea. Anal. Chem. 80: 1235-1239 (2008). *
Jiang J, He M. Clinical features of primary biliary cirrhosis and treatment of it by integrated traditional Chinese and western medicine. Zhong Xi Yi Jie He Xue Bao 1: 99-102 (2003).
Jiang W, Miyamoto T, Kakizawa T, Nishio SI, Oiwa A, Takeda T, Suzuki S, Hashizume K. Inhibition of LXRalpha signaling by vitamin D receptor: possible role of VDR in bile acid synthesis. Biochem. Biophys. Res. Commun. 351: 176-184 (2006). *
Jiang YD, Xiong JT, Cao J, Li GZ, Wang SR. Effects of peroxisome proliferators activated receptors on caveolin-1 expression in foam cells. Zhonghua Xin Xue Guan Bing Za Zhi 35: 661-665 (2007).
Jiang YD, Yen CJ, Chou WL, Kuo SS, Lee KC, Chiu KC, Chuang LM. Interaction of the G182C polymorphism in the APOA5 gene and fasting plasma glucose on plasma triglycerides in type 2 diabetic subjects. Diabet. Med. 22: 1690-1695 (2005).
Jiang YJ, Kim P, Elias PM, Feingold KR. LXR and PPAR activators stimulate cholesterol sulfotransferase (SULT2B1b) in human keratinocytes. J. Lipid Res. 46: 2657-2666 (2005). *
Jiang YJ, Lu B, Kim P, Elias PM, Feingold KR. Regulation of ABCA1 expression in human keratinocytes and murine epidermis. J. Lipid Res. 47: 2248-2258 (2006). *
Jiang ZY, Parini P, Eggertsen G, Davis MA, Hu H, Suo GJ, Zhang SD, Rudel LL, Han TQ, Einarsson C. Increased expression of LXRalpha , ABCG5, ABCG8 and SRBI in the liver from normolipidemic nonobese Chinese gallstone patients. J. Lipid Res. 49: 464-472 (2008). *
Jin S, Mathis AS, Rosenblatt J, Minko T, Friedman GS, Gioia K, Serur DS, Knipp GT. Insights into cyclosporine A-induced atherosclerotic risk in transplant recipients: macrophage scavenger receptor regulation. Transplantation 77: 497-504 (2004).
Jin X, Lok E, Caldwell D, Mueller R, Kapal K, Liston V, Kubow S, Chan HM, Mehta R. Dietary fats altered nephrotoxicity profile of methylmercury in rats. J. Appl. Toxicol. 29: 126-140 (2009).
Jirsa M, Cebecauerova D, Budisova L, Chuzhanova N, Hrebicek M, Dvorakova L, Vitek L, Brodanova M, Hulek P, Taimr P. Indel in the FIC1/ATP8B1 gene - a novel rare type of mutation associated with benign recurrent intrahepatic cholestasis. Hepatol. Res. 30: 1-3 (2004).
Johnson LE, Elias MS, Bolick DT, Skaflen MD, Green RM, Hedrick CC. The G protein-coupled receptor G2A: involvement in hepatic lipid metabolism and gallstone formation in mice. Hepatology 48: 1138-1148 (2008). *
Johnston TP, Waxman DJ. Circulating free fatty acids are increased independently of PPAR-gamma activity after administration of poloxamer 407 to mice. Can. J. Physiol. Pharmacol. 86: 643-649 (2008).
Jones GT, van Rij AM, Cole J, Williams MJ, Bateman EH, Marcovina SM, Deng M, McCormick SP. Plasma lipoprotein(a) indicates risk for 4 distinct forms of vascular disease. Clin. Chem. 53: 679-685 (2007). *
Jones KS, Alimov AP, Rilo HL, Jandacek RP, Woollett LA, Penberthy WT. A high throughput live transparent animal bioassay to identify non-toxic small molecules or genes that regulate vertebrate fat metabolism for obesity drug development. Nutr. Metab. (Lond.) 5: 23 (2008). *
Jones MD PH. Treatment of dyslipidemias. Endocr. Pract. 2: 30-36 (1996).
Jones PJ, Demonty I, Chan YM, Herzog Y, Pelled D. Fish-oil esters of plant sterols differ from vegetable-oil sterol esters in triglycerides lowering, carotenoid bioavailability and impact on plasminogen activator inhibitor-1 (PAI-1) concentrations in hypercholesterolemic subjects. Lipids Health Dis. 6: 28 (2007). *
Jones PJ, Varady KA. Are functional foods redefining nutritional requirements? Appl. Physiol. Nutr. Metab. 33: 118-123 (2008).
Jones SA, Moore LB, Shenk JL, Wisely GB, Hamilton GA, McKee DD, Tomkinson NC, LeCluyse EL, Lambert MH, Willson TM, Kliewer SA, Moore JT. The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol. Endocrinol. 14: 27-39 (2000). *
Jonkers IJ, Smelt AH, Ledeboer M, Hollum ME, Biemond I, Kuipers F, Stellaard F, Boverhof R, Meinders AE, Lamers CH, Masclee AA. Gall bladder dysmotility: a risk factor for gall stone formation in hypertriglyceridaemia and reversal on triglyceride lowering therapy by bezafibrate and fish oil. Gut 52: 109-115 (2003). *
Jonkers IJ, Smelt AH, Princen HM, Kuipers F, Romijn JA, Boverhof R, Masclee AA, Stellaard F. Fish oil increases bile acid synthesis in male patients with hypertriglyceridemia. J. Nutr. 136: 987-991 (2006). *
Jorgensen RA, Lindor KD, Sartin JS, LaRusso NF, Wiesner RH. Serum lipid and fat-soluble vitamin levels in primary sclerosing cholangitis. J. Clin. Gastroenterol. 20: 215-219 (1995).
Joseph SB, Bradley MN, Castrillo A, Bruhn KW, Mak PA, Pei L, Hogenesch J, O'connell RM, Cheng G, Saez E, Miller JF, Tontonoz P. LXR-dependent gene expression is important for macrophage survival and the innate immune response. Cell 119: 299-309 (2004). *
Joseph SB, Laffitte BA, Patel PH, Watson MA, Matsukuma KE, Walczak R, Collins JL, Osborne TF, Tontonoz P. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J. Biol. Chem. 277: 11019-11025 (2002). *
Jump DB. Dietary polyunsaturated fatty acids and regulation of gene transcription. Curr. Opin. Lipidol. 13: 155-164 (2002).
Jung D, Elferink MG, Stellaard F, Groothuis GM. Analysis of bile acid-induced regulation of FXR target genes in human liver slices. Liver Int. 27: 137-144 (2007). *
Jung D, Fried M, Kullak-Ublick GA. Human apical sodium-dependent bile salt transporter gene (SLC10A2) is regulated by the peroxisome proliferator-activated receptor alpha. J. Biol. Chem. 277: 30559-30566 (2002). *
Jung D, Inagaki T, Dawson PA, Kliewer SA, Mangelsdorf DJ, Moschetta A. FXR agonists and FGF15 reduce fecal bile acid excretion in a mouse model of bile acid malabsorption. J. Lipid Res. 48: 2693-2700 (2007). *
Jung D, Kullak-Ublick GA. Hepatocyte nuclear factor 1 alpha: a key mediator of the effect of bile acids on gene expression. Hepatology 37: 622-631 (2003). *
Jung D, Podvinec M, Meyer UA, Mangelsdorf DJ, Fried M, Meier PJ, Kullak-Ublick GA. Human organic anion transporting polypeptide 8 promoter is transactivated by the farnesoid X receptor/bile acid receptor. Gastroenterology 122: 1954-1966 (2002). *
Jung SH, Park HS, Kim KS, Choi WH, Ahn CW, Kim BT, Kim SM, Lee SY, Ahn SM, Kim YK, Kim HJ, Kim DJ, Lee KW. Effect of weight loss on some serum cytokines in human obesity: increase in IL-10 after weight loss. J. Nutr. Biochem. 19: 371-375 (2008). *
Jung UJ, Torrejon C, Tighe AP, Deckelbaum RJ. n-3 Fatty acids and cardiovascular disease: mechanisms underlying beneficial effects. Am. J. Clin. Nutr. 87: 2003S-2009S (2008).
Junge G, Neuhaus R, Schewior L, Klupp J, Guckelberger O, Langrehr JM, Tullius S, Neuhaus P. Withdrawal of steroids: a randomized prospective study of prednisone and tacrolimus versus mycophenolate mofetil and tacrolimus in liver transplant recipients with autoimmune hepatitis. Transplant. Proc. 37: 1695-1696 (2005). *
Jungst C, Kullak-Ublick GA, Jungst D. Microlithiasis and sludge. Best Pract. Res. Clin. Gastroenterol. 20: 1053-1062 (2006).
Jungst C, Sreejayan N, Zundt B, Muller I, Spelsberg FW, Huttl TP, Kullak-Ublick GA, del Pozo R, Jungst D, von Ritter C. Ursodeoxycholic acid reduces lipid peroxidation and mucin secretagogue activity in gallbladder bile of patients with cholesterol gallstones. Eur. J. Clin. Invest. 38: 634-639 (2008).
Juran BD, Lazaridis KN. Is the FXR the fix for cholesterol gallstone disease? Hepatology 42: 218-221 (2005). *
Jury EC, Ehrenstein MR. Statins: immunomodulators for autoimmune rheumatic disease? Lupus 14: 192-196 (2005).
Jury EC, Isenberg DA, Mauri C, Ehrenstein MR. Atorvastatin restores lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus. J. Immunol. 177: 7416-7422 (2006). *
Juzyszyn Z, Kurzawski M, Lener A, Modrzejewski A, Pawlik A, Drozdzik M. Cholesterol 7alpha-hydrolase (CYP7A1) c.-278A>C promoter polymorphism in gallstone disease patients. Genet. Test. 12: 97-100 (2008).
Kaaja RJ, Kontula KK, Raiha A, Laatikainen T. Treatment of cholestasis of pregnancy with peroral activated charcoal. A preliminary study. Scand. J. Gastroenterol. 29: 178-181 (1994).
Kabir M, Skurnik G, Naour N, Pechtner V, Meugnier E, Rome S, Quignard-Boulange A, Vidal H, Slama G, Clement K, Guerre-Millo M, Rizkalla SW. Treatment for 2 mo with n-3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study. Am. J. Clin. Nutr. 86: 1670-1679 (2007). *
Kaeding J, Bouchaert E, Belanger J, Caron P, Chouinard S, Verreault M, Larouche O, Pelletier G, Staels B, Belanger A, Barbier O. Activators of the farnesoid X-receptor negatively regulate androgen glucuronidation in human prostate cancer LNCaP cells. Biochem. J. 410: 245-253 (2008). *
Kagalwalla AF, Al Amir AR, Khalifa A, Sylven M, Al Ajaji S, Kagalwalla YA. Progressive familial intrahepatic cholestasis (Byler's disease) in Arab children. Ann. Trop. Paediatr. 15: 321-327 (1995).
Kagawa H, Nomura S, Nagahama M, Ozaki Y, Fukuhara S. Effect of bezafibrate on soluble adhesion molecules and platelet activation markers in patients with connective tissue diseases and secondary hyperlipidemia. Clin. Appl. Thromb. Hemost. 7: 153-157 (2001).
Kajinami K, Brousseau ME, Nartsupha C, Ordovas JM, Schaefer EJ. ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin. J. Lipid Res. 45: 653-656 (2004). *
Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ. CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia. Am. J. Cardiol. 93: 104-107 (2004). *
Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ. Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. Am. J. Cardiol. 93: 1046-1050 (2004). *
Kakimoto H, Kawata S, Imai Y, Inada M, Matsuzawa Y, Tarui S. Changes in lipid composition of erythrocyte membranes with administration of S-adenosyl-L-methionine in chronic liver disease. Gastroenterol. Jpn. 27: 508-513 (1992).
Kakko S, Kelloniemi J, von Rohr P, Hoeschele I, Tamminen M, Brousseau ME, Kesaniemi YA, Savolainen MJ. ATP-binding cassette transporter A1 locus is not a major determinant of HDL-C levels in a population at high risk for coronary heart disease. Atherosclerosis 166: 285-290 (2003).
Kakumu S. Is mortality from liver disease associated with normal serum aminotransferase concentrations? Nat. Clin. Pract. Gastroenterol. Hepatol. 1: 2-3 (2004). *
Kalaany NY, Gauthier KC, Zavacki AM, Mammen PP, Kitazume T, Peterson JA, Horton JD, Garry DJ, Bianco AC, Mangelsdorf DJ. LXRs regulate the balance between fat storage and oxidation. Cell. Metab. 1: 231-244 (2005). *
Kalaany NY, Mangelsdorf DJ. LXRs and FXR: the Yin and Yang of cholesterol and fat metabolism. Annu. Rev. Physiol. 68: 159-191 (2006). *
Kalab M, Krechler T. The effect of the heptoprotective agent LIV 52 on liver damage. Cas. Lek. Cesk. 136: 758-760 (1997).
Kalantar-Zadeh K, Balakrishnan VS. The kidney disease wasting: inflammation, oxidative stress, and diet-gene interaction. Hemodial. Int. 10: 315-325 (2006). *
Kalischuk LD, Inglis GD, Buret AG. Campylobacter jejuni induces transcellular translocation of commensal bacteria via lipid rafts. Gut Pathog. 1: 2 (2009). *
Kamisako T, Ogawa H. Alteration of the expression of adenosine triphosphate-binding cassette transporters associated with bile acid and cholesterol transport in the rat liver and intestine during cholestasis. J. Gastroenterol. Hepatol. 20: 1429-1434 (2005). *
Kamisako T, Ogawa H. Effects of pravastatin and bezafibrate on biliary lipid excretion and hepatic expression of Abcg5 and Abcg8 in the rat. J. Gastroenterol. Hepatol. 19: 879-883 (2004). *
Kamisako T, Ogawa H. Regulation of biliary cholesterol secretion is associated with abcg5 and abcg8 expressions in the rats: effects of diosgenin and ethinyl estradiol. Hepatol. Res. 26: 348-352 (2003).
Kamisako T, Ogawa H. Effect of obstructive jaundice on the regulation of hepatic cholesterol metabolism in the rat. Disappearance of abcg5 and abcg8 mRNA after bile duct ligation. Hepatol. Res. 25: 99-104 (2003).
Kamisako T, Ogawa H, Yamamoto K. Effect of cholesterol, cholic acid and cholestyramine administration on the intestinal mRNA expressions related to cholesterol and bile acid metabolism in the rat. J. Gastroenterol. Hepatol. 22: 1832-1837 (2007). *
Kamiya S, Nagino M, Kanazawa H, Komatsu S, Mayumi T, Takagi K, Asahara T, Nomoto K, Tanaka R, Nimura Y. The value of bile replacement during external biliary drainage: an analysis of intestinal permeability, integrity, and microflora. Ann. Surg. 239: 510-517 (2004). *
Kanayama T, Arito M, So K, Hachimura S, Inoue J, Sato R. Interaction between sterol regulatory element-binding proteins and liver receptor homolog-1 reciprocally suppresses their transcriptional activities. J. Biol. Chem. 282: 10290-10298 (2007). *
Kanazawa Y, Koizumi M, Hirakawa H, Endo K, Yoshida S, Miyakawa T, Konno Y, Goto Y, Goto J, Nambara T. The effect of ursodeoxycholic acid on biliary bile acid composition in patients with cholesterol gallstone. Tohoku. J. Exp. Med. 136: 235-249 (1982). *
Kanchanapoo J, Rao MC, Sophasan S, Suksamrarn A, Piyachaturawat P. Inhibitory effects of choleretic hydroxyacetophenones on ileal bile acid transport in rats. Life Sci. 78: 1630-1636 (2006). *
Kanda T, Yokosuka O, Kojima H, Imazeki F, Nagao K, Tatsuno I, Saito Y, Saisho H. Severe hypercholesterolemia associated with primary biliary cirrhosis in a 44-year-old Japanese woman. World J. Gastroenterol. 10: 2607-2608 (2004). *
Kannenberg F, Ellinghaus P, Assmann G, Seedorf U. Aberrant oxidation of the cholesterol side chain in bile acid synthesis of sterol carrier protein-2/sterol carrier protein-x knockout mice. J. Biol. Chem. 274: 35455-35460 (1999). *
Kanterewicz E, Sanmarti R, Riba J, Trias I, Autonell J, Brugues J. Bezafibrate induced rhabdomyolysis. Ann. Rheum. Dis. 51: 536-538 (1992). *
Kaplan MM, Alling DW, Zimmerman HJ, Wolfe HJ, Sepersky RA, Hirsch GS, Elta GH, Glick KA, Eagen KA. A prospective trial of colchicine for primary biliary cirrhosis. N. Engl. J. Med. 315: 1448-1454 (1986).
Kaplan MM, Knox TA. Treatment of primary biliary cirrhosis with low-dose weekly methotrexate. Gastroenterology 101: 1332-1338 (1991).
Kaplan R, Gan X, Menke JG, Wright SD, Cai TQ. Bacterial lipopolysaccharide induces expression of ABCA1 but not ABCG1 via an LXR-independent pathway. J. Lipid Res. 43: 952-959 (2002). *
Kaplowitz N. Hepatology highlights. Hepatology 39: 271-272 (2004). *
Kapoor P, Ansari MN, Bhandari U. Modulatory effect of curcumin on methionine-induced hyperlipidemia and hyperhomocysteinemia in albino rats. Indian J. Exp. Biol. 46: 534-540 (2008).
Karlaganis G, Bremmelgaard A, Karlaganis V, Sjovall J. Precursor of 27-nor-5 beta-cholestane-3 alpha, 7 alpha, 12 alpha, 24,25-pentol in man. J. Steroid Biochem. 18: 725-729 (1983).
Karten B, Campenot RB, Vance DE, Vance JE. Expression of ABCG1, but not ABCA1, correlates with cholesterol release by cerebellar astroglia. J. Biol. Chem. 281: 4049-4057 (2006). *
Kasai S, Inoue T, Yoshitomi H, Hihara T, Matsuura F, Harada H, Shinoda M, Tanaka I. Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs. J. Pharmacol. Sci. 108: 40-48 (2008). *
Kase ET, Thoresen GH, Westerlund S, H�jlund K, Rustan AC, Gaster M. Liver X receptor antagonist reduces lipid formation and increases glucose metabolism in myotubes from lean, obese and type 2 diabetic individuals. Diabetologia 50: 2171-2180 (2007). *
Kassab A, Ajmi T, Issaoui M, Chaeib L, Miled A, Hammami M. Homocysteine enhances LDL fatty acid peroxidation, promoting microalbuminuria in type 2 diabetes. Ann. Clin. Biochem. 45: 476-480 (2008).
Katz A, Udata C, Ott E, Hickey L, Burczynski ME, Burghart P, Vesterqvist O, Meng X. Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants. J. Clin. Pharmacol. 49: 643-649 (2009). *
Kaur IP, Chopra K, Saini A. Probiotics: potential pharmaceutical applications. Eur. J. Pharm. Sci. 15: 1-9 (2002). *
Kawasaki M, Yagasaki K, Miura Y, Funabiki R. Comparison of the changes in lipid metabolism between hepatoma-bearing and lipopolysaccharide-treated rats. Biosci. Biotechnol. Biochem. 68: 72-78 (2004). *
Kazama H, Usui S, Okazaki M, Hosoi T, Ito H, Orimo H. Effects of bezafibrate and pravastatin on remnant-like lipoprotein particles and lipoprotein subclasses in type 2 diabetes. Diabetes Res. Clin. Pract. 59: 181-189 (2003).
Kazawa T, Kawasaki T, Sakamoto A, Imamura M, Ohashi R, Jiang S, Tanaka T, Iwanari H, Hamakubo T, Sakai J, Kodama T, Naito M. Expression of liver X receptor alpha and lipid metabolism in granulocyte-macrophage colony-stimulating factor-induced human monocyte-derived macrophage. Pathol. Int. 59: 152-160 (2009). *
Kedzia A, Krysiak R, Madej A, Okopien B. Is every case of muscle damage during hypolipemic therapy the side effect of this therapy? A case report. Pol. Arch. Med. Wewn. 117: 473-476 (2007).
Keech A. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, a randomized, placebo-controlled trial: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. Cardiovasc. Diabetol. 4: 13 (2005). *
Keech AC, The Field Study Investigators. The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study ISRCTN64783481. Cardiovasc. Diabetol. 3: 9 (2004). *
Keizman D, Goldiner I, Leikin-Frenkel A, Konikoff FM. Innovations in the medical treatment of gallstones and fatty liver: FABACs (fatty acid bile acid conjugates). Harefuah. 147: 344-349, 373, 372 (2008).
Kelley DS, Siegel D, Vemuri M, Chung GH, Mackey BE. Docosahexaenoic acid supplementation decreases remnant-like particle-cholesterol and increases the (n-3) index in hypertriglyceridemic men. J. Nutr. 138: 30-35 (2008). *
Kemper JK, Kim H, Miao J, Bhalla S, Bae Y. Role of an mSin3A-Swi/Snf chromatin remodeling complex in the feedback repression of bile acid biosynthesis by SHP. Mol. Cell. Biol. 24: 7707-7719 (2004). *
Kendall CW, Emam A, Augustin LS, Jenkins DJ. Resistant starches and health. J. AOAC Int. 87: 769-774 (2004).
Kendall DM, Rubin CJ, Mohideen P, Ledeine JM, Belder R, Gross J, Norwood P, O'mahony M, Sall K, Sloan G, Roberts A, Fiedorek FT, Defronzo RA. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin � Diabetes Care 29: 1016-1023 (2006). *
Kennedy MA, Barrera GC, Nakamura K, Baldan A, Tarr P, Fishbein MC, Frank J, Francone OL, Edwards PA. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell. Metab. 1: 121-131 (2005). *
Kennedy MA, Venkateswaran A, Tarr PT, Xenarios I, Kudoh J, Shimizu N, Edwards PA. Characterization of the human ABCG1 gene: liver X receptor activates an internal promoter that produces a novel transcript encoding an alternative form of the protein. J. Biol. Chem. 276: 39438-39447 (2001). *
Kenny RP, Czaja AJ, Ludwig J, Dickson ER. Frequency and significance of antimitochondrial antibodies in severe chronic active hepatitis. Dig. Dis. Sci. 31: 705-711 (1986).
Kerkeni M, Addad F, Chauffert M, Myara A, Gerhardt M, Chevenne D, Trivin F, Farhat MB, Miled A, Maaroufi K. Hyperhomocysteinaemia, methylenetetrahydrofolate reductase polymorphism and risk of coronary artery disease. Ann. Clin. Biochem. 43: 200-206 (2006).
Kern F Jr, Everson GT. Contraceptive steroids increase cholesterol in bile: mechanisms of action. J. Lipid Res. 28: 828-839 (1987). *
Kern F Jr, Everson GT, DeMark B, McKinley C, Showalter R, Braverman DZ, Szczepanik-Van Leeuwen P, Klein PD. Biliary lipids, bile acids, and gallbladder function in the human female: effects of contraceptive steroids. J. Lab. Clin. Med. 99: 798-805 (1982).
Kern F Jr, Everson GT, DeMark B, McKinley C, Showalter R, Erfling W, Braverman DZ, Szczepanik-van Leeuwen P, Klein PD. Biliary lipids, bile acids, and gallbladder function in the human female. Effects of pregnancy and the ovulatory cycle. J. Clin. Invest. 68: 1229-1242 (1981). *
Kersten S. Peroxisome proliferator activated receptors and lipoprotein metabolism. PPAR Res. 2008: 132960 (2008). *
Kesaniemi YA, Miettinen TA, Salaspuro MP. Biliary lipids, faecal steroids, and liver function in patients with chronic active hepatitis and primary biliary cirrhosis: significance of hepatic orcein-stained complexes. Gut 22: 579-584 (1981). *
Kesaniemi YA, Salaspuro MP, Vuoristo M, Miettinen TA. Biliary lipid secretion in chronic cholestatic liver disease. Gut 23: 931-938 (1982). *
Kevresan S, Kuhajda K, Kandrac J, Fawcett JP, Mikov M. Biosynthesis of bile acids in mammalian liver. Eur. J. Drug Metab. Pharmacokinet. 31: 145-156 (2006).
Key TJ, Appleby PN, Rosell MS. Health effects of vegetarian and vegan diets. Proc. Nutr. Soc. 65: 35-41 (2006). *
Khan AA, Parveen N, Mahaboob VS, Rajendraprasad A, Ravindraprakash HR, Venkateswarlu J, Rao P, Pande G, Lakshmi Narusu M, Khaja MN, Pramila R, Habeeb A, Habibullah CM. Management of hyperbilirubinemia in biliary atresia by hepatic progenitor cell transplantation through hepatic artery: a case report. Transplant. Proc. 40: 1153-1155 (2008).
Khan MA, Gallo RM, Renukaradhya GJ, Du W, Gervay-Hague J, Brutkiewicz RR. Statins impair CD1d-mediated antigen presentation through the inhibition of prenylation. J. Immunol. 182: 4744-4750 (2009).
Khandelwal S, Demonty I, Jeemon P, Lakshmy R, Mukherjee R, Gupta R, Snehi U, Niveditha D, Singh Y, van der Knaap HC, Passi SJ, Prabhakaran D, Reddy KS. Independent and interactive effects of plant sterols and fish oil n-3 long-chain polyunsaturated fatty acids on the plasma lipid profile of mildly hyperlipidaemic Indian adults. Br. J. Nutr. Mar 19 [Epub ahead of print] (2009). *
Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid Res. 45: 1169-1196 (2004). *
Khovidhunkit W, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR. Endotoxin down-regulates ABCG5 and ABCG8 in mouse liver and ABCA1 and ABCG1 in J774 murine macrophages: differential role of LXR. J. Lipid Res. 44: 1728-1736 (2003). *
Kilpelainen T, Lakka T, Laaksonen D, Mager U, Salopuro T, Kubaszek A, Todorova B, Laukkanen O, Lindstrom J, Eriksson J, Hamalainen H, Aunola S, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Tuomilehto J, Laakso M, Uusitupa M. Interaction of single nucleotide polymorphisms in ADRB2, ADRB3, TNF, IL6, IGF1R, LIPC, LEPR, and GHRL with physical activity on the risk of type 2 diabetes mellitus and changes in characteristics of the metabolic syndrome. Metabolism 57: 428-436 (2008). *
Kim EJ, Yoo YG, Yang WK, Lim YS, Na TY, Lee IK, Lee MO. Transcriptional activation of HIF-1 by RORalpha and its role in hypoxia signaling. Arterioscler. Thromb. Vasc. Biol. 28: 1796-1802 (2008).
Kim GH, Park K, Yeom SY, Lee KJ, Kim G, Ko J, Rhee DK, Kim YH, Lee HK, Kim HW, Oh GT, Lee KU, Lee JW, Kim SW. Characterization of ASC-2 as an anti-atherogenic transcriptional coactivator of liver X receptors in macrophages. Mol. Endocrinol. Apr 2 [Epub ahead of print] (2009). *
Kim HJ, Fan X, Gabbi C, Yakimchuk K, Parini P, Warner M, Gustafsson JA. Liver X receptor beta (LXRbeta): a link between beta-sitosterol and amyotrophic lateral sclerosis-Parkinson's dementia. Proc. Natl. Acad. Sci. U.S.A. 105: 2094-2099 (2008). *
Kim HJ, Lee KT, Park YB, Jeon SM, Choi MS. Dietary docosahexaenoic acid-rich diacylglycerols ameliorate hepatic steatosis and alter hepatic gene expressions in C57BL/6J-Lep(ob/ob) mice. Mol. Nutr. Food Res. 52: 965-973 (2008). *
Kim HJ, Miyazaki M, Ntambi JM. Dietary cholesterol opposes PUFA-mediated repression of the stearoyl-CoA desaturase-1 gene by SREBP-1 independent mechanism. J. Lipid Res. 43: 1750-1757 (2002). *
Kim JY, Kim HJ, Kim KT, Park YY, Seong HA, Park KC, Lee IK, Ha H, Shong M, Park SC, Choi HS. Orphan nuclear receptor small heterodimer partner represses hepatocyte nuclear factor 3/Foxa transactivation via inhibition of its DNA binding. Mol. Endocrinol. 18: 2880-2894 (2004). *
Kim KH, Yoon JM, Choi AH, Kim WS, Lee GY, Kim JB. Liver X receptor ligands suppress ubiquitination and degradation of LXRalpha by displacing BARD1/BRCA1. Mol. Endocrinol. 23: 466-474 (2009). *
Kim KM, Choi JY, Yoo SE, Park MY, Lee BS, Ko YH, Sung SH, Shin HM, Park JE. HMCO5, herbal extract, inhibits NF-kappaB expression in lipopolysaccharide treated macrophages and reduces atherosclerotic lesions in cholesterol fed mice. J. Ethnopharmacol. 114: 316-324 (2007). *
Kim MH, Lee HS, Park HJ, Kim WY. Risk factors associated with metabolic syndrome in Korean elderly. Ann. Nutr. Metab. 51: 533-540 (2008). *
Kim MK, Chae YN, Son MH, Kim SH, Kim JK, Moon HS, Park CS, Bae MH, Kim E, Han T, Choi HH, Shin YA, Ahn BN, Lee CH, Lim JI, Shin CY. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo. Eur. J. Pharmacol. 595: 119-125 (2008). *
Kim MS, Shigenaga J, Moser A, Grunfeld C, Feingold KR. Suppression of DHEA sulfotransferase (Sult2A1) during the acute phase response. Am. J. Physiol. Endocrinol. Metab. 287: E731-E738 (2004). *
Kim ND, Im EO, Choi YH, Yoo YH. Synthetic bile acids: novel mediators of apoptosis. J. Biochem. Mol. Biol. 35: 134-141 (2002). *
Kim S, Sohn I, Ahn JI, Lee KH, Lee YS, Lee YS. Hepatic gene expression profiles in a long-term high-fat diet-induced obesity mouse model. Gene 340: 99-109 (2004). *
Kim SY, Jo DS, Hwang PH, Park JH, Park SK, Yi HK, Lee DY. Preproghrelin Leu72Met polymorphism is not associated with type 2 diabetes mellitus. Metabolism 55: 366-370 (2006). *
Kim TH, Baek JI, Hong JM, Choi SJ, Lee HJ, Cho HJ, Park EK, Kim UK, Kim SY. Significant association of SREBP-2 genetic polymorphisms with avascular necrosis in the Korean population. BMC Med. Genet. 9: 94 (2008). *
Kim WS, Fitzgerald ML, Kang K, Okuhira KI, Bell SA, Manning JJ, Koehn SL, Lu N, Moore KJ, Freeman MW. Abca7 null mice retain normal macrophage phosphatidylcholine and cholesterol efflux activity despite alterations in adipose mass and serum cholesterol levels. J. Biol. Chem. 280: 3989-3995 (2005). *
Kimura M, Okuno E, Inada J, Ohyama H, Kido R. Purification and characterization of amino-acid N-choloyltransferase from human liver. Hoppe Seylers Z. Physiol. Chem. 364: 637-645 (1983).
Kimura Y, Morita SY, Matsuo M, Ueda K. Mechanism of multidrug recognition by MDR1/ABCB1. Cancer Sci. 98: 1303-1310 (2007). *
Kintscher U, Bramlage P, Paar WD, Thoenes M, Unger T. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc. Diabetol. 6: 12 (2007). *
Kiortsis DN, Mavridis AK, Filippatos TD, Vasakos S, Nikas SN, Drosos AA. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J. Rheumatol. 33: 921-923 (2006).
Kis E, Ioja E, Nagy T, Szente L, Heredi-Szabo K, Krajcsi P. Effect of membrane cholesterol on BSEP/Bsep activity - species specificity studies for substrates and inhibitors. Drug Metab. Dispos. Jun 11 [Epub ahead of print] (2009). *
Kis E, Rajnai Z, Ioja E, Heredi Szabo K, Nagy T, Mehn D, Krajcsi P. Mouse Bsep ATPase assay: a nonradioactive tool for assessment of the cholestatic potential of drugs. J. Biomol. Screen. 14: 10-15 (2009).
Kitayama K, Nakai D, Kono K, van der Hoop AG, Kurata H, de Wit EC, Cohen LH, Inaba T, Kohama T. Novel non-systemic inhibitor of ileal apical Na(+)-dependent bile acid transporter reduces serum cholesterol levels in hamsters and monkeys. Eur. J. Pharmacol. 539: 89-98 (2006). *
Kitchens RL, Thompson PA, Munford RS, O'Keefe GE. Acute inflammation and infection maintain circulating phospholipid levels and enhance lipopolysaccharide binding to plasma lipoproteins. J. Lipid Res. 44: 2339-2348 (2003). *
Kivisto KT, Niemi M. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm. Res. 24: 239-247 (2007). *
Kivisto KT, Niemi M, Schaeffeler E, Pitkala K, Tilvis R, Fromm MF, Schwab M, Eichelbaum M, Strandberg T. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 14: 523-525 (2004).
Kiyici M, Gulten M, Gurel S, Nak SG, Dolar E, Savci G, Adim SB, Yerci O, Memik F. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can. J. Gastroenterol. 17: 713-718 (2003).
Kiyosawa N, Ito K, Niino N, Sakuma K, Kanbori M, Yamoto T, Manabe S, Matsunuma N. Effect of serum cholesterol on the mRNA content of amyloid precursor protein in rat livers. Toxicol. Lett. 150: 157-166 (2004). *
Klaassen CD, Lu H. Xenobiotic transporters: ascribing function from gene knockout and mutation studies. Toxicol. Sci. 101: 186-196 (2008). *
Kleemann R, Verschuren L, van Erk MJ, Nikolsky Y, Cnubben NH, Verheij ER, Smilde AK, Hendriks HF, Zadelaar S, Smith GJ, Kaznacheev V, Nikolskaya T, Melnikov A, Hurt-Camejo E, van der Greef J, van Ommen B, Kooistra T. Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis. Genome Biol. 8: R200 (2007). *
Klein A, Amigo L, Retamal MJ, Morales MG, Miquel JF, Rigotti A, Zanlungo S. NPC2 is expressed in human and murine liver and secreted into bile: potential implications for body cholesterol homeostasis. Hepatology 43: 126-133 (2005). *
Klett EL, Lu K, Kosters A, Vink E, Lee MH, Altenburg M, Shefer S, Batta AK, Yu H, Chen J, Klein R, Looije N, Oude Elferink RP, Groen AK, Maeda N, Salen G, Patel SB. A mouse model of sitosterolemia: absence of Abcg8/sterolin-2 results in failure to secrete biliary cholesterol. BMC Med. 2: 5 (2004). *
Klett EL, Patel SB. Biomedicine. Will the real cholesterol transporter please stand up. Science 303: 1149-1150 (2004). *
Kliewer SA. Cholesterol detoxification by the nuclear pregnane X receptor. Proc. Natl. Acad. Sci. U.S.A. 102: 2675-2676 (2005). *
Kliewer SA, Lehmann JM, Milburn MV, Willson TM. The PPARs and PXRs: nuclear xenobiotic receptors that define novel hormone signaling pathways. Recent Prog. Horm. Res. 54: 345-367 (1999).
Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358: 771-774 (1992). *
Kliewer SA, Xu HE, Lambert MH, Willson TM. Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog. Horm. Res. 56: 239-263 (2001). *
Klucken J, Buchler C, Orso E, Kaminski WE, Porsch-Ozcurumez M, Liebisch G, Kapinsky M, Diederich W, Drobnik W, Dean M, Allikmets R, Schmitz G. ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport. Proc. Natl. Acad. Sci. U.S.A. 97: 817-822 (2000). *
Kniepeiss D, Iberer F, Schaffellner S, Jakoby E, Duller D, Tscheliessnigg Kh. Dyslipidemia during sirolimus therapy in patients after liver transplantation. Clin. Transplant. 18: 642-646 (2004). *
Knight BL, Hebbachi A, Hauton D, Brown AM, Wiggins D, Patel DD, Gibbons GF. A role for PPAR-alpha in the control of SREBP activity and lipid synthesis in the liver. Biochem. J. 389: 413-421 (2005). *
Knight BL, Patel DD, Humphreys SM, Wiggins D, Gibbons GF. Inhibition of cholesterol absorption associated with a PPAR alpha-dependent increase in ABC binding cassette transporter A1 in mice. J. Lipid Res. 44: 2049-2058 (2003). *
Kocarek TA, Shenoy SD, Mercer-Haines NA, Runge-Morris M. Use of dominant negative nuclear receptors to study xenobiotic-inducible gene expression in primary cultured hepatocytes. J. Pharmacol. Toxicol. Methods 47: 177-187 (2002). *
Kocher O, Pal R, Roberts M, Cirovic C, Gilchrist A. Targeted disruption of the PDZK1 gene by homologous recombination. Mol. Cell. Biol. 23: 1175-1180 (2003). *
Kocher O, Yesilaltay A, Cirovic C, Pal R, Rigotti A, Krieger M. Targeted disruption of the PDZK1 gene in mice causes tissue-specific depletion of the high density lipoprotein receptor scavenger receptor class B type I and altered lipoprotein metabolism. J. Biol. Chem. 278: 52820-52825 (2003). *
Kocher O, Yesilaltay A, Shen CH, Zhang S, Daniels K, Pal R, Chen J, Krieger M. Influence of PDZK1 on lipoprotein metabolism and atherosclerosis. Biochim. Biophys. Acta 1782: 310-316 (2008). *
Koeijvoets KC, Mooijaart SP, Dallinga-Thie GM, Defesche JC, Steyerberg EW, Westendorp RG, Kastelein JJ, Martin van Hagen P, Sijbrands EJ. Complement factor H Y402H decreases cardiovascular disease risk in patients with familial hypercholesterolaemia. Eur. Heart J. 30: 618-623 (2009).
Koeijvoets KC, van der Net JB, Dallinga-Thie GM, Steyerberg EW, Mensink RP, Kastelein JJ, Sijbrands EJ, Plat J. ABCG8 gene polymorphisms, plasma cholesterol concentrations, and risk of cardiovascular disease in familial hypercholesterolemia. Atherosclerosis 204: 453-458 (2009).
Koeijvoets KC, van Rossum EF, Dallinga-Thie GM, Steyerberg EW, Defesche JC, Kastelein JJ, Lamberts SW, Sijbrands EJ. A functional polymorphism in the glucocorticoid receptor gene and its relation to cardiovascular disease risk in familial hypercholesterolemia. J. Clin. Endocrinol. Metab. 91: 4131-4136 (2006). *
Koga S, Miyata Y, Ibayashi H. Plasma lipoproteins and apoproteins in primary biliary cirrhosis. Hepatology 5: 286-292 (1985).
Koh KK, Ahn JY, Jin DK, Han SH, Kim HS, Choi IS, Ahn TH, Shin EK, Jeong EM. Comparative effects of statin and fibrate on nitric oxide bioactivity and matrix metalloproteinase in hyperlipidemia. Int. J. Cardiol. 97: 239-244 (2004).
Koh KK, Quon MJ, Rosenson RS, Chung WJ, Han SH. Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates. Int. J. Cardiol. 124: 149-159 (2008).
Kohno H, Sakai T, Saito S, Okano K, Kitahara K. Treatment of experimental autoimmune uveoretinitis with atorvastatin and lovastatin. Exp. Eye Res. 84: 569-576 (2007). *
Koike K. Hepatitis C as a metabolic disease: implication for the pathogenesis of NASH. Hepatol. Res. 33: 145-150 (2005).
Koizumi A, Mizukami H, Inoue M. pX gene causes hypercholesterolemia in hypercholesterolemia-resistant BALB/c mice. Biol. Pharm. Bull. 28: 1731-1735 (2005). *
Kojima S, Toyota Y, Shiba M, Tsushima M, Matsuoka H, Yamamoto A. Different apheresis methods in the treatment of hypercholesterolemia in primary biliary cirrhosis: a case report. Artif. Organs 19: 938-941 (1995).
Kok T, Bloks VW, Wolters H, Havinga R, Jansen PL, Staels B, Kuipers F. Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. Biochem. J. 369: 539-547 (2003). *
Kok T, Hulzebos CV, Wolters H, Havinga R, Agellon LB, Stellaard F, Shan B, Schwarz M, Kuipers F. Enterohepatic circulation of bile salts in farnesoid X receptor-deficient mice: efficient intestinal bile salt absorption in the absence of ileal bile acid-binding protein. J. Biol. Chem. 278: 41930-41937 (2003). *
Kok T, Wolters H, Bloks VW, Havinga R, Jansen PL, Staels B, Kuipers F. Induction of hepatic ABC transporter expression is part of the PPARalpha-mediated fasting response in the mouse. Gastroenterology 124: 160-171 (2003). *
Koldamova RP, Lefterov IM, Ikonomovic MD, Skoko J, Lefterov PI, Isanski BA, DeKosky ST, Lazo JS. 22R-Hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid beta secretion. J. Biol. Chem. 278: 13244-13256 (2003). *
Koletzko B, Decsi T. Metabolic aspects of trans fatty acids. Clin. Nutr. 16: 229-237 (1997).
Kolovou G, Anagnostopoulou K, Kostakou P, Marvaki C, Mihas C, Mikhailidis DP, Cokkinos DV. Association between the TaqIB polymorphism in the cholesteryl ester transfer protein gene locus and postprandial plasma lipoprotein levels in heterozygotes for familial hypercholesterolemia. Clin. Chem. Lab. Med. 45: 1190-1198 (2007). *
Kolovou G, Damaskos D, Anagnostopoulou K, Cokkinos DV. Apolipoprotein E gene polymorphism and gender. Ann. Clin. Lab. Sci. 39: 120-133 (2009).
Kolovou GD, Anagnostopoulou KK, Cokkinos DV. Pathophysiology of dyslipidaemia in the metabolic syndrome. Postgrad. Med. J. 81: 358-366 (2005). *
Kolsch H, Lutjohann D, Jessen F, Popp J, Hentschel F, Kelemen P, Friedrichs S, Maier W, Heun R. RXRA gene variations influence Alzheimer's disease risk and cholesterol metabolism. J. Cell. Mol. Med. Jun 9 [Epub ahead of print] (2008). *
Kolsch H, Lutjohann D, Jessen F, Von Bergmann K, Schmitz S, Urbach H, Maier W, Heun R. Polymorphism in ABCA1 influences CSF 24S-hydroxycholesterol levels but is not a major risk factor of Alzheimer's disease. Int. J. Mol. Med. 17: 791-794 (2006). *
Komori H, Arai H, Kashima T, Huby T, Kita T, Ueda Y. Coexpression of CLA-1 and human PDZK1 in murine liver modulates HDL cholesterol metabolism. Arterioscler. Thromb. Vasc. Biol. 28: 1298-1303 (2008).
Kong B, Luyendyk JP, Tawfik O, Guo GL. Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. J. Pharmacol. Exp. Ther. 328: 116-122 (2009). *
Kong FM, Sui CY, Li YJ, Guo KJ, Guo RX. Hepatobiliary membrane transporters involving in the formation of cholesterol calculus. Hepatobiliary Pancreat. Dis. Int. 5: 286-289 (2006). *
Konig B, Spielmann J, Haase K, Brandsch C, Kluge H, Stangl GI, Eder K. Effects of fish oil and conjugated linoleic acids on expression of target genes of PPARalpha and sterol regulatory element-binding proteins in the liver of laying hens. Br. J. Nutr. 100: 355-363 (2008). *
Konikoff FM. Gallstones - approach to medical management. MedGenMed. 5: 8 (2003). *
Konikoff FM, Leikin-Frenkel A, Goldiner I, Michowitz M, Brezowski E, Harats D, Gilat T. Biliary and systemic effects of fatty acid bile acid conjugates. Eur. J. Gastroenterol. Hepatol. 15: 649-655 (2003).
Kooner JS, Chambers JC, Aguilar-Salinas CA, Hinds DA, Hyde CL, Warnes GR, Gomez Perez FJ, Frazer KA, Elliott P, Scott J, Milos PM, Cox DR, Thompson JF. Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides. Nat. Genet. 40: 149-151 (2008). *
Koopen NR, Wolters H, Voshol P, Stieger B, Vonk RJ, Meier PJ, Kuipers F, Hagenbuch B. Decreased Na+-dependent taurocholate uptake and low expression of the sinusoidal Na+-taurocholate cotransporting protein (Ntcp) in livers of mdr2 P-glycoprotein-deficient mice. J. Hepatol. 30: 14-21 (1999). *
Korolenko TA, Savchenko NG, Yuz'ko JV, Alexeenko TV, Sorochinskaya NV. Activity of lysosomal enzymes in the bile and serum of mice with intrahepatic cholestasis. Bull. Exp. Biol. Med. 145: 560-563 (2008).
Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin. Pharmacokinet. 44: 467-494 (2005).
Kosters A, Frijters RJ, Kunne C, Vink E, Schneiders MS, Schaap FG, Nibbering CP, Patel SB, Groen AK. Diosgenin-induced biliary cholesterol secretion in mice requires Abcg8. Hepatology 41: 141-150 (2005). *
Kosters A, Frijters RJ, Schaap FG, Vink E, Plosch T, Ottenhoff R, Jirsa M, De Cuyper IM, Kuipers F, Groen AK. Relation between hepatic expression of ATP-binding cassette transporters G5 and G8 and biliary cholesterol secretion in mice. J. Hepatol. 38: 710-716 (2003). *
Kosters A, Jirsa M, Groen AK. Genetic background of cholesterol gallstone disease. Biochim. Biophys. Acta 1637: 1-19 (2003). *
Kosters A, Kunne C, Looije N, Patel SB, Oude Elferink RP, Groen AK. The mechanism of ABCG5/ABCG8 in biliary cholesterol secretion in mice. J. Lipid Res. 47: 1959-1966 (2006). *
Koubaa N, Hammami S, Nakbi A, Ben Hamda K, Mahjoub S, Kosaka T, Hammami M. Relationship between thiolactonase activity and hyperhomocysteinemia according to MTHFR gene polymorphism in Tunisian Behcet's disease patients. Clin. Chem. Lab. Med. 46: 187-192 (2008). *
Koubaa N, Nakbi A, Hammami S, Attia N, Mehri S, Hamda KB, Farhat MB, Miled A, Hammami M. Association of homocysteine thiolactonase activity and PON1 polymorphisms with the severity of acute coronary syndrome. Clin. Biochem. 42: 771-776 (2009). *
Koutroubakis IE, Dilaveraki E, Vlachonikolis IG, Vardas E, Vrentzos G, Ganotakis E, Mouzas IA, Gravanis A, Emmanouel D, Kouroumalis EA. Hyperhomocysteinemia in Greek patients with inflammatory bowel disease. Dig. Dis. Sci. 45: 2347-2351 (2000). *
Koutroubakis IE, Oustamanolakis P, Malliaraki N, Karmiris K, Chalkiadakis I, Ganotakis E, Karkavitsas N, Kouroumalis EA. Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 21: 283-288 (2009).
Kovacs P, Kress R, Rocha J, Kurtz U, Miquel JF, Nervi F, Mendez-Sanchez N, Uribe M, Bock HH, Schirin-Sokhan R, Stumvoll M, Mossner J, Lammert F, Wittenburg H. Variation of the gene encoding the nuclear bile salt receptor FXR and gallstone susceptibility in mice and humans? J. Hepatol. 48: 116-124 (2008). *
Kovacs P, Kurtz U, Wittenburg H. Hepatic insulin resistance ties cholesterol gallstone formation and the metabolic syndrome. Ann. Hepatol. 7: 262-264 (2008). *
Kovacs WJ, Shackelford JE, Tape KN, Richards MJ, Faust PL, Fliesler SJ, Krisans SK. Disturbed cholesterol homeostasis in a peroxisome-deficient PEX2 knockout mouse model. Mol. Cell Biol. 24: 1-13 (2004). *
Kowdley KV. Ursodeoxycholic acid therapy in hepatobiliary disease. Am. J. Med. 108: 481-486 (2000). *
Kowdley KV. Lipids and lipid-activated vitamins in chronic cholestatic diseases. Clin. Liver Dis. 2: 373-389, x (1998).
Kozarek RA. Pancreaticobiliary biofilm: is cholesterol the answer? Gut 54: 326-328 (2005). *
Krahenbuhl S, Stucki J, Reichen J. Reduced activity of the electron transport chain in liver mitochondria isolated from rats with secondary biliary cirrhosis. Hepatology 15: 1160-1166 (1992).
Kralova Lesna I, Suchanek P, Kovar J, Stavek P, Poledne R. Replacement of dietary saturated FAs by PUFAs in diet and reverse cholesterol transport. J. Lipid Res. 49: 2414-2418 (2008). *
Kramer JA, LeDeaux J, Butteiger D, Young T, Crankshaw C, Harlow H, Kier L, Bhat BG. Transcription profiling in rat liver in response to dietary docosahexaenoic acid implicates stearoyl-coenzyme a desaturase as a nutritional target for lipid lowering. J. Nutr. 133: 57-66 (2003). *
Kramer W, Girbig F, Corsiero D, Pfenninger A. Molecular elucidation of intestinal cholesterol absorption. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 54. June 18-19 (2004). *
Kramer W, Glombik H. Bile acid reabsorption inhibitors (BARI): novel hypolipidemic drugs. Curr. Med. Chem. 13: 997-1016 (2006).
Krapivner S, Chernogubova E, Ericsson M, Ahlbeck-Glader C, Hamsten A, van 't Hooft FM. Human evidence for the involvement of insulin-induced gene 1 in the regulation of plasma glucose concentration. Diabetologia 50: 94-102 (2007). *
Kratzer A, Buchebner M, Pfeifer T, Becker TM, Uray G, Miyazaki M, Miyazaki-Anzai S, Ebner B, Chandak PG, Kadam RS, Calayir E, Rathke N, Ahammer H, Radovic B, Trauner M, Hoefler G, Kompella UB, Fauler G, Levi M, Levak-Frank S, Kostner GM, Kratky D. Synthetic LXR agonist attenuates plaque formation in apoE-deficient mice without inducing liver steatosis and hypertriglyceridemia. J. Lipid Res. 50: 312-326 (2009). *
Kravitz MS, Pitashny M, Shoenfeld Y. Protective molecules - C-reactive protein (CRP), serum amyloid P (SAP), pentraxin3 (PTX3), mannose-binding lectin (MBL), and apolipoprotein A1 (Apo A1), and their autoantibodies: prevalence and clinical significance in autoimmunity. J. Clin. Immunol. 25: 582-591 (2005). *
Krayenbuehl PA, Wiesli P, Schmid M, Schmid C, Ehses JA, Hersberger M, Vetter W, Schulthess G. TNF-alpha -308G>A polymorphism modulates cytokine serum concentrations and macrovascular complications in diabetic patients on aspirin. Exp. Clin. Endocrinol. Diabetes 115: 322-326 (2007).
Krisans SK, Thompson SL, Pena LA, Kok E, Javitt NB. Bile acid synthesis in rat liver peroxisomes: metabolism of 26-hydroxycholesterol to 3 beta-hydroxy-5-cholenoic acid. J. Lipid Res. 26: 1324-1332 (1985). *
Kruit JK, Groen AK, van Berkel TJ, Kuipers F. Emerging roles of the intestine in control of cholesterol metabolism. World J. Gastroenterol. 12: 6429-6439 (2006). *
Kruit JK, Plosch T, Havinga R, Boverhof R, Groot PH, Groen AK, Kuipers F. Increased fecal neutral sterol loss upon liver X receptor activation is independent of biliary sterol secretion in mice. Gastroenterology 128: 147-156 (2005). *
Kryczka W, Grieb P. Clinical pharmacology of ursodeoxycholic acid (UDCA). Postepy. Hig. Med. Dosw. 48: 53-68 (1994).
Kubitz R, Keitel V, Burdelski M, Haussinger D. Regulation of hepatobiliary transporters in chronic cholestasis. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 33-35 (2006). *
Kubota K, Itho M, Kishi H, Igarashi S, Minegishi T. Primary hypothyroidism presenting as multiple ovarian cysts in an adult woman: a case report. Gynecol. Endocrinol. 24: 586-589 (2008).
Kuhajda K, Kevresan S, Kandrac J, Fawcett JP, Mikov M. Chemical and metabolic transformations of selected bile acids. Eur. J. Drug Metab. Pharmacokinet. 31: 179-235 (2006).
Kuipers F, Stroeve JH, Caron S, Staels B. Bile acids, farnesoid X receptor, atherosclerosis and metabolic control. Curr. Opin. Lipidol. 18: 289-297 (2007).
Kuisma J, Nuutinen H, Luukkonen P, Jarvinen H, Kahri A, Farkkila M. Long term metabolic consequences of ileal pouch-anal anastomosis for ulcerative colitis. Am. J. Gastroenterol. 96: 3110-3116 (2001). *
Kuliczkowska J, Filus A, Trzmiel A, Tworowska U, Demissie M, Jedrzejuk D, Milewicz A. PPAR-gamma2 Pro12Ala polymorphism in the population of obese and non-obese men of the city of Wroclaw. Endokrynol. Pol. 59: 312-315 (2008).
Kullak-Ublick GA. Regulation of hepatic and intestinal bile acid transport by FXR controlled signaling pathways. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 51-52 (2006). *
Kullak-Ublick GA, Stieger B, Meier PJ. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 126: 322-342 (2004). *
Kumagai S, Kawano S, Atsumi T, Inokuma S, Okada Y, Kanai Y, Kaburaki J, Kameda H, Suwa A, Hagiyama H, Hirohata S, Makino H, Hashimoto H. Vertebral fracture and bone mineral density in women receiving high dose glucocorticoids for treatment of autoimmune diseases. J. Rheumatol. 32: 863-869 (2005).
Kumar N, Wang H, Liu D, Collins S. Liver X receptor is a regulator of orphan nuclear receptor NOR-1 gene transcription in adipocytes. Int. J. Obes. (Lond.) 33: 519-524 (2009). *
Kurian KC, Rai P, Sankaran S, Jacob B, Chiong J, Miller AB. The effect of statins in heart failure: beyond its cholesterol-lowering effect. J. Card. Fail. 12: 473-478 (2006).
Kurihara T, Akimoto M, Abe K, Hashimoto H, Ishiguro H, Niimi A, Maeda A, Shigemoto M, Yamashita K, Yokoyama I. Inhibitory effect of ursodeoxycholic acid on the progression of chronic hepatic disorders with special reference to increases in blood flow. Clin. Ther. 15: 866-874 (1993).
Kurihara T, Akimoto M, Abe K, Ishiguro H, Niimi A, Maeda A, Shigemoto M, Yamashita K, Yokoyama I, Suzuki Y, et al. Experimental use of pravastatin in patients with primary biliary cirrhosis associated with hypercholesterolemia. Clin. Ther. 15: 890-898 (1993).
Kurtovic J, Riordan S. Clinical aspects of primary biliary cirrhosis. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper�s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 31-32. October 15-16 (2003). *
Kurzawski M, Juzyszyn Z, Modrzejewski A, Pawlik A, Wiatr M, Czerny B, Adamcewicz R, Drozdzik M. Apolipoprotein B (APOB) gene polymorphism in patients with gallbladder disease. Arch. Med. Res. 38: 360-363 (2007).
Kusunoki S, Kaida KI, Ueda M. Antibodies against gangliosides and ganglioside complexes in Guillain-Barre syndrome: new aspects of research. Biochim. Biophys. Acta 1780: 441-444 (2008). *
Kutz K, Schulte A. Effect of ursodeoxycholic acid on bile supersaturated with cholesterol in patients pretreated with clofibrate. Z. Gastroenterol. 19: 231-236 (1981).
Kuzuya M, Ando F, Iguchi A, Shimokata H. Glutathione peroxidase 1 Pro198Leu variant contributes to the metabolic syndrome in men in a large Japanese cohort. Am. J. Clin. Nutr. 87: 1939-1944 (2008). *
Kwon MK, Rhee SY, Chon S, Oh S, Woo JT, Kim SW, Kim JW, Kim YS, Jeong KH, Lee SH, Lee TW, Ihm CG. Association between apolipoprotein E genetic polymorphism and the development of diabetic nephropathy in type 2 diabetic patients. Diabetes Res. Clin. Pract. 77 Suppl. 1: S228-S232 (2007).
Kyoko U, Seiji U, Shinichi I, Masakazu T, Shinji K, Tohru F, Masunori M. Comparative effects of pitavastatin and probucol on oxidative stress, Cu/Zn superoxide dismutase, PPAR-gamma, and aortic stiffness in hypercholesterolemia. Am. J. Physiol. Heart Circ. Physiol. 291: H2522-H2532 (2006). *
Kyriakou T, Pontefract DE, Viturro E, Hodgkinson CP, Laxton RC, Bogari N, Cooper G, Davies M, Giblett J, Day IN, Simpson IA, Albrecht C, Ye S. Functional polymorphism in ABCA1 influences age of symptom onset in coronary artery disease patients. Hum. Mol. Genet. 16: 1412-1422 (2007). *
Labori KJ, Bjornbeth BA, Hvattum E, Lyberg T, Raeder MG. Intravenous bilirubin, dibromosulfophthalein, and bromosulfophthalein infusions uncouple biliary phospholipid and cholesterol secretion from bile acid secretion by inhibiting hepatic phosphoglycoprotein-3 activity in pigs. Scand. J. Gastroenterol. 35: 873-882 (2000). *
Lacaille F. Bile acids and their therapeutic use in children. Arch. Pediatr. 2: 1200-1208 (1995).
Laffitte BA, Joseph SB, Chen M, Castrillo A, Repa J, Wilpitz D, Mangelsdorf D, Tontonoz P. The phospholipid transfer protein gene is a liver X receptor target expressed by macrophages in atherosclerotic lesions. Mol. Cell. Biol. 23: 2182-2191 (2003). *
Laffitte BA, Joseph SB, Walczak R, Pei L, Wilpitz DC, Collins JL, Tontonoz P. Autoregulation of the human liver X receptor alpha promoter. Mol. Cell Biol. 21: 7558-7568 (2001). *
Laffitte BA, Repa JJ, Joseph SB, Wilpitz DC, Kast HR, Mangelsdorf DJ, Tontonoz P. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc. Natl. Acad. Sci. U.S.A. 98: 507-512 (2001). *
Lagogianni I, Papapanagiotou A, Piperi C, Kalofoutis C, Troupis G, Zachari A, Kalofoutis A. Evidence of reduced plasma HDL subfractions in patients with cutaneous discoid lupus erythematosus. Clin. Biochem. 38: 286-290 (2005). *
Lai K, Harnish DC, Evans MJ. Estrogen receptor alpha regulates expression of the orphan receptor small heterodimer partner. J. Biol. Chem. 278: 36418-36429 (2003). *
Lai MS, Hsieh MS, Chiu YH, Chen TH. Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection. Hepatology 43: 1295-1302 (2006). *
Laios E, Glynou K. Allelic drop-out in the LDLR gene affects mutation detection in familial hypercholesterolemia. Clin. Biochem. 41: 38-40 (2008). *
Lakoski SG, Li L, Langefeld CD, Liu Y, Howard TD, Brosnihan KB, Xu J, Bowden DW, Herrington DM. The association between innate immunity gene (IRAK1) and C-reactive protein in the Diabetes Heart Study. Exp. Mol. Pathol. 82: 280-283 (2007). *
Lalloyerc F, Fievet C, Lestavel S, Torpier G, van der Veen J, Touche V, Bultel S, Yous S, Kuipers F, Paumelle R, Fruchart JC, Staels B, Tailleux A. The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia. Arterioscler. Thromb. Vasc. Biol. 26: 2731-2737 (2006).
Lally S, Owens D, Tomkin GH. The different effect of pioglitazone as compared to insulin on expression of hepatic and intestinal genes regulating post-prandial lipoproteins in diabetes. Atherosclerosis 193: 343-351 (2007).
Lam CK, Chen J, Cao Y, Yang L, Wong YM, Yeung SY, Yao X, Huang Y, Chen ZY. Conjugated and non-conjugated octadecaenoic acids affect differently intestinal acyl coenzyme A: cholesterol acyltransferase activity. Atherosclerosis 198: 85-93 (2008).
Lam NV, Chen W, Suruga K, Nishimura N, Goda T, Yokogoshi H. Enhancing effect of taurine on CYP7A1 mRNA expression in Hep G2 cells. Amino Acids 30: 43-48 (2006). *
Lam RS, Shaw AR, Duszyk M. Membrane cholesterol content modulates activation of BK channels in colonic epithelia. Biochim. Biophys. Acta 1667: 241-248 (2004). *
Lambert G, Amar MJ, Guo G, Brewer HB Jr, Gonzalez FJ, Sinal CJ. The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J. Biol. Chem. 278: 2563-2570 (2003). *
Lamberts SW, Uitterlinden AG. Genetic testing in clinical practice. Annu. Rev. Med. Oct 23 [Epub ahead of print] (2008). *
Lambou-Gianoukos S, Heller SJ. Lithogenesis and bile metabolism. Surg. Clin. North Am. 88: 1175-1194 (2008).
Lambrinoudaki I, Kaparos G, Rizos D, Galapi F, Alexandrou A, Sergentanis TN, Creatsa M, Christodoulakos G, Kouskouni E, Botsis D. Apolipoprotein E and paraoxonase 1 polymorphisms are associated with lower serum thyroid hormones in postmenopausal women. Clin. Endocrinol. (Oxf.) Nov 8 [Epub ahead of print] (2008). *
Lamireau T, Bouchard G, Yousef IM, Clouzeau-Girard H, Rosenbaum J, Desmouliere A, Tuchweber B. Dietary lecithin protects against cholestatic liver disease in cholic acid-fed Abcb4- deficient mice. Pediatr. Res. 61: 185-190 (2007). *
Lammert F, Carey MC, Paigen B. Chromosomal organization of candidate genes involved in cholesterol gallstone formation: a murine gallstone map. Gastroenterology 120: 221-238 (2001). *
Lammert F, Marschall HU, Matern S. Intrahepatic cholestasis of pregnancy. Curr. Treat. Options Gastroenterol. 6: 123-132 (2003).
Lammert F, Matern S. Evidence-based prevention of cholecystolithiasis. Dtsch. Med. Wochenschr. 129: 1548-1550 (2004).
Lammert F, Matern S. The genetic background of cholesterol gallstone formation: an inventory of human lithogenic genes. Curr. Drug Targets Immune Endocr. Metabol. Disord. 5: 163-170 (2005).
Lammert F, Sauerbruch T. Genetics of gallstone disease. Falk Symposium 156. XIII Falk Liver Week (Part II). GENETICS IN LIVER DISEASES, Freiburg (Germany), October 8-9, 2006, p. 16-18 (2006). *
Lammert F, Wang DQ, Hillebrandt S, Geier A, Fickert P, Trauner M, Matern S, Paigen B, Carey MC. Spontaneous cholecysto- and hepatolithiasis in Mdr2-/- mice: a model for low phospholipid-associated cholelithiasis. Hepatology 39: 117-128 (2004). *
Lammert F, Wasmuth HE, Mendez-Sanchez N, Rahbar-Tabrizi N, Schirin-Sokhan R, King-Martinez AC, Marschall HU, Wittenburg H, Uribe M, Matern S. Common haplotypes of the ABCG5/G8 genes encoding the hepatocanalicular cholesterol transporter are associated with cholecystolithiasis. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 56. June 18-19 (2004). *
Lan Y, Liu J, Cheng H, Zou SL, Gan XL. Expressions of SHP and CYP7A1 in pregnant rats with intrahepatic cholestasis. Zhonghua Gan Zang Bing Za Zhi 16: 453-456 (2008).
Landis MS, Patel HV, Capone JP. Oxysterol activators of liver X receptor and 9-cis-retinoic acid promote sequential steps in the synthesis and secretion of tumor necrosis factor-alpha from human monocytes. J. Biol. Chem. 277: 4713-4721 (2002). *
Landrier JF, Eloranta JJ, Vavricka SR, Kullak-Ublick GA. The nuclear receptor for bile acids, FXR, transactivates the human organic solute transporter-alpha and -beta genes. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G476-G485 (2006). *
Landrier JF, Grober J, Demydchuk J, Besnard P. FXRE can function as an LXRE in the promoter of human ileal bile acid-binding protein (I-BABP) gene. FEBS Lett. 553: 299-303 (2003). *
Landrier JF, Thomas C, Grober J, Duez H, Percevault F, Souidi M, Linard C, Staels B, Besnard P. Statin induction of liver fatty acid-binding protein (L-FABP) gene expression is PPARalpha-dependent. J. Biol. Chem. 279: 45512-45518 (2004). *
Landrier JF, Thomas C, Grober J, Zaghini I, Petit V, Poirier H, Niot I, Besnard P. The gene encoding the human ileal bile acid-binding protein (I-BABP) is regulated by peroxisome proliferator-activated receptors. Biochim. Biophys. Acta 1735: 41-49 (2005). *
Lange Y, Ye J, Steck TL. How cholesterol homeostasis is regulated by plasma membrane cholesterol in excess of phospholipids. Proc. Natl. Acad. Sci. U.S.A. 101: 11664-11667 (2004). *
Langheim S, Yu L, von Bergmann K, Lutjohann D, Xu F, Hobbs HH, Cohen JC. ABCG5 and ABCG8 require MDR2 for secretion of cholesterol into bile. J. Lipid Res. 46: 1732-1738 (2005). *
Langmade SJ, Gale SE, Frolov A, Mohri I, Suzuki K, Mellon SH, Walkley SU, Covey DF, Schaffer JE, Ory DS. Pregnane X receptor (PXR) activation: a mechanism for neuroprotection in a mouse model of Niemann-Pick C disease. Proc. Natl. Acad. Sci. U.S.A. 103: 13807-13812 (2006). *
Langmann T, Liebisch G, Moehle C, Schifferer R, Dayoub R, Heiduczek S, Grandl M, Dada A, Schmitz G. Gene expression profiling identifies retinoids as potent inducers of macrophage lipid efflux. Biochim. Biophys. Acta 1740: 155-161 (2005). *
Langmann T, Porsch-Ozcurumez M, Unkelbach U, Klucken J, Schmitz G. Genomic organization and characterization of the promoter of the human ATP-binding cassette transporter-G1 (ABCG1) gene. Biochim. Biophys. Acta 1494: 175-180 (2000). *
Lanzarotto F, Panarotto B, Sorbara R, Panteghini M, Pagani F, Sosta S, Lanzini A. Effect of long term simvastatin administration as an adjunct to ursodeoxycholic acid: evidence for a synergistic effect on biliary bile acid composition but not on serum lipids in humans. Gut 44: 552-556 (1999). *
Lapidus A, Akerlund JE, Einarss on C. Gallbladder bile composition in patients with Crohn 's disease. World J. Gastroenterol. 12: 70-74 (2006). *
Lapidus A, Einarsson C. Bile composition in patients with ileal resection due to Crohn's disease. Inflamm. Bowel Dis. 4: 89-94 (1998). *
Lara LF, Levy MJ. Idiopathic recurrent acute pancreatitis. MedGenMed. 6: 10 (2004). *
Larson-Meyer DE, Newcomer BR, Heilbronn LK, Volaufova J, Smith SR, Alfonso AJ, Lefevre M, Rood JC, Williamson DA, Ravussin E. Effect of 6-month calorie restriction and exercise on serum and liver lipids and markers of liver function. Obesity (Silver Spring) 16: 1355-1362 (2008). *
LaRusso NF, Thistle JL. Ursodeoxycholic acid ingestion after ileal resection. Effect on biliary bile acid and lipid composition. Dig. Dis. Sci. 26: 705-709 (1981).
Lau P, Fitzsimmons R, Raichur S, Wang SC, Lechtken A, Muscat GE. The orphan nuclear receptor, RORalpha, regulates gene expression that controls lipid metabolism: staggerer (sg/sg) mice are resistant to diet induced obesity. J. Biol. Chem. 283: 18411-18421 (2008). *
Lauretani F, Semba RD, Bandinelli S, Miller ER 3rd, Ruggiero C, Cherubini A, Guralnik JM, Ferrucci L. Plasma polyunsaturated fatty acids and the decline of renal function. Clin. Chem. 54: 475-481 (2008). *
Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, McGill DB. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 23: 1464-1467 (1996). *
Lavery DJ, Schibler U. Circadian transcription of the cholesterol 7 alpha hydroxylase gene may involve the liver-enriched bZIP protein DBP. Genes Dev. 7: 1871-1884 (1993). *
Lawman S, Mauri C, Jury EC, Cook HT, Ehrenstein MR. Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand Black/White F1 mice. J. Immunol. 173: 7641-7646 (2004). *
Lazaridis KN, LaRusso NF. Bile formation: do not ignore the role of plasma membrane-cytoskeleton linking proteins. Hepatology 37: 218-220 (2003). *
Lazo PA. Functional implications of tetraspanin proteins in cancer biology. Cancer Sci. 98: 1666-1677 (2007). *
Le Goff W, Settle M, Greene DJ, Morton RE, Smith JD. Reevaluation of the role of the multidrug resistant P-glycoprotein in cellular cholesterol homeostasis. J. Lipid Res. 47: 51-58 (2006). *
Le Jossic-Corcos C, Duclos S, Ramirez LC, Zaghini I, Chevillard G, Martin P, Pineau T, Bournot P. Effects of peroxisome proliferator-activated receptor alpha activation on pathways contributing to cholesterol homeostasis in rat hepatocytes. Biochim. Biophys. Acta 1683: 49-58 (2004). *
Lebherz C, Gao G, Louboutin JP, Millar J, Rader D, Wilson JM. Gene therapy with novel adeno-associated virus vectors substantially diminishes atherosclerosis in a murine model of familial hypercholesterolemia. J. Gene Med. 6: 663-672 (2004). *
Leblond F, Seidah NG, Precourt LP, Delvin E, Dominguez M, Levy E. Regulation of the proprotein convertase subtilisin/kexin type 9 in intestinal epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. 296: G805-G815 (2009). *
Lebovitz HE. Insulin resistance - a common link between type 2 diabetes and cardiovascular disease. Diabetes Obes. Metab. 8: 237-249 (2006).
Lecerf JM. Fatty acids and cardiovascular disease. Nutr. Rev. 67: 273-283 (2009). *
Leckel K, Blaheta RA, Markus BH. State of hepatocyte transplantation: a risk or a chance? Zentralbl. Chir. 128: 283-290 (2003).
Lee AH, Scapa EF, Cohen DE, Glimcher LH. Regulation of hepatic lipogenesis by the transcription factor XBP1. Science 320: 1492-1496 (2008). *
Lee C, Martin KO, Javitt NB. Bile acid synthesis: 7 alpha-hydroxylation of intermediates in the sterol 27-hydroxylase metabolic pathway. J. Lipid Res. 37: 1356-1362 (1996). *
Lee DD, Stojadinovic O, Krzyzanowska A, Vouthounis C, Blumenberg M, Tomic-Canic M. Retinoid-responsive transcriptional changes in epidermal keratinocytes. J. Cell Physiol. 220: 427-439 (2009).
Lee FY, Lee H, Hubbert ML, Edwards PA, Zhang Y. FXR, a multipurpose nuclear receptor. Trends Biochem. Sci. 31: 572-580 (2006). *
Lee H, Hubbert ML, Osborne TF, Woodford K, Zerangue N, Edwards PA. Regulation of the sodium/sulfate co-transporter by farnesoid X receptor alpha. J. Biol. Chem. 282: 21653-21661 (2007). *
Lee J, Choi HS. Reverse cholesterol transport in cultured gallbladder epithelial cells. Korean J. Gastroenterol. 43: 145-152 (2004).
Lee J, Hong EM, Byun HW, Choi MH, Jang HJ, Eun CS, Kae SH, Choi HS. The effect of PPARalpha and PPARgamma ligands on inflammation and ABCA1 expression in cultured gallbladder epithelial cells. Dig. Dis. Sci. 53: 1707-1715 (2008). *
Lee J, Hong EM, Koh DH, Choi MH, Jang HJ, Kae SH, Choi HS. HMG-CoA reductase inhibitors (statins) activate expression of PPARalpha/PPARgamma and ABCA1 in cultured gallbladder epithelial cells. Dig. Dis. Sci. Feb 19 [Epub ahead of print] (2009). *
Lee J, Scheri RC, Zhang Y, Curtis LR. Chlordecone, a mixed pregnane X receptor (PXR) and estrogen receptor alpha (ERalpha) agonist, alters cholesterol homeostasis and lipoprotein metabolism in C57BL/6 mice. Toxicol. Appl. Pharmacol. 233: 193-202 (2008). *
Lee J, Shirk A, Oram JF, Lee SP, Kuver R. Polarized cholesterol and phospholipid efflux in cultured gall-bladder epithelial cells: evidence for an ABCA1-mediated pathway. Biochem. J. 364: 475-484 (2002). *
Lee JH, Lee W, Kwon OH, Kim JH, Kwon OW, Kim KH, Lim JB. Cytokine profile of peripheral blood in type 2 diabetes mellitus patients with diabetic retinopathy. Ann. Clin. Lab. Sci. 38: 361-367 (2008).
Lee KH, Choi EM. Effect of pine pollen extract on experimental chronic arthritis. Phytother. Res. 23: 651-657 (2009).
Lee L, Alloosh M, Saxena R, Van Alstine W, Watkins BA, Klaunig JE, Sturek M, Chalasani N. Nutritional model of steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. Hepatology Feb 11 [Epub ahead of print] (2009).
Lee S. Gallstones: how do we translate an old story into future therapy? Nat. Clin. Pract. Gastroenterol. Hepatol. 1: 2-3 (2004). *
Lee SJ, Choi MG, Kim DS, Kim TW. Manganese superoxide dismutase gene polymorphism (V16A) is associated with stages of albuminuria in Korean type 2 diabetic patients. Metabolism 55: 1-7 (2006).
Lee TS, Lin CY, Tsai JY, Wu YL, Su KH, Lu KY, Hsiao SH, Pan CC, Kou YR, Hsu YP, Ho LT. Resistin increases lipid accumulation by affecting class A scavenger receptor, CD36 and ATP-binding cassette transporter-A1 in macrophages. Life Sci. 84: 97-104 (2009). *
Lee YH, Alberta JA, Gonzalez FJ, Waxman DJ. Multiple, functional DBP sites on the promoter of the cholesterol 7 alpha-hydroxylase P450 gene, CYP7. Proposed role in diurnal regulation of liver gene expression. J. Biol. Chem. 269: 14681-14689 (1994). *
Lee YK, Moore DD. Dual mechanisms for repression of the monomeric orphan receptor liver receptor homologous protein-1 by the orphan small heterodimer partner. J. Biol. Chem. 277: 2463-2467 (2002). *
Lee YK, Moore DD. Liver receptor homolog-1, an emerging metabolic modulator. Front. Biosci. 13: 5950-5958 (2008).
Lee YK, Schmidt DR, Cummins CL, Choi M, Peng L, Zhang Y, Goodwin B, Hammer RE, Mangelsdorf DJ, Kliewer SA. Liver receptor homolog-1 regulates bile acid homeostasis but is not essential for feedback regulation of bile acid synthesis. Mol. Endocrinol. 22: 1345-1356 (2008). *
Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev. 89: 147-191 (2009). *
Lefkowitch JH. Hepatobiliary pathology. Curr. Opin. Gastroenterol. 23: 221-231 (2007).
Lefterov I, Bookout A, Wang Z, Staufenbiel M, Mangelsdorf D, Koldamova R. Expression profiling in APP23 mouse brain: inhibition of A-beta amyloidosis and inflammation in response to LXR agonist treatment. Mol. Neurodegener. 2: 20 (2007).
Leheska JM, Thompson LD, Howe JC, Hentges E, Boyce J, Brooks JC, Shriver B, Hoover L, Miller MF. Effects of conventional and grass feeding systems on the nutrient composition of beef. J. Anim. Sci. 86: 3575-3585 (2008).
Lehmann B. Role of the vitamin D3 pathway in healthy and diseased skin - facts, contradictions and hypotheses. Exp. Dermatol. 18: 97-108 (2009).
Lehmann JM, Kliewer SA, Moore LB, Smith-Oliver TA, Oliver BB, Su JL, Sundseth SS, Winegar DA, Blanchard DE, Spencer TA, Willson TM. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J. Biol. Chem. 272: 3137-3140 (1997). *
Lehrke M, Lebherz C, Millington SC, Guan HP, Millar J, Rader DJ, Wilson JM, Lazar MA. Diet-dependent cardiovascular lipid metabolism controlled by hepatic LXRalpha. Cell. Metab. 1: 297-308 (2005). *
Leik CE, Carson NL, Hennan JK, Basso MD, Liu QY, Crandall DL, Nambi P. GW3965, a synthetic liver X receptor (LXR) agonist, reduces angiotensin II-mediated pressor responses in Sprague-Dawley rats. Br. J. Pharmacol. 151: 450-456 (2007). *
Leikin-Frenkel A, Goldiner I, Leikin-Gobbi D, Rosenberg R, Bonen H, Litvak A, Bernheim J, Konikoff FM, Gilat T. Treatment of preestablished diet-induced fatty liver by oral fatty acid-bile acid conjugates in rodents. Eur. J. Gastroenterol. Hepatol. 20: 1205-1213 (2008).
Leiss O, Meyer-Krahmer K, von Bergmann K. Biliary lipid secretion in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia. Influence of bezafibrate and fenofibrate. J. Lipid Res. 27: 213-223 (1986).
Leitzmann C. Vegetarian diets: what are the advantages? Forum Nutr. 57: 147-156 (2005).
Lelliott CJ, Medina-Gomez G, Petrovic N, Kis A, Feldmann HM, Bjursell M, Parker N, Curtis K, Campbell M, Hu P, Zhang D, Litwin SE, Zaha VG, Fountain KT, Boudina S, Jimenez-Linan M, Blount M, Lopez M, Meirhaeghe A, Bohlooly-Y M, Storlien L, et al. Ablation of PGC-1beta results in defective mitochondrial activity, thermogenesis, hepatic function, and cardiac performance. PLoS Biol. 4: e369 (2006). *
Lemaire G, Benod C, Nahoum V, Pillon A, Boussioux AM, Guichou JF, Subra G, Pascussi JM, Bourguet W, Chavanieux A, Balaguer P. Discovery of a highly active ligand of human pregnane X receptor: a case study from pharmacophore modeling and virtual screening to "in vivo" biological activity. Mol. Pharmacol. 72: 572-581 (2007). *
Lemberg A, Schreier L, Romay S, Fernandez MA, Rosello D, Gonzales S, Perazzo JC, Filinger EJ, Tomaro ML. Involvement of serum apolipoprotein AI and B100 and lecithin cholesterol acyl transferase in alcoholic cirrhotics. Ann. Hepatol. 6: 227-232 (2007). *
Lemos ET, Reis F, Baptista S, Pinto R, Sepodes B, Vala H, Rocha-Pereira P, Silva GC, Teixeira N, Silva AS, Carvalho L, Teixeira F, Das UN. Exercise training decreases proinflammatory profile in Zucker diabetic (type 2) fatty rats. Nutrition 25: 330-339 (2009). *
Leo MA, Kim C, Lowe N, Lieber CS. Interaction of ethanol with beta-carotene: delayed blood clearance and enhanced hepatotoxicity. Hepatology 15: 883-891 (1992).
Lepage G, Paradis K, Lacaille F, Senechal L, Ronco N, Champagne J, Lenaerts C, Roy CC, Rasquin-Weber A. Ursodeoxycholic acid improves the hepatic metabolism of essential fatty acids and retinol in children with cystic fibrosis. J. Pediatr. 130: 52-58 (1997). *
Lepercq P, Hermier D, David O, Michelin R, Gibard C, Beguet F, Relano P, Cayuela C, Juste C. Increasing ursodeoxycholic acid in the enterohepatic circulation of pigs through the administration of living bacteria. Br. J. Nutr. 93: 457-469 (2005). *
Leung JK, Cases S, Vu TH. P311 functions in an alternative pathway of lipid accumulation that is induced by retinoic acid. J. Cell Sci. 121: 2751-2758 (2008). *
Leuschner M, Leuschner U, Lazarovici D, Kurtz W, Hellstern A. Dissolution of gall stones with an ursodeoxycholic acid menthol preparation: a controlled prospective double blind trial. Gut 29: 428-432 (1988). *
Leuschner U. Drug therapy of gallstone disease. Schweiz. Rundsch. Med. Prax. 81: 905-906 (1992).
Leuschner U. Oral bile acid treatment of biliary cholesterol stones. Recenti Prog. Med. 83: 392-399 (1992).
Leuschner U, Guldutuna S, Bhatti S, Elze A, Imhof M, You T, Zimmer G. TUDCA and UDCA are incorporated into hepatocyte membranes: different sites, but similar effects. Ital. J. Gastroenterol. 27: 376-377 (1995).
Leuschner U, Leuschner M, Sieratzki J, Kurtz W, Hubner K. Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study. Dig. Dis. Sci. 30: 642-649 (1985).
Leuschner U, Reber E, Erb W. Treatment of patients with gallstones with chenodeoxycholic acid. Dtsch. Med. Wochenschr. 102: 156-160 (1977).
Leuschner U, Schneider M, Korte L. The influence of chenodeoxycholic acid and ursodeoxycholic acid on the hepatic structure of the rat. Z. Gastroenterol. 17: 244-255 (1979).
Levin N, Bischoff ED, Daige CL, Thomas D, Vu CT, Heyman RA, Tangirala RK, Schulman IG. Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists. Arterioscler. Thromb. Vasc. Biol. 25: 135-142 (2005). *
Levy C, Lindor KD. Treatment options for primary biliary cirrhosis and primary sclerosing cholangitis. Curr. Treat. Options Gastroenterol. 6: 93-103 (2003).
Levy C, Lindor KD. Current management of primary biliary cirrhosis and primary sclerosing cholangitis. J. Hepatol. 38: S24-S37 (2003). *
Levy E, Brunet S, Alvarez F, Seidman E, Bouchard G, Escobar E, Martin S. Abnormal hepatobiliary and circulating lipid metabolism in the Long-Evans Cinnamon rat model of Wilson's disease. Life Sci. 80: 1472-1483 (2007). *
Levy E, Spahis S, Sinnett D, Peretti N, Maupas-Schwalm F, Delvin E, Lambert M, Lavoie MA. Intestinal cholesterol transport proteins: an update and beyond. Curr. Opin. Lipidol. 18: 310-318 (2007).
Levy G, Villamil F, Samuel D, Sanjuan F, Grazi GL, Wu Y, Marotta P, Boillot O, Muehlbacher F, Klintmalm G; LIS2T Study Group. Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation 77: 1632-1638 (2004).
Levy J, Budai K, Javitt NB. Bile acid synthesis in HepG2 cells: effect of cyclosporin. J. Lipid Res. 35: 1795-1800 (1994). *
Levy O, Elsbach P. Bactericidal/permeability-increasing protein in host defense and its efficacy in the treatment of bacterial sepsis. Curr. Infect. Dis. Rep. 3: 407-412 (2001).
Lew JL, Zhao A, Yu J, Huang L, De Pedro N, Pelaez F, Wright SD, Cui J. The farnesoid X receptor (FXR) controls gene expression in a ligand- and promoter- selective fashion. J. Biol. Chem. 279: 8856-8861 (2004). *
Lewis GF. Determinants of plasma HDL concentrations and reverse cholesterol transport. Curr. Opin. Cardiol. 21: 345-352 (2006).
Lewis SJ. Prevention and treatment of atherosclerosis: a practitioner's guide for 2008. Am. J. Med. 122: S38-S50 (2009). *
Lewkowicz P, Banasik M, Glowacka E, Lewkowicz N, Tchorzewski H. Effect of high doses of shark liver oil supplementation on T cell polarization and peripheral blood polymorphonuclear cell function. Pol. Merkuriusz. Lek. 18: 686-692 (2005).
Li AC, Binder CJ, Gutierrez A, Brown KK, Plotkin CR, Pattison JW, Valledor AF, Davis RA, Willson TM, Witztum JL, Palinski W, Glass CK. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J. Clin. Invest. 114: 1564-1576 (2004). *
Li AC, Glass CK. PPAR and LXR-dependent pathways controlling lipid metabolism and development of atherosclerosis. J. Lipid Res. 45: 2161-2173 (2004). *
Li C, Xu M, Gu Q. ATP binding cassette transporter G1 gene expression is reduced in type 2 diabetic patients. Endocr. J. 56: 313 (2009). *
Li CP, Tong MJ, Hwang SJ, Luo JC, Co RL, Tsay SH, Chang FY, Lee SD. Autoimmune cholangitis with features of autoimmune hepatitis: successful treatment with immunosuppressive agents and ursodeoxycholic acid. J. Gastroenterol. Hepatol. 15: 95-98 (2000). *
Li D, Wu Y, Zhang AZ, Wahlqvist ML. Omega-3 PUFA status in type 2 diabetes mellitus patients, a case-control study. Asia Pac. J. Clin. Nutr. 14: S101 (2005).
Li FQ, Sempowski GD, McKenna SE, Laskowitz DT, Colton CA, Vitek MP. Apolipoprotein E-derived peptides ameliorate clinical disability and inflammatory infiltrates into the spinal cord in a murine model of multiple sclerosis. J. Pharmacol. Exp. Ther. 318: 956-965 (2006). *
Li H, Xu G, Shang Q, Pan L, Shefer S, Batta AK, Bollineni J, Tint GS, Keller BT, Salen G. Inhibition of ileal bile acid transport lowers plasma cholesterol levels by inactivating hepatic farnesoid X receptor and stimulating cholesterol 7alpha-hydroxylase. Metabolism 53: 927-932 (2004). *
Li J, Scherl A, Medina F, Frank PG, Kitsis RN, Tanowitz HB, Sotgia F, Lisanti MP. Impaired phagocytosis in caveolin-1 deficient macrophages. Cell Cycle 4: 1599-1607 (2005). *
Li J, Wilson A, Kuruba R, Zhang Q, Gao X, He F, Zhang LM, Pitt BR, Xie W, Li S. FXR-mediated regulation of eNOS expression in vascular endothelial cells. Cardiovasc. Res. 77: 169-177 (2008). *
Li J, Zhang JZ, Zou CP, Fang BJ, Liang XQ. Shengqing Capsule down-regulates estrogen and progesterone receptors in epithelial tissue of gallbladder in guinea pigs with gallstone. Zhong Xi Yi Jie He Xue Bao 6: 1040-1044 (2008).
Li JQ, Li MY, Dai YX, Liu YM, Zheng J, Liu WB. Serum adiponectin and free fatty acid profile in essential hypertensive patients with or without metabolic syndrome. Zhonghua Xin Xue Guan Bing Za Zhi 36: 232-235 (2008).
Li L, Cheng LX, Nsenga R, He MA, Wu TC. Association between Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma 2 and myocardial infarction in the Chinese Han population. Clin. Cardiol. 29: 300-304 (2006).
Li L, Xu X, Lu F, Zhao N. Effects of ursodeoxycholic acid on intrahepatic cholestasis in rats. Chin. Med. J. (Engl.) 116: 1099-1103 (2003).
Li LL, Kang XL, Ran XJ, Wang Y, Wang CH, Huang L, Ren J, Luo X, Mao XM. Associations between 45T/G polymorphism of the adiponectin gene and plasma adiponectin levels with type 2 diabetes. Clin. Exp. Pharmacol. Physiol. 34: 1287-1290 (2007). *
Li LL, Ma XL, Ran JX, Sun XF, Xu LM, Ren J, Mao XM. Genetic polymorphism of peroxisome proliferator-activated receptor-gamma 2 Pro12Ala on ethnic susceptibility to diabetes in Uygur, Kazak and Han subjects. Clin. Exp. Pharmacol Physiol. 35: 187-191 (2008).
Li P, Kim SW, Li X, Datta S, Pond WG, Wu G. Dietary supplementation with cholesterol and docosahexaenoic acid affects concentrations of amino acids in tissues of young pigs. Amino Acids Oct 30 [Epub ahead of print] (2008). *
Li S, Zhang ZW, Guan YF. On the bile acid receptor FXR. Sheng Li Ke Xue Jin Zhan 34: 314-318 (2003).
Li T, Chen W, Chiang JY. PXR induces CYP27A1 and regulates cholesterol metabolism in the intestine. J. Lipid Res. 48: 373-384 (2007). *
Li T, Chiang JY. Mechanism of rifampicin and pregnane X receptor inhibition of human cholesterol 7alpha-hydroxylase gene transcription. Am. J. Physiol. Gastrointest. Liver Physiol. 288: G74-G84 (2005). *
Li T, Chiang JY. A novel role of transforming growth factor beta1 in transcriptional repression of human cholesterol 7alpha-hydroxylase gene. Gastroenterology 133: 1660-1669 (2007). *
Li T, Jahan A, Chiang JY. Bile acids and cytokines inhibit the human cholesterol 7 alpha-hydroxylase gene via the JNK/c-Jun pathway in human liver cells. Hepatology 43: 1202-1210 (2006). *
Li T, Kong X, Owsley E, Ellis E, Strom S, Chiang JY. Insulin regulation of cholesterol 7alpha-hydroxylase expression in human hepatocytes: roles of forkhead box O1 and sterol regulatory element binding protein 1c. J. Biol. Chem. 281: 28745-28754 (2006). *
Li T, Ma H, Chiang JY. TGFbeta1, TNFalpha, and insulin signaling crosstalk in regulation of the rat cholesterol 7alpha-hydroxylase gene expression. J. Lipid Res. 49: 1981-1989 (2008). *
Li X, Zhang S, Blander G, Tse JG, Krieger M, Guarente L. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol. Cell 28: 91-106 (2007). *
Li X, Zhou Z, Huang G, Su H, Yan X, Yang L. Metabolic syndrome in adult-onset latent autoimmune diabetes. Metab. Syndr. Relat. Disord. 3: 174-180 (2005).
Li Y, Bolten C, Bhat BG, Woodring-Dietz J, Li S, Prayaga SK, Xia C, Lala DS. Induction of human liver X receptor alpha gene expression via an autoregulatory loop mechanism. Mol. Endocrinol. 16: 506-514 (2002). *
Li Y, Choi M, Suino K, Kovach A, Daugherty J, Kliewer SA, Xu HE. Structural and biochemical basis for selective repression of the orphan nuclear receptor liver receptor homolog 1 by small heterodimer partner. Proc. Natl. Acad. Sci. U.S.A. 102: 9505-9510 (2005). *
Li Y, Fisher E, Klapper M, Boeing H, Pfeiffer A, Hampe J, Schreiber S, Burwinkel B, Schrezenmeir J, Doring F. Association between functional FABP2 promoter haplotype and type 2 diabetes. Horm. Metab. Res. 38: 300-307 (2006).
Li Y, Mezei O, Shay NF. Human and murine hepatic sterol-12-alpha-hydroxylase and other xenobiotic metabolism mRNA are upregulated by soy isoflavones. J. Nutr. 137: 1705-1712 (2007). *
Li Z, Zhang Q, Peng X, Wu Y, Xia Y, Liu X. The influence of adiponectin gene polymorphism on the pioglitazone response in the Chinese with type 2 diabetes. Diabetes Obes. Metab. 10: 794-802 (2008). *
Li-Hawkins J, Gafvels M, Olin M, Lund EG, Andersson U, Schuster G, Bjorkhem I, Russell DW, Eggertsen G. Cholic acid mediates negative feedback regulation of bile acid synthesis in mice. J. Clin. Invest. 110: 1191-1200 (2002). *
Li-Hawkins J, Lund EG, Bronson AD, Russell DW. Expression cloning of an oxysterol 7alpha-hydroxylase selective for 24-hydroxycholesterol. J. Biol. Chem. 275: 16543-16549 (2000). *
Li-Hawkins J, Lund EG, Turley SD, Russell DW. Disruption of the oxysterol 7alpha-hydroxylase gene in mice. J. Biol. Chem. 275: 16536-16542 (2000). *
Liang CP, Tall AR. Transcriptional profiling reveals global defects in energy metabolism, lipoprotein, and bile acid synthesis and transport with reversal by leptin treatment in ob/ob mouse liver. J. Biol. Chem. 276: 49066-49076 (2001). *
Liang XM, Otani H, Zhou Q, Tone Y, Fujii R, Mune M, Yukawa S, Akizawa T. Various dietary protein intakes and progression of renal failure in spontaneously hypercholesterolemic Imai rats. Nephron. Exp. Nephrol. 105: e98-e107 (2007).
Liang Y, Lin S, Beyer TP, Zhang Y, Wu X, Bales KR, DeMattos RB, May PC, Li SD, Jiang XC, Eacho PI, Cao G, Paul SM. A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes. J. Neurochem. 88: 623-634 (2004). *
Liangpunsakul S, Chalasani N. Treatment of nonalcoholic fatty liver disease. Curr. Treat. Options Gastroenterol. 6: 455-463 (2003).
Liao H, Langmann T, Schmitz G, Zhu Y. Native LDL upregulation of ATP-binding cassette transporter-1 in human vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 22: 127-132 (2002). *
Liao YF, Chen LL, Zeng TS, Zheng J, Li HQ. Association of the +33371 A/G polymorphism in adiponectin receptor 2 gene with type 2 diabetes in the Chinese population. J. Endocrinol. Invest. 30: 860-864 (2007).
Lichti-Kaiser K, Xu C, Staudinger JL. Cyclic AMP-dependent protein kinase signaling modulates pregnane X receptor activity in a species-specific manner. J. Biol. Chem. 284: 6639-6649 (2009). *
Liddle C, Goodwin B. Regulation of hepatic drug metabolism: role of the nuclear receptors PXR and CAR. Semin. Liver Dis. 22: 115-122 (2002).
Lilja HE, Suviolahti E, Soro-Paavonen A, Hiekkalinna T, Day A, Lange K, Sobel E, Taskinen MR, Peltonen L, Perola M, Pajukanta P. Locus for quantitative HDL-cholesterol on chromosome 10q in Finnish families with dyslipidemia. J. Lipid Res. 45: 1876-1884 (2004). *
Lillienau J, Hagey LR, Borgstrom B. Hepatic and ileal transport and effect on biliary secretion of norursocholic acid and its conjugates in rats. Am. J. Physiol. 261: G1057-G1064 (1991).
Lim A, Manley K, Roberts M, Fraenkel M. Fish oil for kidney transplant recipients. Cochrane Database Syst. Rev. 2: CD005282 (2007). *
Lim C, Bijvelds M, Nigg A, Schoonderwoerd K, Houtsmuller A, de Jonge H, Tilly B. Cholesterol depletion and genistein as tools to promote F508delCFTR retention at the plasma membrane. Cell. Physiol. Biochem. 20: 473-482 (2007). *
Lim GH, Roslani AC, Pang B, Bih-Shiou CT. Cholesterol atheroembolism of the colon can mimic the endoscopic features of pseudomembranous colitis. Surg. Laparosc. Endosc. Percutan. Tech. 18: 616-618 (2008).
Lin CC, Chuang FR, Lee CH, Wang CC, Chen YS, Liu YW, Jawan B, Chen CL. The renal-sparing efficacy of basiliximab in adult living donor liver transplantation. Liver Transpl. 11: 1258-1264 (2005). *
Lin CC, Yin MC, Liu WH. Alleviative effects of S-allyl cysteine and S-ethyl cysteine on MCD diet-induced hepatotoxicity in mice. Food Chem. Toxicol. 46: 3401-3406 (2008). *
Lin DC. Probiotics as functional foods. Nutr. Clin. Pract. 18: 497-506 (2003). *
Lindegaard ML, Wassif CA, Vaisman B, Amar M, Wasmuth EV, Shamburek R, Nielsen LB, Remaley AT, Porter FD. Characterization of placental cholesterol transport: ABCA1 is a potential target for in utero therapy of Smith-Lemli-Opitz syndrome. Hum. Mol. Genet. 17: 3806-3813 (2008).
Linden D, William-Olsson L, Ahnmark A, Ekroos K, Hallberg C, Sjogren HP, Becker B, Svensson L, Clapham JC, Oscarsson J, Schreyer S. Liver-directed overexpression of mitochondrial glycerol-3-phosphate acyltransferase results in hepatic steatosis, increased triacylglycerol secretion and reduced fatty acid oxidation. FASEB J. 20: 434-443 (2006). *
Lindenthal B, Sudhop T, Schiedermaier P, Agnan M, Sauerbruch T, von Bergmann K. Serum plant sterols and biliary cholesterol secretion in humans: studies with ursodeoxycholic acid. J. Lipid Res. 43: 1072-1077 (2002). *
Lindi V, Schwab U, Louheranta A, Vessby B, Hermansen K, Tapsell L, Riccardi G, Rivellese AA, Laakso M, Uusitupa MI; KANWU Study Group. The G-250A polymorphism in the hepatic lipase gene promoter is associated with changes in hepatic lipase activity and LDL cholesterol: the KANWU study. Nutr. Metab. Cardiovasc. Dis. 18: 88-95 (2008).
Lindner MA. A fish oil diet inhibits colon cancer in mice. Nutr. Cancer 15: 1-11 (1991).
Lindqvist HM, Sandberg AS, Fagerberg B, Hulthe J. Plasma phospholipid EPA and DHA in relation to atherosclerosis in 61-year-old men. Atherosclerosis Dec 30 [Epub ahead of print] (2008).
Lindshield BL, King JL, Wyss A, Goralczyk R, Lu CH, Ford NA, Erdman JW Jr. Lycopene biodistribution is altered in 15,15'-carotenoid monooxygenase knockout mice. J. Nutr. 138: 2367-2371 (2008). *
Liou YA, King DJ, Zibrik D, Innis SM. Decreasing linoleic acid with constant alpha-linolenic acid in dietary fats increases (n-3) eicosapentaenoic acid in plasma phospholipids in healthy men. J. Nutr. 137: 945-952 (2007). *
Lipozencic J. The 1st world congress on gender-specific medicine men, women and medicine a new view of the biology of sex/gender differences and aging. Acta Dermatovenerol. Croat. 14: 132-134 (2006).
Lirussi F, Vaja S, Murphy GM, Dowling RH. Cholestasis of total parenteral nutrition: bile acid and bile lipid metabolism in parenterally nourished rats. Gastroenterology 96: 493-502 (1989).
Liscovitch M, Lavie Y. Multidrug resistance: a role for cholesterol efflux pathways? Trends Biochem. Sci. 25: 530-534 (2000). *
Liu CL, Fan ST, Lo CM, Chan SC, Ng IO, Lai CL, Wong J. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage. Liver Transpl. 10: 728-733 (2004). *
Liu HL, Lin YG, Wu J, Sun H, Gong ZC, Hu PC, Yin JY, Zhang W, Wang D, Zhou HH, Liu ZQ. Impact of genetic polymorphisms of leptin and TNF-alpha on rosiglitazone response in Chinese patients with type 2 diabetes. Eur. J. Clin. Pharmacol. 64: 663-671 (2008). *
Liu HR, Tao L, Gao E, Qu Y, Lau WB, Lopez BL, Christopher TA, Koch W, Yue TL, Ma XL. Rosiglitazone inhibits hypercholesterolemia-induced myeloperoxidase upregulation - a novel mechanism for the cardioprotective effects of PPAR agonists. Cardiovasc. Res. 81: 344-352 (2009). *
Liu JJ, Glickman JN, Masyuk AI, LaRusso NF. Cholangiocyte bile salt transporters in cholesterol gallstone-susceptible and resistant inbred mouse strains. J. Gastroenterol. Hepatol. 23: 1596-1602 (2008). *
Liu JP. New functions of cholesterol binding proteins. Mol. Cell. Endocrinol. 303: 1-6 (2009).
Liu R, Iqbal J, Yeaong C, Wang DQ, Hussain MM, Jiang XC. Phospholipid transfer protein-deficient mice absorb less cholesterol. Arterioscler. Thromb. Vasc. Biol. 27: 2014-2021 (2007). *
Liu SP, Li YS, Chen YJ, Chiang EP, Li AF, Lee YH, Tsai TF, Hsiao M, Hwang SF, Chen YM. Glycine N-methyltransferase-/- mice develop chronic hepatitis and glycogen storage disease in the liver. Hepatology 46: 1413-1425 (2007). *
Liu W, Li WM, Gao C, Sun NL. Effects of atorvastatin on the Th1/Th2 polarization of ongoing experimental autoimmune myocarditis in Lewis rats. J. Autoimmun. 25: 258-263 (2005).
Liu Y, Havinga R, van der Leij FR, Boverhof R, Sauer PJ, Kuipers F, Stellaard F. Dexamethasone exposure of neonatal rats modulates biliary lipid secretion and hepatic expression of genes controlling bile acid metabolism in adulthood without interfering with primary bile acid kinetics. Pediatr. Res. 63: 375-381 (2008). *
Liu Y, Yu H, Zhang Y, Zhao Y. TLRs are important inflammatory factors in atherosclerosis and may be a therapeutic target. Med. Hypotheses 70: 314-316 (2008).
Ljungberg A, Linden D, Ameen C, Bergstrom G, Oscarsson J. Importance of PPARalpha for the effects of growth hormone on hepatic lipid and lipoprotein metabolism. Growth Horm. IGF Res. 17: 154-164 (2007).
Ljungh A, Wadstrom T. Lactic acid bacteria as probiotics. Curr. Issues Intest. Microbiol. 7: 73-89 (2006).
Lo JC, Wang Y, Tumanov AV, Bamji M, Yao Z, Reardon CA, Getz GS, Fu YX. Lymphotoxin beta receptor-dependent control of lipid homeostasis. Science 316: 285-288 (2007). *
Lo Sasso G, Petruzzelli M, Moschetta A. A translational view on the biliary lipid secretory network. Biochim. Biophys. Acta 1781: 79-96 (2008). *
Lobaccaro JM, Repa JJ, Lu TT, Caira F, Henry-Berger J, Volle DH, Mangelsdorf DJ. Regulation of lipid metabolism by the orphan nuclear receptors. Ann. Endocrinol. (Paris) 62: 239-247 (2001).
Lockman AR, Tribastone AD, Knight KV, Franko JP. Treatment of cholesterol abnormalities. Am. Fam. Physician 71: 1137-1142 (2006). *
Lodde BM, Sankar V, Kok MR, Leakan RA, Tak PP, Pillemer SR. Adult heart block is associated with disease activity in primary Sjogren's syndrome. Scand. J. Rheumatol. 34: 383-386 (2005). *
Lodde BM, Sankar V, Kok MR, Leakan RA, Tak PP, Pillemer SR. Serum lipid levels in Sjogren's syndrome. Rheumatology (Oxford) 45: 481-484 (2006). *
Loginov AS, Matiushin BN, Tkachev VD, Iakimchuk GN. A new approach to the diagnosis of cholestasis by the activity of copper-containing enzymes. Ter. Arkh. 65: 34-36 (1993).
Loginov AS, Reshetniak VI, Petrakov AV. The treatment of primary biliary liver cirrhosis with rifampicin. Ter. Arkh. 65: 57-62 (1993).
Loguercio C, Federico A, Masarone M, Torella R, Blanco CD, Persico M. The impact of diet on liver fibrosis and on response to interferon therapy in patients with HCV-related chronic hepatitis. Am. J. Gastroenterol. 103: 3159-3166 (2008). *
London RM, George J. Pathogenesis of NASH: animal models. Clin. Liver Dis.11: 55-74 (2007).
Longo M, Crosignani A, Battezzati PM, Squarcia Giussani C, Invernizzi P, Zuin M, Podda M. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut 51: 265-269 (2002). *
Longo M, Crosignani A, Podda M. Hyperlipidemia in chronic cholestatic liver disease. Curr. Treat. Options Gastroenterol. 4: 111-114 (2001).
Look MP, Reichel C, von Falkenhausen M, Hahn C, Stockinger K, von Bergmann K, Rao GS, Spengler U, Sauerbruch T. Vitamin E status in patients with liver cirrhosis: normal or deficient? Metabolism 48: 86-91 (1999).
Lopez D, McLean MP. Estrogen regulation of the scavenger receptor class B gene: anti-atherogenic or steroidogenic, is there a priority? Mol. Cell. Endocrinol. 247: 22-33 (2006).
Lopez LR, Hurley BL, Simpson DF, Matsuura E. Oxidized low-density lipoprotein/beta2-glycoprotein I complexes and autoantibodies in patients with type 2 diabetes mellitus. Ann. N. Y. Acad. Sci. 1051: 97-103 (2005). *
Lopez P, Gutierrez C, Suarez A. IFNalpha treatment generates antigen-presenting cellsinsensitive to atorvastatin inhibition of MHC-II expression. Clin. Immunol. 129: 350-359 (2008). *
Lorkowski S, Kratz M, Wenner C, Schmidt R, Weitkamp B, Fobker M, Reinhardt J, Rauterberg J, Galinski EA, Cullen P. Expression of the ATP-binding cassette transporter gene ABCG1 (ABC8) in Tangier disease. Biochem. Biophys. Res. Commun. 283: 821-830 (2001). *
Lorkowski S, Rust S, Engel T, Jung E, Tegelkamp K, Galinski EA, Assmann G, Cullen P. Genomic sequence and structure of the human ABCG1 (ABC8) gene. Biochem. Biophys. Res. Commun. 280: 121-131 (2001). *
Lourida ES, Georgiadis AN, Papavasiliou EC, Papathanasiou AI, Drosos AA, Tselepis AD. Patients with early rheumatoid arthritis exhibit elevated autoantibody titers against mildly oxidized LDL and decreased activity of the lipoprotein-associated phospholipase A2. Arthritis Res. Ther. 9: R19 (2007). *
Love JD, Gooch JT, Benko S, Li C, Nagy L, Chatterjee VK, Evans RM, Schwabe JW. The structural basis for the specificity of retinoid-X receptor-selective agonists: new insights into the role of helix H12. J. Biol. Chem. 277: 11385-11391 (2002). *
Love MW, Dawson PA. New insights into bile acid transport. Curr. Opin. Lipidol. 9: 225-229 (1998).
Lowyck I, Fevery J. Statins in hepatobiliary diseases: effects, indications and risks. Acta Gastroenterol. Belg. 70: 381-388 (2007).
Lozano A, Vildosola H, Takano J, Vargas G, Uribe R, Moreno C. Clinical and immunological profile in 22 patients with primary biliary cirrhosis. Rev. Gastroenterol. Peru. 20: 14-24 (2000).
Lozanoska-Ochser B, Barone F, Pitzalis C, Peakman M. Atorvastatin fails to prevent the development of autoimmune diabetes despite inhibition of pathogenic beta-cell-specific CD8 T-cells. Diabetes 55: 1004-1010 (2006). *
Lu H, Sun J, Sun L, Shu X, Xu Y, Xie D. Polymorphism of human leptin receptor gene is associated with type 2 diabetic patients complicated with non-alcoholic fatty liver disease in China. J. Gastroenterol. Hepatol. 24: 228-232 (2009). *
Lu J, Wu DM, Zheng YL, Sun DX, Hu B, Shan Q, Zhang ZF, Fan SH. Trace amounts of copper exacerbate beta amyloid-induced neurotoxicity in the cholesterol-fed mice through TNF-mediated inflammatory pathway. Brain Behav. Immun. 23: 193-203 (2009).
Lu K, Lee MH, Hazard S, Brooks-Wilson A, Hidaka H, Kojima H, Ose L, Stalenhoef AF, Mietinnen T, Bjorkhem I, Bruckert E, Pandya A, Brewer HB Jr, Salen G, Dean M, Srivastava A, Patel SB. Two genes that map to the STSL locus cause sitosterolemia: genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 and ABCG8, respectively. Am. J. Hum. Genet. 69: 278-290 (2001). *
Lu R, Ito JI, Iwamoto N, Nishimaki-Mogami T, Yokoyama S. Fibroblast growth factor-1 induces expression of LXRalpha and production of 25-hydroxycholesterol to up-regulate apolipoprotein E gene transcription in rat astrocytes. J. Lipid Res. 50: 1156-1164 (2009). *
Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, Auwerx J, Mangelsdorf DJ. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol. Cell 6: 507-515 (2000). *
Luley C. Lipometabolic disorder - cholesterol and triglycerides. Clin. Res. Cardiol. 95 Suppl. 6: vi17-vi22 (2006).
Lund E, Boberg KM, Bystrom S, Olund J, Carlstrom K, Bjorkhem I. Formation of novel C21-bile acids from cholesterol in the rat. Structure identification of the major di- and trihydroxylated species. J. Biol. Chem. 266: 4929-4937 (1991). *
Lund EG, Peterson LB, Adams AD, Lam MH, Burton CA, Chin J, Guo Q, Huang S, Latham M, Lopez JC, Menke JG, Milot DP, Mitnaul LJ, Rex-Rabe SE, Rosa RL, Tian JY, Wright SD, Sparrow CP. Different roles of liver X receptor alpha and beta in lipid metabolism: effects of an alpha-selective and a dual agonist in mice deficient in each subtype. Biochem. Pharmacol. 71: 453-463 (2006). *
Lundasen T, Andersson EM, Schreyer S, Ostlund-Lindqvist AM, Angelin B, Rudling M. Ileal bile acid transport inhibition lowers plasma glucose and lipid levels in ob/ob mice. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 45 (2006). *
Lundell K, Wikvall K. Species-specific and age-dependent bile acid composition: aspects on CYP8B and CYP4A subfamilies in bile acid biosynthesis. Curr. Drug Metab. 9: 323-331 (2008).
Lundin EA, Zhang JX, Lairon D, Tidehag P, Aman P, Adlercreutz H, Hallmans G. Effects of meal frequency and high-fibre rye-bread diet on glucose and lipid metabolism and ileal excretion of energy and sterols in ileostomy subjects. Eur. J. Clin. Nutr. 58: 1410-1419 (2004). *
Luoma PV. Cytochrome P450 - physiological key factor against cholesterol accumulation and the atherosclerotic vascular process. Ann. Med. 39: 359-370 (2007).
Lutjohann D. Cholesterol metabolism in the brain: importance of 24S-hydroxylation. Acta Neurol. Scand. Suppl. 185: 33-42 (2006).
Lutjohann D, Hahn C, Prange W, Sudhop T, Axelson M, Sauerbruch T, von Bergmann K, Reichel C. Influence of rifampin on serum markers of cholesterol and bile acid synthesis in men. Int. J. Clin. Pharmacol. Ther. 42: 307-313 (2004).
Lv S, Fan R, Du Y, Hou M, Tang Z, Ling W, Zhu H. Betaine supplementation attenuates atherosclerotic lesion in apolipoprotein E-deficient mice. Eur. J. Nutr. Mar 3 [Epub ahead of print] (2009).
Lykavieris P, Bernard O, Hadchouel M. Neonatal cholestasis as the presenting feature in cystic fibrosis. Arch. Dis. Child. 75: 67-70 (1996). *
Lyons MA, Wittenburg H. Cholesterol gallstone susceptibility loci: a mouse map, candidate gene evaluation, and guide to human LITH genes. Gastroenterology 131: 1943-1970 (2006). *
L�v�s K, R�st TH, Skorve J, Ulvik RJ, Gudbrandsen OA, Bohov P, Wensaas AJ, Rustan AC, Berge RK, Husebye ES. Tetradecylthioacetic acid attenuates dyslipidaemia in male patients with type 2 diabetes mellitus, possibly by dual PPAR-alpha/delta activation and increased mitochondrial fatty acid oxidation. Diabetes Obes. Metab. 11: 304-314 (2009).
Ma KL, Ruan XZ, Powis SH, Chen Y, Moorhead JF, Varghese Z. Inflammatory stress exacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout mice. Hepatology 48: 770-781 (2008).
Ma SW, Benzie IF, Yeung VT. Type 2 diabetes mellitus and its renal complications in relation to apolipoprotein E gene polymorphism. Transl. Res. 152: 134-142 (2008). *
Ma X, Hu YW, Mo ZC, Li XX, Liu XH, Xiao J, Yin WD, Liao DF, Tang CK. NO-1886 up-regulates Niemann-Pick C1 protein (NPC1) expression through liver X receptor alpha signaling pathway in THP-1 macrophage-derived foam cells. Cardiovasc. Drugs Ther. Feb 20 [Epub ahead of print] (2009).
Ma Y, Xu L, Rodriguez-Agudo D, Li X, Heuman DM, Hylemon PB, Pandak WM, Ren S. 25-Hydroxycholesterol-3-sulfate regulates macrophage lipid metabolism via the LXR/SREBP-1 signaling pathway. Am. J. Physiol. Endocrinol. Metab. 295: E1369-E1379 (2008). *
Mabley JG, Wallace R, Pacher P, Murphy K, Szabo C. Inhibition of poly(adenosine diphosphate-ribose) polymerase by the active form of vitamin D. Int. J. Mol. Med. 19: 947-952 (2007). *
Maccio DR, Calfa G, Roth GA. Oral testosterone in male rats and the development of experimental autoimmune encephalomyelitis. Neuroimmunomodulation 12: 246-254 (2005).
MacDonald AC, Williams CN. Studies of bile lipids and bile acids of wild North American black bears in Nova Scotia, showing a high content of ursodeoxycholic acid. J. Surg. Res. 38: 173-179 (1985).
MacDonald IA, Williams CN, Sutherland JD, MacDonald AC. Estimation of ursodeoxycholic acid in human and bear biles using Clostridium absonum 7 beta-hydroxysteroid dehydrogenase. Anal. Biochem. 135: 349-354 (1983).
Mace S, Cousin E, Ricard S, Genin E, Spanakis E, Lafargue-Soubigou C, Genin B, Fournel R, Roche S, Haussy G, Massey F, Soubigou S, Brefort G, Benoit P, Brice A, Campion D, Hollis M, Pradier L, Benavides J, Deleuze JF. ABCA2 is a strong genetic risk factor for early-onset Alzheimer's disease. Neurobiol. Dis. 18: 119-125 (2005).
Macias RI, Jimenez S, Serrano MA, Monte MJ, Marin JJ. Effect of maternal cholestasis and treatment with ursodeoxycholic acid on the expression of genes involved in the secretion of biliary lipids by the neonatal rat liver. Life Sci. 79: 1014-1019 (2006). *
Macias RI, Serrano MA, Monte MJ, Jimenez S, Hernandez B, Marin JJ. Long-term effect of treating pregnant rats with ursodeoxycholic acid on the congenital impairment of bile secretion induced in the pups by maternal cholestasis. J. Pharmacol. Exp. Ther. 312: 751-758 (2005). *
Mack JT, Beljanski V, Tew KD, Townsend DM. The ATP-binding cassette transporter ABCA2 as a mediator of intracellular trafficking. Biomed. Pharmacother. 60: 587-592 (2006).
Mack JT, Townsend DM, Beljanski V, Tew KD. The ABCA2 transporter: intracellular roles in trafficking and metabolism of LDL-derived cholesterol and sterol-related compounds. Curr. Drug Metab. 8: 47-57 (2007).
Madden J, Carrero JJ, Brunner A, Dastur N, Shearman CP, Calder PC, Grimble RF. Polymorphisms in the CD36 gene modulate the ability of fish oil supplements to lower fasting plasma triacyl glycerol and raise HDL cholesterol concentrations in healthy middle-aged men. Prostaglandins Leukot. Essent. Fatty Acids 78: 327-335 (2008). *
Madsen L, Petersen RK, Steffensen KR, Pedersen LM, Hallenborg P, Ma T, Froyland L, D�skeland SO, Gustafsson JA, Kristiansen K. Activation of liver X receptors prevents statin-induced death of 3T3-L1 preadipocytes. J. Biol. Chem. 283: 22723-22736 (2008). *
Maes M, Christophe A, Delanghe J, Altamura C, Neels H, Meltzer HY. Lowered omega-3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res. 85: 275-291 (1999).
Magadmi ME, Ahmad Y, Turkie W, Yates AP, Sheikh N, Bernstein RM, Durrington PN, Laing I, Bruce IN. Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. J. Rheumatol. 33: 50-56 (2006). *
Mahadevan U, Sandborn WJ. Evolving medical therapies for Crohn's disease. Curr. Gastroenterol. Rep. 3: 471-476 (2001).
Mahmutefendic H, Blagojevic G, Kucic N, Lucin P. Constitutive internalization of murine MHC class I molecules. J. Cell. Physiol. 210: 445-455 (2006). *
Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, Thomson D, Kishimoto T. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 54: 2817-2829 (2006). *
Mainous AG 3rd, Gill JM, Carek PJ. Elevated serum transferrin saturation and mortality. Ann. Fam. Med. 2: 133-138 (2004). *
Maki KC, McKenney JM, Reeves MS, Lubin BC, Dicklin MR. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. Am. J. Cardiol. 102: 429-433 (2008).
Maki-Petaja KM, Wilkinson IB. Anti-inflammatory drugs and statins for arterial stiffness reduction. Curr. Pharm. Des. 15: 290-303 (2009).
Makino I, Nakagawa S. Changes in biliary lipid and biliary bile acid composition in patients after administration of ursodeoxycholic acid. J. Lipid Res. 19: 723-728 (1978). *
Makishima M. Nuclear receptors as targets for drug development: regulation of cholesterol and bile acid metabolism by nuclear receptors. J. Pharmacol. Sci. 97: 177-183 (2005). *
Makishima M. Regulation of cholesterol homeostasis by nuclear receptors. Seikagaku 76: 509-516 (2004).
Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, Shan B. Identification of a nuclear receptor for bile acids. Science 284: 1362-1365 (1999). *
Makni M, Fetoui H, Gargouri NK, Garoui EM, Jaber H, Makni J, Boudawara T, Zeghal N. Hypolipidemic and hepatoprotective effects of flax and pumpkin seed mixture rich in omega-3 and omega-6 fatty acids in hypercholesterolemic rats. Food Chem. Toxicol. 46: 3714-3720 (2008). *
Makowski P, Pikula S. Participation of the multispecific organic anion transporter in hepatobiliary excretion of glutathione S-conjugates, drugs and other xenobiotics. Pol. J. Pharmacol. 49: 387-394 (1997).
Maksimowicz-McKinnon K, Magder LS, Petri M. Predictors of carotid atherosclerosis in systemic lupus erythematosus. J. Rheumatol. 33: 2458-2463 (2006).
Malandrino N, Capristo E, Farnetti S, Leggio L, Abenavoli L, Addolorato G, Gasbarrini G. Metabolic and nutritional features in adult celiac patients. Dig. Dis. 26: 128-133 (2008).
Malerod L, Sporstol M, Juvet LK, Mousavi SA, Gjoen T, Berg T, Roos N, Eskild W. Bile acids reduce SR-BI expression in hepatocytes by a pathway involving FXR/RXR, SHP, and LRH-1. Biochem. Biophys. Res. Commun. 336: 1096-1105 (2005). *
Malesci D, Valentini G, La Montagna G. Metabolic syndrome in inflammatory rheumatic diseases. Reumatismo 58: 169-176 (2006).
Malinowski JM, Metka K. Elevation of low-density lipoprotein cholesterol concentration with over-the-counter fish oil supplementation. Ann. Pharmacother. 41: 1296-1300 (2007).
Mallbris L, Granath F, Hamsten A, Stahle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J. Am. Acad. Dermatol. 54: 614-621 (2006).
Mamianetti A, Garrido D, Carducci CN, Vescina MC. Fecal bile acid excretion profile in gallstone patients. Medicina (B. Aires) 59: 269-273 (1999).
Mamoon A, Ventura-Holman T, Maher JF, Subauste JS. Retinoic acid responsive genes in the murine hepatocyte cell line AML 12. Gene 408: 95-103 (2008). *
Man MQ, Choi EH, Schmuth M, Crumrine D, Uchida Y, Elias PM, Holleran WM, Feingold KR. Basis for improved permeability barrier homeostasis induced by PPAR and LXR activators: liposensors stimulate lipid synthesis, lamellar body secretion, and post-secretory lipid processing. J. Invest. Dermatol. 126: 386-392 (2006). *
Mandeville WH, Arbeeny C. Bile acid sequestrants: their use in combination with other lipid-lowering agents. IDrugs 2: 237-242 (1999).
Manes S, del Real G, Martinez-A C. Pathogens: raft hijackers. Nat. Rev. Immunol. 3: 557-568 (2003).
Manfredi R, Chiodo F. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate. J. Infect. 42: 181-188 (2001).
Manson ME, Corey DA, White NM, Kelley TJ. cAMP-mediated regulation of cholesterol accumulation in cystic fibrosis and Niemann-Pick type C cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 295: L809-L819 (2008). *
Mantaring M, Rhyne J, Ho Hong S, Miller M. Genotypic variation in ATP-binding cassette transporter-1 (ABCA1) as contributors to the high and low high-density lipoprotein-cholesterol (HDL-C) phenotype. Transl. Res. 149: 205-210 (2007). *
Marai I, Shoenfeld Y. The beneficial effects of statins in autoimmune disease therapy. Drug News Perspect. 20: 165-169 (2007).
Marasini B, Pipia C, DeValle G, Crosignani A, Petroni L, Cugno M, Zeni S, Bruno S, Bassani C. Vascular impairment in patients with primary biliary cirrhosis. Int. J. Microcirc. Clin. Exp. 15: 75-79 (1995).
Marcil M, Vu H, Cui W, Dastani Z, Engert JC, Gaudet D, Castro-Cabezas M, Sniderman AD, Genest Jr J, Cianflone K. Identification of a novel C5L2 variant (S323I) in a French Canadian family with familial combined hyperlipemia. Arterioscler. Thromb. Vasc. Biol. 26: 1619-1625 (2006). *
Marin JJG, Romero MR, Vallejo M, Perez MJ, Briz O. Emerging interest in bile acid transporters in pathophysiology and pharmacology. Med. Hypotheses Res. 2: 425-448 (2005). *
Marouf R, Mojiminiyi O, Qurtom M, Abdella N, Al Wazzan H, Al Humood S, Al Mazeedy M. Plasma homocysteine and hematological factors in patients with venous thromboembolic diseases in Kuwait. Acta Haematol. 117: 98-105 (2006).
Marrapodi M, Chiang JY. Peroxisome proliferator-activated receptor alpha (PPARalpha) and agonist inhibit cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription. J. Lipid Res. 41: 514-520 (2000). *
Marrink SJ, Vries AH, Harroun TA, Katsaras J, Wassall SR. Cholesterol shows preference for the interior of polyunsaturated lipid membranes. J. Am. Chem. Soc. 130: 10-11 (2008).
Marschall HU, Busch N. CSE (cholesterol-synthesis enzyme) inhibitors in the treatment of hypercholesterolemia in primary biliary cirrhosis. Dtsch. Med. Wochenschr. 125: 100-101 (2000).
Marschall HU, Einarsson C. Gallstone disease. J. Intern. Med. 261: 529-542 (2007). *
Marschall HU, Wagner M, Zollner G, Fickert P, Diczfalusy U, Gumhold J, Silbert D, Fuchsbichler A, Benthin L, Grundstrom R, Gustafsson U, Sahlin S, Einarsson C, Trauner M. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 129: 476-485 (2005). *
Marschall HU, Wagner M, Zollner G, Fickert P, Gumhold J, Silbert D, Diczfalusy U, Benthin L, Grundstrom R, Gustafsson U, Sahlin S, Einarsson C, Trauner M. Comprehensive study of the effects of rifampicin and ursodeoxycholic acid on genes and proteins involved in regulation, transport and detoxification of biliary compounds in gallstone patients. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 47. June 18-19 (2004). *
Martin GG, Atshaves BP, McIntosh AL, Mackie JT, Kier AB, Schroeder F. Liver fatty acid binding protein (L-FABP) gene ablation potentiates hepatic cholesterol accumulation in cholesterol-fed female mice. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G36-G48 (2006). *
Martin GG, Atshaves BP, McIntosh AL, Mackie JT, Kier AB, Schroeder F. Liver fatty-acid-binding protein (L-FABP) gene ablation alters liver bile acid metabolism in male mice. Biochem. J. 391: 549-560 (2005). *
Martin GG, Atshaves BP, McIntosh AL, Payne HR, Mackie JT, Kier AB, Schroeder F. Liver fatty acid binding protein gene ablation enhances age-dependent weight gain in male mice. Mol. Cell. Biochem. 324: 101-115 (2009). *
Martin JM, Beshears J, Milkman KL, Bazerman MH, Sutherland LA. Modeling expert opinions on food healthfulness: a nutrition metric. J. Am. Diet. Assoc. 109: 1088-1091 (2009). *
Martin KO, Budai K, Javitt NB. Cholesterol and 27-hydroxycholesterol 7 alpha-hydroxylation: evidence for two different enzymes. J. Lipid Res. 34: 581-588 (1993). *
Martin KO, Reiss AB, Lathe R, Javitt NB. 7 alpha-Hydroxylation of 27-hydroxycholesterol: biologic role in the regulation of cholesterol synthesis. J. Lipid Res. 38: 1053-1058 (1997). *
Martin MT, Brennan R, Hu W, Ayanoglu E, Lau C, Ren H, Wood CR, Corton JC, Kavlock RJ, Dix DJ. Toxicogenomic study of triazole fungicides and perfluoroalkyl acids in rat livers predicts toxicity and categorizes chemicals based on mechanisms of toxicity. Toxicol. Sci. 97: 595-613 (2007). *
Martin SC, Viljoen A. The value of a specialist lipid clinic. Int. J. Clin. Pract. 62: 961-966 (2008).
Martinez LO, Jacquet S, Terce F, Collet X, Perret B, Barbaras R. New insight on the molecular mechanisms of high-density lipoprotein cellular interactions. Cell. Mol. Life Sci. 61: 2343-2360 (2004). *
Martinez N, Capobianco E, White V, Pustovrh M, Higa R, Jawerbaum A. Peroxisome proliferator-activated receptor alpha activation regulates lipid metabolism in the feto-placental unit from diabetic rats. Reproduction 136: 95-103 (2008).
Martinez-Berriotxoa A, Ruiz-Irastorza G, Egurbide Arberas MV, Rueda Gutierrez M, Aguirre Errasti C. Plasma homocysteine levels in systemic lupus erythematosus. Med. Clin. (Barc.) 120: 681-685 (2003).
Martinez-Calatrava MJ, Martinez-Larrad MT, Zabena C, Gonzalez-Sanchez JL, Fernandez-Perez C, Serrano-Rios M. The 4G/4G PAI-1 genotype is associated with elevated plasma PAI-1 levels regardless of variables of the metabolic syndrome and smoking status. A population-based study in Spanish population. Diabetes Obes. Metab. 9: 134-135 (2007). *
Martini C, Pallottini V, De Marinis E, Marino M, Cavallini G, Donati A, Straniero S, Trentalance A. Omega-3 as well as caloric restriction prevent the age-related modifications of cholesterol metabolism. Mech. Ageing Dev. 129: 722-727 (2008).
Martins F, Suzan AJ, Cerutti SM, Arcari DP, Ribeiro ML, Bastos DH, Carvalho PD. Consumption of mate tea (Ilex paraguariensis) decreases the oxidation of unsaturated fatty acids in mouse liver. Br. J. Nutr. 101: 519-524 (2009). *
Marzoa-Rivas R, Crespo-Leiro MG, Paniagua-Marin MJ, Llinares-Garcia D, Muniz-Garcia J, Aldama-Lopez G, Pinon-Esteban P, Campo-Perez R, Castro-Beiras A. Safety of statins when response is carefully monitored: a study of 336 heart recipients. Transplant. Proc. 37: 4071-4073 (2005). *
Marzolini C, Tirona RG, Gervasini G, Poonkuzhali B, Assem M, Lee W, Leake BF, Schuetz JD, Schuetz EG, Kim RB. A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression. Mol. Endocrinol. 21: 1769-1780 (2007). *
Mas MR, Comert B, Mas N, Yamanel L, Ozotuk H, Tasci I, Jazrawi RP. Effects of long term hydrophilic bile acid therapy on in vitro contraction of gallbladder muscle strips in patients with cholesterol gallstones. World J. Gastroenterol. 13: 4336-4339 (2007). *
Masclee AA, Vu MK. Gallbladder motility in inflammatory bowel diseases. Dig. Liver Dis. 35 Suppl. 3: S35-S38 (2003).
Mascrez B, Ghyselinck NB, Watanabe M, Annicotte JS, Chambon P, Auwerx J, Mark M. Ligand-dependent contribution of RXRbeta to cholesterol homeostasis in Sertoli cells. EMBO Rep. 5: 285-290 (2004). *
Masson D, Lagrost L, Athias A, Gambert P, Brimer-Cline C, Lan L, Schuetz JD, Schuetz EG, Assem M. Expression of the pregnane X receptor in mice antagonizes the cholic acid-mediated changes in plasma lipoprotein profile. Arterioscler. Thromb. Vasc. Biol. 25: 2164-2169 (2005). *
Masson D, Qatanani M, Sberna AL, Xiao R, Pais de Barros JP, Grober J, Deckert V, Athias A, Gambert P, Lagrost L, Moore DD, Assem M. Activation of the constitutive androstane receptor decreases HDL in wild-type and human apoA-I transgenic mice. J. Lipid Res. 49: 1682-1691 (2008). *
Mataki C, Magnier BC, Houten SM, Annicotte JS, Argmann C, Thomas C, Overmars H, Kulik W, Metzger D, Auwerx J, Schoonjans K. Compromised intestinal lipid absorption in mice with a liver-specific deficiency of liver receptor homolog 1. Mol. Cell Biol. 27: 8330-8339 (2007). *
Mathis AS, Jin S, Friedman GS, Peng F, Carl SM, Knipp GT. The pharmacodynamic effects of sirolimus and sirolimus-calcineurin inhibitor combinations on macrophage scavenger and nuclear hormone receptors. J. Pharm. Sci. 96: 209-222 (2007). *
Mathur A, Al-Azzawi HH, Lu D, Yancey KW, Swartz-Basile DA, Nakeeb A, Pitt HA. Steatocholecystitis: the influence of obesity and dietary carbohydrates. J. Surg. Res. 147: 290-297 (2008). *
Mathur A, Marine M, Lu D, Swartz-Basile DA, Saxena R, Zyromski NJ, Pitt HA. Nonalcoholic fatty pancreas disease. HPB (Oxford) 9: 312-318 (2007). *
Mathur SN, Watt KR, Field FJ. Regulation of intestinal NPC1L1 expression by dietary fish oil and docosahexaenoic acid. J. Lipid Res. 48: 395-404 (2007). *
Matic M, Mahns A, Tsoli M, Corradin A, Polly P, Robertson GR. Pregnane X receptor: promiscuous regulator of detoxification pathways. Int. J. Biochem. Cell. Biol. 39: 478-483 (2007). *
Maton PN, Ellis HJ, Higgins MJ, Dowling RH. Hepatic HMGCoA reductase in human cholelithiasis: effects of chenodeoxycholic and ursodeoxycholic acids. Eur. J. Clin. Invest. 10: 325-332 (1980).
Maton PN, Murphy GM, Dowling RH. Ursodeoxycholic acid treatment of gallstones. Dose-response study and possible mechanism of action. Lancet 2: 1297-1301 (1977).
Matsumoto S, Hashimoto K, Yamada M, Satoh T, Hirato J, Mori M. Liver X receptor-alpha positively regulates proopiomelanocortin (POMC) gene expression at the transcriptional level in the pituitary. Mol. Endocrinol. 23: 47-60 (2009). *
Matsuura F, Oku H, Koseki M, Sandoval JC, Yuasa-Kawase M, Tsubakio-Yamamoto K, Masuda D, Maeda N, Tsujii KI, Ishigami M, Nishida M, Hirano KI, Kihara S, Hori M, Shimomura I, Yamashita S. Adiponectin accelerates reverse cholesterol transport by increasing high density lipoprotein assembly in the liver. Biochem. Biophys. Res. Commun. 358: 1091-1095 (2007). *
Matsuura F, Wang N, Chen W, Jiang XC, Tall AR. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. J. Clin. Invest. 116: 1435-1442 (2006). *
Matsuyama M, Suzuki T, Tsuboi H, Ito S, Mamura M, Goto D, Matsumoto I, Tsutsumi A, Sumida T. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease. Intern. Med. 46: 771-774 (2007). *
Matsuzaki M, Yokoyama M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Matsuzawa Y; The JELIS Investigators. Incremental